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Abstract 
 
Aim: To investigate potential markers for depression and poor quality of life (QoL) 
in head and neck (HN) and colorectal (CR) cancer patients. 
Background: Comorbid depression is strongly related to decreased QoL in cancer 
patients and may increase the risk of mortality.  Many psychosocial factors, such 
as childhood trauma (CT), neuroticism (NE), past history of depression (PH) and 
current life events (LE) increase the risk of depression.  Depression is also 
associated with increased levels of pro-inflammatory cytokines and patients with 
comorbid depression and cancer show higher levels compared to patients with 
either condition alone.  Thus, increased inflammation may also be a risk factor for 
low mood.  This thesis explores relationships between inflammation and 
psychosocial risk factors and their potential as predictive markers for depression in 
cancer patients. 
Methods: Ninety-one newly diagnosed cancer patients due for surgical treatment 
(57 HN and 34 CR) completed the Hospital Anxiety and Depression Scale and 
European Organisation for Research and Treatment of Cancer QoL Questionnaire 
before surgery and one, three and six months following surgery.  Patients gave 
blood samples before and one week and one month after surgery to measure 
levels of C-reactive protein and pro-inflammatory cytokines and saliva samples 
before surgery.  The Brief Life Events Questionnaire was completed at one month 
and the Eysenck Personality Questionnaire, Childhood Trauma Questionnaire and 
Brief COPE at three months.  Patients completed a diagnostic interview between 
three and six months for diagnosis of past or current episode of depression. 
Results: Childhood trauma, NE, PH and LE were all related to low mood and 
poorer QoL.  Increased inflammation was associated with lower mood post 
treatment in CR patients, but there were fewer associations in the HN patients. 
Conclusions: Both psychosocial and inflammatory markers are related to lower 
mood after treatment.  PH is a simple but informative marker for increased risk of 
depression in cancer patients.  
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Overview 
 
Both cancer and depression are common conditions in the UK: 293,601 people 
were diagnosed with cancer in 2006 and 2.6 million people were diagnosed with 
depression in 2000 and probably many more remained undiagnosed[1-3].  Comorbid 
depression is often assumed to be highly prevalent among cancer patients, and is 
associated with poorer quality of life[4], and some evidence of increased mortality[5].  
Despite these negative consequences, depression is also reported to be under 
treated and under diagnosed in many cancer clinics[6, 7].  The aims of this thesis are 
to: 
1. Measure the prevalence of depressive disorders in two cancer clinics. 
2. Explore what factors might increase the risk of developing a depressive 
episode in cancer patients. 
This is so future patients who are at an increased risk of developing depression 
can be monitored and provided with appropriate support to improve their treatment 
outcome. 
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The thesis comprises two complementary studies: 
1. A quantitative cross sectional study. 
2. A multidisciplinary prospective study. 
Both of the studies are conducted on colorectal cancer patients recruited from The 
Royal London Hospital and head and neck cancer patients recruited from St 
Bartholomew‟s Hospital. 
 
The cross sectional study investigates the prevalence of depressive symptoms and 
point prevalence of a depressive episode in the respective clinics.  The results from 
some exploratory analyses investigating the relationship between depressive 
symptoms and quality of life are also presented. 
 
The greater part of this thesis focuses on the prospective study.  This study 
investigates potential physiological and psychological markers of depression in 
order to explore what factors might increase the risk of development of a 
depressive disorder in cancer patients soon after their diagnosis. 
 
The cross sectional study and the prospective study have been presented in 
different ways.  Also, due to the inter-disciplinary nature of the prospective study a 
review of a substantial amount of literature is required.  As a result in order to 
present the contents in the most comprehensive manner the thesis has been split 
into four parts: 
1. Background 
2. Cross sectional study 
3. Prospective study 
4. General discussion 
 
The background is an introduction to the relevant literature on cancer and 
depression and provides the context of the thesis within medical research.  It 
presents the rational to the hypotheses and the methodology of the studies.  The 
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more technical aspects to the literature are presented with the relevant aspects of 
the study.  Similarly, a technical discussion is included in each of the results 
chapters.  The findings are reiterated in the general discussion and presented in 
the context of clinical implications and further research. 
 
The cross sectional and prospective study are presented in different formats.  The 
cross sectional study is presented in two chapters; firstly an introduction and 
methods, secondly the results and discussion.  The prospective study is presented 
in six parts; the methods and five results chapters: 1) the sample, 2) psychological 
factors, 3) physiological factors, 4) covariates and 5) adjusted models.  Each 
results chapter is accompanied by an introduction, results and discussion, and an 
additional methods section in the final results chapter.  The aims of the chapters 
are: 
1. Summary – introduce the data set and report prevalence of mood 
disorders. 
2. Psychological factors – test for associations between psychological risk 
factors and later depressive symptomatology and poorer quality of life. 
3. Physiological factors – test for associations between physiological risk 
factors and later depressive symptomatology and poorer quality of life. 
4. Covariates – test for associations between physiological and 
psychological risk factors and justify need for adjusted models 
5. Adjusted models – present adjusted models for risk of depressive 
symptomatology and poorer quality of life. 
 
Wherever possible the findings from each chapter are linked to previous chapters 
in order to build on the overall conclusions of the thesis, which are then brought 
together in the final discussion.  Please see figure 0.1 for a diagram of the thesis 
structure. 
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1 Literature review 
 
This section introduces the background and rationale for the hypotheses and 
methodology underlying this study.  Firstly, an overview of the classification and 
treatment of head and neck (HN) and colorectal (CR) cancers and diagnosis and 
measurement of depression are covered.  The review then focuses on the 
associations between depression and cancer: i) prevalence of depression in 
cancer patients; and ii) consequences of comorbid depression on cancer treatment 
outcome.  The review is limited to areas relevant to the thesis title.  However, 
where only limited data exist on HN or CR cancer, results from heterogeneous 
cancer groups are also included. 
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1.1 Cancer 
 
“Cancer” is an umbrella term that covers a wide range of different diseases in 
which cells undergo genetic mutation and continue dividing uncontrollably. Cancer 
can occur in any cell and create a tumour which does not spread (benign) or which 
can be locally invasive or metastasize to different organs (malignant)[8]. 
 
The risk factors for cancer, including genetic risk, vary greatly depending on the 
type and location of the cancer.  Similarly, the treatment and prognosis vary 
according to the site and stage.  Head and neck, and CR cancers are two distinct 
types of cancer, affected by different risk factors and with different consequences 
on quality of life (QoL).  The inclusion of such disparate cancers allows for 
comparison between different cancer groups. 
 
1.1.1 Colorectal cancer 
 
Colorectal cancer includes malignancies of the colon or rectum.  According to 
Cancer Research UK[9] CR cancer is the third most common form of cancer in the 
UK, with 29,565 new cases reported in 2005.  Around two thirds of all cases are of 
the colon, the rest are rectal.  The cancers can be either squamous cell 
carcinomas or adenocarcinomas. 
 
Most solid tumours are staged using the universal TNM staging by the International 
Union Against Cancer (UICC) to indicate the extent of disease.  TNM stands for 
tumour, node and metastasis.  T stage indicates the extent of the tumour and 
scores range from zero to four; N stage indicates the number of lymph node 
metastases and scores range from zero to a maximum of four (depending on the 
cancer site) and M is either zero or one (one indicating the presence of one or 
more metastasis).  The grading of the T and N aspects depends on the tumour 
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site.  For CR cancer patients the tumour and node status are allocated as 
follows[10] (see figure 1.1 for cross section diagram of the intestine). 
 
Tumour status: 
T1: Tumor invades submucosa.  
T2: Tumor invades muscularis propria.  
T3: Tumor invades through the muscularis propria into the subserosa, or into the 
pericolic or perirectal tissues.  
T4: Tumor directly invades other organs or structures, and/or perforates.  
 
Nodal status: 
N0: No regional lymph node metastasis.  
N1: Metastasis in 1 to 3 regional lymph nodes.  
N2: Metastasis in 4 or more regional lymph nodes.  
 
 
Figure 1.1: The layers of the colon wall. Reprinted by the permission of the American Cancer 
Society, Inc. from www.cancer.org. All rights reserved 
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1.1.1.1 Risk factors 
 
As with HN cancer there are genetic, lifestyle and some predisposing diseases that 
increase the risk of developing CR cancer.  Familial adenomatous polyposis and 
hereditary non-polyposis CR cancer, Human Papilloma Virus (HPV) (squamous 
anal carcinoma only), inflammatory bowel diseases (Crohn‟s and ulcerative colitis) 
all increase the risk of CR cancer.  However, the pathway to carcinogenesis 
appears to differ in these cancers compared to sporadic carcinomas and most CR 
cancers are sporadic[11, 12]. Inflammatory bowel diseases (IBD) confer an increased 
risk of 0.5-1% per year[13] compared to a 2x greater risk of CR cancer if one 
immediate family member suffered from CR cancer[14]. Despite the hereditary 
aspect to CR cancer, at the time of writing, there is less conclusive evidence for 
individual genes[15]. 
 
The behavioural risk factors for CR cancer are not as well defined as those for HN 
cancer.  Alcohol is considered to confer a moderate risk[16] though this was not 
significant for higher rectal tumours.  There is still some debate about whether 
smoking increases the risk of CR cancer; Paskett and colleagues (2007)[17] found 
evidence of an increased risk in US female current smokers in a prospective cohort 
study.  However, a review by the International Agency for Research on Cancer[18] 
recently reported that the effects are so small that they could be due to poor control 
for other associated risks, although they do not give any information on the studies 
included in their review or their respective findings. 
 
It has been suggested that dietary factors play a role in the aetiology of CR cancer.  
Norat et al. (2005)[19] found an increased risk for red meat intake of over 100g/day, 
as supported by a previous meta-analysis by the same author[20].  Many studies 
and some reviews have found an increased risk of CR cancer in people with a 
body mass index (BMI) of over 30[21-23].  
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1.1.1.2 Treatments 
 
The main treatment for CR cancer is surgical resection, which in some cases may 
be accompanied by either preoperative or adjuvant chemotherapy.  People with 
rectal cancer may also receive radiotherapy.  Patients with advanced stage bowel 
cancer may be treated with primary chemotherapy.  Also, some patients may 
require a colostomy or ileostomy.  In most cases this is temporary, to let the bowel 
heal.  However, in a small number of patients a permanent colostomy is necessary.  
This is more common in rectal tumours than colon cancer (roughly 41% and 7% 
respectively[24]). 
 
A course of chemotherapy typically takes about two months.  In this time the 
patient will alternate between drug and recovery phases (allowing tissue repair 
during the rest periods).  Chemotherapy results in severe fatigue and may be 
accompanied by: fever and chills, skin changes, feeling weak, loss of appetite, dry 
mouth and/or ulcers, taste changes and changes in nails and possibly nausea and 
vomiting, hair loss or sensitivity to sunlight.  Radiotherapy involves 15 minute 
hospital visits for five days a week for between three and seven weeks.  The side 
effects are fatigue and soreness of skin around the treated area and possibly 
nausea. 
1.1.1.3 Prognosis 
 
For each type of cancer there are two main aspects to prognosis: length of survival 
and QoL.  A patient‟s prognosis is affected by the size and site of the tumour as 
well as by their general health (which will also determine their treatment). 
1.1.1.3.1 Mortality 
 
Colorectal cancer is the second most frequent cause of cancer death in the UK[9] 
causing 16000 deaths in the UK in 2005.  However, the high death rate is mainly 
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due to high incidence rates and in fact 46% of patients are still alive 5 years after 
their diagnosis[9]. 
1.1.1.3.2 Quality of life 
 
Colorectal cancer patients may suffer from a brief period of poor bowel function, 
but generally most can expect their QoL to return to levels similar to that of the 
general population[25-27].  Patients with a stoma have to adapt to using a colostomy 
bag.  A recent review reported that use of a stoma led to a decrease in QoL[28].  
However, perhaps counter-intuitively, a meta-analysis and Cochrane review both 
report that stomata appear to have little impact on long term QoL when compared 
to anterior resection for rectal cancer[29, 30]. 
 
All types of cancers are associated with a risk of „sickness behaviour‟[31].  This 
syndrome is characterised by depressed mood, decreased appetite, weight loss 
and fatigue and many symptoms that overlap with depression (see table 1.1).  This 
obviously affects the QoL of any cancer patient.  Sickness behaviour is considered 
to be related to inflammation secondary to the tumour.  Physical trauma, such as 
surgery or radiotherapy, increases the levels of inflammatory mediators in the 
blood.  These include molecules known as cytokines that have been shown to 
induce the symptoms of sickness behaviour[31] (the role of cytokines is reviewed in 
more depth in section 1.2.4.2.)  Sickness behaviour is also known to increase the 
risk of experiencing a depressive episode (DE).  However, not everyone who 
suffers from sickness behaviour develops a DE and it has been suggested that 
vulnerability to a depressive disorder (DD) increases the risk of a DE following 
cytokine-induced sickness behaviour[31]. 
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Major Depression Sickness Behaviour 
Depressed mood 
Anhedonia 
Decreased appetite 
Weight loss 
Sleep disturbances 
Psychomotor retardation 
Decreased libido 
Fatigue 
Cognitive problems 
Guilt/worthlessness 
Suicidality 
Depressed mood 
Anhedonia 
Decreased appetite 
Weight loss 
Sleep disturbances 
Psychomotor retardation 
Decreased libido 
Fatigue 
Cognitive problems 
Flu-like symptoms 
Table 1.1: Comparison of major depression and cytokine-induced sickness behaviour 
 
1.1.2 Head and neck cancer 
 
The term HN cancer includes malignancies of the: 
 Mouth (hard palate, soft palate, tongue, floor of mouth, tonsils, uvula, 
 oropharynx, mandible, maxilla and salivary glands) 
 Nose (nasal cavity, nasopharynx and paranasal sinuses) 
 Throat (pharyngeal wall, larynx, pharynx, oesophagus and thyroid) 
 
See figure 1.2 for cross section of HN anatomy. 
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Figure 1.2: Head and neck anatomy diagram 
 
According to cancer research statistics, HN cancer is the 16th most common form 
of cancer (laryngeal cancers are 20th) with just over 4,500 new cases of oral cancer 
in the UK in 2005[2].  The incidence increases dramatically when laryngeal and 
oesophageal cancers are included; 12,725 new HN cases were reported in 2005 in 
the UK[2].  Most malignancies (90% of oral cancers[32]) are squamous cell 
carcinomas, the rest are sarcomas or adenocarcinomas. 
 
TNM staging can also be used in HN cancer, where the M staging is the same.  
There are many sites within the HN umbrella and the precise staging varies 
according to the site, but broadly speaking the T and N stagings are defined as 
follows: 
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Tumour: 
 TX: Primary tumor cannot be assessed  
 T0: No evidence of primary tumor  
 Tis: Carcinoma in situ  
 T1: Tumor 2 cm or less in greatest dimension  
 T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension  
 T3: Tumor more than 4 cm in greatest dimension  
 T4: Tumor invades adjacent structures (e.g., through cortical bone, into 
deep [extrinsic] muscle of tongue, maxillary sinus, skin. Superficial erosion 
alone of bone/tooth socket by gingival primary is not sufficient to classify as 
T4) 
 
Node involvement: 
 
 NX Regional lymph nodes cannot be assessed  
 N0 No regional lymph node metastasis  
 N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest 
dimension  
 N2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not 
more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, 
none more than 6 cm in greatest dimension; or in bilateral or contralateral 
lymph nodes, none more than 6 cm in greatest dimension  
 N3 Metastasis in a lymph node more than 6 cm in greatest dimension  
 
1.1.2.1 Risk factors 
 
There have been reports on genetic polymorphisms leading to an increased risk of 
HN cancer[33] as well as social factors and HPV[34].  The risks for HN cancer for 
which there is most evidence are behavioural factors, such as tobacco and alcohol 
use[32].  There are less conclusive risks such as low fruit and vegetable intake and 
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low BMI.  HPV confers a considerable risk and approximately 20% of HN cancers 
are HPV positive[34, 35]. 
 
By far the biggest risk factor for development of HN cancer is use of tobacco: 
cigarettes, pipes or chewing tobacco or betel nut (with or without tobacco) all 
substantially increase the risk of HN malignancies[36].  Over 90% of oral cancer 
patients use tobacco in some form[32], and a study by Rodriguez et al. (2004)[37] 
found that even smoking fewer than 15 cigarettes a day increased the odds of 
developing cancer by 4.37 compared to never having smoked.  Similarly, 
Freedman et al. (2007)[38] reported an odds ratio of 6.65 for men and 16.17 for 
women smoking more than 20 cigarettes/day. 
 
The second biggest risk is use of alcohol; 75-80% of HN patients drink alcohol 
regularly[32].  From the same sample Freedman et al. (2007)[39] found that over 
three alcoholic drinks a day increases the risk of HN cancer.  Likewise Rodriguez 
et al. (2004)[37] found that drinking between 6-10 drinks per day increases the risk 
of HN cancer by 3.69, but they found no increased risk for fewer than six drinks a 
day.  However the risk conferred by alcohol is much weaker in the absence of 
tobacco use[40].  There is a greatly increased risk with combined alcohol and 
tobacco use[37, 41], but alcohol and smoking are not associated with HPV related 
pharyngeal cancers[42].  Other much smaller, though still significant, risks include 
low intake of fruit and vegetables[43] and low BMI[44-46]. 
 
Finally, it should be noted that all of these environmental risks are usually 
associated with each other.  For example, alcohol consumption is associated with 
tobacco use[47] as well as poor nutrition (decreased intake, impaired metabolism 
and poor absorption)[48].  Also, the associations vary by cancer site even within the 
umbrella term of HN cancers.  For instance the increased risk of malignancy from 
smoking is strongest for cancers of the larynx[40]. 
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A point of particular relevance to this study is that all of these risk factors are also 
more common in patients with a DD[49]. 
1.1.2.2 Treatments 
 
Cancer treatment varies according to the site and stage of the tumour.  Surgery is 
usually the first choice for treating HN tumours, but sometimes the tumour is 
considered to be technically impossible to resect, or the result would be 
functionally too disabling.  Also, some patients are not fit enough to cope with the 
physical trauma of surgery.  The amount of disability and recovery time after 
surgery depends on the tissue removed; this can range from a day in hospital with 
no long term impairment to a hospital admission lasting months or permanent 
effects such as complete loss of voice. 
 
When surgery is contraindicated, primary chemotherapy and/or radiotherapy are 
offered.  The side effects of chemotherapy are similar to those of the CR patients.  
Similarly HN patients undergoing radiotherapy can expect side effects including 
fatigue and soreness of skin around the treated area, as well as sore throat and 
mouth, dry mouth, dental complications and halitosis, loss of taste and appetite, 
jaw stiffness and possibly hair loss.  Many patients undergo more then one 
modality of treatment in order to minimise the possibility of recurrence without long 
term loss of function.  Often patients are offered radiotherapy after an operation to 
eradicate undetected cancer cells.  Occasionally a patient is offered surgery after 
radiotherapy and chemotherapy treatment.  This may be because the tumour is 
very large and would be resectable if the patient responds well to chemo- or 
radiotherapy.  However, sometimes if the tumour is not controlled by chemo- or 
radiotherapy a patient may be offered „salvage surgery‟.  This refers to unplanned 
surgery, but it is associated with poorer prognosis[50].  The side effects are fatigue 
and soreness of skin around the treated area, throat and mouth, dry mouth, dental 
complications and halitosis, loss of taste and appetite, tiredness and jaw stiffness 
and possibly hair loss and nausea. 
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It is notable that thyroid cancers are treated by thyroidectomy even before 
confirming the diagnosis and removal of the thyroid gland affects endocrine 
function, resulting in additional complications.  For these reasons, thyroid cancer is 
considered to differ from other HN cancers and is not included in this thesis. 
1.1.2.3 Prognosis 
1.1.2.3.1 Mortality 
 
The 2 year all cause survival rate for oral cavity malignancies is estimated at 
62%[32] and 5 year relative survival for all HN malignancies is estimated at 
52.5%[51]. 
1.1.2.3.2 Quality of life 
 
As well as having to deal with a life threatening illness, a person with HN cancer 
may suffer impairments of speech, eating, aesthetics, pain and social function.  
Surgery to the mouth may cause numbness, poorer opening and/or loss of teeth.  If 
the patient undergoes a neck dissection then the extent of the dissection will 
further affect their QoL due to neck and shoulder pain and restricted range of 
movement[52].  Patients undergoing a laryngectomy must learn other ways to 
communicate.  Of particular relevance to HN patients (compared to CR patients) is 
the likelihood of potentially obvious and difficult to conceal disfigurement (figure 
1.3)[53, 54].  However, whilst some patients do experience great disfigurement, the 
majority of patients do not.  Also, although some studies have found a relationship 
between greater disfigurement and increased distress[55], others have failed to find 
an association between level of disfigurement (both patient perceived and surgeon 
rated) and QoL[54].  One study found an association, but only in those with low 
social self-efficacy[53], suggesting the relationship is dependent on other factors.  It 
has also been suggested that a lack of an association between distress and 
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disfigurement is because the disfigurement is seen as an inevitable trade off 
between life and death[54]. 
 
 
Figure 1.3: Head and neck cancer patient.  Picture 
provided by The Facial Surgery Research Foundation. 
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1.1.3 Comparing head and neck, and colorectal cancer 
 
 HN cancer CR cancer 
Prevalence 
 
 
Almost 5,000 new cases 
each year in the UK 
Over 35,000 new cases 
each year in the UK 
Risks 
 
 
Smoking and alcohol 
substantial risk factors 
Risk factors still 
inconclusive 
Treatment 
 
 
 
 
 
Varied.  Ranges from simple 
operation to complicated 
operation and chemotherapy 
and/or radiotherapy 
Usually resection, 
sometimes adjuvant 
chemotherapy is offered 
and/or radiotherapy for 
rectal cancer patients 
Mortality 
 
5 year survival 56% 5 year survival 46% 
Possible 
functional 
limitations 
Speech (10%), difficulty 
eating/drinking (swallowing 
15%, chewing 18%), 
restricted mouth 
opening/movement, dry 
mouth, loss of taste, pain 
(34%), disfigurement (32%)* 
Permanent colostomy, 
diarrhoea (14-49%), 
constipation (7%), 
incontinence (39%) 
bloating, pain. 
Table 1.2: Comparing HN, and CR cancer. * percentages given are proportion of patients reported 
to have moderate or severe problems as reported in a group of 68 HN patients and a review of CR 
symptoms
[56, 57]
. 
 
1.2 Depression 
1.2.1 Defining and assessing depression 
 
It is important to define depression and to clarify the difference between depressive 
symptoms and DDs and how both are assessed and measured. 
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1.2.1.1 Depressive symptoms 
 
Depressive symptoms are common, transient and experienced by most people at 
some point in their lifetime, especially in response to a stressor.  Depressive 
symptoms are usually assessed with the use of a questionnaire such as the 
Hospital Anxiety and Depression Scale (HADS) or Centre for Epidemiological 
Studies Depression Scale (CES-D).  These questionnaires are very useful in that 
they give an indication of how many symptoms are present at the time of 
completing the questionnaire.  The questionnaires are brief and provide a useful 
screening tool for depression in clinical settings by drawing attention to patients 
who may be suffering from a DD.  For instance, if a patient scored from 7-10 (out of 
14) on the HADS depression subscale then they have a sufficient number of 
depressive symptoms to be considered as a possible case of depression, and a 
score of 11 or above is considered to be a likely case of depression[58].  In both 
cases the patient should be followed up and referred to psychological or psychiatric 
services if necessary.  However, the questionnaires alone do not provide a 
diagnosis of a major DD. 
1.2.1.2 Depressive disorders 
 
A DD, such as major depression (MD), is a syndromal condition that is 
characterized by recurrent episodes of depressed mood and disturbed 
neurovegetative and cognitive functioning for a period of at least two weeks (see 
table 1.3) resulting in functional impairment.  Major depression is generally 
reported to have a 12 month incidence of about 10%[59].  A DE has a point 
prevalence of 2.8% and mixed anxiety and DD has a point prevalence of 8.8% in 
adults living in private households in the UK[60].  Sufferers are more likely to be 
female with average age of onset between 20-30 years old[60]. 
 
Major depression often results in recurrent episodes of depression over the lifetime 
and once a person has experienced one DE they are much more likely to 
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experience another episode in the future.  A structured clinical interview provides 
information on whether a minimum number of symptoms are present for a given 
duration above the threshold for a DE defined by a recognised categorical 
classification system (DSM-IV or ICD-10).  Structured clinical interviews using DSM 
or ICD criteria should be conducted by a trained and standardised interviewer who 
can thus provide a robust assessment of a DD.  Depressive disorders have a 
multifactorial aetiology involving both genetic and environmental components and 
occur in individuals who have an increased vulnerability to the effects of 
environmental stressors, often accompanied by dysregulation and hyper-reactivity 
of the stress hormone axis[61].  Episodes of MD in these individuals are often 
triggered by a stressful life event[62]. 
1.2.2 Aetiology of depression 
 
There are psychosocial and biological theories of aetiology of depression.  A full 
review is beyond the scope of this chapter, therefore it will focus on the biological 
and stress related aspects of depression that are particularly relevant to this study.  
However, it is important to note that genetic and psychosocial components are 
involved.   
 
The current widely accepted view is that environmental stressors increase the risk 
of a DD in those who are vulnerable through genetic predisposition[62, 63] and most 
episodes of depression are precipitated by a stressful life event. Those with history 
of childhood trauma (CT) are more vulnerable[62]. 
 
A variety of twin and genome linkage studies have demonstrated that depression 
has a strong genetic component and certain genes e.g. the serotonin transporter 
linked promoter region (5-HTTLPR) have been shown to interact with 
environmental factors in the development of a DD[63-65].  There is also a genetic 
component to certain personality traits, particularly neuroticism (NE), which is a 
strong predictor of MD following a major stressor[62].
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ICD-10 DSM-IV 
Lowering of mood, reduction of energy, and 
decrease in activity. 
 
The lowered mood varies little from day to 
day and is unresponsive to circumstances. 
 
Capacity for enjoyment, interest, and 
concentration is reduced, and marked 
tiredness after even minimum effort is 
common. 
 
Disturbed sleep. 
 
Self-esteem and self-confidence are almost 
always reduced and, even in the mild form, 
some ideas of guilt or worthlessness are 
often present. 
 
 
May be accompanied by: 
Early waking in the morning; several hours 
before the usual time. 
Depression worst in the morning. 
Marked psychomotor retardation. 
Agitation. 
Loss of appetite, weight loss. 
Loss of libido. 
 
Depending upon the number and severity of 
the symptoms, a DE may be specified as 
mild, moderate or severe. 
Five (or more) of the following symptoms 
have been present during the same 2-
week period and represent a change 
from previous functioning; at least one of 
the symptoms is either (1) depressed 
mood or (2) loss of interest or pleasure.  
 
(1) depressed mood most of the day, 
nearly every day. 
 
(2) markedly diminished interest or 
pleasure in all, or almost all, activities 
most of the day, nearly every day. 
 
(3) significant weight loss when not 
dieting or weight gain, or decrease or 
increase in appetite nearly every day. 
 
(4) insomnia or hypersomnia nearly 
every day 
 
(5) psychomotor agitation or retardation 
nearly every day (observable by others, 
not merely subjective feelings of 
restlessness or being slowed down) 
 
(6) fatigue or loss of energy nearly every 
day 
 
(7) feelings of worthlessness or 
excessive or inappropriate guilt (which 
may be delusional) nearly every day 
 
(8) diminished ability to think or 
concentrate, or indecisiveness, nearly 
every day 
 
(9) recurrent thoughts of death, recurrent 
suicidal ideation, plan or attempt. 
Table 1.3: ICD and DSM-IV criteria for major DE. 
 
There are many psychosocial aspects that are associated with depression; most 
notably MD patients are more likely to have lower social economic status[66], 
smoke[67], consume more alcohol[68], exercise less and are more likely to be 
obese[69].  Also, people suffering from MD are more likely to suffer from certain 
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physical illnesses such as coronary heart disease[70] and express fewer satisfactory 
forms of social support[71].  In some cases the lifestyle choices may be partly 
responsible for the increase in comorbidities, but the level of cause and effect has 
yet to be elucidated[70].  There is also evidence towards increased mortality in MD 
patients independent of the risk of suicide[72]. 
1.2.3 Psychological risk factors 
 
Early life stress (ELS) is considered to be a major risk factor for the development of 
depression; Widom et al. (2007)[73] reported an odds ratio of 1.51 of current adult 
MD in adults who suffered from childhood abuse and/or neglect compared to 
controls.  Early life stress includes physical, emotional and sexual abuse, as well 
as unstable families, poor parental care or dysfunctional relationships between the 
carer and child, as well as poverty and/or parental loss through death or 
separation[74]. 
 
Stressful life events (LE) also play a major role in the occurrence of a DD.  
Stressful life events are any events that result in considerable life change.  Life 
events can be positive or negative (e.g. loss of job, death of a loved one, moving 
house or marriage) but negative stressful LE are stronger predictors of mental 
health outcome[75].  Some studies have shown that life stressors account for more 
of the variance (39%) in predicting depression than any other factor[76].  However, it 
is worth noting that one third of this variance is non-causal stress: for example, 
individuals at high risk of depression tend to select high stress environments and 
depression can cause stressful events (e.g. loss of job)[77].  In addition, as the 
number of DEs increases, future episodes are more likely to occur spontaneously 
or be preceded by a less pronounced stressor[75]. 
 
Many other psychological issues play a major role in depression, for instance how 
a person copes with stress, thought patterns and aspects of personality, such as 
NE.  The background of these aspects is discussed further in chapter 7. 
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1.2.4 Physiological mechanisms 
 
There is also robust neurophysiological evidence for the role of stress in 
depression, particularly findings reporting abnormalities in the stress hormone axis 
and inflammatory pathways in those with depression and those at increased risk of 
depression, e.g. highly neurotic individuals or those who suffered from ELS. 
 
1.2.4.1 The Hypothalamic-pituitary-adrenal axis 
 
One of the main components of the physiological stress response is the 
hypothalamic-pituitary-adrenal axis (HPAA) which, together with the autonomic 
nervous system enables the body to respond to stressors and to maintain 
homeostasis.  The hypothalamus releases corticotrophin releasing hormone (CRH) 
in response to stress which causes the pituitary to release adrenocorticotrophic 
hormone (ACTH).  ACTH controls the release of glucocorticoids from the adrenal 
glands (cortisol in humans and corticosterone in rodents), which stimulate the body 
ready for a fight or flight response.  Cortisol also acts as its own negative feedback, 
such that circulating cortisol inhibits further release of ACTH from the pituitary and 
(independently) inhibits the release of CRH from the hypothalamus (see figure 1.4).  
In healthy individuals cortisol secretion shows a circadian rhythm with a night time 
nadir then a morning rise within the first half an hour after waking up, followed by a 
gradual decline throughout the day[78]. 
 
Dysregulation and hyperactivity of the HPAA is a robust finding in 50% of patients 
suffering from a DD[79, 80].  Many patients suffering from a DD show an increase in 
the daily mean cortisol expression, an increased morning rise[81] and increased 
evening activation[82].  This evidence is supported by animal studies using animals 
with mutated glucocorticoid receptors who show similar HPAA dysregulation and 
exhibit increased depressive-like behaviours in response to stress, compared to 
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wild type mice[83].  More details on the relationship between cortisol and depression 
are provided in chapter 8. 
 
Figure 1.4: The Hypothalamic-pituitary-adrenal axis. 
 
1.2.4.2 Inflammatory Cytokines 
 
Cytokines are small messenger molecules which form part of the immune 
response.  There are over 100 types of cytokines, with multiple and shared 
functions, but broadly speaking they can be divided into two categories: pro-
inflammatory and anti-inflammatory.  There is a growing literature on an 
association between increased cytokines in depression, first proposed by Maes in 
1995[84].  Although there is a lot of evidence to support this hypothesis, there 
remains a great deal of inconsistency in the literature, most likely due to the variety 
of cytokines and the types of depression being investigated.  Basal cytokine levels 
follow a circadian rhythm, so it is important to consider the time of day[85].  Also, 
cytokines function through autocrine and paracrine communication and have 
multiple and shared functions.  Many cytokines stimulate the production of 
themselves and others[86] and as cells are rarely, if ever, exposed to just one 
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cytokine it is often easier to view them as components of a message.  The 
strongest evidence suggests a link between four inflammatory cytokines and 
depression.  These are: interleukin-6 (IL6), interleukin-1 beta (IL1ß), tumour 
necrosis factor alpha (TNFα) and interferon gamma (IFNγ).  There is also some 
evidence of an association between C-reactive protein (CRP) and depression[87].  
CRP is a non-specific acute phase protein the production of which is stimulated by 
IL6[88].  CRP is often monitored as part of routine hospital blood tests so could be a 
quick and easy biomarker. 
 
Evidence of the effects of cytokines on mood has been found through three types 
of studies: cytokine therapy studies, differences in levels of inflammation in 
depressed and non-depressed individuals, and neurobiological in vivo and in vitro 
studies investigating potential mechanisms by which cytokines may induce a 
change in mood.  Although increased cytokines are still not considered suitable for 
use as a biomarker for depression in the general population[89], two meta-analyses 
have concluded that there is a significant increase in inflammation in depressed 
patients[87, 90].  There is also evidence towards the effects of cytokines on mood 
through cytokine therapy studies[91, 92] and neurobiological in vivo and in vitro 
studies investigating potential mechanisms by which cytokines may induce a 
change in mood (e.g. Harrison et al., 2009[93] or see Dantzer et al., 2008[31]).  Also, 
like cortisol, cytokine levels increase in response to psychological and physical 
stress[94, 95].  More detail regarding specific cytokines is provided in chapter 8. 
1.2.4.3 Cytokines, stress and the HPAA 
 
Several theories have been proposed for the mechanisms underlying the 
association of cytokines with depression.  For instance, studies have shown 
dysregulation of the neurotransmitters serotonin and noradrenaline in patients with 
depression when compared to controls[96].  Increased levels of cytokines are 
associated with increases in noradenaline[96] and decreased levels of the serotonin 
precursor tryptophan, which is required for the synthesis of serotonin[97, 98].  Whilst 
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all possible mechanisms are likely to play some role in cytokine induced 
depression, the most compelling evidence supports a connection between 
cytokines and the HPAA.  Although, initially, research focused on the well founded 
suppressive effects of the HPA on the immune system, later studies demonstrated 
a bidirectional relationship: cytokines enhance glucocorticoid release and 
glucocorticoids inhibit cytokine production[99] (see figure 1.5). 
 
Figure 1.5: Cytokines and the HPAA, adapted from Evans et al. (2005)
[100]
. 
 
Like the HPA response, cytokine levels increase in response to psychosocial and 
physical stress both soon after the stressful event and up to 6 months later[99, 101, 
102].  It is now well accepted that cytokines activate the HPAA pathway during 
physical stress and recent evidence suggests that cytokine regulation of the HPAA 
also occurs in response to psychological stress[99].  In vivo studies demonstrated 
increases in ACTH and corticosterone in rats after intravenous injections of IL1, 
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IL6, TNFα and IFNγ.  Zhou et al. (1993)[94] also found that an adrenalectomy 
further increased the post stress IL6 increase usually seen in rats.  These findings 
have also been supported by in vivo work by Pariante and colleagues (1998)[103].   
Similarly, in humans intravenous injections of IL6 result in increased ACTH levels 
one hour after infusion and raised cortisol levels after two hours.  Following 
participants over a longer period of time Mastorakos and colleagues (2006)[104] 
found that administering IL6 led to increased levels of ACTH and cortisol for seven 
days, followed by a blunted response.  Comparable short term effects have been 
achieved using much lower doses of these cytokines when infusing 
intracerebroventricularly, suggesting much of the activation occurs directly in the 
central nervous system (CNS), supported by the presence of cytokine receptors in 
the CNS[80].  However, this seemingly refreshingly straight forward story has now 
been superseded by a more complicated picture suggested by several studies, 
which will be further elaborated in chapter 9.  For instance, labelling techniques 
suggest that very little of intravenously infused cytokines actually pass through the 
blood brain barrier, and the intravenous infusions contained high doses of 
cytokines which suggests that only high doses of cytokines or prolonged lower 
doses are likely to have a pronounced effect on the HPA though this 
mechanism[99]. 
1.2.5 Relationship between psychological and physiological factors 
 
Repeated stress and especially ELS are associated with alterations in the central 
neurobiological system which leads to dysregulation of the HPAA[82].  Early life 
stress does not always lead to depression and not all MD patients have suffered 
ELS, with many other factors influencing the development of depression.  
Nevertheless, many of the neurobiological effects of ELS resemble those in MD.  
Those who experienced ELS also show increased cortisol secretion compared to 
controls[74]. This evidence is supported by similar findings in animal models[105].  
Accordingly, retrospective studies by Heim‟s group (2000)[106] investigating HPAA 
function in women who were abused in childhood have found greater plasma 
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ACTH and cortisol responses to laboratory induced acute social stress.  However, 
it is worth noting that more participants in the ELS and MD group in Heim and 
colleagues‟ study had comorbid post traumatic stress disorder (PTSD) than those 
in the MD group.  Past work has shown that anxiety and PTSD are also associated 
with abnormalities in the HPAA[107] and PTSD is also associated with an increased 
cortisol response to laboratory induced stress[108]. 
 
Exposure to stress is far from the only influence on a person‟s response to a 
stressor.  As one might expect, there is a genetic component to the HPAA 
response.  A twin study showed significant heritability estimates for the mean 
increase of cortisol and the cortisol awakening response[109] and single genes have 
been shown to affect the cortisol response to an acute stressor[110].  Also a 
person‟s response to a stressor will depend on the type of stress as this will affect 
their perception and appraisal of the stressor and method of coping[111].  
Furthermore, stress reactivity is greatly affected by other recent or current 
psychosocial or physical stressors and the level of available support[62, 112].  Finally, 
HPAA abnormalities have also been found in people showing high levels of NE[113-
115]. 
 
Cytokine levels are also related to other psychosocial risk factors for depression.  
People with ELS show increased levels of IL6[116] in adulthood as well as an 
increased cytokine response to infection[117] or social stress[116].  Neuroticism has 
been shown to be directly associated with IL6 levels in elderly subjects[118], where 
NE accounted for a large part of the variance in IL6 levels originally attributed to 
depressive symptoms.  Also, coping with the stress of a cancer diagnosis by 
seeking instrumental social support (e.g. help with shopping or travel to 
appointments) has been associated with lower levels of cytokines compared to not 
seeking instrumental social support[119], as have high levels of social 
attachment[120]. 
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In summary, the likelihood of a person developing depression depends on their 
genetic predisposition interacting with a combination of early life and ongoing 
stress.  There is also a strong relationship between vulnerability to depression and 
dysregulation of the HPAA and increased inflammatory mediator levels. 
1.3 Cancer and depression 
 
Most people assume that many cancer patients are depressed, probably due to the 
difficulties that they face, but this view does not take into account the difference 
between a normal reaction to a life event and a depressive illness; nor the 
complicated aetiology of depression, the variety of individual responses to being 
diagnosed with a major illness and the range of cancer treatments and prognoses.  
This assumption is also largely unsupported by the evidence from the literature 
and, as is often the case, there is at least one methodological issue which 
complicates the picture. 
 
Many symptoms of depression overlap with symptoms associated with cancer and 
sickness behaviour such as fatigue, sleep and appetite problems (see table 1.1).  
This makes assessing depression in cancer patients more difficult.  The problem is 
avoided in questionnaires and interviews by focusing on mood and cognitions as 
opposed to somatic symptoms.  However, it still needs to be taken into 
consideration as some questionnaires use more somatic measures than others, 
which may result in a bias towards high depressive symptoms in cancer patients. 
 
There is also a possibility that people with a past history (PH) of depression are 
more at risk for cancer because people with depression are more likely to make 
unhealthy life style choices (see table 1.4).  Past research does not support the 
thesis that depression independently increases the risk of cancer when these 
factors are taken into account. But there is not enough research on whether the life 
style factors in depression specifically increase the risk for either CR or HN cancer.  
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This would therefore select for a population at increased risk of depression after a 
cancer diagnosis[121]. 
 
Depression HN cancer CR cancer 
Increased alcohol 
consumption 
Smoking 
Obesity 
Increased alcohol 
consumption 
Smoking 
Increased alcohol 
consumption 
Obesity 
Table 1.4: Lifestyle factors associated with depression and HN, and CR cancer. 
 
1.4 Prevalence of depression in cancer patients 
 
A diagnosis of HN or CR cancer constitutes a major stressor.  Most cancer patients 
experience transient levels of distress but comparatively few develop MD.  Studies 
show that depressive symptoms tend to peak at about three months after diagnosis 
before returning to pre-cancer levels[122].  Some studies report that depressive 
symptoms vary according to the site and stage of the cancer, although stage often 
fails to reach significance[123, 124].  More recently, investigators are suggesting that 
rates of depression in ambulatory cancer patients are no higher than those of 
patients in primary care[125]. 
1.4.1 Colorectal cancer 
1.4.1.1 Depressive symptoms 
 
Thirteen studies have used validated questionnaires to measure high levels of 
depressive symptoms in CR cancer patients (see appendix 1. 1).  These studies 
reported prevalences ranging from 5-37% with an average of about 15%.  Two 
papers that also included a control group found similar levels of depressive 
symptoms in CR cancer patients to that of the general population[126, 127]. 
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1.4.1.2 Depressive disorder 
 
Only one study investigated DDs using a structured interview[128] and reported that 
of 98 pre-treatment patients, no patients were suffering from MD.  Ashbury et 
al.[129] (2003) reported the number of patients prescribed anti-depressants in a 
sample of 299 American colon cancer patients.  They found 11% of the patients 
were taking anti-depressants, but point out that anti-depressants may also be 
prescribed as pain relief and pain medication was associated with anti-depressant 
use. 
1.4.2 Head and neck cancer 
1.4.2.1 Depressive symptoms 
 
Comparatively more studies have been carried out on the prevalence of depressive 
symptoms in HN cancer patients, compared to CR cancer patients.  Twenty-eight  
studies have used validated questionnaires to measure high levels of depressive 
symptoms in HN cancer patients[121].  These studies found a prevalence ranging 
from 0.05% to 48% depending on the cancer and timing of the assessment, most 
reporting levels of 28%.  However, Hammerlid and Taft[4] (2001) found no 
difference in mental health or emotional functioning scores in HN cancer patients 
compared to the general population by three years after diagnosis. 
1.4.2.2 Depressive disorder 
 
Despite a large body of literature on depression in HN cancer, only four studies 
used a structured clinical interview to measure prevalence of a DD[130-133].  Again, 
the prevalences found in these studies vary a lot.  Kugaya‟s group found a 
prevalence of 3.7% and Katz and colleagues found a prevalence of 5% for MD and 
15% for minor depression, both of which correspond to the prevalence of 
depression in the general population of the respective countries[134, 135].  
Nevertheless, Morton‟s group[132] (1984) reported a prevalence of 40% in an earlier 
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study using DSM III criteria in a small sample of 48 elderly men.  However 35% of 
these patients were undergoing salvage surgery, which as indicated in the 
treatment section 1.1.2.2 is indicative of poor response to treatment.  Also, a more 
recent study found a prevalence of 27% in 23 pre-treatment cancer patients.  
However this was a small study in patients with advanced cancer, a large 
proportion of whom appeared to have a PH of a psychiatric disorder[133]. 
1.4.3 Conclusions 
 
A large proportion of HN, and some CR cancer patients appear to suffer from high 
levels of depressive symptoms, with higher levels reported in HN cancer patients.  
However, despite high levels of depressive symptoms, the prevalence of DDs is 
lower and close to that of the general population.  Unfortunately, there are not 
enough studies on the prevalence of MD in CR cancer to be able to compare this 
to the prevalence of MD in HN cancer. 
1.5 Consequences of developing comorbid depression and 
cancer 
 
There are physiological and prognostic consequences of depression in cancer 
patients.  Increased cytokine levels may affect the tumour and depression is 
associated with poorer treatment outcome.  One of the aims of this thesis is to 
investigate possible relationships between the physiological and prognostic factors. 
1.5.1 Cytokines and cancer 
 
Cytokine levels are increased in cancer patients; some tumour cells express 
cytokines[136] and cancer treatment increases inflammation[137].  Furthermore, the 
majority of studies that investigated the levels of cytokines in depression and 
cancer have found a significant difference in IL6 levels in patients with a DD and 
cancer compared to those with a DD or cancer only, or healthy controls[138-140] and 
Allen-Mersh and colleagues[141] (1998) found a significant correlation between IL-
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2receptor antagonist levels, but not IL6, and HADS scores.  However, Kudoh et 
al.[137] (2001) found no difference in IL6 levels in pre operative cancer patients with 
a DD compared to those without a DD.  They also found that the IL6 and IL8 
response to surgical trauma was lower in depressed patients compared to controls.  
Interestingly, all of the studies that found a relationship between depression and 
IL6 levels studied patients free of psychotropic medication, whereas those that 
found no difference failed to mention the patients‟ treatment status. 
 
The full story of the relationship between inflammation and cancer is still under 
investigation.  At present inflammation is often seen as a double edged sword; as 
although in one sense cytokines activate the immune system, some cytokines are 
also thought to be involved in tumour progression.  It is now accepted that a large 
part of the tumour micro environment is inflammatory and that cytokines play a 
major role in tumour progression, but the exact mechanisms and the complex 
relationships between different cytokines and different tumour cell lines remain 
largely unresolved[145].  The findings of increased cytokine levels in depressed 
cancer patients have significant clinical implications, as these patients are not only 
going to suffer from more of the symptoms of sickness behaviour but some studies 
have shown IL6 levels to be an independent predictor of cancer survival[142, 143].  A 
more structured tale of the inflammatory aspect to malignancy is provided in 
chapter 8. 
1.5.2 Quality of life 
 
First and foremost, comorbid depression undoubtedly has a negative impact on 
patients‟ QoL[146].  Depression itself is a distressing and debilitating condition, 
which when dealing with cancer at the same time, is likely to exacerbate the trials 
that cancer patients must endure.  Also, depressed patients are less likely to have 
access to social support which has been shown to help patients cope with a 
stressor such as a diagnosis of cancer[147].  There is also evidence towards an 
effect of depression on symptom reporting[148].  Koller‟s group[148] (1996) reported 
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that patients‟ report of symptoms was more strongly associated with their 
emotional status at that time compared to that of clinician rated estimates of the 
QoL based on their physical function. 
1.5.3 Mortality 
 
Cancer patients with comorbid depression are already at risk of increased mortality 
due to the association between depression, poorer overall health and increased all 
cause mortality.  Moreover, depression leads to a number of complications.  A 
meta-analysis found depressed patients show poorer compliance to treatment[149] 
and poorer adherence to programmes designed to help cut down tobacco use[150].  
Also, cancer patients with depression show higher levels of inflammation, which is 
associated with increased mortality.  Taken together, this implies that patients with 
comorbid depression and cancer may have a higher mortality.  Nevertheless, it is 
unclear whether depression itself increases the risk of cancer mortality, or if 
depression is a result of poorer prognosis, especially when controlling for all of the 
other confounding factors. 
Chapter 1: Literature review 
53 
 
Figure 1.6: Cytokines, HPA, cancer and depression. 
 
1.5.4 Clinical implications 
 
Despite its negative consequences depression continues to be under treated and 
under diagnosed in cancer patients.  Fallowfield and colleagues[6] (2001) reported 
that less than 30% of patients showing high levels depressive symptoms indicative 
of a DD were rated as depressed by the clinicians.  Keller and colleagues[7] (2004) 
report higher rates of detection of a DD when compared to DSM-IV diagnosis, but 
they also report poor specificity - over 50% of those without a disorder were also 
thought to be depressed by the clinicians.  Moreover, only 40% of the patients 
suffering from a DD were referred to psychological liaison services, despite 
evidence that comorbid depression and cancer is treatable[151].  Depressive 
symptom questionnaires can be used to screen for a DD, for instance using a total 
score of 15 or over on the HADS as indicative of a DD picked up 72% of patients 
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with a current DD.  However reliance on the HADS would mean that clinicians 
would still miss 28% of patients with a DD and with only 81% specificity almost one 
in five of DD case level patients according to the HADS score would not have a 
DD.  Given these findings the benefits of using screening instruments as the 
primary method of identifying patients with depression may not outweigh the costs.  
This is especially true in busy resource limited cancer clinics.  Thus it is perhaps 
not surprising that screening has not been widely adopted in clinics throughout the 
UK[125].  One of the aims of this thesis is to explore what factors might increase the 
risk of developing a DD, including risk factors applicable to general population as 
well as unique to cancer patients.  This is so future patients who are at an 
increased risk of developing depression can be monitored and provided support to 
help improve treatment outcome. 
1.5.4.1 Studies investigating mortality in cancer patients with comorbid 
depression 
 
There are no studies that have investigated the impact of depression on cancer 
mortality in HN, or CR cancer specifically.  However there is a reasonably large 
literature including many other different cancer types.  Most studies look at all 
cause mortality. Four studies used diagnostic criteria to investigate the effect of 
comorbid depression on cancer mortality[152-155].  Two of these studies found a 
significant effect of a DD on cancer mortality[152, 155], but only one of these included 
cancer variables and neither adjusted for smoking or alcohol consumption.  Fifteen 
studies investigated the impact of depressive symptoms on mortality[121] of which 
nine showed a significant impact on mortality, but again only one of these studies 
adjusted for cancer stage or smoking.  Studies that investigated single measures of 
depressive symptoms usually found no effect.  All of the studies investigating a PH 
of depression found an increased risk of cancer mortality[152, 153, 155, 156].  No studies 
found a decreased risk of cancer mortality in patients with comorbid depression. 
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It is difficult to interpret the results of these studies due to the multiple confounding 
factors and the extent of variation in different cancers and depression 
assessments.  These results, if purely based on numbers, are, as Evans et al[100] 
(2005) state, “intriguing, but by no means definite” (pp179).  There appears to be a 
trend towards increased mortality in people with a syndromal DD, but few of these 
studies adjusted for important confounders, which would undoubtedly affect the 
findings.  Also, no studies have investigated just CR or HN cancer, probably due to 
the numbers that would be required for such an investigation. 
1.6 Conclusions 
 
1. Past investigations suggest that although many patients suffer from 
depressive symptoms (which could be transient) following a diagnosis of 
cancer, prevalence of MD is closer to that of the general population.  
2. Depressive disorders are associated with ELS, ongoing stress, 
dysregulated stress hormone response and increased inflammation. 
3. Inflammation plays a role in the proliferation and invasiveness of 
malignant tumours.  Although the exact role depends on the tumour and 
cytokine, often cytokines aid tumour progression and proliferation. 
4. There is evidence that cancer patients who have comorbid depression 
are less compliant with treatments and have higher cytokine levels 
5. Comorbid depression and cancer lead to poorer QoL, and possibly 
increased mortality. 
 
There is a lot of research on prevalence of depressive symptoms in cancer 
patients, but much less on prevalence of DDs.  Also, a lot of studies have 
documented the detrimental impact of comorbid depressive symptoms on QoL in 
cancer patients, but relatively few have studied the biological impact of depression 
in cancer patients.  Also, those investigating mortality often fail to adjust for key 
covariates. 
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There are very few studies using long term assessments and validated diagnostic 
measures and no prospective studies that also look at possible mechanisms by 
which cancer and mood may influence each other. 
Despite a varied literature on the associations and individual aspects of 
inflammation in depression and cancer, it is still not clear whether 
i) The increased inflammation in patients with comorbid depression results in 
increased risk of mortality due to the poorer prognosis associated with increased 
cytokine levels 
ii) Poorer prognosis and associated inflammation lead to depression (see figure 
1.7). 
Or iii) Both of the above. 
 
 
 
Figure 1.7: Cancer, depression and inflammation. 
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1.6.1 Aims and Hypotheses 
 
The main aims of this study are to: 
1. Measure the prevalence of DDs in two different cancer clinic 
populations. 
2. Test the hypotheses that: 
(i) Patients with a PH of depression are more likely to 
experience a DE following a cancer diagnosis. 
(ii) Depressive symptoms have a significant negative effect 
on QoL. 
(iii) Patients with higher cytokine levels show more 
depressive symptoms. 
(iv) Patients with increased HPAA activity (increased salivary 
cortisol levels) show increased depressive symptoms. 
(v) Patients with increased HPAA activity show increased 
inflammation (increased cytokine and CRP levels). 
 
As well as the main hypotheses this study explores associations between other 
possible explanatory factors on depressive symptomatology, inflammation and 
cortisol dysregulation such as coping styles, personality and patient rated cancer 
related symptoms. 
 
This thesis investigates some of the major factors in an exploratory manner, as no 
power calculations are possible.  It is acknowledged that some factors, such as 
genetics, are not considered; including such variables would be beyond the scope 
of this study even for exploratory purposes.  The thesis focuses on psychosocial 
variables which are associated with stress responses and vulnerability to 
depression.  A conceptual model of hypotheses is shown below (figure 1.8) which 
is based on previous research described in this chapter.  Specific hypotheses and 
relevant studies are presented in each results chapter. 
Chapter 1: Literature review 
58 
 
Figure 1.8: Schematic representation of vulnerability for depression after cancer diagnosis. 
 
This work should inform future, larger studies looking at depression and 
inflammation in cancer patients. 
1.6.2 Introduction to design and methods 
 
Two studies were conducted in order to address the aims of this thesis: 
 
The first is a cross sectional study based on all patients attending the HN or CR 
clinics at St Bartholomew‟s and The Royal London hospitals for a period of six 
months.  This study investigates depressive symptoms and QoL in HN and CR 
cancer patients.  The major strength of this study is a larger sample size to address 
the first aim of the thesis. 
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The second study is a longitudinal investigation on two groups of newly diagnosed 
patients with HN and CR cancer respectively, who presented to the clinics at St 
Bartholomew‟s and The Royal London hospitals between March 2007 and March 
2009 and were followed for six months.  This study aims to investigate prognostic 
markers for depression in cancer patients to test the main hypotheses. 
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2 General Methods 
 
The thesis uses data from two main studies: a prevalence and a prospective study 
each based at both St Bartholomew‟s Hospital and The Royal London hospital.  
This general methods section details the clinics, evaluations and analyses that 
were used in both studies.  Methods specific to each study are explained in the 
relevant sections: chapter 3 for the cross sectional study and chapter 5 for the 
prospective study.  Both studies were conducted recruiting patients from the same 
clinics and used the same mood and QoL questionnaires, diagnostic psychiatric 
interview and regression analysis methods. 
Chapter 2: General methods 
61 
2.1 Clinics 
 
The CR patients were recruited from the CR clinic on Thursday mornings at The 
Royal London Hospital.  The majority of clinicians are general surgeons and CR 
specialists and stoma nurses. 
 
The HN cancer patients were recruited from the HN clinic on Wednesday 
afternoons at St Bartholomew‟s Hospital.  The HN clinic is run as a multidisciplinary 
clinic consisting of maxillofacial surgeons, Ear Nose and Throat surgeons, speech 
therapists, dieticians, oncologists and cancer nurse specialists. 
2.2 Evaluations 
2.2.1 Hospital anxiety and depression scale 
 
The Hospital and Anxiety Depression Scale (HADS) is a well validated 
questionnaire designed to assess depressive and anxiety symptoms in hospital 
patients, therefore the questions relate to non somatic symptoms of depression or 
anxiety (see appendix 2. 1 for the full questionnaire).  The HADS comprises of 14 
questions; Spindhoven[157] (1997) report a two factor structure to the HADS with 
seven questions indicating level of depressive symptoms and seven indicating 
level of anxiety.  Each question has four possible answers rated from zero to three, 
so that patients‟ answers can range from 0-21 for each subscale of the 
questionnaire.  Reports suggest that scores of 8-10 on either scale are indicative of 
a possible anxiety/depressive disorder and scores of greater than 11 suggest a 
probable anxiety/depressive disorder[58].  Past studies report good performance 
when used in cancer patient samples, in those with stable disease and free from 
disease[158].  The HADS is also reported to have high reliability with Cronbach‟s 
alpha 0.81 and 0.86 for the anxiety (HADS-A) and depression (HADS-D) subscales 
(respectively)[159]. 
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2.2.2 European Organisation for Research and Treatment of Cancer 
 
The European Organisation for Research and Treatment for Cancer Quality of Life 
Questionnaire (EORTC-QLQ)[160] is an integrated system for assessing health 
related QoL in cancer patients.  The core questionnaire has five functional scales, 
nine symptoms scales and one global QoL measure and is the product of over 10 
years of collaborative research (see appendix 2. 2). 
 
The function scales are (number of items): 
 Physical function (5) 
 Cognitive function (2) 
 Role (2) 
 Social function (2) 
 Emotional function (4) 
The symptom scales are: 
 Fatigue (3) 
 Pain (2) 
 Nausea and vomiting (2) 
 Dyspnoea (1) 
 Insomnia (1) 
 Appetite Loss (1) 
 Constipation (1) 
 Diarrhoea (1) 
 Financial difficulties (1) 
Past reports suggest good reliability coefficients ranging from .52 to .89 during 
treatment[160]. 
 
For the purposes of this study, the functional scales in this section of the EORTC-
QLQ were excluded, as theoretically they could be treated as an outcome as well 
as a symptom, given that any functional impairment is likely to be related to 
symptoms and a function related to global QoL.  Other studies have used these 
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measures as outcomes[161] and the functional scales are all reported to have high 
colinearity with the global QoL measure[162].  Thus, in order to prevent multiple 
testing for the QoL outcome only the global QoL scale was used in this thesis.  The 
limitations to this method are reported in the final discussion. 
 
The EORTC-QLQ cancer specific modules were also used: CR29 for CR cancer 
patients and H&N35 for HN cancer patients (see appendix 2. 3 and appendix 2. 
4for the CR29 and H&N35 respectively). 
 
The CR29 is still in the final stages of development and currently comprises four 
functional scales and 13 symptom scales. 
The functional scales are (number of items): 
 Anxiety (2) 
 Body image (3) 
 Sexual function (men) (1) 
 Sexual function (women) (1) 
The symptom scales are: 
 Micturition problems (3) 
 Defaecation problems (4) 
 Abdominal or pelvic pain (3) 
 Faecal incontinence (2) 
 Bloating (1) 
 Dry mouth (1) 
 Hair loss (1) 
 Trouble with taste (1) 
 Sore skin (1) 
 Embarrassed by bowel movement (1) 
 Stoma related problems (1) 
 Impotence (1) 
 Dyspareunia (1) 
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The module has recently shown good validity and reliability for use in CR cancer 
patients in clinical trials and research[163]. 
 
The H&N35 comprises 35 questions assessing symptoms and side effects of 
treatment, social function and body image/sexuality. The module has been tested 
in Norway, Sweden and The Netherlands, as well as in a large cross-cultural study 
involving more than 10 countries.  It has shown acceptable reliability[164]. 
The symptom scales are (number of items): 
 Pain (4) 
 Swallowing difficulties (4) 
 Senses problems (2) 
 Speech problems (3) 
 Problems with social eating (4) 
 Problems with social contact (5) 
 Less sexuality (2) 
 Teeth problems (1) 
 Restricted mouth opening (1) 
 Dry mouth (1) 
 Sticky saliva (1) 
 Coughing (1) 
 Felt ill (1) 
 Taking pain killers (1) 
 Taking nutritional supplements (1) 
 Using a feeding tube (1) 
 Weight loss (1) 
 Weight gain (1) 
 
The internal consistency of the scales is good, with past studies demonstrating 
Cronbach's alpha coefficients of 0.81 (pain), 0.82 (swallowing), 0.72 (senses), 0.74 
(speech), 0.87 (social eating), 0.83 (social contact) and 0.95 (sexuality)[165]. 
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2.2.3 Schedules for Clinical Assessment in Neuropsychiatry 
 
Past history of depression or current DE were assessed using the Schedules for 
Clinical Assessment in Neuropsychiatry (SCAN) interview[166].  The SCAN is based 
on phenomenological descriptions based on the Present State Exam 
encompassing many symptoms and signs of psychiatric illness.  Ratings on the 
SCAN are based on clinical interview.  Clinical vignettes were made for each 
patient recording their cancer diagnosis and psychiatric history.  The semi-
structured interview focuses on specific symptoms, which are rated according to 
their presence, duration and severity.  For the purpose of assessing past episodes 
of depression in these studies, patients were asked to choose their worst past 
episode and to focus on the worst period of four to six weeks.  Participants are 
taken through the checklist of symptoms and each symptom is rated.  A mild 
symptom is scored as one, a moderate symptom for more than half the period as 
two and a severe level of the symptom for more than half the period of worst 
intensity is classed as three.  A computer scoring programme (CATEG05) then 
uses ICD-10 and DSM-IV based algorithms to indicate whether the level of 
symptoms indicates a psychiatric disorder.  Where there was any ambiguity 
between DSM-IV and ICD-10 a decision was reached by consensus with a 
psychiatrist using all patient details from the vignettes.  Interviews were recorded 
and a randomly chosen proportion of these were checked for reliability of ratings by 
two psychiatrists trained in SCAN (Anne Farmer and Ania Korszun). 
2.3 Missing data 
2.3.1 Items 
 
Single missing items on the HADS and EORTC-QLQ were handled according to 
the instructions in the HADS and EORTC-QLQ instruction manuals.  If only one 
item was missing on either HADS subscale, the score was calculated by using the 
mean of other items on the same subscale.  Missing items on the EORTC-QLQ 
were calculated in a similar manner provided that it was a multi-item scale.  
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Incomplete data in a multi-item scale could be calculated in the EORTC-QLQ by 
using other items provided that over half of the questions had been answered. 
2.3.2 Scales 
 
Multiple imputation was tested for the prevalence data, as it is the preferred 
method of dealing with the effect of missing data.  However, in order to run the 
imputation, the format of the data needed to be considerably modified so it was 
considered inappropriate for both samples.  Median or mean imputes and 
sensitivity analyses would also be inappropriate as these methods could easily 
skew the data, given the high range of scale answers and the relatively small 
samples.  Thus, complete case analyses were considered the most appropriate 
way to deal with the missing data.  There are still disadvantages to complete case 
analyses such as misrepresentation due to biased samples.  However, there were 
few single missing items in the cross sectional study, except for some more 
sensitive scales (e.g. sexual function) or those that are inapplicable to many 
patients (e.g. stoma function).  Also, appropriate checks were made for the 
prospective study; regression analyses were used to investigate biases in 
participation, based on demographic and baseline data.  Further details are 
provided in the prospective methods in chapter 5.  The number of participants 
included is stated for each analysis.   
2.4  Analyses 
 
All EORTC-QLQ scales were treated as continuous.  Due to high colinearity, the 
functional scales on the core EORTC-QLQ were excluded (cognitive function, 
physical function, social function, emotional function, role function).  The item “Felt 
ill” in the H&N35 was also excluded as it was considered an uninformative 
measure. 
 
Both studies use regression models for the analyses, which rely on the following 
assumptions: 
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1. Independence 
2. Normality of residual errors 
3. Homoscedasticity 
 
In some cases, it was apparent that the third assumption was not met. Thus 
„robust‟ standard errors were used throughout as these are robust to 
heteroscedastic error terms (therefore relaxing the rule of homoscedasticity).  
Using robust standard errors in analyses where the third assumption was met did 
not change the results. 
2.5 Methodological issues 
2.6 Self report questionnaires 
 
Self report questionnaires have been criticised because there is a risk that 
participants answer as they think the experimenter wants them to answer, as 
opposed to giving their honest answer[167].  This is known as the social desirability 
effect.  Some of the questionnaires used in the prospective study attempt to 
measure this, in order to estimate the degree to which the participants‟ answers 
are due to social desirability.  Details of these are provided in the prospective 
methods in chapter 5. 
 
Self report questionnaires have also been criticised for increased probability of 
recall bias (as compared to interviews)[168].  This is especially problematic in 
questionnaires that may be biased by mood (e.g. retrospective stress measures), 
which may affect the validity of the findings for the prospective study.  Also, all of 
the questionnaires used are therefore affected by the precise timing of the 
questionnaire, as especially in the case of the HADS the score will be affected by 
the patients‟ mood at the time of completion.  This may not be truly representative 
of their mood in the previous few weeks, especially if completing the questionnaire 
during a clinic visit. 
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2.7 Participation bias 
 
As with all studies, there is also a risk of participation bias.  Although the patients 
who were not asked to join the study were missed at random, there was no way to 
investigate differences in those who took part compared to those who declined.  
Checks were made to investigate differences between participating and non 
participating patients with the limited data that was available, such as sex and age 
for the prospective study.  Similar checks were conducted to investigate the 
representativeness of follow up samples using baseline data; potential biases are 
reported in the results. 
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3 Cross sectional study 
 
Part 2 of this thesis explores the relationship between depressive symptoms and 
QoL and point prevalence of DEs in HN and CR patients.  The study uses cross 
sectional data from the HN cancer clinic at St Bartholomew‟s Hospital and the CR 
clinic at The Royal London Hospital.  The background and methods are described 
in this chapter.  The following chapter reports the results of this study followed by a 
discussion.  The study aims to report: 
1. The practicalities of using a screening questionnaire in the respective 
clinics 
2. The prevalence of depressive symptoms and point prevalence of a DE 
3. The level of cancer related difficulties reported in the QoL questionnaire 
4. Results from some exploratory analyses investigating the relationship 
between depressive symptoms and QoL 
 
The study was conducted in the same clinics as the prospective study which is 
described in part 1. 
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3.1 Background 
3.1.1 Prevalence of depression and levels of depressive symptoms 
 
As reported in chapter 2, the prevalence of DDs in both patient groups is expected 
to be similar to that of the general population (about 10%[59]).  Based on the 
reported literature in Chapter 1, the proportion of patients with high levels of 
depressive symptoms (over eight on the HADS-D) is expected to be around 15% 
for CR patients and 25-30% in HN patients. 
3.1.2 Variables associated with higher depressive symptoms 
 
Very few studies have investigated the association between physical and 
depressive symptoms in CR cancer patients.  Kurtz and colleagues[169] (2002) 
found that more physical symptoms, comorbid conditions and being female were 
all associated with higher depressive symptoms in a sample of 234 older patients.  
Physical functioning was also highly associated with depressive symptoms.  Thus, 
it is expected that symptoms that interfere with physical function, such as fatigue, 
will be associated with increased depressive symptoms in CR cancer patients. 
 
Many more studies have been conducted on HN cancer patients, which report 
comparable findings to those of the CR cancer patients; overall symptoms that 
interfered with social function were more likely to be associated with depressive 
symptoms.  Pain, disfigurement, social problems, difficulty chewing, swallowing 
and speaking have all been reported to be associated with depressive symptoms, 
along with fatigue and lack of appetite, in a heterogeneous group of 68 patients, all 
at least six months post surgery[56, 170].  Similarly, others have found loss of social 
function to be associated with reduced life satisfaction in a similar set of 115 
patients[171].  Other moderate predictors of poor QoL are: receiving chemotherapy 
and/or radiotherapy; site and stage of the tumour; time since diagnosis; and 
tracheotomy[172].  Functionally, speech, swallowing and chewing have a high 
influence on QoL[52] and patients often report persistent functional problems even 
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after 12 months.  One study found that over 35% of pharyngeal cancer patients still 
had a lot of difficulty swallowing solid food three years after their diagnosis[146].  
Thus, high scores on the pain, fatigue, appetite loss, dysphagia, social eating and 
social contact scales of the EORTC-QLQ H&N35 are expected to be associated 
with increased depressive symptoms in HN patients. 
3.1.3 Variables associated with poorer quality of life 
 
As with depressive symptoms, relatively few studies have been conducted on QoL 
using CR cancer patient samples.  Two recent reviews[57, 173] on long term QoL in 
CR cancer patients suggest that CR cancer patients have fewer concerns relative 
to other cancer patient groups, with fatigue and poorer physical function reported to 
be the most problematic.  Patients with colon cancer are also reported to have 
fewer symptoms than patients with rectal cancer.  However, many patients still 
report difficulties with defaecation and sexual function: the sexual function 
problems are more likely in the rectal patients due to lower pelvic resection[173-175].  
Both those with and without stomas report problems with diet restrictions, bowel 
movement, body image and medication dependence[57, 174], though more so in 
stoma patients than those without a colostomy.  Very few studies have used the 
CR29 due to its recent validation and no studies have looked at associations 
between CR29 symptoms and overall QoL.  However, past studies that have 
reported on QoL in CR cancer patients have focused on patients who finished 
treatment over 12 months previously.  This study focuses on patients who finished 
treatment at least six months previously, so in that sense the findings from this 
study should be comparable to past studies.  Thus, defaecation problems, sexual 
function and body image problems are expected to be the physical symptoms most 
highly associated with global QoL in CR cancer patients. 
 
Many studies have been conducted on QoL in HN cancer patients.  As mentioned 
in chapter 1, HN cancer patients may have to deal with disfigurement as well as 
numerous functional difficulties.  Most studies report the findings that overall QoL 
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usually falls soon after diagnosis before returning to baseline 12 months after 
diagnosis[4, 176-178].  However, the studies also report long term functional 
impairments that persist, such as pain, disfigurement, poorer social function, 
difficulty chewing, swallowing, speaking, teeth problems, dry mouth and poor 
shoulder function[146, 177, 179].  Some have found an improvement throughout 
radiotherapy[180] whereas others find a decrease in relation to adjuvant 
radiotherapy over time[178] due to disfigurement, dysphagia and chewing difficulties.  
Overall, studies indicate that some functional difficulties continue (particularly side 
effects from radiotherapy), but these do not necessarily translate to poorer self-
rated overall QoL, possibly due to psychological adjustment or reduction in the 
severity of the symptoms over time.  Terrell and colleagues[172] (2004) found that a 
tracheotomy tube and other comorbid conditions were reported to be the most 
troubling symptoms in HN cancer patients; whereas other researchers have 
reported pain, swallowing, dry mouth and problems with taste and smell to be the 
most problematic[146].  Thus, as with depressive symptoms, impairments that 
interfere with social function are expected to have a high association with overall 
QoL. 
 
Depression is hypothesised to be strongly associated with QoL in both sets of 
cancer patients[146, 181]. 
 
3.2 Methods 
3.2.1 Aim and design 
 
A quantitative cross sectional study was carried out to investigate the association 
between PH of depression, current depressive symptoms, QoL and DD in HN 
cancer patients and CR cancer patients.  Ethics approval was obtained (Ref: 
08/H0701/63) from the local NHS research ethics committee. 
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3.2.2 Evaluations 
 
The following assessments were used: 
 
Questionnaires: 
1. The HADS as described in the evaluations section of chapter 3. 
 
2. The EORTC-QLQ, including the cancer specific modules CR29 and H&N35 
as described in the evaluations section of chapter 3. 
 
3. A Past Mental Health Screening Questionnaire (PMHS) (see appendix 3. 1 
and appendix 3. 2).  This questionnaire asked 5 questions on whether a 
patient has experienced or been treated for either depression or anxiety: 
i. Have you ever been treated for depression? 
ii. Have you ever been treated for anxiety? 
iii. Have you ever been prescribed anti-depressants? 
iv. Do you think you have ever suffered from depression? 
v. Do you think you have ever suffered from anxiety? 
The questionnaire also asked if the patient would be willing to be contacted 
by a researcher for an interview. 
 
 Finally, a structured diagnostic interview was also used, as follows: 
 
The SCAN as described in chapter 2.  This study used an annotated SCAN, which 
is shorter than the regular version of the SCAN, as used at the Social Genetic and 
Developmental Psychiatry department at the Institute of Psychiatry (personal 
communication from Anne Farmer).  The ratings from the SCAN interview are 
entered into a computerised scoring programme CATEGO5 which provides 
diagnoses according to DSM-IV or ICD-10 operational definitions. 
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3.2.3 Colorectal methods 
3.2.3.1 Procedure 
 
All CR patients attending the clinic on a Thursday morning for a six month period 
were given the HADS, EORTC-QLQ, and PMHS (once) to be completed whilst 
they waited for their appointment. The reasons for not completing the questionnaire 
were noted and are mentioned in the results section in chapter 4. 
 
The treatment team were alerted if a patient had a total score of 15 or above on the 
HADS. 
 
Patients who scored over seven on either HADS subscale, or answered yes to any 
of the mental health questions on the past mental health screening questionnaire 
and who consented to be contacted on the PMHS were called at a time convenient 
to the patient.  This phone call took an average of 20 minutes and was used to give 
an annotated SCAN interview. 
3.2.3.2 Participants 
 
Three hundred and forty patients completed the questionnaire.  Seventy-one 
patients were CR cancer patients, 258 patients were suffering from benign CR 
related health problems or were undergoing investigations for bowel related 
symptoms such as blood in stools or change in bowel habit.  Eleven patients were 
suffering from non CR cancers and were excluded from the analyses as there was 
not enough power to analyse this group as a discrete sample, but they were too 
different to be combined with either the control or CR cancer patients.  Of the 340 
patients, 222 provided a telephone number for a SCAN interview.  Of those 
contactable, 78 patients met criteria to be contacted for interview, 64 of whom 
completed a full interview.  Full details of completion are provided in the results 
section of chapter 4. 
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Figure 3.1 shows the flowchart of the procedure and patient participation. 
 
Figure 3.1: Flowchart of the procedure and patient participation in the CR clinic. 
3.2.4 Head and neck methods 
3.2.4.1 Procedure 
 
In an initial audit, all maxillofacial HN cancer patients attending the HN clinic on a 
Wednesday afternoon between January and June 2007 were asked to complete 
the EORTC-QLQ and HADS whilst waiting for their appointment. 
 
All HN cancer patients who completed the HADS and EORTC-QLQ as part of the 
initial audit were sent the PMHS, HADS, EORTC-QLQ and H&N35 along with a 
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covering letter and freepost envelope, in January 2009.  Patients who had yet to 
return the questionnaire were sent out one more pack with only the PMHS cover 
letter and freepost envelope included, in May 2009. 
 
Patients who scored over seven on either HADS subscale, or answered yes to any 
of the mental health questions on the past mental health screening questionnaire 
and who consented to be contacted on the PMHS, were called at a time 
convenient to the patient.  This phone call took an average of 20 minutes and was 
used to give an annotated SCAN interview. 
 
The clinicians were alerted to all patients who scored over 15 on the depression 
subscale on the HADS. 
3.2.4.2 Participants 
 
Two-hundred and thirty seven HN cancer patients completed the HADS and the 
EORTC-QLQ between January 2007 and July 2007 as part of an initial audit.  Two 
hundred and twenty-five patients were followed up in January 2009 (11 patients 
had since passed away and three patients had given insufficient information to 
track their records).  Of the 225 patients, 86 returned all three questionnaires and a 
further 19 completed the PMHS.  Thirty-three of those patients met criteria to be 
contacted and took part in the SCAN interview.  Percentage completion and 
reasons for non completion are reported in the results section in chapter 4. 
 
See figure 3.2 for a consort diagram of the procedure and patient participation. 
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Figure 3.2: Consort diagram of procedure and participation for HN clinic. 
3.2.5 Analyses 
1. Checks were made for missing data.  Item non response is reported in the 
results section of chapter 4. 
 
2. ANOVAs and Chi square tests were carried out to test for differences and 
variance in demographics and depression variables between CR controls 
and cancer patients and CR cancer and HN cancer patients. 
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3. Regression analyses were carried out to check the representativeness of 
the patients who returned the questionnaire and agreed to be contacted for 
an interview compared to those who did not agree to be contacted for an 
interview. 
 
4. Univariate and multivariate regression analyses were carried out on each 
patient sample with depressive symptoms, global QoL and current DE as 
dependent variables.  Age, sex, all other QoL measures, HADS scores and 
PH of depression or anxiety were all used as independent variables in the 
model. 
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4 Cross sectional results 
 
This chapter presents the results from the cross sectional study including: 
 The practicalities of the screening method 
 The prevalence of high levels of depressive symptoms and the percentage 
of those patients who had a DD 
 The chapter also shows the results of an exploratory analysis designed to 
investigate  
1. The symptoms that were most strongly independently associated with 
depressive symptoms 
2. The factors most strongly associated with present DE 
3. The symptoms that were independently associated with global QoL 
The results are reported in the order presented above, always presenting the 
results for the CR patients first, followed by the results for the HN patients.  The 
chapter concludes with a discussion of the main findings. 
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4.1 Practicalities of screening method 
4.1.1 Colorectal clinic 
 
Three hundred and forty (63%) patients completed the questionnaires, out of 536 
attending the clinic in the six months.  Of the 340, 21% were CR cancer patients, 
which is slightly below the estimated proportion of clinic appointments allocated for 
cancer patients (30-35%).  Unfortunately, no diagnosis is available for those that 
did not complete the questionnaires so it is not possible to test whether diagnosis 
affected completion rates.  Reasons for non-completion are shown in figure 4.1.  A 
number of patients were not reached during their visit to the clinic, due to limited 
resources in the clinic (termed unapproached). 
 
340
107
17
39
22 11
Completed
Not approached
Incomplete
Declined
Non English Speaker
No name
 
Figure 4.1: Number of patients who completed questionnaire and reasons for non completion in the 
CR clinic. 
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4.1.2 Head and neck clinic 
 
67% of the patients attending the clinic completed the questionnaires and only 8% 
of patients refused (figure 4.2). 
239
75
10
28
6
Completed
Not approached
Incomplete
Declined
Non English Speaker
 
Figure 4.2: Number of patients completing questionnaire and reasons for non completion in the HN 
clinic. 
4.2 Participant information 
4.2.1 Colorectal clinic 
4.2.1.1 HADS and QoL Descriptives 
 
After calculating incomplete data on multi-item scales, of the 342 completed 
questionnaires 109 patients had complete data on all sections of the 
questionnaires.  The majority of single missing items (51) were related to sexual 
function and 258 patients had less than five missing items not including the sexual 
function items. 
Chapter 4: Cross sectional results 
83 
 
Demographic information for the CR cancer and control groups is shown in table 
4.1.  Colorectal cancer patients were significantly older than the controls.  The 
diagnoses of the non cancer patients are shown in figure 4.3. 
 
 
CR controls CR cancer 
Patients 258 71 
Age         Mean (sd)  50.79 (16.88) 65.50 (13.23)* 
Sex  N (%) 
 
Female 
Male 
154 (59.69) 
104 (40.31) 
39 (54.93) 
32 (45.07) 
Table 4.1: Diagnoses and demographic information for all CR patients.*p<0.0005 
 
Figure 4.3: Diagnoses of CR control group 
 
There were no significant differences in prevalences of high HADS scores or PH of 
depression between CR cancer patients and controls (see table 4.2).  However, 
the cancer sample reported higher levels of global QoL overall, which is 
approaching significance. 
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Score 
CR control CR cancer 
N (%) N (%) 
HADS-D 0-7 176 (73.95) 52 (73.24) 
≥ 8 62 (26.05) 19 (26.76) 
HADS-A 0-7 134 (56.54) 45 (63.38) 
≥ 8 103 (43.46) 26 (36.62) 
>7 on either HADS scale  116 (48.95) 29 (40.85) 
Global QoL  Mean (sd) 241 59.49 (1.65) 67 66.17 (3.12)* 
Past treatment for depression 59 (22.87) 16 (22.54) 
Past treatment for anxiety 28 (10.85) 7 (9.86) 
PH of depression 77 (29.84) 20 (28.17) 
PH of anxiety 62 (24.03) 15 (21.13) 
Any PH 98 (37.98) 26 (36.62) 
Any PH or >7 on either HADS scale 155 (60.08) 41 (57.75) 
Table 4.2: HADS scores and patient reported past mental health in all CR patients. *p=0.06 
4.2.1.2 Representativeness 
 
Of the 155 controls patients that were eligible for a follow up interview 58 control 
patients (37.42%) were happy to be contacted, whereas 20 CR cancer patients 
(60.61%) were happy to be contacted.  Older patients and those presenting to the 
clinic with a diagnosis of CR cancer were more likely to provide a telephone 
number.  Moreover, those with a self reported PH of depression or anxiety were 
more likely to provide contact details (see table 4.3). 
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 No contact provided Contact provided  
Baseline characteristic N (%)* N (%)* OR (95% CI) 
Gender 
Male 
Female 
 
89 
128 
 
(65.44) 
(66.32) 
 
47 
65 
 
(34.56) 
(33.68) 
 
 
1.04 (0.65-1.65) 
Diagnosis 
CR control 
CR cancer 
 
181 
36 
 
(70.16) 
(50.70) 
 
77 
35 
 
(29.84) 
(49.30) 
 
 
2.29 (1.34-3.91)* 
Age Mean (sd) 217 52.62 (17.86) 112 56.56 (15.74) 1.01 (1.00-1.03)* 
HADS-D (N=309) 
<7 
≥8 
 
149 
52 
 
(65.35) 
(64.20) 
 
79 
29 
 
(34.65) 
(35.80) 
 
 
1.05 (0.62-1.79) 
HADS-A (N=308) 
<7 
≥8 
 
123 
78 
 
(68.72) 
(60.72) 
 
56 
51 
 
(31.28) 
(39.53) 
 
 
1.43 (0.89-2.31) 
>7 on either HADS subscale 91 (45.27) 54 (50.47) 0.92 (0.50-1.68) 
Global Qol Mean (sd) 202 59.30 (26.46) 106 64.07 (23.94) 1.01 (1.00-1.02) 
Past treatment for 
depression 
 
34 
 
(15.67) 
 
41 
 
(36.61) 
 
3.11 (1.83-5.28)* 
Past treatment for anxiety 17 (7.83) 18 (16.07) 2.25 (1.11-4.57)* 
PH of depression 44 (20.28) 53 (47.32) 3.53 (2.15-5.81)* 
PH of anxiety 39 (17.97) 38 (33.93) 2.34 (1.39-3.95)* 
Any PH 12 (26.09) 32 (54.24) 3.36 (1.46-7.73)* 
Met criteria to be contacted 114 (52.53) 82 (73.21) 2.47 (1.50-4.05)* 
Table 4.3: Representativeness of follow up sample in CR clinic.  *p<0.05 
 
All other QoL measures were non significant (figures not shown) and there was no 
linear association between HADS scores and likelihood of agreeing to a follow up 
interview. 
4.2.2 Head and neck clinic 
4.2.2.1 HADS and QoL Descriptives 
 
Demographics and HADS scores for HN patients at T1 and T2 are shown in table 
4.4.  Comparison between the scores at T1 and T2 and patient rated past mental 
health are shown in table 4.5.  There was no significant difference between anxiety 
and depressive categories at the two time points, but the mean depression and 
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anxiety scores were significantly lower at T2 [mean HADS-D T1=4.91, T2=3.77 
t(321)=2.05, p=0.041; HADS-A T1=5.98, T2=4.27,t(320)=3.06, p=0.002]. 
 
 
T1 T2 
Patients 239 105 
Age  Mean (sd) 58.02 (15.68) 61.36 (12.43) 
Sex N (%) Male 
Female 
111 (46.44) 
128 (53.56) 
46 (43.81) 
59 (56.19) 
Table 4.4: Demographics of HN patients who completed the questionnaires at each time point. 
 
  HN cancer T1* HN cancer T2 
 Score N  (%) N  (%) 
HADS-D 0-7 182 (76.79) 72 (83.72) 
≥8 55 (23.21) 14 (16.28) 
HADS-A 0-7 158 (66.67) 64 (75.29) 
≥8 79 (33.33) 21 (24.71) 
>7 on either subscale  96  (40.51) 25  (29.41) 
Global QoL Mean (sd) 213 64.26 (25.97) 72 68.29 (24.77) 
Past treatment for depression   24  (22.86) 
Past treatment for anxiety  11  (10.58) 
Taken anti-depressants  21  (20.19) 
PH of depression  38  (36.89) 
PH of anxiety  32  (30.77) 
Any PH  44  (41.90) 
Any PH or >7 on either HADS scale  52  (49.52) 
Table 4.5: HADS scores and past mental health answers in HN cancer patients. * These figures 
include the entire sample at T1, but figures are comparable when testing only those in the follow up 
sample. 
4.2.2.2 Representativeness 
 
To find out if the sample at T2 was representative of the clinical sample, regression 
analyses were carried out, to see whether any baseline characteristics were 
associated with patient response.  As can be seen in table 4.6 response rate was 
unrelated to most baseline characteristics, apart from age, with older patients more 
likely to respond. 
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 No response Response  
Baseline characteristic N (%) N (%) OR (95% CI) 
Gender 
Male 
Female 
 
61 
59 
 
(50.83) 
(56.19) 
 
59 
46 
 
(49.17) 
(43.81) 
 
 
1.24 (0.73-2.10) 
Age Mean (sd) 119 53.21 (16.04) 105 61.04 (12.79) 1.04 (1.02-1.06)* 
HADS-D T1 
<7 
≥8 
 
93 
27 
 
(53.14) 
(55.10) 
 
82 
22 
 
(46.86) 
(44.90) 
 
 
0.92 (0.49-1.75) 
HADS-A T1 
<7 
≥8 
 
86 
34 
 
(56.95) 
(46.58) 
 
65 
39 
 
(43.05) 
(53.42) 
 
 
1.52 (0.87-2.66) 
Global Qol  Mean (sd) 109 64.71 (23.24) 93 66.76 (26.31) 1.00 (0.99-1.01) 
Table 4.6: Baseline characteristics of those who responded to mail out follow up compared to those 
that did not in HN cancer patients. *p<0.05. 
 
As the follow up sample was relatively representative of the sample at T1, analyses 
were carried out using the sample at T2 which provided more information.  More 
regression analyses were carried out to see which characteristics were associated 
with providing a telephone number.  As can be seen in table 4.7 older patients, with 
lower HADS-D scores and increased QoL at T1 and those that had a PH of 
depression or anxiety were more likely to return the questionnaire and give a 
contact number for an interview. 
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 No contact provided* Contact provided  
Baseline characteristic N (%) N (%) OR (95% CI) 
Gender 
Male 
Female 
 
97 
83 
 
(75.78) 
(74.77) 
 
31 
28 
 
(24.22) 
(25.23) 
 
 
0.95 (0.53-1.71) 
Age Mean (sd) 178 56.11 (16.19) 59 62.15 (9.98) 1.03 (1.01-1.05)* 
HADS-D T1 
<7 
≥8 
 
132 
46 
 
(72.53) 
(83.64) 
 
50 
9 
 
(27.47) 
(16.36) 
 
 
0.52 (0.24-1.13)
Ŧ
 
HADS-A T1 
<7 
≥8 
 
119 
59 
 
(75.32) 
(74.68) 
 
39 
20 
 
(24.68) 
(25.32) 
 
 
1.03 (0.55-1.93) 
HADS-D T2 
<7 
≥8 
 
30 
9 
 
(41.67) 
(64.29) 
 
42 
5 
 
(58.33) 
(35.71) 
 
 
0.40 (0.12-1.30) 
HADS-A T2 
<7 
≥8 
 
27 
11 
 
(42.19) 
(52.38) 
 
37 
10 
 
(57.81) 
(47.62) 
 
 
0.66 (0.25-1.78) 
>7 on either HADS subscale 73 (41.01) 23 (38.98) 0.92 (0.50-1.68) 
Global Qol T1 Mean (sd) 160 62.11 (25.97) 53 70.75 (25.09) 1.01 (1.00-1.03)* 
Global Qol T2  Mean (sd) 62 61.98 (52.74) 42 73.33 (23.05) 1.02 (1.00-1.04)** 
Past treatment for 
depression 
6 (1.04) 18 (30.51) 2.93 (1.05-8.13)* 
Past treatment for anxiety 4 (8.70) 7 (12.07) 1.44 (0.39-5.26) 
Prescribed anti-depressants 6 (13.04) 15 (25.86) 2.33 (0.82-6.58) 
PH of depression 11 (24.44) 27 (46.55) 2.69 (1.15-6.32) 
PH of anxiety 10 (22.22) 22 (37.29) 2.08 (0.86-5.01) 
Any PH 12 (26.09) 32 (54.24) 3.36 (1.46-7.73)* 
Met criteria to be contacted 19 (41.30) 33 (55.93) 2.40 (1.30-4.41)* 
Table 4.7: Comparison of baseline characteristics of patients who gave their telephone number 
compared to those that did not in HN cancer patients.  * p<0.05, ** p=0.056, Ŧ p=0.10 
4.3 Prevalence of depressive disorder 
 
The estimated prevalence of a DD in the clinics is shown in figure 4.1.  There were 
no significant differences between the different diagnoses [χ2(2)=3.31, p=0.191]. 
4.3.1 Colorectal clinic 
 
Of the 192 CR patients who met criteria to be contacted 82 patients gave their 
telephone number.  Of the 82 patients, 78 patients were contacted, of whom 63 
completed enough of the interview for a diagnosis (four declined, three were 
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excluded due to lack of information and seven were unreachable).  Figure 4.4 
shows the number of patients who met contact criteria, were contacted and 
provides an estimated prevalence of mental health diagnoses in CR cancer 
patients and controls.  However, although there were no significant differences in 
those who met criteria to be contacted, cancer patients were more likely to agree to 
a follow up compared to the number of controls who met criteria for a follow up 
interview [N=392, OR(CI)=2.36 (1.13 -4.82) p=0.001]. 
4.3.2 Head and neck clinic 
 
As shown in figure 4.4 only 5% of those willing to be contacted met criteria for 
follow up and were currently suffering from a DE, whereas almost 30% had 
suffered a past DE. 
≥8 on either 
HADS scale
25 (29%)
Stated PH
41 (42%)
Met criteria for contact
52 (50%)
No telephone 
number provided
19
Patients interviewed
331
Current DE
16 (27%)
3 (5.08%)
≥8 on either 
HADS scale
29 (41%)
Stated PH
26 (37%)
Met criteria for contact
41 (58%)
No telephone 
number provided
17
Patients interviewed
231
Current DE
11 (31%)
5 (14.29%)
≥8 on either 
HADS scale
116 (49%)
Stated PH
98 (38%)
Met criteria for contact
155 (60%)
No telephone 
number provided
97
Patients interviewed
551
Current DE
27 (35%)
11 (14.29%)
CR control CR cancer HN cancer
Past DE Past DEPast DE
 
Figure 4.4: Consort diagram of those patients who underwent SCAN interview for diagnosis of DD.  
1, some patients were not contactable or did not provide enough information for a diagnosis (see 
text).  Percentages are given as number of patients with PH depression or current DE out of those 
that were willing to be contacted.  Number of patients willing to be contacted is: CR control, 77, CR 
cancer, 35,
 
HN cancer, 59. 
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4.3.3 Comparison of depressive symptoms and depressive disorder in head 
and neck and colorectal cancer patients 
 
Comparison of the screening success and depressive symptoms from cancer 
patients attending the HN and CR clinic indicate similar patterns of depressive 
symptoms in the two cancer populations (see figure 4.5 and table 4.8).  There was 
no significant difference in the proportion of patients with high HADS-D scores 
(scoring ≥8) [N=308, p=0.129].  There was no significant difference in the mean 
HADS-D or QoL score [HADS-D, p=0.863, QoL, p=0.599]. 
 
 CR cancer T1 HN cancer 
 N Mean (sd) N Mean (sd) 
HADS-D 71 4.80 (4.16) 237 4.91 (4.42) 
HADS-A 71 6.33 (5.48) 237 5.98 (4.49) 
Table 4.8: Mean HADS-D scores by cancer diagnosis 
0
10
20
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40
50
60
70
80
90
% HADS-D <7 % HADS-D ≥8 % Past history Mean Qol
CR cancer
HN cancer
 
Figure 4.5: Graph showing percentage of patients in each HADS-D 
category, mean QoL scores and percentage of patients who responded 
yes to any of the past mental health screener questionnaires. 
(HADS-D and QoL scores based on T1 data, PH based on T2 data in HN 
cancer patients.) 
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4.4 Quality of life descriptives 
 
Descriptives for the QoL scores on the core EORTC-QLQ are presented in table 
4.9.  There are no significant differences between CR cancer patients compared to 
non cancer CR patients.  Colorectal cancer patients suffered from significantly 
higher levels of insomnia compared to HN cancer patients at T1.  Also, CR cancer 
patients reported higher levels of diarrhoea compared to HN cancer patients at 
either time point. 
 
Descriptives for the CR29 module for CR cancer patients are presented in table 
4.10.  Colorectal cancer patients reported significantly higher levels of micturition 
problems, hair loss, problems with taste and impotence compared to the control 
group.  However, the control group reported higher levels of abdominal and/or 
pelvic pain. 
 
Descriptives for the HN specific EORTC-QLQ measures are presented in table 
4.11. 
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Mean 
(sd) 
 
CR HN Difference between 
CR and HN 
Control Cancer T1 T2  
HN T1 
 
HN T2 N  N  N  N  
Global QoL 241 59.49 
(25.59) 
 
67 66.17 
(25.54) 
 
213 64.26 
(25.97) 
 
72 68.29 
(24.77) 
 
  
Fatigue 243 39.16 
(28.38) 
 
66 36.53 
(32.03) 
 
218 35.70 
(29.49) 
 
73 32.88 
(30.33) 
 
  
Nausea and 
vomiting 
244 13.73 
(22.36) 
 
67 10.15 
(21.48) 
 
216 9.49 
(18.64) 
 
73 5.93 
(11.90) 
 
  
Pain 244 37.09 
(33.96) 
 
66 28.68 
(30.80) 
 
218 28.98 
(33.32) 
 
74 22.07 
(31.10) 
 
  
Dyspnoea 236 18.64 
(29.02) 
 
64 23.44 
(31.81) 
 
221 20.97 
(29.09) 
 
72 24.07 
(31.76) 
 
  
Insomnia 242 39.39 
(37.07) 
 
66 41.92 
(37.58) 
 
217 30.49 
(35.19) 
 
73 31.96 
(33.99) 
 
*  
Appetite loss 236 22.74 
(30.22) 
 
66 22.67 
(32.11) 
 
210 23.97 
(32.31) 
 
72 25.00 
(34.37) 
 
  
Constipation 239 23.29 
(32.07) 
 
66 20.20 
(31.42) 
 
214 19.16 
(31.01 
 
72 12.96 
(24.74) 
 
  
Diarrhoea 242 22.72 
(32.60) 
 
66 20.20 
(34.03) 
 
216 6.33 
(17.49) 
 
73 5.48 
(14.71) 
 
* * 
Financial difficulties 241 18.81 
(32.15) 
 
65 23.59 
(35.22) 
 
217 24.12 
(33.90) 
 
74 17.12 
(23.60) 
 
  
Table 4.9: Descriptives for core EORTC-QLQ symptoms.  *=p<0.05
Chapter 4: Cross sectional results 
93 
Mean (sd) 
 
Control Cancer  
N  N  Sig 
Health anxietyŦ 222 61.26 (28.99) 
 
57 61.11 (28.58) 
 
 
Body imageŦ 
Function 
215 77.93 (27.56) 
 
55 79.19 (28.58) 
 
 
Sexual functionŦ 181 62.98 (32.37) 
 
42 69.84 (35.92) 
 
 
Micturition 
problems 
223 28.03 (22.78) 
 
57 35.09 (26.29) 
 
* 
Abdominal/pelvic 
pain 
223 19.36 (21.02) 
 
57 12.96 (19.68) 
 
* 
Defaecation 
problems 
215 19.37 (21.99) 
 
57 15.45 (23.76) 
 
 
Faecal 
incontinence 
151 22.30 (24.79) 
 
48 29.86 (30.93) 
 
 
Bloating 217 33.03 (34.84) 
 
58 25.86 (35.89) 
 
 
Dry mouth 220 26.06 (28.80) 
 
56 32.14 (33.61) 
 
 
Hair loss 217 3.84 (14.00) 
 
54 10.49 (22.27) 
 
* 
Taste problems 218 9.17 (20.17) 
 
55 20.00 (29.12) 
 
* 
Sore skin 148 21.97 (32.03) 
 
45 20.00 (34.38) 
 
 
Embarrassment 147 24.49 (33.86) 
 
44 20.45 (33.11) 
 
 
Stoma problems 14 19.05 (31.25) 
 
7 14.29 (17.82) 
 
 
Impotence 79 22.36 (31.45) 
 
23 42.03 (47.37) 
 
* 
Dyspareunia 84 23.41 (35.01) 
 
12 11.11 (21.71) 
 
 
Table 4.10: Descriptives for EORTC-QLQ CR29 for CR cancer patients and controls. *p<0.05 
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Mean (sd) 
 
T2 
N  
HN pain 74 18.09 (21.96) 
 
Swallowing difficulties 74 21.21 (29.69) 
 
Problems with taste and smell 74 21.40 (29.39) 
 
Speech problems 73 26.64 (27.15) 
 
Problems with social eating 71 33.06 (36.34) 
 
Problems with social contact 73 19.82 (24.45) 
 
Less sexuality 62 46.51 (38.66) 
 
Problems with teeth 73 30.59 (39.58) 
 
Restricted mouth opening 74 32.88 (35.97) 
 
Dry mouth 74 37.39 (35.97) 
 
Sticky saliva 73 35.16 (39.63) 
 
Coughing 74 29.73 (30.00) 
 
Taking pain killers 72 37.50 (48.75) 
 
On nutritional supplements 72 23.61 (42.62) 
 
Presence of feeding tube 73 8.22 (27.66) 
 
Weight loss 73 19.18 (37.64) 
 
Weight gain 72 31.94 (46.95) 
 
Table 4.11: Descriptives for EORTC-QLQ H&N35 at T2.
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4.5 Regression analyses 
4.5.1 Factors associated with HADS-D 
4.5.1.1 Colorectal cancer patients 
 
 Multivariate regression analyses show that only fatigue, defaecation problems 
and body image were independently significantly associated with HADS-D (see 
table 4.12). 
 
 All of the symptoms on the EORTC-QLQ (including the CR29) were significantly 
associated with HADS-D in CR cancer patients in univariate analyses, apart 
from impotence and dyspareunia. 
 Age and sex were not associated with HADS-D. 
 None of the PH depression variables were associated with HADS-D. 
 Adjusting for age or sex did not change the results. 
 
Independent Variables N ß (CI) P value Adjusted R2 
Fatigue 55 0.06 (0.03 to 0.10) <0.0005 0.65 
Defaecation problems 0.07 (0.03 to 0.11) 0.001 
Body image -0.04 (-0.07 to -0.01) 0.021 
Table 4.12: Regression model showing factors associated with HADS-D in CR cancer patients. 
4.5.1.2 Head and neck clinic 
 
The analyses for the HN clinic sample were only conducted using the second set of 
data as less information is available from the T1 sample. 
 
 The multivariate analyses showed that only fatigue and problems with social 
contact were significantly independently associated with HADS-D at T2 (see 
table 4.13). 
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 All of the EORTC-QLQ symptoms were associated with increased depressive 
symptoms except for presence of feeding tube, nutritional supplements and 
weight gain. 
 Similar to the CR findings, age, sex and PH depression were not associated with 
depressive symptoms. 
 Adjusting for age or sex did not change the model. 
 HADS-D at T1 was significantly associated with HADS-D at T2 in the 
multivariate model and did not affect the associations between fatigue and social 
contact problems (from the EORTC-QLQ H&N35) and T2 HADS-D. 
 
Independent Variables N ß value (CI) P value Adjusted R2 
Fatigue 65 0.08 (0.05 to 0.10) <0.0005 0.73 
Social contact problems 0.08 (0.04 to 0.12) <0.0005 
Table 4.13: Regression model showing factors associated with HADS-D in HN cancer patients. 
4.5.2 Factors associated with global QoL 
4.5.2.1 Colorectal clinic 
 
HADS-D, problems with taste, dry mouth and sore skin were the only variables 
independently associated with poorer QoL (see table 4.14). 
 
 All EORTC-QLQ symptoms were univariately associated with poorer QoL in CR 
patients except for dyspareunia and impotence. 
 As with the results in HADS-D age and sex were not associated with QoL. 
 Stoma problems were associated with poorer QoL, but this variable was not 
included in the multivariate analyses as only 7 patients completed this item. 
 Adding age or sex to the model did not change the model. 
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Independent Variables N ß value (CI) P value Adjusted R2 
HADS-D 42 -2.37 (-3.42 to -1.32) <0.0005 0.77 
Taste problems -0.18 (-0.29 to -0.07) 0.003 
Dry mouth -0.20 (-0.33 to -0.08) 0.003 
Sore skin -0.15 (-0.30 to -0.01) 0.039 
Table 4.14: Regression model showing factors associated with global QoL in CR cancer patients. 
4.5.2.2 Head and neck clinic 
 
Only fatigue, problems with social contact, pain and age were independently 
associated with QoL (see table 4.15). 
 
 All of the EORTC-QLQ symptoms were univariately associated with poorer QoL 
except from being on nutritional supplements, diarrhoea, weight loss, problems 
with taste or smell, presence of feeding tube and weight gain. 
 Sex was not associated with QoL and age was positively associated with global 
QoL ratings. 
 Adding sex to the model confounded the relationship between age and QoL. 
 T1 HADS-D and global QoL did not change the model and were not significantly 
associated with QoL at T2. 
 
Independent Variables N ß value (CI) P value Adjusted R2 
Fatigue 70 -0.26 (-0.97 to -0.05) 0.018 0.70 
Problems with social contact -0.38 (-0.57 to -0.19) <0.0005 
Pain -0.20 (-0.38 to -0.02) 0.029 
Age 0.31 (0.01 to 0.60) 0.040 
Table 4.15: Regression model showing factors associated with global QoL in HN cancer patients. 
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4.5.3 Factors associated with a current depressive episode 
4.5.3.1 Colorectal clinic 
 
No QoL variables, demographics or HADS scales were associated with current DE 
when analysing just the CR cancer patients.  HADS-D was associated with a DE 
when treated as a categorical variable (over 8) [N=19, ß(CI)=2.97 (0.19 to 5.75), 
p=0.036]. 
 
A second analysis was run that included all the CR patients.  In this model only 
HADS-D and SCAN rated PH depression were independently associated with a 
current DE (see model 1 table 4.17). 
 
Univariate associations 
Financial difficulties (61) 
HADS-D (63) 
SCAN rated PH depression (65) 
HADS-A (63) 
Body image* (53) 
Patient reported PH depression (65) 
Past treatment for depression (65) 
Increasing age* (65) 
Insomnia (63) 
Table 4.16: Univariate associations for current DE in CR patients.  
Variables are in order of R
2
.* negative association 
 
 Table 4.16 shows the variables univariately associated with a current DE in CR 
patients. 
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 All of the associated variables increased the risk of a DE except for body image 
function in which better body image function was protective against a DE and 
age where increasing age was protective. 
 Adding sex or age did not affect the model. 
 
As the SCAN rated PH depression is unlikely to be a practical assessment in a 
cancer clinic another model was run excluding SCAN PH depression.  In this 
model only body image function was significantly independently associated with a 
current DD (model 2, table 4.17), although fewer patients completed that item on 
the questionnaire.  Age, sex and diagnosis were not significant in the model and 
did not affect the presented associations. 
 
Model Independent 
Variables 
N OR (CI) P value R2 
1 
 
HADS-D 63 6.49 (1.23- 34.06) 0.011 0.31 
SCAN PH 
depression 
1.31 (1.07-1.61) 0.024 
2 Body image 53 0.97 (0.94-1.00) 0.024 0.12 
Table 4.17: Regression models showing factors associated with current DE in all CR 
patients and only CR cancer patients. 
 
Body image was also significantly associated with a SCAN rated PH of depression 
[N=53, ß(CI)=-18.20 (-32.77 to -3.63) p=0.015]. 
4.5.3.2 Head and neck clinic 
 
Only three people out of those interviewed for a DD were suffering from a current 
DE, so no further analyses were carried out with current DD as a dependent 
variable as there would not be sufficient power. 
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4.6 Summary 
 
About two thirds of patients completed the questionnaires in both clinics, but many 
patients were missed due to limited resources. 
 
There were very few differences in the CR cancer patients compared to the CR 
controls, except that the cancer patients were older and had higher ratings of QoL.  
The CR cancer patients were also more likely to agree to a follow up interview 
compared to non cancer patients. 
 
Younger HN cancer patients were more likely to return the mailed out 
questionnaires and they were more likely to agree to a follow up interview if they 
had a PH of depression.  This was also true of the CR patients. 
 
The levels of depressive symptoms were similar in the CR and HN cancer patients 
(means of 4.80 and 4.42 respectively, with 27% CR cancer patients and 16-23% of 
HN patients having HADS-D scores indicative of a possible DE).  Although it was 
hoped that comparisons could be made between the CR cancer patients and the 
HN patients for prevalence of a DE, this is unlikely to be reliable due to the biases 
in the followed up HN sample, therefore the prevalence of depression in the HN 
population is probably much lower than the true prevalence in the clinic. 
 
The multivariate analyses showed that only fatigue and symptoms specific to the 
cancer site were independently associated with increased depressive symptoms 
(defaecation and body image function in CR cancer patients and problems with 
social contact in HN cancer patients).  However, HADS-D was only independently 
associated with poorer QoL in CR cancer patients, along with taste problems, dry 
mouth and sore skin.  The former symptoms of which are likely to be related to 
chemotherapy treatment.  In HN cancer patients the cancer symptoms associated 
with HADS-D; fatigue and problems with social contact appear to have a stronger 
association with poorer QoL then HADS-D alone, along with pain and age.  This 
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may be because even though there was no difference in HADS-D scores at the 
time of the interviews the HN sample was biased towards patients with lower 
HADS-D levels at T1 and better QoL at T1 and T2. 
 
Multivariate analyses on factors associated with current DE could only be carried 
out on CR patients due to low numbers in the HN cancer group.  Not surprisingly, 
HADS-D and SCAN rated PH depression were the only variables independently 
associated with a current DE.  Another second model was tested which excluded 
the SCAN rated PH depression from the model because the SCAN rated PH 
depression would not be a practical indication of risk of a DE in a busy clinic.  In 
this model only poor body image function (i.e. lack of confidence in body image) 
was significantly associated with a DE (and HADS-D was no longer significant – 
due to the association between HADS-D and body image).  This finding could be 
expected given SCAN rated PH depression was also associated with poorer body 
image function. 
4.7 Discussion 
4.7.1 Prevalence of depression 
 
The response rate for the questionnaires was relatively good and the refusal rate 
was low.  The mean HADS-D scores were similar in each diagnosis and slightly 
higher than the mean HADS-D scores in the general population at all ages 
(3.68)[182], and close to the mean in those over 65 years old (4.6)[183].  The 
prevalence of high depressive symptoms was slightly higher in the CR cancer 
group then most studies report, though still well within the range of past studies 
and not much above the range of general practice patients2 (18.5% (16.5-
20.6%)[184].  Conversely the prevalence of high depressive symptoms in the HN 
cancer patients was lower than in previous reports, though again still within the 
expected range.  Despite a slightly lower prevalence in the HN clinic this was not 
                                            
2
 From a sample of >1500 Norwegian patients 
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significant and there were no significant differences with regard to HADS scores 
between the two groups, or the CR control group.  This finding conflicts with 
previous reviews on depression in cancer patients which suggest that HN patients 
would have higher levels of depressive symptoms then CR patients[185], but a 
comparative study of psychological distress by cancer site found little difference 
between the two groups[186].  However, both findings were within the expected 
range and depressive symptoms only give a snapshot of patients‟ mood, so the 
prevalence of DDs in the respective clinics should be more informative. 
 
Head and neck cancer patients were more likely to be willing to be contacted if 
they had a self-rated PH of depression, but currently good levels of QoL.  
Therefore the HN sample had disproportionately high levels of patients with a PH 
of depression and fewer patients with a current DE, so it would be inadvisable to 
compare this sample to other cancer groups and previous studies.  It is possible 
that the low level of DDs in this sample is genuine and possibly even unique to St 
Bartholomew‟s hospital but it is not possible to test that given this data. 
4.7.2 Troubling symptoms 
 
As expected CR cancer patients (and controls) reported higher levels of diarrhoea 
than the HN patients.  Interestingly the CR cancer patients also reported higher 
levels of insomnia compared to the HN patients at first assessment.  With regard to 
other QoL symptoms, the HN patients reported higher levels of symptoms on the 
HN module than previous reports[4, 176, 187].  Similarly the CR cancer patients also 
reported higher levels of symptoms then previous reports[28].  Despite the functional 
impairments, both sets of cancer patients reported reasonable global QoL levels, 
which did not differ between diagnoses and are only marginally lower then that of 
the general population (estimated mean based on a sample of 276 participants 
from a Norwegian sample was 72)[4].  This supports previous reports that global 
QoL levels compare to the general population in later cancer survivors, despite 
continued functional impairments. 
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4.7.3 Symptoms associated with depression 
 
The most highly associated symptom associated with depressive symptoms in both 
sets of cancer patients was fatigue.  The other variables closely associated with 
depressive symptoms were defaecation and body image problems in CR cancer 
patients and social contact problems in HN patients.  Stoma problems were also 
associated with depressive symptoms in CR cancer patients, but could not be 
included in the multivariate analyses due to small numbers. 
 
Fatigue is highly likely to be strongly associated with depressive symptoms, partly 
due to the high comorbidity of depression and fatigue.  The other independently 
associated symptoms are symptoms unique to each cancer that are most likely to 
interfere with social functioning.  Again, supporting previous literature that impaired 
social function is associated with increased depressive symptomatology[171].  As 
the ratings are self reported symptoms it is not possible to say whether the 
depressive symptoms are due to the social difficulties caused by the cancer 
diagnosis, or whether patients with higher levels of depressive symptoms are more 
distressed by social difficulties that may be related to their cancer. 
 
In keeping with the HADS-D findings, the only independently associated symptom 
with an increased risk of a DE in CR patients was poorer body image, albeit less 
associated than a PH depression as rated by the clinical interview.  As would be 
expected from a screening instrument, HADS-D was also associated with 
increased risk of a DD.  Interestingly, PH depression as assessed by the interview, 
but not patient rated measures, was also associated with poorer body image, 
suggesting that PH clinical depression may lead to poorer body image, or that 
there is a third explanatory factor.  Also, it should be noted that the confidence 
intervals for these findings are quite broad implying the results could be interpreted 
as having low reliability and a need for further studies with larger sample sizes is 
required. 
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4.7.4 Factors associated with poorer quality of life 
 
The most highly associated symptoms with global QoL in CR cancer patients were 
depressive symptoms, problems with taste, dry mouth and sore skin.  Stoma 
problems were also highly related, but due to small numbers were not included in 
the multivariate analyses.  Taste problems and dry mouth are highly likely to be 
side effects of chemotherapy, providing more evidence towards persistent 
functional difficulties in cancer patients.  However, as with HN cancer patients, past 
studies suggest that CR cancer patients treated with chemotherapy report similar 
global QoL scores as non chemotherapy patients[188].  Despite previous findings, 
sexual function was not independently associated with QoL, and there were no 
univariate associations between impotence or dyspareunia and poorer QoL.  
However, fewer patients completed the impotence and dyspareunia scales so this 
may be due to lower numbers or sample bias.  Also, there was no difference 
between sexual function scores between CR cancer patients and controls as may 
be suggested by the literature.  However, the CR control group was also evidently 
a symptomatic group, so perhaps also experience more problems with sexual 
function than healthy controls.  The lack of patients with colostomies meant it was 
not possible to investigate the independent association of a stoma with mood or 
QoL and the univariate effects should be interpreted with caution.  Although if the 
univariate effects are representative of the population, then for the effect to be 
significant in such a small sample implies it is of great concern to a select group of 
patients, so the issue of stoma complications should be investigated further. 
 
Counter to the hypothesis, HADS-D was not independently associated with global 
QoL in HN patients.  The only variables associated with poorer global QoL in HN 
patients were fatigue, pain, problems with social contact and increasing age.  
Fatigue and pain are symptoms that are often associated with depression, 
accordingly the univariate relationship between HADS-D and global QoL was 
confounded by fatigue.  This indicates that whilst depressive symptoms were 
associated with global QoL, depressive symptoms were not independently 
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associated with poorer QoL, and fatigue had a stronger association with QoL than 
depressive symptoms.  Unfortunately it is impossible to ascertain the origin of the 
fatigue, or the cause or effect relationship between depression and fatigue in a 
cross sectional analysis on cancer patients.  HADS-D scores at T1 did not 
confound the model, but it is unlikely that depressive symptoms would lead to 
fatigue by a delay of over two years.  In keeping with the hypotheses, problems 
with social contact was the only other symptom variable independently associated 
with poorer global QoL, supporting past work showing that interference with social 
function is important to overall QoL. 
4.7.5 Limitations and conclusions 
 
Despite a relatively good completion rate, the study is limited by the lack of 
completion by about 40% of patients.  If there are differences in those that declined 
to complete the questionnaires or were missed by the researchers this may mean 
that the results are biased.  Also, this highlights potential barriers of using 
questionnaires as a screening tool for depression.  The 40% completion rate is 
despite the availability of a researcher for most of the study in the HN clinic and for 
half the study time period in the CR clinic.  There are obvious barriers to 
completion, such as language difficulties and no reading glasses.  Also many 
patients were reluctant to complete questionnaires about how they were feeling.  
However, the most pronounced barrier to higher completion rates was that many 
patients were missed by the researchers whilst the researcher was with another 
patient.  This suggests that if questionnaires were to be used in clinics for 
screening purposes, the clinical team need to be involved in the distribution of the 
questionnaires.   
 
The prevalence of DDs must be interpreted cautiously because those who met 
criteria to be contacted (e.g. indicated a PH depression) were more likely to 
provide their number, so in that sense the estimated prevalence based on those 
individuals who provided their contact number is probably over estimating the true 
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prevalence.  It is because of this bias that the prevalence of PH depression was 
not calculated, as patients with a PH depression had not only been selected for by 
the study protocol, but also by self selection therefore likely to lead to a sizable 
difference between the estimated and true prevalence in the clinics.  However, with 
regard to the prevalence of a current DE only those patients that were at risk of a 
DD on screening were interviewed, so false negatives would not be accounted for, 
leading to an estimated prevalence that is lower than the true prevalence in the 
clinics.  This is likely to mean that some cases have been missed, but probably 
only a small number as the inclusion criteria for follow up was very broad and 60% 
of the CR patients and 50% of the HN patients were eligible for follow up. 
 
There is also a possibility that the different operating procedures of the two clinics 
have affected the results.  Firstly, different people were involved in the distribution 
and collection in the two clinics, so although the response rates are comparable, 
there may be differences in the population that were missed by the researchers.  
Also, HN patients are followed up at the clinic much more frequently then CR 
patients; unless there are any complications HN patients are issued follow up 
appointments every month after surgery for the first year, followed by a gradual 
decline in appointment frequency to once a year for 10 years.  This is compared to 
a six to eight week post operative follow up for CR cancer patients, then a six 
month follow up and then the last follow up is at five years post treatment.  
Therefore, the time between diagnosis and completing the questionnaires may 
differ between the CR cancer and HN cancer group which may affect depressive 
symptoms and QoL.  Also, since HN patients attend the clinic more frequently they 
may be more accommodated to the clinic setting, meaning the CR cancer patients 
might score higher on the HADS because of an increased emotional effect from 
being in the clinic.  The results may also have been affected by differences in stage 
of cancer and type of treatment.  This information was not available in this study, 
so it is not possible to test for differences or adjust for them.  The analyses using 
the HN T2 data may also be slightly biased by the fact that those HN patients 
completed the questionnaire at home and not in a busy clinic setting, as was the 
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case previously and in the CR sample; this may have affected their mood at the 
time of completion.  Also, the study does not include a general population control 
sample, so whilst it is possible to compare the results to that of previous reports on 
levels of depression and QoL measures in the general population, it is not possible 
to test for differences. 
 
In conclusion, most of the findings from this sample support the previous literature; 
the levels of depressive symptoms are slightly higher than the levels you might 
expect in medical general practice samples, but still within the estimated range.  
However, the point prevalence of a DD appears to be within the range of the 
general population in the two clinics.  Only 11 of the contacted CR non cancer 
patients were currently experiencing a DE which indicates an estimated prevalence 
of 14%.  This is compared to an identical point prevalence in the CR cancer 
patients and 5% of HN patients.  Whilst the point prevalence looks to be much 
lower in HN cancer patients, this is not significant.  The apparent lower prevalence 
could be due to the sample bias towards those with a PH depression, but improved 
QoL and lower depressive symptom levels around the time of the interview.  
Suggesting that this sample has selected for patients with a PH depression but 
who are less likely to be suffering from a current episode. 
 
Also, although the difference was not significant, it was surprising that HN cancer 
patients had lower levels of depressive symptoms then CR patients, given that the 
previous literature suggests that they would show higher levels of distress due to 
the greater functional impairment associated with HN cancer.  As previously stated, 
this may be due to chance, but may also be due to the differences in clinic 
protocols. 
 
Finally, the data show that both sets of patients have similar global QoL levels to 
that of the normal population.  However, there are continued functional problems in 
both cancer groups (and the CR controls) as supported by past studies[146, 173].  
This finding in some respect appears to contradict the finding of a relationship 
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between these functional difficulties and depressive symptoms and global QoL.  
The most likely explanation is that the effect sizes are small; the clinical 
implications of this are expanded on in the final discussion section of this thesis. 
 
To summarise, the cross sectional study (part 2) of the thesis investigated the 
relationship between depression and QoL in a cross sectional sample.  This part of 
the thesis partly addressed: 
1. The first aim of the thesis; to measure the prevalence of DD in the CR 
cancer and HN cancer clinics at The Royal London and St Bartholomew‟s 
hospitals. 
2. The first hypothesis that PH depression would be an important risk factor for 
a current DE in cancer patients. 
3. The third aim of the thesis: to explore associations between other 
explanatory factors (such as symptoms) and depressive symptomatology. 
 
The results showed no significant differences between any of the depression 
measures between the two cancer populations or between the CR cancer 
patients and CR controls.  In keeping with the previous literature, cancer 
specific items that are likely to interfere with social function were the most likely 
to be associated with depressive symptoms.  Similarly, depressive 
symptomatology (including pain and fatigue) were very strongly associated with 
poorer QoL, more so than any other cancer symptoms.  The next section (part 
3) of the thesis further addresses the aims of the thesis using a prospective 
design.  Wherever possible the results are compared to these findings. 
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5 Prospective methods 
 
The previous part described the methods and results to a cross sectional approach 
to investigating depression in cancer patients.  This part explains the methods, 
background and results to a longitudinal study investigating potential markers for 
depression and poorer QoL in newly diagnosed HN or CR cancer patients.  This 
chapter explains the recruitment, procedure and analysis for the study.  The results 
from this study are presented in Chapters 6-10.  Most of the methods are 
described in this section, with the exception of the multivariate procedure used in 
Chapter 10, which is reported along with the respective results. 
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Ethics approval was obtained (06/Q0605/144) from the East London and The City 
Research Ethics Committee three on 15 January 2007. 
5.1 Participants 
 
All newly diagnosed cancer patients who presented to the HN cancer clinic or CR 
clinic between March 2007 and March 2009 and who spoke English were eligible 
to take part in the study.  See appendix 5. 1 for patient information sheet. 
5.2 Evaluations 
5.2.1 Demographic and cancer related variables 
 
 Patient age on joining the study, sex, ethnicity and marital status were all 
recorded. 
o Marital status was recorded as: married, cohabiting, widowed, 
divorced/separated or single. 
o Self identified ethnicity was recorded for each patient, but due to low 
power, ethnicity was simply coded as white and non-white for 
analyses. 
 Patients were asked their height and weight to calculate their BMI. 
 Patients were also asked to provide information on smoking and alcohol 
consumption.  If the patient could not be asked because they withdrew from 
the study or died soon after their treatment then the information was taken 
from their notes (where available). 
 Information on comorbid disabilities (e.g. chronic obstructive pulmonary 
disorders (COPD), arthritis, ischaemic heart disease and diabetes) was 
recorded using patient reported symptoms and patient notes.  Comorbid 
disabilities were coded from zero to two based on level of severity of 
symptoms, such that severe COPD would score two, whereas milder 
versions (e.g. controlled asthma) would score zero.  Hypertension was 
scored as zero unless there was evidence of symptoms.  Diabetes was 
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scored as one.  The comorbidity rating was scored independently by a 
psychiatrist (AK) and one non-medic (JA) and then reaching consensus. 
 Past or present alcohol abuse was assessed during the SCAN interview and 
through consensus with a psychiatrist. 
 
 Tumour, node, metastases (TNM) staging was used as an indication of the 
extent of the tumour.  T stage, N stage and metastases were all coded as 
separate variables. 
 Treatment with adjuvant chemotherapy or radiotherapy was also recorded. 
 A variable to code for surgical severity was also derived for the purposes of 
this study.  The variable was scored from zero to five, with one point for 
each of the following criteria: 
o Colorectal cancer patients 
1. Length of operation 
2. Significant post operative complications 
3. Extended length of hospital stay 
4. Stoma formation 
o Head and neck cancer patients 
1. Length of operation 
2. Need for sophisticated construction 
3. Significant post operative complications 
4. Extended length of hospital stay 
5. Surgery resulting in adverse effect on aesthetics of function 
 
The criteria were decided by consultation with surgeons and the surgeon made the 
rating for each of their patients. 
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5.2.2 Questionnaires and interview 
 
The following were used: 
 
•   The HADS, as described in the evaluations section of chapter 3. 
 
•   The EORTCQ and the H&N35 module for HN cancer patients or the CR29 
module for CR cancer patients as described in the evaluations section of chapter 3.  
The CR29 was only completed by the minority of CR patients because it was only 
available towards the end of the recruitment period. 
 
 The Childhood Trauma Questionnaire- Short form (CTQ) (appendix 5. 1) – The 
CTQ is a 28 item inventory that provides a reliable and valid screening for history 
of abuse and neglect [189].  The CTQ has shown a consistent five factor structure 
assessing emotional, physical and sexual abuse and emotional and physical 
neglect with five items contributing to each subscale.  A further three items assess 
a tendency towards minimising negative experiences known as the denial scale as 
a way of checking for social desirability effects.  This scale asks questions such as: 
“There was nothing I wanted to change about my family”.  It is thought that few 
individuals would have always thought “There was nothing I wanted to change 
about my family” when growing up.  Therefore answering “very often true” to such 
questions is thought to indicate possible minimisation of any negative memories.  
(Thus “very often true” is scored as one and any other answer is scored zero.)  The 
greater the score on the denial scale, the greater the likelihood of minimisation.  
The CTQ correlates with clinician and therapist ratings of abuse and demonstrates 
excellent reliability in clinical and community samples[189].  Test retest reliability 
coefficients are reported to range from 0.79 to 0.86 over an average of four 
months.  Internal consistency of the CTQ is excellent overall (alpha = 0.91) and 
acceptable for each subscale (0.58 for physical neglect, 0.69 for physical abuse, 
0.83 for emotional abuse, 0.85 for emotional neglect and  0.94 for sexual abuse) in 
a community sample[190].  The scale can also be used as a total score through 
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combining all the subscales (not including denial).  The total score was used in this 
study because total score was considered a more inclusive and sensitive measure. 
 
•  Eysenck Personality Questionnaire (EPQ) (appendix 5. 3) - The EPQ, first 
published in 1975, is a well validated questionnaire to assess personality traits[191].  
The inventory consists of 88 questions and is considered to have a three factor 
structure assessing extraversion, NE and psychoticism and a „lie‟ scale to indicate 
a bias towards socially desirable answers.  Twenty-three questions relate to NE 
which is the scale of interest in this study.  For each item, patients are instructed to 
answer „yes‟ or „no‟; a yes answer scores one point and a higher score indicates a 
higher degree of NE.  All four scales have been found to have high validity with 
alphas of 0.86, 0.83, 0.80 and 0.61 for extroversion, NE, lie and psychoticism 
respectively[192]. 
 
•   The Brief Life Events Questionnaire (BLEQ) (appendix 5. 4) – The BLEQ 
screens for any significant LE in the preceding six months[193]. The questionnaire 
includes 12 events and participants are asked to indicate whether the event has 
happened to them in the last six months.  If yes, then the participant indicates the 
level of distress caused by that event, choosing from „very bad‟, „moderately bad‟ 
and „not too bad‟.  The questionnaire also has two open ended questions.  The first 
asks whether anything has happened to them in their life that has caused them a 
lot of stress (and if so, what) and the second asks if they think anything has 
happened to them in their life that has caused them to feel depressed (and if so, 
what).  Each item is scored to give an indication of the number of stressful LE that 
happened in the last six months, giving a total number out of 12.  The 
questionnaire was also scored to include only responses that indicated a moderate 
or very bad level of distress.  Finally, the questionnaire was also used as a scale 
where each item scores either zero (no event) one (not too bad) two (moderately 
bad) or three (very bad). 
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•   The brief COPE (appendix 5. 5) - The brief COPE consists of 28 items relating 
to coping and support seeking strategies and is considered a reliable tool to assess 
14 conceptually different coping styles[194].  Each item details a behaviour which 
may offer support (e.g. I‟ve been taking action to try to make the situation better) 
and the participant is asked to indicate the level to which they usually use that type 
of support on a scale of zero to three.  Each coping style scale is the sum of two 
items randomly placed in the questionnaire.  The scales are shown below with 
respective Cronbach‟s reliability alpha: 
 Active coping (0.68) 
 Planning (0.73) 
 Positive reframing (0.64) 
 Acceptance (0.57) 
 Humour (0.73) 
 Religious coping (0.82) 
 Use of emotional support (0.71) 
 Use of instrumental support (0.64) 
 Self distraction (0.71) 
 Denial (0.54) 
 Venting (0.50) 
 Substance use (0.90) 
 Behavioural disengagement (0.65) 
 Self-blame (0.69) 
Patients were asked to complete the questionnaire with respect to how they have 
coped with their cancer diagnosis. 
 
 The SCAN interview as described in the evaluations section of chapter 2. 
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5.2.3 Physiological evaluations 
5.2.3.1 Cortisol protocol 
 
Saliva samples for cortisol analyses were collected in plastic salivettes, consisting 
of a sterile cotton swab inside a plastic tube (Sarstedt, UK).  Patients were 
instructed to chew on the cotton swab for a minute and return the swab to the tube 
and store the salivettes in the fridge.  Each kit contained nine labelled salivettes 
with patient identification and the appropriate measurement time (e.g. Day 1, PM), 
full instructions for sampling and a freepost envelope with which to return the 
samples.  Patients were asked to take samples on waking, 30 minutes after waking 
and before going to bed on three consecutive days.  Patients were also asked to 
write down the time and date of each sample, either on the tube or on the 
instructions checklist.  Patients were asked not to smoke, eat or drink for 30 
minutes before each sample.  Patients were told that it was imperative for them to 
be honest about what time they took the sample and if they forgot a sample, to 
miss out that one and wait until the next sample was due.  Full patient instructions 
are provided in appendix 5. 6. 
 
Once patients had completed all nine samples they were instructed to post them in 
the first class envelope provided.  On receiving the samples, the salivettes were 
centrifuged, and the saliva was aliquoted into eppendorf tubes and frozen at -20ºC 
until ready for analysis. 
 
Samples were sent on dry ice to the Laboratories of Integrative Neuroscience and 
Endocrinology at the University of Bristol, under the care of David Jessop for 
radioimmunoassay.  Intra and inter assay variability has been reported to be less 
than 5% and 10% respectively[195].  See appendix 5. 7 for full assay protocol. 
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5.2.3.2 Cytokine and CRP protocol 
 
5ml blood samples were collected between 8am and midday, with the majority of 
samples collected between 8:30 and 10:00am.  Blood was kept on ice before being 
centrifuged at 1500 rpm or 3000 rcf for 10 minutes at 4°C.  Plasma was aliquoted 
into 5 x 200 µl aliquots and the remaining plasma aliquoted in 1ml volumes into 
appropriately labelled vials.  The blood pellet was disposed of.  The aliquoted 
plasma was snap frozen in liquid nitrogen and then stored at -80 until analysis. 
 
Cytokine assays were conducted with a Meso Scale Discovery (MSD) multiplex 
imager (www.mesoscale.com) using the multi-spot human plasma protocol at the 
Centre for Cancer and Inflammation, Institute of Cancer, Barts and The London 
School for Medicine and Dentistry, Queen Mary University of London.  The MSD 
small spot was found to be the most consistent and sensitive method for 
assessment of IL1ß and IL6 levels in human serum[196].  Average intra assay 
variation for IL6, IL1ß, TNFα and IFNγ was 4.52%, 5.40%, 3.33% and 2.82% 
respectively.  In total nine assay plates were run.  Average inter assay variation for 
the last five assay plates was 7.23%.  Results taken from assays one to four were 
anchored to the fifth plate due to an unacceptable level of inter assay variation in 
previous assays, caused by using assay kits from different batches.  Full cytokine 
analysis details can be found in appendix 5. 8. 
 
C-reactive protein assays were carried out by the Glasgow Department of Clinical 
Biochemistry.  Samples were sent on dry ice and were measured according to the 
Abbott Architect method.  Intra and inter assay coefficients of variation (cv) are all 
reported to be <3% at 3 levels of quality control (see table 5.1). 
 
Level Mean CRP (mg/l) Intra assay cv (%) Inter assay cv (%) 
1 5 1.02 2.15 
2 18.1 0.32 0.49 
3 73.3 0.50 0.54 
Table 5.1: Coeffecients of variation for CRP assay results. 
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5.3 Procedure 
 
All eligible patients were invited to join the study after confirmation of their 
diagnosis and treatment plan.  All patients taking part gave written informed 
consent. 
 
 See figure 5.1 for an overview of patient involvement. 
 Before treatment, patients completed the HADS and EORTC-QLQ and the 
appropriate cancer specific module.  Patients also took home the saliva sampling 
kit and were instructed to choose 3 days in which to take the saliva samples 
between the date of recruitment and their surgery. 
 Blood samples were taken just before surgery (T1), one week after surgery (T2) 
and 6-8 weeks (T3) post surgery. 
 The HADS and EORTC-QLQ were repeated at six to eight weeks (T3), three 
months (T4) and six months (T5) post operation. 
 Patients completed the BLEQ at one (T3) and six months post treatment (T5). 
 Patients completed the SCAN, COPE, EPQ and CTQ between three to six 
months after treatment. 
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Figure 5.1: Flowchart depicting overview of questionnaire and sampling timetable. 
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5.4 Analyses 
 
All ordinal variables (T stage, N stage, cormorbid disability) were treated as 
continuous.  Treating ordinal items as categorical would reduce power and the 
relationships were expected to be linear 
 
Past studies indicate that relatively small samples (50 patients) should be 
adequate to detect an association between the psychological variables and 
depressive symptoms[161].  The most power limited factor for this study was most 
likely to be the cortisol and cytokine analyses, due to the large variation between 
patients.  The variation may be caused partly by measurable factors such as 
medication, smoking and body mass index (BMI) as well as harder to measure 
factors such as location of tumour in the case of saliva samples in oral cancers.  
Although some previous studies have found significant differences in IL6 in cancer 
patients with a DD compared to those without[139, 140], their analyses were non 
parametric, so no power calculation could be conducted.  This study is considered 
as a predominantly exploratory pilot study to assess which variables give the 
greatest effect, thus informing future larger scale studies which can focus on the 
most promising variables. 
5.4.1 Exclusions 
 
For the most part an inclusive approach was taken to the data, as the 
questionnaires were self limiting and cancer patients are expected to have a wide 
range of cytokine levels, especially after surgery[197]. 
5.4.1.1 Questionnaire and demographic data 
 
No individual patient questionnaire data was excluded from the study. 
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Due to power restrictions, items were excluded from multivariate analyses if fewer 
than 17 patients had completed the item.  Seventeen was chosen as that was the 
lowest number of patients who completed all the main variables of investigation 
(CT, NE, LE or PH depression).  Categories in categorical variables were excluded 
if less than seven patients were in that category.  Ordinal data were also excluded 
if less than three patients scored higher than baseline in the variable. 
 
As a result of the above exclusion criteria, questions regarding PH depression or 
DE were only investigated using both cancer groups, as too few patients had a DD 
for the analyses to be stratified.  Due to low numbers: 
 Ethnicity and metastases were excluded from further analyses. 
 Radiotherapy was only used in HN analyses. 
 Marital status was condensed into married and unmarried. 
 Alcohol consumption was condensed into current drinker and teetotal. 
 Smoking was condensed into never smoked, past smoker and current smoker. 
The numbers for the new variables are given in the next chapter. 
5.4.1.2 Recruitment and sample characteristics 
 
Body mass index was also excluded from the multivariate analyses.  Baseline BMI 
was taken, as it was a possible covariate of cytokine levels and depressive 
symptoms.  Body mass index was not associated with any cytokine levels.  Body 
mass index was not considered an appropriate covariate for depressive symptoms 
alone in CR or HN cancer patients, as BMI can change dramatically over the 
course of cancer development, diagnosis and treatment. 
5.4.1.3 Physiological data 
 
Despite the inclusive approach there were a few findings that appeared to be 
obvious outliers so these were removed from the dataset: 
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Most cortisol levels were between 0.2 and 5pg/ml.  Any results which were over 
15pg/ml more than the overall mean for that individual for that sampling time (when 
excluding the high finding) were excluded.  This resulted in the loss of 10 samples, 
but no lost data points when analysing the means.  One patient also had morning 
samples over 30 but did not sample on any other days so these data were 
excluded as the levels were over two standard deviations above the total group 
mean.  This resulted in losing the morning samples of one patient. 
 
All IL1ß data were excluded from analyses because the range was very small 
[mean(sd)=0.24 (0.40), median=0.08 range 0-3.52] and 66% of patients were 
below the level of minimum detection. 
 
The IL6 data for one patient were excluded as the IL6 levels were over twice that of 
the second highest level and their IL6 levels did not correlate with their CRP levels 
[IL6 levels (pg/ml) T1=46, T2=391, T3=67].  All other cytokine and CRP results 
were retained. 
 
Please see chapter 8 for summaries (including range) of included physiological 
measures. 
5.4.2 Sample and data checks 
 
1. Logistic regressions were carried out to check representativeness of the 
recruited sample with regard to demographic information. 
 
2. Logistic regressions were carried out to check representativeness of sample 
at each study wave compared to patient wave non-completion or permanent 
patient loss. 
 
3. Due to clinical restrictions there was some variation between date of 
diagnosis and treatment and completion of questionnaires and blood 
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samples.  Linear regressions were conducted to test for an effect of time 
between  
a. Diagnosis and cytokine levels, depressive symptoms and QoL. 
b. Time between first and later blood samples. 
c. Time between start of treatment and later cytokine levels, depressive 
symptoms and QoL. 
5.4.3 Hypothesis testing 
 
T tests or Mann-Whitney and Chi-squared analyses were used to test for 
differences between the two cancer groups.  The results indicated some important 
differences between HN and CR patients, so for the purposes of the regression 
models, the analyses were stratified as the samples were too small to test for an 
interaction.  Stratifying the results still allowed for (non statistical) comparison 
between the two groups and helped to prevent the possibility of misinterpreting 
effects that were only applicable to one patient group.  However, it was not 
possible to stratify for analyses involving PH depression or DE6 due to low 
numbers, so for these analyses the groups were combined. 
 
Linear regression models were carried out at each wave of data collection to check 
for associations between CT, NE, LE, PH depression and 1) depressive symptoms 
and 2) global QoL at each time point. 
 
Logistic regression models were carried out to test for an association between CT, 
NE, LE, PH depression and development of a DE within six months (DE6) after 
treatment starts. 
 
Multilevel regression analyses were used to investigate an overall effect of CT, NE, 
LE or PH depression on depressive symptoms or QoL using patient identity as the 
panel variable.  This technique allows the relationships between variables to be 
investigated in all data waves through relaxing the assumption of independence 
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between the panel variable (see below).  Multilevel regression was also used to 
test for an interaction with time, to indicate whether the strength of any relationship 
is greater at later time points. 
 
Multiple tests were required to test the many hypotheses.  No correction for 
multiple testing was made, due to the small sample size and pilot nature of the 
study that could increase the risk of false negative findings.  Thus, anomalous 
findings were interpreted with caution and the p values were presented in order to 
give an indication of the strength of the association and therefore whether the 
association is worthy of further investigation. 
5.4.3.1 Regression assumptions 
 
As stated in Chapter 2, robust standard errors were used in the analyses.  
Unfortunately, due to computational restrictions it was not possible to use robust 
standard errors in multilevel logistic regression. 
 
The associations found using robust errors were also checked using bootstrapped 
standard errors.  Bootstrapping works by taking numerous sub samples of the data 
and then averaging out the standard error terms, thus the confidence intervals 
(CIs) are less likely to be skewed by extreme values.  Bootstrapping is considered 
to be useful in smaller samples and in non parametric samples.  However, 
bootstrapping has been criticised for reporting 95% CIs which aren‟t truly 
representative of 95% of the population, resulting in a bias towards positive 
results[198].  To prevent a bias towards positive results the analyses were also run 
using 99.99% CIs, which showed the same results as using 95% CIs.  
Nevertheless, in order to be extra conservative, bootstrapping was only used to 
check any significant results from using the robust standard errors.  Using 
bootstrapped standard errors made no difference to the psychological results, but it 
did make a difference to the physiological results.  Due to the inclusive approach 
with the physiological data it was possible that the results were skewed by outliers, 
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thus regressions for the cytokine and cortisol analyses were rerun using 
bootstrapped standard errors and both results are reported.  The final multivariate 
models were also checked using bootstrapped standard errors.  Unfortunately, due 
to computational restrictions it was not possible to use bootstrapped standard 
errors in multilevel logistic regression. 
5.4.4 Missing data 
5.4.4.1 Missing single items 
 
Missing items on the HADS and EORTC-QLQ were dealt with as described in the 
main methods in Chapter 2.  Seven patients were missing an item on one or more 
scale, thus their scores were inferred by using the mean of the remaining six items.  
No patient had more than one item missing on either scale for the HADS.  Fifteen 
patients were missing single items on the multi-item scales in the core EORTC-
QLQ (not including the functional scales).  Similarly another 37 on the H&N35 and 
15 on the CR29 were imputed.  Many more single items on the EORTC-QLQ were 
missing and were treated as missing data. 
 
Missing items on the CTQ were imputed using a mean of the other four items on 
the subscale, provided that only one item was missing on the subscale.  If the 
patient missed out an item on the denial scale, the denial score was simply the 
total of the other two items.  Six patients had imputed data on one or two scales 
and four patients had a missing item on the denial scale.  No patients missed more 
than one item on any one scale or were missing more than two items overall.  
There was no apparent pattern to which items were missed. 
 
Missing items on the EPQ-N scale were assumed as „No‟ answers therefore 
potentially biasing towards lower NE scores in these patients.  Five patients were 
missing one item, two patients missed two items, one person missed three items, 
two patients missed five items and two patients missed six items (out of 29 
possible items). 
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Items on the BLEQ were treated as if no LE had occurred, potentially biasing 
towards lower levels of LE.  Seven people missed one item (three at T3 and four at 
T5), four people missed two items (one at T3 and three at T5) and one person 
missed three items (T3).  Two patients missed seven items so their LE data were 
discarded. 
 
Only three people missed one item on the COPE.  There are no specific 
instructions for dealing with missing items on the COPE.  As each scale consists of 
two items, in cases of one missing item, the score of the completed item was 
doubled to be representative of a two item scale score.  One person missed 
thirteen items on the COPE and their COPE data were discarded. 
5.4.4.2 Missing scales or measures 
 
There were relatively few missing data for each of the measures, apart from on the 
H&N35 and CR29 modules, due to the late introduction of those modules to the 
protocol.  Complete case analyses were conducted.  In the case of the multivariate 
analyses further post hoc tests were carried out to check the patients in the final 
model were representative of the univariate analyses (please see multivariate 
methods in chapter 10).  Missing data numbers are reported in the next chapter. 
5.5 Summary 
 
This chapter explained the data collection and the procedure for the analyses for 
the following results chapters.  More detail on the multivariate analyses is given in 
chapter 10. 
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6 Recruitment and sample characteristics 
 
This chapter focuses on the following:  
1. Measurement of the prevalence of DDs in the two cancer clinics (aim 1 of 
the thesis –section 1.6.1) 
2. Testing the hypothesis that depressive symptoms are strongly related to 
poorer QoL in cancer patients (hypothesis 1, section 1.6.1) 
3. Introducing the dataset that is used in the following results chapters. 
4. Describing the recruitment, patient characteristics and representativeness 
for the prospective study.  The demographic and cancer related variables 
are presented, as well as the prevalences and means of depressive 
symptoms, global QoL scores and incidence of a DE6. 
The background to this section briefly covers the expected prevalences of both 
depression measures and the levels of QoL in this population as well as the 
rationale behind the hypotheses.  The discussion summarises the results and 
compares the results to that of the cross sectional data in chapter 4. 
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6.1 Background 
 
It has been suggested that HN cancer patients experience higher levels of 
depressive symptoms[185] compared to patients with other types of cancer, but a 
closer inspection of the literature suggests that this may not be the case and 
depressive symptom levels are not especially high in ambulatory HN patients 
compared to other cancer patients[121, 186].  However, a transient rise in depressive 
symptoms following diagnosis has been described in HN patients which is more 
marked than in those with CR cancers[146, 169]. This could be explained by the 
immediate high impact of HN surgery on patients‟ function and appearance and the 
increased used of radiotherapy in treating HN patients compared to CR patients.  
However, very few prospective studies have focused on mood and QoL in CR 
patients and the majority of QoL studies have studied patients over one year past 
diagnosis. 
 
Based on the research reported above, the prevalence of a DD would be expected 
to be similar to that found in the general population (only slightly higher then that of 
a 6 month prevalence)[125], which has been reported to be between 10 and 20%[59, 
60, 199].  No major differences were expected between the two samples in terms of 
depression or QoL.  HADS-D scores were expected to be highly correlated with 
global QoL at each data wave as reported in the cross sectional study (chapter 4). 
6.2 Patient recruitment 
 
Figure 6.1 details the flow of patient recruitment and attrition.  Overall 58% of 
eligible HN and 71% of eligible CR patients (total 65%) took part.  The reason for 
lower participation of HN patients was most likely because HN patients were often 
“fast tracked” with surgery taking place within a few days of diagnosis and 
therefore there was less opportunity for patients to be contacted before treatment.  
Forty-one HN and 22 CR patients completed the study.  There was a total of 20 HN 
and 18 CR patients who either withdrew from the study (five HN and six CR), died 
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(seven HN, seven CR) or were lost to follow up for other reasons (details shown in 
figure 6.1). 
 
There was no difference between demographic variables in patients who took part 
compared to those who were uncontactable before their treatment or who refused 
to take part.  Although, there was a trend for younger patients taking part [N=163, 
p=0.071].  Full details are shown in appendix 6. 1. 
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Figure 6.1: Consort diagram for prospective study. Permanent patient loss and reasons is shown in 
the centre.  Temporary loss of patient data and reasons is given on the right.  NR=Not returned or 
received, VP=Venepuncture problem  *HN 1 benign, 2  too extensive disease, 1 went private, 1 
excluded due to cognitive impairment, 1 dropped out.  CR: 1 benign, 1 went private, 2 changed 
treatment, 2 dropped out. 
Chapter 6: Recruitment and sample characteristics 
131 
6.3 Questionnaire reliability 
 
With the exception of a few scales on the EORTC-QLQ CR29 where very few 
patients completed the scale, or where there was little variation between scores, all 
the questionnaires used in the study show acceptable reliability (Cronbach‟s 
alpha>0.60) with the majority showing good internal consistency.  See appendix 6. 
2 for Cronbach‟s alphas for each questionnaire scale. 
6.4 Representativeness 
 
Logistic regression analyses were conducted for each wave of data collection to 
investigate differences between those who took part compared to those who did 
not, as detailed in section 6.2 (including permanent and temporary exclusions). 
Type of cancer did not affect whether patients completed each wave of data 
collection.  The data were representative at each wave with the following 
exceptions: 
 Patients with higher IL6 levels at baseline were less likely to provide the T2 
blood sample. 
 Those who took part in T2 and T3 waves (but not T4 or T5) of data collection 
were younger then those that did not. 
 From T3 onwards patients who took part had fewer comorbid illnesses and 
lower cytokine levels at T2. 
 Patients who took part in waves T4 and T5 also had lower IL6 and CRP levels at 
T3, but higher levels of IFNγ. 
 All other variables were non significant. 
 
All of the significant results for T2, T3, T4 and T5 are presented in appendix 6. 3 to 
appendix 6. 6 respectively.  Appendix 6. 7 presents an example of the all of the 
variables tested using T5. 
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These findings are consistent with the fact that some patients with very high levels 
of inflammation died soon after their operation and those with greater disability 
were more likely to struggle with taking part in the study alongside the cancer and 
their other illnesses. 
6.5 Effect of time 
 
There was a significant effect of time taken from diagnosis to first blood sample on 
TNFα at T1 in CR patients [N=28 ß(CI)=0.02 (0.00 to 0.05) p=0.039].  If a model was 
found to be significant the model was adjusted for the time taken from diagnosis to 
first blood sample and it did not affect the model. 
 
IFNγ levels were significantly associated with time between the blood sample at T1 
and T2 [N=39 ß(CI)=0.10 (0.00 to 0.19) p=0.041] in HN patients, but this did not 
affect any of the findings when models were adjusted for the amount of time 
between samples.  Also the time from starting treatment to T3 global QoL 
measurements and T4 HADS-D measurements were associated.  With longer time 
associated with poorer QoL at T3 and increased HADS-D at T4 [N=45 ß(CI)=-0.34 
(-0.67 to 0.00) p=0.047; N=42 ß(CI)=0.04 (0.01 to 0.07) p=0.022; respectively]. 
6.6 Patient characteristics 
 
Table 6.2 shows the baseline demographic characteristics of the sample.  To 
summarise, the mean (standard deviation [sd]) age of patients at baseline was 66 
years (12.47), although CR patients were significantly older and had significantly 
more comorbidities.  
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Measure CR  HN  
N 35 56 
Age*     mean (sd) 70.41 (9.91) 62.61 (13.03) 
Sex 
Male 
Female 
 
17 (48.57) 
18 (51.43) 
 
32 (57.14) 
24 (42.86) 
BMI                       
N 
Mean (sd) 
27 
25.87 (4.29) 
41 
25.29 (4.53) 
Ethnicity 
White 
Other 
 
31 (88.57) 
4 (11.43) 
 
48 (85.71) 
8 (14.29) 
Married 
No 
Yes 
 
13 (39.39) 
20 (60.61) 
 
15 (27.78) 
39 (72.22) 
Comorbidity 
rating* 
0 
1 
2 
Missing 
 
11 (33.33) 
10 (30.30) 
12 (36.36) 
1 
 
30 (60.00) 
12 (24.00) 
8 (16.00) 
6 
Table 6.1: Demographics for all patients at baseline. N(%) 
unless otherwise stated. *p<0.05. 
 
Table 6.2 shows the prevalence of smoking and alcohol consumption in the two 
patient groups.  HN patients were more likely to smoke and have a history of 
alcohol abuse.  However, the difference in smoking was only statistically significant 
if smoking was categorised into five groups, the effect was reduced to a trend 
when smoking habits were categorised into the three groups that were used in 
multivariate analyses. 
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Measure CR  HN  significance 
Smoking 
Never 
Past 
Present 
 
10 (40.00) 
12 (48.00) 
17 (12.00) 
 
12 (25.00) 
19 (39.58) 
17 (35.42) 
 
 
 
χ2(2)=4.79, p=0.09 
Alcohol 
No 
Yes 
 
8 (36.36) 
14 (63.64) 
 
8 (17.78) 
37 (82.22) 
 
 
χ2(2)=2.81, p=0.10 
Alcohol abuse 
No 
Yes 
 
33 (100) 
0 
 
39 (82.98) 
8 (17.02) 
 
 
χ2(2)=6.24, p=0.01 
Table 6.2: Smoking and alcohol consumption in all patients at baseline.  Reported as N(%). 
 
Table 6.3 shows the cancer-related information for HN and CR patients.  Colorectal 
patients tended to have more extensive tumours than HN patients; most CR 
patients had T stage III, whereas most HN patients had T stage I tumours.  
Colorectal patients were also more likely to have metastases, whereas HN patients 
were more likely to be treated with RT. 
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Measure CR HN significance 
T stage 
I 
II 
III 
IV 
Missing 
 
2 (5.88) 
6 (17.65) 
20 (58.82) 
6 (17.65) 
0 
 
23 (41.82) 
12 (21.82) 
8 (14.55) 
12 (21.82) 
1 
 
 
 
 
 
χ2(3)=23.11, 
p<0.001 
N stage 
0 
I 
II 
Missing 
 
21 (63.64) 
7 (21.21) 
5 (15.15) 
1 
 
33 (63.46) 
6 (11.54) 
13 (25.00) 
4 
 
 
 
 
χ2(2)=2.16, p=0.34 
Presence of 
metastases 
 
6 (17.65) 
 
1 (1.79) 
 
χ2(1)=7.42, p=0.01 
Surgery 33 (97.06) 54 (96.43) χ
2
(1)=0.03, p=0.87 
Chemotherapy 
Missing 
13 (44.83) 
5 
15 (29.41) 
5 
 
χ2(1)=1.93, p=0.17 
Radiotherapy 
Missing 
1 (3.45) 
5 
24 (47.06) 
5 
 
χ2(1)=16.37, 
p<0.001 
Recurrence 1 (2.94) 8 (14.29) χ
2
(1)=3.03, p=0.08 
Deceased 7 (20.59) 10 
(117.86) 
χ2(1)=0.10, p=0.75 
Cause of death 
Cancer 
Cancer recurrence 
Other 
Missing 
 
3 (50.00) 
1 (16.67) 
2 (33.33) 
1 
 
5 (55.56) 
4 (44.44) 
0 
1 
 
 
 
 
χ2(2)=3.85, p=0.15 
Table 6.3: Descriptives for cancer related variables for all patients at baseline.  
Reported as N (%). 
 
6.7 Depression and quality of life 
6.7.1 Prevalences and means 
 
Figure 6.2 shows HADS scores indicating the proportion of possible or probable 
(score of >7) cases for a depressive or anxiety disorder for each diagnosis and at 
each data wave.  There were no differences between the cancer groups, with 
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relatively few patients showing signs of possible or probable depression at T1.  
There was a general trend towards increasing number of cases towards T4, which 
then declined back to levels similar to baseline by T5.  The figures are provided in 
appendix 6. 8. 
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Figure 6.2: Prevalence of case level anxiety and depressive symptoms by time for CR and HN 
cancer patients based on a score >7 on the respective HADS subscale 
 
Figure 6.3 presents the mean values of HADS-D scores for CR and HN patients 
over time.  Longitudinal analyses showed that there was a significant effect of time 
in the HN group showing increased HADS-D scores at T3 and T4 compared to T1 
and no significant difference between depressive symptoms at T5 and baseline.  
There was a similar but non-significant trend in the CR group, and the effect was 
even more pronounced when both groups were combined.  These effects were still 
significant after adjusting for global QoL scores (appendix 6. 9).  The means, 
medians and standard deviations of the HADS and global QoL scores are provided 
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in appendix 6. 10 and appendix 6. 11 respectively.  The regression coefficients for 
the effects of time are provided in appendix 6. 12 and appendix 6. 13, respectively. 
 
Figure 6.3 also shows the mean global QoL scores for CR and HN patients over 
time.  There was a significant difference in QoL scores in HN patients at T3 
compared to baseline, but there were no other significant differences.  Also, the 
significant difference between T3 and T1 in QoL scores was no longer significant 
after adjusting for HADS-D scores (appendix 6. 14). 
 
 
Figure 6.3: Mean HADS-D and global QoL scores over time for each diagnosis. + p<0.10, * p<0.05.  
Symbols signify significance of difference compared to baseline.  Upper symbols for HADS-D, lower 
symbols for QoL. 
 
Table 6.4 shows prevalences of an anxiety disorder or DD.  The prevalence of a 
DE6 was 12.50% for CR cancer patients and 21.43% for HN cancer patients.  
Again, there were no significant differences between the two groups. 
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 CR N(%) HN N(%) 
 
PH depression 
N 
Y 
 
 
26  
3    (10.34) 
 
 
39  
8       (17.02) 
DE within 6 months 
N 
Y 
 
21  
3    (12.50) 
 
33  
9       (21.43) 
 
 
PH of anxiety 
N 
Y 
 
 
26  
3    (10.34) 
 
 
43  
3        (6.52) 
Anxiety within 6 months 
N 
Y 
 
21  
3    (12.50) 
 
39  
3        (7.14) 
 
Table 6.4: PH of depressive or anxiety disorder and 6 month incidence of 
depressive or anxiety episode 
6.7.2 Association between HADS-D and global QoL 
 
Depressive symptoms and global QoL were strongly correlated in both sets of 
patients at each time point (table 6.5 and table 6.6). 
 
N Time 
point 
ß (CI) P value 
32 T1 -4.99 (-6.18 to -3.80) <0.0005 
25 T3 -4.24 (-6.58 to -1.92) 0.001 
24 T4 -2.03 (-3.88 to -0.18) 0.033 
21 T5 -4.91 (-6.93 to -2.89) <0.0005 
Table 6.5: Coefficients and p values for associations between 
HADS-D and global QoL at each time point in CR patients 
 
N Time 
point 
ß (CI) P value 
52 T1 -4.08 (-5.48 to -2.68) <0.0005 
45 T3 -4.40 (-5.31 to -3.50) <0.0005 
41 T4 -2.74 (-4.15 to -4.53) <0.0005 
40 T5 -2.48 (-3.93 to -1.03) 0.001 
Table 6.6: Coefficients and p values for associations 
between HADS-D and global QoL at each time point in HN 
patients 
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HADS-D and global QoL were also highly associated when viewed over 6 months 
in both CR and HN patients [CR:N=102(34), ß(CI)=-3.74 (-4.93 to -2.56) p<0.0005; 
HN:N=178(56), ß(CI)=-3.12 (-3.87 to -2.38) p<0.0005].  Including an interaction with 
time indicated a significant interaction between T4 and HADS-D on QoL [p=0.009].  
This appeared to be mainly due to the interaction in the CR patients, hence the 
lower association between HADS-D and global QoL at T4 in CR patients 
(compared to other time points). 
6.8 Discussion 
6.8.1 Recruitment 
 
The results indicate that a high proportion of patients agreed to take part in the 
study and very few measures were excluded from the dataset.  Unfortunately, as 
may be expected, those patients who continued to take part tended to be healthier.  
For questionnaire data completed at T3 and T4 a delay in completion was 
associated with higher depressive symptoms and poorer QoL.  This was most 
likely because these patients were unable to complete the questionnaires on time 
due to complications and distress.  Thus higher levels of symptoms were 
associated with poorer compliance to the protocol.  
 
There were some marked differences in demographic and cancer related variables 
between the two cancer groups (particularly, smoking, levels of CT and 
inflammation), therefore the groups were analysed separately for the remainder of 
the analyses whenever the samples were large enough.  However the number of 
patients with a PH of depression or current DE was too low for stratified analyses, 
thus these analyses were not stratified by diagnosis.  Summaries for the 
investigated variables are presented at the beginning of the chapters on 
psychological and physiological factors respectively and relevant differences are 
highlighted. 
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6.8.2 Depressive symptoms and quality of life 
 
The mean HADS scores and proportion of patients with high HADS levels was not 
significantly different between the two groups.  As expected, there was an increase 
in HADS-D levels after diagnosis, which then fell back to baseline levels.  
Interestingly, this pattern was present in both the CR and HN cancer patients, 
despite the previous literature suggesting that CR cancer patients would be more 
likely to start with high levels of depressive symptoms which gradually decline over 
time[169].  However, the increase in depressive symptoms at one month and three 
months post surgery was only significant in the HN sample, suggesting a smaller 
effect in the CR group, although lower power cannot be ruled out as an 
explanation.  The mean HADS-D scores at six months post surgery (4.14 and 3.95 
for CR cancer and HN cancer respectively) were similar to the mean HADS-D 
scores found in the cross sectional study (4.80 and 4.91 for CR and HN 
respectively). 
 
With respect to QoL scores, again there was no significant difference between the 
two diagnoses.  However, in this case there was very little difference in the QoL 
scores in the CR cancer patients over time, whereas the HN cancer patients 
showed a significant drop in QoL one month post surgery.  This may be related to 
the extent of surgery or radiotherapy: at this point some of the HN patients would 
still be learning to speak and eat again and/or starting adjuvant radiotherapy. 
 
Consistent with the findings from the cross sectional study, HADS-D and global 
QoL were highly associated.  As stated previously, levels of depressive symptoms 
were significantly higher at one and three months after surgery.  Interestingly, in 
the longitudinal analyses the QoL of CR cancer patients did not vary significantly 
over time.  There was a significant decrease in QoL scores in HN patients at one 
month post surgery.  However, there was no significant difference over time in QoL 
scores in HN patients after adjusting for depressive symptoms.  Whereas, the 
change in depressive symptoms over time was significant even after adjusting for 
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global QoL scores.  This suggests that what little change there is in global QoL 
scores is related to depressive symptoms, whereas depressive symptoms vary 
independently of QoL.  However, this may be because the HADS is a more 
sensitive measure then the global QoL score. 
6.8.3 Depressive disorder 
 
The percentage of CR patients with a PH depression was comparable to that of the 
general population (10%).  More HN cancer patients had a PH depression (17%) 
than would be expected given the level in the general population.  Though the 
difference between CR and HN patients was not significant, the trend is consistent 
with the theory that HN patients are more likely to have a PH depression as many 
of the behavioural risk factors for HN cancer (e.g. tobacco and alcohol use) are 
associated with a DD. 
 
The incidence of a DE6 was similar to the proportion of patients with a PH 
depression; 13% for CR cancer patients and 21% for HN cancer patients.  
Although, if rates of depression are higher in less healthy individuals, these rates 
are probably substantially affected by the trend towards healthier individuals 
remaining in the study.  Again, the rates are not significantly different between the 
diagnoses.  The rate in the CR patients was similar to the point prevalence found in 
that of the cross sectional study (14%).  However, the rate in the HN patients was 
much higher than that in the cross sectional study (5%) (chapter 4) and that is 
reported in previous literature[121].  This suggests that either biases in the cross 
sectional HN study led to a lower than true estimation of the point prevalence in 
that particular clinical sample or that only recently diagnosed HN patients are at 
increased risk of a DE.  The incidence of a DE6 in CR patients was similar to that 
of the general population and supports the more recent opinion that rates of DDs in 
(curative) cancer patients are similar to that of those in general medical primary 
care patients[125].  On the other hand, the incidence of a DE6 in HN patients was 
quite high at 21%.  Although this may not be significantly different from that of the 
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general population, it does indicate that more studies with larger samples are 
needed to investigate the prevalence of a PH depression and DEs in HN cancer 
patients using a structured diagnostic interview.  This would help answer the 
question whether HN cancer patients are at increased risk of a post operative DE 
and whether this can be attributed to a greater likelihood of their having a PH 
depression. 
6.8.4 Conclusions 
 
In summary, this chapter introduced the data set for the following results chapters 
and reported and compared the levels of depressive symptomatology and QoL in 
the two cancer patient samples.  Healthier individuals tend to remain longer in the 
study compared to those with greater disability which may be expected in a 
prospective study on newly diagnosed cancer patients.  This chapter addressed 
the first aim of the thesis and reported the prevalence of depression in the CR and 
HN cancer clinics.  The levels of depressive symptoms are similar in the two 
cancer groups, though there was a non-significantly higher incidence of a DE6 in 
the HN group.  The study also tested the hypothesis that depressive symptoms will 
be strongly related to poorer QoL.  As with the cross sectional data, HADS-D and 
global QoL were highly correlated, but the extent of this relationship varied over the 
study period and HADS-D scores appeared more susceptible to change then the 
global QoL scores.  The following chapters report the relationship between the 
investigated psychological and physiological markers and depression and QoL 
scores. 
Chapter 8: Physiological factors 
143 
 
 
7 Role of psychological factors 
 
The previous chapter described the sample and the relationship between 
depressive symptoms and QoL.  This chapter aims to: 
1. Test the first hypothesis of this thesis: that patients with a PH depression 
are more likely to experience a DE following a cancer diagnosis. 
2. Explore the associations between other explanatory factors of depressive 
symptomatology and QoL. 
 
The chapter will address these aims by reporting on the relationship between the 
psychological variables included in the study (CT, NE, LE, PH depression and 
coping) and the risk of increased depressive symptoms, DE6 and/or poorer QoL. 
 
Firstly the literature on psychological variables and methodological issues is 
reviewed, followed by a summary of the data, the main findings and a brief 
discussion. 
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7.1 Background 
 
Depression has a complicated aetiology and the currently accepted view is that a 
combination of early life and ongoing stress increase the risk of a DD in those who 
are vulnerable through genetic predisposition (reviewed in section 1.2)  Kendler 
and colleagues[62] (2002) proposed a very comprehensive model of the 
development of a depression and risk for a DE in women.  This model included 
genetic risk, CT, NE, low self-esteem, early and mid life psychiatric problems 
(including anxiety, conduct disorder and drug misuse), low education, stressful LE, 
PH of depression and low social support as risk factors for a DE in the past year. 
This study has since been replicated and extended to include male participants by 
Sjöholm‟s group[200] (2009).  There are still other variables that may contribute to 
the risk of a DE, such as low socio-economic status, low self-esteem and coping 
strategies[201].  Including all the psychological variables involved in the aetiology of 
depression is beyond the scope of this study.  As the study also investigates 
physiological mechanisms that are particularly related to stress, the psychological 
variables related to stress are included. 
 
Studies investigating the risk of a DE following a cancer diagnosis have often 
focused on the impact of cancer related variables, and there is less focus on non 
cancer related risk (see background in section 3.1.3).  Of the studies that have 
investigated pre-cancer factors, most have been of breast cancer patients and 
there has been very little focus on HN patients and even less on CR patients.  This 
study focuses on the relationship between CT, NE, LE, PH depression, coping and 
depression. 
7.1.1 Childhood trauma 
 
Childhood trauma can include many types of adversity occurring during childhood, 
such as family problems, neglect, abuse or experience of natural disasters.  There 
is good evidence for CT as a risk factor for DD in the general population[202].  
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Retrospective reports on childhood adversities have shown that early stress is 
associated with occurrence of first DE and increased persistence of DD; although 
only abuse and not neglect was associated with persistence[203].  Similar findings 
have been reported in case control studies by other groups using a retrospective 
childhood abuse questionnaire (the Childhood Trauma Questionnaire [CTQ]).  
However, some groups found no such association with persistence[75].  One 
prospective case control study reported a relationship between past CT and risk of 
MDD in a sample of 1196 participants where the abuse was severe enough to 
involve a court hearing[73].  Childhood trauma reports have also been found to be 
associated with depressive symptoms[204].  Thus, in the present study CT would be 
expected to show an association with increased levels of depressive symptoms 
and increased risk of a DE6 in both groups of cancer patients. 
 
Results from CT studies should be interpreted with due caution as mood congruent 
memory biases may increase reports of CT in those who feel depressed at the time 
of completing questionnaires[205], thus ideally data would be collected 
prospectively, but that was not feasible in this study.  Also, despite reservations 
regarding the efficacy of CT questionnaires, one review found that, counter to most 
expectations, retrospective reports of CT tend to generate more false negatives 
than false positives, though the bias is not sufficiently great to invalidate results[206].  
Furthermore, although there may be different relationships between specific 
categories of CT (such as sexual or physical abuse) with depression, there is also 
evidence of strong associations between different types of abuse[207].  Thus, in this 
study the total score of the CTQ was used. 
7.1.2 Neuroticism 
 
Neuroticism is a personality trait which is characterised by a tendency towards 
anxiety driven cognitions and negative affect.  Neuroticism is known to be a risk 
factor for a DD in non cancer patients[208] and is significantly associated with 
genetic risk for a DD[62] as was introduced in section 1.2.2.  Neuroticism is also 
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strongly related to levels of depressive symptoms[209].  The association between 
NE and depressive symptoms has been replicated in breast cancer patient 
samples, both three and six months after treatment[210, 211].  Similar results were 
reported in a group of 200 HN cancer patients[212].  The association between NE 
and depressive symptoms extended to poorer QoL and increased cancer related 
symptoms[212].  Therefore, NE appears to be a likely risk factor for increased 
depressive symptoms and DE in HN and CR cancer patients. 
7.1.3 Stressful life events 
 
Stressful LE in adult life, as opposed to childhood adversity, such as divorce, 
financial crisis or an illness, are known to increase the risk of a DE in the general 
population[213].  A few studies have investigated the effects of non cancer related 
stressors and depressive symptoms in cancer patients.  Severe non cancer related 
difficulties were associated with a DE from four months to five years after diagnosis 
in a sample of 222 breast cancer patients[214].  Thus, non-cancer related LE are 
likely to increase the risk of a DE.  Although interviews are considered to be the 
best method to assess LE, these are time consuming and would add a further 
burden on participants in an already intense study.  Questionnaires, whilst slightly 
less reliable, are still widely considered to be valuable measures to capture the 
experience of major events[75].  This study uses the Brief Life Events Questionnaire 
(BLEQ) to assess total LE around the time of the cancer diagnosis.  The BLEQ 
includes a list of 12 possible LE from a larger checklist of 673 and is considered to 
be a reliable measure of external life stressors[193, 215]. 
7.1.4 PH depression 
 
One of the strongest predictors of a DE is a PH of depression[62].  The average age 
of onset of a DD is 25 years[199] whereas CR or HN cancers are more likely to 
                                            
3
 The original list was devised from a survey using free text to report major LE and 82.5% of the 
reported LE are covered by the 67 item inventory.  The chosen 12 accounted for 77% of the LE on 
the 67 item inventory. 
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occur in patients over the age of 50.  Therefore, most cancer patients with a 
genetic vulnerability to a DD are likely to have already experienced a DE.  Burgess 
and colleagues[214] found that past psychological treatment was a risk factor for a 
DE from one month to five years after a diagnosis of breast cancer, using the same 
sample as the LE investigations.  Thus, PH depression is also likely to be a risk 
factor for increased depressive symptoms and development of a DE in CR and HN 
cancer patients.  The most reliable way to assess a PH of depression is by using a 
diagnostic clinical interview such as the SCAN. 
7.1.5 Coping 
 
There is substantial literature on the effects of coping on depression and QoL in 
cancer patients.  Coping refers to the efforts made to tolerate negative 
consequences of internal or external demands[216].  The study of ways of coping is 
a complex area involving aspects such as personality, threat appraisal and present 
environment.  Past studies on coping have devised broad (not necessarily mutually 
exclusive) categories, such as emotional focused vs. problem focused and active 
coping vs. avoidance.  Coping can also be defined by form of support such as 
religious coping, instrumental social support (practical support) and emotional 
support or voluntary and involuntary forms of coping.  Also, different methods of 
coping may be adaptive in some circumstances, but less so in others.  For 
example, a study investigating pre surgical distress found planning, instrumental 
support, humour and venting to be associated with increased distress, even though 
they are normally considered to be adaptive responses[217].  Acceptance was also 
found to be a risk factor for increased depressive symptoms and poorer QoL in HN 
cancer patients, but as the authors rightly point out, acceptance may be related to 
the extent of the cancer and resulting symptoms, for which no adjustment was 
made.  Due to the broad range of categories and mixed findings, a full literature 
review is beyond the scope of this thesis, and in this study coping was included as 
an exploratory variable.  There are many possible ways of measuring coping, the 
brief COPE[194] was chosen as it is widely used in cancer studies as well as in non 
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cancer groups and includes a broad range of conceptually different types of 
coping.  The COPE allows for us to test the broad range and if a pattern emerges 
the types of coping could be appropriately interpreted under more general 
categories, such as problem or emotion focused[218]. 
7.1.6 Limitations and conclusions 
 
In summary, this chapter focuses on the relationship between a group of well 
founded risk factors for development of a DE in the general population (CT, NE, LE 
and PH depression) and depression and QoL in cancer patients.  Despite the 
strong association between CT, LE, NE, PH depression and coping and DDs in the 
general population, there have been few studies investigating these factors with 
respect to risk of depression in CR or HN cancer patients, which is the focus of this 
study.  There are some limitations to the study, such as the use of self report 
questionnaires (see general methods, section 2.6).  Interviews were considered 
unsuitable due to the extra burden on the patients and prospective measures are 
not available.  
 
Childhood trauma, LE, NE and PH depression would all be expected to be 
associated with increased depressive symptoms, risk of DE6 and poorer QoL.  
There is a high possibility of covariation between the investigated variables as 
demonstrated by Kendler‟s model[62], which is discussed in chapters 9 and 10.  No 
specific hypotheses for coping have been made and only patterns of associations 
are reported.  
7.2 Results 
 
The findings for each variable are presented in turn and follow the same structure 
i.e. starting with depressive symptoms as a dependent variable at baseline (T1), 
then at each prospective study wave (T3 to T5), supplemented by longitudinal 
analyses to look at time interactions and finally the risk of a DE.  Quality of life 
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findings are presented in a similar manner.  In all the analyses, the results for CR 
then HN patients are shown for each analysis unless the groups were combined. 
7.2.1 Childhood trauma 
7.2.1.1 Descriptives 
 
Variable CR patients HN patients General 
population[189, 
219] 
Significance 
N Mean (sd) 
 
N Mean (sd) 
 
SA 20 4.80   (1.15) 34 7.12    (4.79) 5-9 z=1.93, p=0.05 
PA 20 4.95   (0.83) 34 7.35    (4.15) 6-8 z=3.04, p=0.002 
EA 20 5.85   (2.39) 34 8.85    (4.98) 6-7 z=2.49, p=0.01 
PN 20 7.75   (3.48) 34 7.77     (3.60) 6-7 z=0.69, p=0.49 
EN 20 11.10 (6.98) 34 11.65   (5.74) 7-10 z=0.15, p=0.89 
Total 20 34.45 (7.49) 34 42.74  (17.53) 31-40 z=-1.65, =0.10 
Table 7.1: Level of early life stress as indicated on the CTQ. SA= sexual abuse; PA=physical 
abuse; EA=emotional abuse; PN=physical neglect; EN=emotional neglect. 
 
Even though the total scores were not significantly different, as can be seen in 
table 7.1 there was a higher level of abuse in the HN group compared to the CR 
group.  Whilst the total difference was not significant, the results were still stratified 
as there was a different distribution of abuse in the two groups. 
 
Sixty percent of CR patients and 44% of HN patients scored more than one on the 
denial score of the CTQ, indicating that this proportion of patients may be 
minimising any negative memories.  There was a strong negative relationship 
between denial score and total score [N=54 ß(CI)=-5.92 (-8.45 to -3.39)  p<0.0005].  
Emotional abuse and neglect were also closely associated with minimisation. 
7.2.1.2 Depression findings 
 
There was no association between CT and depressive symptoms at T1 in CR 
patients [p=0.403].  However, there was a strong positive association between CT 
and HADS-D in HN patients [N=32, ß(CI)=0.07 (0.03 to 0.11) p=0.001]. 
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There was a strong positive association between CT and depressive symptoms at 
T3 in CR and HN patients [CR:N=20, ß(CI)=0.27 (0.13 to 0.41) p=0.001; HN:N=31, 
ß(CI)=0.07 (0.00 to 0.15) p=0.041]. 
 
There was a positive association between CT and T4 HADS-D in CR patients, but 
only a trend in HN patients [CR:N=19, ß(CI)=0.41 (0.27 to 0.55) p<0.0005; HN:N=34, 
ß(CI)=0.06 (0.01 to 0.13)  p=0.097]. 
 
There was a positive association between CT and T5 HADS-D in both CR and HN 
patients [CR:N=18, ß(CI)=0.35 (0.12 to 0.57) p=0.005; HN:N=33, ß(CI)=0.08 (0.02 to 
0.15) p=0.017]. 
 
Consistent with the above analyses, there was an association between CT and 
HADS-D overall in both patient groups.  However, when a time interaction was 
added to the model, the association became non significant in the CR group; 
however, there was a significant CT by time interaction at T4 [p=0.038], and there 
was a trend towards a significant CT by time interaction at T5 [p=0.096].  In the HN 
group the main effect of CT remained significant [N=34 β(CI)=0.07 (0.04 to 0.11), 
p<0.0005], but there were no time interactions.  Figure 7.1 shows the relationship 
between CT and depressive symptoms at each time wave in CR patients. 
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Figure 7.1: Scatter plot between CT and depressive symptoms at each time point in CR patients. 
 
There was no evidence to suggest an association between CT and increased risk 
of a DE6 in a combined analysis. 
7.2.1.3 Quality of life findings 
 
There was no evidence to suggest an association between CT and poorer QoL in 
either patient group at T1 [CR: p=0.094; HN: p=0.191]. 
 
At T3 there was evidence of an association between CT and poorer QoL in CR and 
HN patients [CR:N=20, ß(CI)=-1.74 (-3.25 to -0.24) p=0.026; HN:N=31, ß(CI)=-0.42 (-
0.74 to -0.10) p=0.012]. 
 
At T4 there was evidence towards an association between CT and poorer QoL in 
CR patients, but not HN patients, but there was a trend in HN patients [CR:N=19, 
ß(CI)=-1.37 (-2.73 to -0.01) p=0.049; HN:N=34, ß(CI)=-0.33 (-0.72 to -0.05) p=0.082]. 
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There was evidence towards an association between CT and poorer QoL in CR 
patients at T5, but not HN patients [CR:N=17, ß(CI)=-2.36 (-4.04 to -0.69) p=0.009; 
HN:N=33, ß(CI)=0.09 (-0.40 to 0.57) p=0.720]. 
 
Overall, there was a negative association between CT and QoL in CR patients, but 
not in HN patients [CR:N=74(20), ß(CI)=-1.65 (-2.57 to -0.72) p<0.0005; 
HN:N=129(34), ß(CI)=-0.25(-0.57 to 0.07) p=0.132].  There was no interaction in 
either group. 
7.2.2 Summary 
 
Childhood trauma was associated with increased depressive symptoms in both CR 
and HN patient groups.  This effect was more pronounced in the CR group after 
treatment, especially at T4, whereas in HN patients the effect is consistent 
throughout.  There was no association between CT and risk of DE6.  Also, CT was 
only associated with poorer QoL in the CR group. 
7.2.3 Neuroticism results 
7.2.3.1 Prevalence 
 
There were no differences in the levels of NE in the two cancer groups (see table 
7.2) and levels are representative of the general population (mean=8.8, 
sd=5.0)[208].  There was no association between the lie scale and NE score. 
 
CR HN 
Significance 
N Mean (sd) N Mean (sd) 
41 8.76 (5.08) 22 7.95 (5.30) t(61)=0.59, p=0.56 
Table 7.2: Means and sd of levels of NE by cancer group. 
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7.2.3.2 Depression findings 
 
At T1 there was a weak trend towards an association between NE and HADS-D in 
CR patients [p=0.167].  Neuroticism was positively associated with depressive 
symptoms at T1 in HN patients.  As the association in CR patients was probably 
insignificant due to smaller numbers, both groups were combined and the 
association found in the HN group remained [N=59, ß(CI)=0.25 (0.13 to 0.38) 
p<0.0005] (figure 7.2). 
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Figure 7.2: Correlation between depressive symptoms at T1 and NE by type of cancer. 
 
Neuroticism was associated with HADS-D at T3 in both CR and HN patients.  
Similarly, NE was associated with HADS-D at T4, T5 and overall in CR and HN 
patients (see table 7.3). 
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 Time N ß(CI) P value 
CR 1 21 0.18 (-0.08 to 0.43) 0.167 
3 21 0.052 (0.31 to 0.75) <0.0005 
4 21 0.59 (0.34 to 0.85) <0.0005 
5 18 0.31 (0.00 to 0.62) =0.048 
Overall 22 0.40 (0.22 to 0.58) <0.0005 
HN 1 38 0.31 (0.17 to 0.46) <0.0005 
3 38 0.29 (0.06 to 0.51) 0.051 
4 41 0.48 (0.30 to 0.65) <0.0005 
5 39 0.32 (0.12 to 0.51) 0.002 
Overall 41 0.35 (0.21 to 0.48) <0.0005 
Table 7.3: Coefficients (CI) and p values of association between NE and HADS-D. 
 
There was an interaction over time in the CR patient group; patients with high 
levels of NE showed increased depressive symptoms at T3 [p=0.008] and T4 
[p<0.0005], but the main effect of NE was reduced to a trend after including the 
interaction term. 
 
There was a weak interaction in HN cancer patients at T4 [p=0.054] again with 
patients with high levels of NE showing higher levels of depressive symptoms.  In 
this case the main effect of NE was still highly significant. 
 
As the two groups showed similar results, the patients were pooled and analysed 
altogether.  These results indicated a positive association between NE and 
depressive symptoms overall and a further increase in depressive symptoms at T4 
in those with higher levels of NE [N=237(63), ß(CI)=0.27 (0.14 to 0.39) p<0.0005, T4 
interaction term p=0.0001]. 
 
High levels of NE were associated with increased risk of a DE6 when analysing all 
patients as one group [N=60, OR(CI)=1.45(1.20-1.74) p<0.0005]. 
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7.2.3.3 QoL findings 
 
There was a trend towards an association between NE and poorer QoL in CR 
patients [p=0.109] and a significant association in HN patients [N=37, ß(CI)=-1.14 (-
2.06 to -0.23) p=0.016].  Thus, as with the results for T1 HADS-D, groups were 
combined [N=57, ß(CI)=-1.23 (-2.18 to -0.27) p=0.013]. 
 
There was a significant association between NE and decreased QoL at T3 in CR 
patients [N=21, ß(CI)=-2.09 (-3.85 to -0.32) p=0.023] and no significant association in 
HN patients [p=0.240]. 
 
Similar to baseline, there was a trend towards an association between NE and 
poorer QoL at T4 in CR patients [p=0.108] and a significant association in HN 
patients [N=41, ß(CI)=-2.00 (-3.15 to -0.84) p=0.001].  Thus, the groups were 
combined [N=62, ß(CI)=-1.76 (-2.68 to -0.83) p<0.0005], which showed a significant 
association between NE and poorer QoL at T4. 
 
There was a trend towards a significant association between NE and poorer QoL at 
T5 in CR patients [p=0.140]. However, there was no association between NE and 
poorer QoL at T5 in HN patients [p=0.918]. 
 
There was an overall association between increased levels of NE and poorer QoL 
in both patient groups (though weaker in HN patients) [CR:N=79(22), ß(CI)=-1.67 (-
2.87 to -0.48) p=0.006; HN:N=155(41), ß(CI)=-0.93 (-1.90 to 0.03) p=0.058].  There 
were no time interactions. 
7.2.3.4 Summary 
 
Neuroticism is a strong risk factor for increased depressive symptoms (and more 
so at T4) and likelihood of a DE after a cancer diagnosis.  Neuroticism is also a risk 
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factor for poorer QoL, but the effect is greater in CR patients and is less 
pronounced by T5 in both patient groups. 
7.2.4 Life events results 
7.2.4.1 Prevalence 
 
Variable CR patients HN patients Significance 
N Mean (sd) N Mean (sd) 
Stressful life events T3 27 1.96 (1.79) 45 2.58 (1.62) z=1.71, p=0.09 
Stressful life events T5 23 1.26 (1.45) 40 1.3 (1.15) z=1.41, p=0.16 
Table 7.4: Mean (sd) number of stressful LE by cancer group. 
 
Table 7.4 shows the mean number of LE by cancer group.  Only findings for 
stressful LE at T3 are reported as the BLEQ scores at T5 were not associated with 
any of the dependent variables.  Also, despite three possible methods of scoring 
the BLEQ, only the findings for the number of stressful LE are reported because 
the other methods generated similar results, but with slightly smaller effect sizes. 
(As stated in chapter 5, the other methods were either 1) including only moderate 
or very bad LE or 2) treating the questionnaire as a scale.) 
7.2.4.2 Depression findings 
 
Life events were positively associated with depressive symptoms at T1 in HN 
patients, but not CR patients.  As there was a trend in CR patients [p=0.152], the 
two groups were combined and the association was significant (see table 7.5). 
 
Life events were positively associated with depressive symptoms at T3, T4 and T5 
in HN patients and a trend was seen in CR patients for each time point [p=0.158, 
0.073 and 0.063 respectively], thus the two groups were combined (see table 7.5). 
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 Time N ß(CI) P value 
HN 1 42 0.80 (0.10 to 1.49) 0.025 
3 44 1.75 (1.34 to 2.16) <0.0005 
4 41 0.48 (0.30 to 0.65) <0.0005 
5 39 1.35 (0.61 to 2.10) 0.001 
CR and HN 1 68 0.63 (0.16 to 1.10) 0.010 
3 69 1.23 (0.75 to 1.70) <0.0005 
4 62 0.51 (0.37 to 0.65) <0.0005 
5 61 0.99 (0.46 to 1.52) <0.0005 
Table 7.5: Coefficients (CI) and p values of association between LE and HADS-D 
 
There was a significant association of LE at T3 with increased depressive 
symptoms overall in CR patients and HN patients [CR:N=27, ß(CI)=0.60 (0.10 to 
1.10) p=0.020; HN: N=45, ß(CI)=1.24 (0.76 to 1.72) p<0.0005].  There was no 
significant interaction with time in the CR group.  However, in the HN group there 
was a significant interaction between HADS-D and number of LE at T3 [p=0.0002] 
and the main effect of LE remained in HN patients [N=165(45), ß(CI)=0.73 (0.04 to 
1.42) p=0.038].  This indicated that those who reported more life events at T3 
tended to have higher levels of depressive symptoms overall and even more so at 
T3 (the same time the BLEQ was completed).  See figure 7.3 for an illustrative 
graph of all groups HADS-D scores over time, split by median BLEQ score. 
 
LE at T3 were associated with increased risk of a DE6 (when analysing all patients 
as one group) [N=63, OR(CI)=2.53 (1.60-4.00) p=0.005]. 
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Figure 7.3: Graph of mean HADS-D scores by BLEQ median split. N=72. 
7.2.4.3 Quality of life findings 
 
There was no association between LE and QoL at baseline in CR patients 
[p=0.711].  There was a strong association in HN patients [N=41, ß(CI)=-6.04 (-
10.32 to -1.76) p=0.007]. 
 
There was no association between LE and QoL at T3 in CR patients [p=0.232].  
There was a strong association in HN patients [N=44, ß(CI)=-7.72 (-11.07 to -4.36), 
p<0.0005]. 
 
There was a significant negative association between LE and QoL at T4 in both 
sets of patients [CR:21, ß(CI)=-2.09 (-3.85 to -0.32) p=0.023; HN:N=41, ß(CI)=-2.00 (-
3.15 to -0.84) p=0.001]. 
 
There was no significant association between LE and QoL at T5 in either patient 
group [combined group p=0.192]. 
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There was a trend of an association overall in CR patients [p=0.129] and a 
significant negative association in HN patients and combined [N=162(45), ß(CI)=-
6.30 (-9.43 to -3.17) p<0.0005; All:N=257(72), ß(CI)=-4.59 (-7.13 to -2.05) p<0.0005].  
There was no interaction with time. 
7.2.4.4 Summary 
 
Life events at T3 were associated with depressive symptoms in both patient 
groups.  Life events were also associated with decreased QoL in HN patients and 
to some extent in CR patients, but the effect was no longer significant at six 
months post treatment. 
7.2.5  PH depression results 
 
As can be seen in table 7.6 only a small number of CR patients had a PH of 
depression.  These analyses were always combined.  There appears to be a 
higher proportion of DEs in the HN group, but this difference was not significant. 
7.2.5.1 Prevalence 
 
SCAN diagnosis CR HN Significance 
N (%) N (%) 
PH depression 
N 
Y 
 
26  
3       (10.34) 
 
39 
8      (17.02) 
 
χ2(1)=0.65, p=0.42 
DE6 
N 
Y 
 
21  
3       (12.50) 
 
33  
9      (21.43) 
 
χ2(1)=0.82, p=0.37 
PH of anxiety 
N 
Y 
 
26  
3       (10.34) 
 
43  
3        (6.52) 
 
χ2(1)=0.35, p=0.55 
Anxiety within 6 months 
N 
Y 
 
21  
3       (12.50) 
 
39  
3        (7.14) 
 
χ2(1)=0.53, p=0.47 
Table 7.6: Prevalence of depressive or anxiety disorder by diagnosis. 
Chapter 8: Physiological factors 
160 
7.2.5.2 Depression findings 
 
There were higher levels depressive symptoms at all time points in patients with a 
PH of depression (see table 7.7). 
 
Time N ß(CI) P value 
1 72 2.27 (0.12 to 4.41) 0.039 
3 67 3.18 (0.83 to 5.53)  0.009 
4 65 4.97 (2.01 to 7.92)  0.001 
5 61 4.32 (0.97 to 7.67) 0.012 
Table 7.7: Coefficients (CI) for association between PH depression 
and HADS-D. 
 
There was a significant association overall between PH depression and increased 
depressive symptoms [N=257(72), ß(CI)=2.53 (0.48 to 4.58) p=0.015].  There was 
also a significant interaction at T4 [p=0.009] indicating that those with a PH 
depression had higher levels of depressive symptoms throughout the study and 
higher still at T4 (see figure 7.4). 
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Figure 7.4: Mean HADS-D scores over time in all patients by those with and without a PH 
of a DD (N=76). 
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Patients with a PH depression were at 50x greater odds of a DE6.  The confidence 
intervals for this result are very high, indicating decreased reliability [N=65, 
OR(CI)=51.00 (7.87 to 330.32) p<0.0005]. 
7.2.5.3 QoL findings 
 
There was a significant association between PH depression and poorer QoL at 
baseline (see table 7.8). 
 
Time N ß(CI) P value 
1 70 -15.83 (-30.59 to -1.08) 0.036 
3 67 -14.77 (-25.91 to -3.62), 0.010 
4 63 -14.66 (-24.18 to -5.14) 0.003 
5 59 2.80 (-14.02 to 19.61) 0.740 
Table 7.8: Coefficients (CI) for association between PH depression 
and global QoL. 
 
There was a significant association between PH depression and reduced QoL 
overall [N=259(76), ß(CI)=-12.38 (-21.29 to -3.48) p=0.006], but no interaction with 
time (although a trend towards an interaction at T5 [p=0.110]). 
7.2.5.4 Summary 
 
Past history of depression was associated with increased depressive symptoms 
throughout the study period and more so at T4.  Past history of depression was 
also associated with an increased risk of a DE6 and poorer QoL, but it was no 
longer related to QoL at T5. 
7.2.6  Coping results 
 
As there were no specific hypotheses involving coping, this was an exploratory 
investigation.  Thus, in order to ensure cautious interpretation of the results, no 
single findings will be reported but just general themes. 
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7.2.6.1 Prevalence 
 
There were no differences in the types of coping used in either cancer group (see 
table 7.9). 
 
Variable CR HN 
N Mean (sd) N Mean (sd) 
Self distraction 22 2.91 (2.33) 40 2.85 (1.92) 
Active 22 3.91 (2.27) 40 4.15 (1.99) 
Denial 22 1.65 (2.17) 40 1.18 (1.81) 
Substance use 22 0.57 (1.56) 40 0.70 (1.29) 
Use of emotional 
support 
22 4.35 (2.17) 40 4.03 (2.09) 
Use of instrumental 
support 
22 2.48 (2.56) 40 2.10 (1.89) 
Behavioural 
disengagement 
22 1.30 (1.87) 40 0.88 (1.67) 
Venting 22 1.61 (1.90) 40 0.98 (1.42) 
Positive reframing 22 3.87 (2.40) 40 3.85 (1.87) 
Planning 22 3.52 (2.41) 40 3.43 (2.31) 
Humour 22 2.35 (2.10) 40 2.10 (2.35) 
Acceptance 22 4.57 (1.85) 40 4.63 (1.48) 
Religious coping 22 2.00 (2.22) 40 1.55 (1.93) 
Self-blame 22 0.74 (1.18) 40 1.00 (1.47) 
Table 7.9: Coping strategies by cancer group. 
7.2.6.2 Results 
 
There were very few consistent findings with regard to any of the coping strategies 
and HADS-D or QoL scores that were considered robust enough to report.  
However, there was an inverse association between humour and HADS-D at T4 in 
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both CR and HN patients [CR:N=22, ß(CI)=-0.76 (-1.53 to 0.00) p=0.004; HN:N=40 
ß(CI)=-0.46 (-0.89 to -0.04) p=0.033].  This effect was only found at T4 and did not 
translate into improved QoL. 
7.3 Discussion 
 
Overall, the findings supported the hypotheses under study and were consistent 
with past research:  CT, NE, LE and PH depression were all associated with 
increased depressive symptoms and poorer QoL.  Neuroticism, LE and PH 
depression were also associated with increased risk of a DE6.  However, there 
were also a few surprising findings (for instance, CT was not associated with an 
increased risk of a DE6).  Also, more detailed analyses suggest these relationships 
are more complex and the results for each variable are discussed in more detail 
below. 
7.3.1 Childhood Trauma 
 
The levels of CT were significantly higher in HN patients compared to the CR 
patients.  When compared to the general population, levels of CT appear to be 
slightly higher in HN patients and slightly lower in CR patients.  This is an intriguing 
finding, and may be spurious due to the small sample size.  It was considered that 
CT could be associated with increased levels of smoking and alcohol consumption, 
but the association remained when using multivariate regression (results not 
shown).  It is also possible that HN cancer is associated with increased levels of 
sexual abuse, since sexual abuse is associated with increased risk of sexually 
transmitted diseases in childhood[220].  Therefore there is a higher level of HPV 
infection from a younger age in those with high levels of sexual abuse.  HPV has 
recently been identified as an important risk factor for oral cancer[35, 221].  However 
this explanation is very speculative as there is limited research in this area. 
 
There was an association between CT and depressive symptoms and QoL in both 
CR and HN patients, but the relationship differs between the two diagnoses.  The 
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association between CT and HADS-D in the CR group was only apparent at T4 
indicating that the effect in CR patients is only apparent at periods where there is 
an overall trend towards low mood, whereas the association between CT and 
HADS-D in HN patients remained consistent throughout the study period.  This 
may be due to a threshold effect in the HN group due to the increased range of 
values in that sample.  However, the CR finding may also be due to the timing of 
the questionnaires, which is discussed in the limitations (section 7.3.6).  
Surprisingly, there was no association between CT and QoL in the HN group but 
there was an association in the CR group, the reasons for this are not clear and 
may be due to the different spread of CT in the two groups.  This may be due to 1) 
stronger relationships between certain types of trauma and QoL, which are more 
apparent in the CR group; 2) cancer related factors confounding the relationship 
between CT and QoL in either cancer group, or most likely 3) a lack of power 
leading to an influence of both factors which has affected the reliability of the 
results. 
 
Despite the emerging theme of an association between CT and depressive 
symptoms, CT did not significantly increase the risk of DE6.  Again, this was an 
unexpected finding and it is possible that only certain types of CT are associated 
with increased risk of a DE, in which case the decision to analyse total CT will have 
obscured that result.  However, it is more likely that the study is simply 
underpowered to detect this, especially given the relatively short period of time of 
follow up for development of a DE and the number of other variables to be 
considered.  Finally, to be able to interpret findings more fully, a qualitative 
approach may be helpful. For instance, one patient reported harrowing amounts of 
CT and reported never having experienced a DE either before or after his cancer 
diagnosis.  However, whilst this patient was not overtly miserable, neither was he 
overtly happy; he showed a generally quite restricted affective range and merely 
agreed that his „life had been tough‟.  Thus, whilst he had never experienced a 
period where his mood was noticeably lower, he appeared to have lower than 
average mood throughout our engagements.  When this patient was excluded from 
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the analysis there was a trend towards CT and increased risk of a DE6, but it still 
was not significant.  This is obviously a single observation, but it helps to illustrate 
the complexity of the relationship between risk factors and depressive illness.  
Further quantitative studies may benefit from conducting some interviews with 
patients, as a qualitative approach could add depth to the findings. 
 
In summary, there was an overall association between CT and depressive 
symptoms in both cancer groups, but the timing and extent of the relationship 
varied and CT did not increase the risk of a DE6.  Also, the relationship between 
CT and QoL was only apparent in CR patients, indicating that the effect of CT on 
depressive symptoms did not extend to QoL.  Further work with more precise 
measures and larger samples should be able to test whether the unexpected 
findings are real effects and if they are related to type of trauma. 
7.3.2 Neuroticism 
 
Neuroticism was strongly associated with depressive symptoms, risk of DE6 and 
poorer QoL in both CR and HN patients, supporting past studies.  The relationship 
between NE and depressive symptoms was most pronounced at T4 and less so by 
T5.  It is possible that the increase at T4 is because that is the time point when 
cancer patients are most vulnerable to low mood after a cancer diagnosis[146], but it 
may also be related to the timing of the questionnaires. 
 
 
7.3.3 Stressful Life Events 
 
Number of LE in the past six months, assessed one month after treatment, was 
associated with increased depressive symptoms and increased risk of a DE6 in 
both patient groups, supporting past findings.  The association was weaker in the 
CR group, but that is most likely to be due to lower power.  There was no 
association between number of LE at six months after treatment with depressive 
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symptomatology or QoL at any time point, suggesting only events around the time 
of the diagnosis were associated with depression and poorer QoL.  However, again 
there is a possibility that this may have been confounded by the timing of the 
questionnaires, which is discussed in the limitations (section 7.3.6).  The 
association between LE and QoL appears to be stronger in the HN patients 
compared to the CR patients.  Nevertheless, there is no evidence of an association 
at six months in either patient group.  In summary, there was a strong association 
between number of LE at the time of cancer diagnosis and depressive symptoms, 
risk of a DE6 and poorer QoL.  This is an important finding which clinicians need to 
be aware of, which is discussed in more detail in the general discussion. 
7.3.4 PH depression 
 
Past history of depression was associated with increased depressive symptoms at 
all time points, particularly at three months after diagnosis, compared to those 
without a PH.  The increased association at three months suggests that PH of 
depression is related to an underlying vulnerability to low mood and has a further 
impact on low mood during periods after a cancer diagnosis which are associated 
with increased low mood in all patients.  Past history of depression was also 
associated with poorer QoL, but this was no longer significant by six months after 
treatment.  There appear to be no past studies on the relationship between PH 
depression and QoL at six months after treatment.  It is possible that the 
relationship between PH depression and depressive symptoms does not result in 
poorer QoL beyond six months after treatment, implying the relationship between 
PH of depression is related to acute stress levels.  However, it is not possible to 
test this using these data.  Past history of depression was also associated with 
increased risk of a DE6, similar to previous reports on breast cancer patients[222].  
However, the confidence intervals for the association were very high, suggesting 
that it is a large effect but that the data set is underpowered and further studies 
with larger samples would be required to test this hypothesis. 
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7.3.5 Coping 
 
The analysis revealed very few consistent patterns between coping and depressive 
symptoms or QoL and no coping methods appeared to increase or decrease the 
risk of a DE6.  However, using humour to help cope with the cancer was 
associated with decreased depressive symptoms three months after treatment in 
both sets of cancer patients.  A similar protective effect of humour at that time has 
previously been reported in a group of breast cancer patients[223].  On the other 
hand, a study in a large sample of 1800 CR patients six months after their 
diagnosis found no association with distress or QoL and coping with humour[224].  
This suggests that perhaps the beneficial effect of coping is only apparent at times 
of greater distress.  Humour has also been associated with poorer QoL in HN 
patients eight years after their diagnosis[212].  However this is a long time to test for 
an association as coping strategies change over time[223]. 
7.3.6 Limitations  
 
The lack of a control condition prevents any interpretation of whether the risk 
factors confer a greater risk of a DE in cancer patients compared to healthy 
controls, or those with other medical conditions.  The sample is also very small, so 
there is an increased risk of false negative findings.  This is especially the case 
since the sample has been stratified by diagnosis.  Whilst normally samples are not 
stratified unless there is a significant interaction, due to the small sample sizes, 
even quite large interactions between the two samples are likely to be statistically 
non-significant.  However, as the CT findings suggest, the relationships vary 
between the samples, so stratification was a necessary precaution.  The difference 
in effects also suggests that it might be worth analysing the relationship between 
the different subtypes of CT and depressive symptoms, as the differentiation may 
be more related to different trauma distributions in the two cancer populations 
rather than the diagnosis.  However, there would not be enough power to conduct 
these analyses in this sample. 
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The study is largely dependent on retrospective self report questionnaires which 
could be biased by current mood and social desirability[167, 168].  This is especially 
concerning given the increased association between CT and NE and depressive 
symptoms at T4, which is when more patients completed that questionnaire.  
Similarly, LE are most significantly associated with depressive symptoms at T3, at 
the time when patients completed the BLEQ. 
 
With respect to the CT finding, a review of studies investigating the reliability of 
retrospective CT reports found that most people tend to minimise childhood 
stress[206], and there was evidence of minimisation in this sample which was 
associated with lower levels of emotional abuse and neglect.  However, it would be 
hard to prove that the scale is a genuine marker of denial.  Despite what the 
minimisation scale implies, it is plausible that some adults truly did enjoy their 
childhood and appreciated it even when they were a child.  The more problematic 
issue in the CT finding is whether there is an effect of low mood on reported levels.  
As stated in the introduction, low mood is associated with a negative memory bias, 
which would lead to reporting more negative memories.  A large Swedish study 
including over 2,000 participants found that 14% of the participants who reported 
ELS at first completion of the questionnaire did not report any three years later 
during a repeated assessment[200].  Although 14% in such a large sample may not 
obscure the true relationship, such variation in this study would have a significant 
effect on the results. 
 
With respect to the association between LE and depressive symptoms, whilst LE 
reporting should be objective, past studies suggest that this is not always the 
case[225].  The greatest association between LE and depressive symptoms was at 
one month post surgery when patients completed the BLEQ.  Some studies have 
found an increase in participant reported LE after a negative mood induction, 
compared to a positive or neutral mood induction[225] suggesting the number of 
reported LE may have been affected by a retrospective response bias.  However, 
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more naturalistic studies have not found this to be the case[226].  It is unlikely, but 
also possible, that those with higher levels of depressive symptoms, if chronic, 
exaggerate the extent or number of stressful LE, thus leading the confidant to also 
over-report the number of LE. 
 
There is also an increased association between NE and depressive symptoms at 
T4.  Whilst some have found that NE levels were stable in a small sample of HN 
cancer patients who were tested for NE levels at the time of diagnosis and four 
years later[227], many other studies report an influence of current mood[228].  Some 
go as far as to describe NE as a proxy measure of a person‟s level of distress with 
test retest reliability diminishing rapidly over longer periods of time[228].  This 
suggests that whilst NE is evidently predictive of lower mood, it may be no more 
informative than using a HADS at baseline. 
 
Despite the findings of CT, LE and NE suggesting that the association may be at 
least in part due to a recall bias, the association between PH depression and 
depressive symptoms is also greatest at T4.  Clinically assessed PH depression 
should be less biased by current mood symptoms, especially as it was assessed 
after T4.  Although PH depression is also likely to be associated with CT, LE and 
NE, this finding does provide some evidence towards a true effect of raised 
association between the group of psychological risk factors and depressive 
symptoms at T4.  The issue of covariance is addressed in chapter 9. 
 
In total, there is evidence to suggest that the effect of CT, NE, LE and possibly 
even PH depression could be, at least in part, due to biases in self report 
questionnaires.  The level of association between HADS scores over time indicates 
that any biases at T4 will also spread to other time points.  No association was 
found between many of the psychological variables and depressive symptoms at 
T3 when adjusting for depressive symptoms at T4, but this could also be due to 
over adjustment (analyses not shown). 
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7.3.7 Conclusions 
 
These results show a relationship between CT, NE, LE and PH depression and 
increased depressive symptoms, poorer QoL and risk of a DE6 in CR and HN 
cancer patients.  Thus, risk factors applicable to the general population also 
increase the risk of depression in cancer patients.  The prospective nature of the 
study has allowed in-depth analyses which have shown there are some differences 
in the relationships between the two cancer diagnoses and over time. Many of 
these relationships appear strongest three months after treatment finishes and are 
weakest or do not persist by six months, which may be an artefact of the protocol 
rather than a true effect.  On the other hand, it is also feasible that, as between one 
and four months appears to be when cancer patients are most vulnerable to lower 
mood, the investigated variables genuinely have a greater effect at those times (as 
indicated by the findings in the previous chapter).  It is therefore of interest to 
compare these findings to those for the physiological markers and whether they 
show a greater effect at the same time points (see next chapter).  There is also the 
possibility of covariance between each of the investigated factors and the relative 
strengths of CT, NE, LE and PH depression which is investigated in later chapters. 
 
In summary, this chapter reports the results of the investigated psychological 
markers for depression and poorer QoL in cancer patients up to six months after 
their diagnosis.  This chapter addressed the first hypothesis of the study and found 
that a PH depression was associated with increased depressive symptoms, poorer 
QoL and an increased risk of a DE6.  These results also addressed parts of the 
third aim of the thesis: exploring associations between other explanatory factors on 
depressive symptomatology and QoL.  The other factors, CT, NE and LE were all 
found to be risk factors for increased depressive symptoms, poorer QoL and risk of 
a DE.  This shows that much of a cancer patient‟s QoL is associated with non 
cancer related variables, though clearly cancer related symptoms are also 
associated with depressive symptoms and overall QoL, as illustrated in chapter 5.  
The next chapter investigates potential physiological markers. 
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8 Role of physiological factors 
The previous results chapters described the sample and reported on the 
association between the psychological factors and depressive symptoms and QoL.  
This chapter investigates associations between physiological variables, cortisol 
and inflammation, and prospective measures of QoL in cancer patients. 
The chapter aims to address the third and fourth hypothesis included in the aims of 
the thesis: iii) that patients with increased HPAA activity will show increased 
depressive symptoms and iv) that patients with increased cytokine levels will show 
more depressive symptoms.  As with previous chapters, a literature review 
precedes the results comprising a brief overview of current understanding of the 
relationship between cortisol and cytokines and depression in cancer patients.  The 
first question addressed is why increased levels of inflammation might be 
especially relevant to cancer treatment outcome, including possible increased 
mortality.  Whilst mortality is not being investigated in this thesis, it is important to 
understand the possible implications of comorbid depression and raised cytokines 
with respect to tumour growth to understand the rationale behind this study.  
Secondly, the literature on cytokines and depression is revisited focusing on the 
salient points regarding each of the cytokines and more technical details which 
underlie the hypotheses for this section.  The section concludes with a discussion 
of the results. 
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8.1 Background 
8.1.1 Cytokines, cancer and progression 
 
Cytokines are messenger molecules that form part of the immune response (see 
section 1.2.4.2).  It is now well established that there is a large inflammatory 
component to tumours and cytokines are known to be both protective and 
damaging to malignant cells.  Whether they help or hinder cancer growth and 
spread appears to be related, not only to the type and development stage of the 
tumour, but also to the level and length of exposure to cytokines.  For example, 
reduction of cytokines can impede growth of some tumours, but promote the 
growth of others[145].  Also, TNF in high doses can help destroy a tumour, but low 
chronic doses are thought to promote tumour growth[229].  Mice deficient in IL1 or 
IL6 show resistance to experimental metastases[229]. 
 
The relationship between IL6 and CR cancer progression has been extensively 
investigated.  A recent review[230] found that CR patients show higher levels of IL6 
compared to healthy controls.  Further studies reported positive associations 
between IL6 and tumour stage, size and decreased survival in CR patients[230].  
Although not all studies show an association between increased IL6 levels and 
decreased survival (e.g. Komoda et al., 1998[231]), four out of five of the reviewed 
studies showed a positive effect[230].  Moreover, a recent study[232] found that IL6 
was associated with decreased survival even after adjusting for TNM stage, though 
the methods or full results for the multivariate analyses were not included.  IL6 has 
also been found to be associated with poorer physical function in older patients[233].  
Less research has been carried out on other inflammatory markers; although 
studies have shown that increased CRP levels are also associated with shorter 
survival and recurrent disease[234]; though another study found that CRP was not 
an independent risk factor after adjusting for tumour stage[235].  Studies comparing 
levels of TNFα in CR patients compared to controls have found the levels to be 
below detection[236].  Conversely, those measuring stimulated TNFα levels found 
higher levels were associated with increased survival, and systemic TNFα 
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correlated with decreased malignant cell proliferation in CR cancer patients[237].  
The same group found no correlation between IFNγ and patient survival although 
there was a weak trend towards a positive association between IFNγ and 
increased survival. 
 
In vitro studies investigating proliferation and invasiveness of CR tumour cells have 
found that IL6 promotes growth of CR cancer cells in a dose dependent manner 
and increases their invasiveness[230].  In vitro studies have also found that 
incubation with TNFα and IL1ß, but not IL6, enhances tumour adhesions to 
mesothelial cells[238].  Similar to previously reported findings, showing IL1ß and 
TNFα increased adhesion of CR cancer cells to lung and umbilical endothelial 
cells, but no findings for IL6[239].  Pre incubation with cytokines did not enhance 
adhesion, but preincubation with IL1ß increased cell growth, whereas four days of 
preincubation with TNFα decreased cell growth[239]. 
 
In HN patients, in vivo studies have similarly shown higher serum levels of IL6 and 
that increased levels of IL6 and CRP are associated with more lymph node 
metastases[240].  CRP was also associated with poorer survival, but this was no 
longer significant when adjusting for cancer stage[240]. IL6 is also associated with 
decreased survival in HN cancer patients[241, 242] though no adjustments were made 
for cancer stage.  Increased stimulated production of IL6 from monocytes has also 
been associated with decreased survival[243, 244]. 
 
In vitro IL6 studies have shown that HN tumour cells express higher levels of IL6 
than normal cells[245] and that recombinant IL6 inhibits the proliferation of some (but 
not all) HN cancer cell lines, but increases invasion potential in all squamous cell 
lines[246, 247]. 
 
Taken together this implies a very complex relationship even between different 
types of cancer cells and individual cytokines.  The in vitro studies suggest some 
cytokines can aid cancer growth and spread under certain conditions.  However, as 
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cytokines rarely act alone, the in vitro studies are only informative when interpreted 
in the context of the prospective studies showing that increased inflammation tends 
to be associated with poorer prognosis. 
 
There have also been some reports proposing a relationship between cortisol and 
cancer progression, as cortisol is reported to be associated with lowered 
immunity[248].  However, HPAA activity is reported to be enhanced by inflammation 
(see section 1.2.4.3), thus any findings between cortisol and cancer progression 
are likely to be confounded by the link between inflammation and cortisol.  The 
nature of this link is further expanded on in the next chapter. 
 
Finally, it is worth noting that there is also evidence to suggest that high levels of 
IL6 and CRP lead to increased all cause mortality in elderly women both with and 
without cancer[144].  In particular, there was no significant difference in mortality 
rates between the cancer patients and those without cancer; suggesting that 
inflammation may not be related to cancer specific mortality and different 
mechanisms may be at play[144].  However, there was no analysis of the same data 
to investigate the effect of inflammation on cancer specific mortality. 
 
In summary, there is evidence for an association between increased inflammation 
and poorer prognosis in CR and HN cancer patients but the underlying 
mechanisms remain to be identified. Overall, it appears that increased 
inflammation in cancer patients is associated with decreased survival. 
8.1.2 HPAA function and depression 
 
As previously discussed (section 1.2.4.1) HPAA dysregulation is often found in 
patients with a DD.  In healthy individuals, cortisol secretion follows a circadian 
rhythm, with high levels on waking followed by a further sharp rise (of about 
50%[249]) then a gradual decline throughout the day with a nighttime nadir.  Many 
patients suffering from a DD show an increase in daily mean cortisol levels, an 
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increased morning rise[81] and increased evening activation[82, 250, 251].  Steptoe and 
colleagues[252] (2008) also found that average cortisol levels were negatively 
associated with positive affect in a sample of almost 3000 participants.  Stress is 
thought to be a major causal factor in the aetiology of DDs and the findings of 
increased morning rise in depressed patients similarly occur in healthy individuals 
who suffer from chronic stress[78, 109, 253].  Those with high levels of depressive 
symptoms have also shown similar patterns to chronically stressed individuals[254].  
Increased cortisol has been reported in those that are vulnerable to depression, 
such as individuals who experienced CT[255], have a family history of DD[256] or 
show high levels of NE[115].  These findings support the hypothesis of a causal role 
of HPAA dysregulation in depression and suggest a possible underlying 
mechanism for the relationship between CT and increased risk of a DD, which is 
elaborated in the next chapter.  Increased cortisol has also been shown to be 
associated with CNS abnormalities related to depression, such as deficient 
monoamine function[257, 258].  As a result of all of these findings, HPAA 
dysregulation has been suggested as a major risk factor for development of a 
DD[61]. 
 
However, the relationship between increased cortisol and depression is not 
consistent and is only apparent in about half of depressed patients[259], therefore 
other factors must be involved.  Furthermore, many investigators have failed to 
replicate the above findings or have found lowered cortisol levels[260].  Similarly, 
there are mixed findings with regard to cortisol utility as a measure of prospective 
risk.  Two prospective studies, with samples of between 100 and 200 participants, 
found no association between cortisol levels and depressive symptoms at 
assessment, but increased morning cortisol was associated with increased risk of a 
DD within 12 months[261, 262].  These studies have been further corroborated by a 
recent study on a relatively small sample of 230 older adolescents who were 
followed up to one year after the cortisol sampling date.  However, a cross 
sectional study with over 400 participants reported a trend towards lowered 
morning cortisol in those with a current DD and those with a vulnerability to 
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depression through increased life stress, but these differences were not statistically 
significant[263]. 
 
Overall, the literature suggests that increased cortisol levels may be a useful 
marker for depression in cancer patients.  Jehn and colleagues[140] (2006) found a 
difference in cortisol levels in patients with comorbid depression and cancer 
compared to those with cancer and no depression in a sample of just over 100 
patients based on mean plasma cortisol levels.  Similarly, urinary cortisol levels (15 
hour mean levels) have been reported to be predictive of increased distress in 
cancer patients one month after treatment, after adjusting for baseline distress, but 
no pre adjusted findings were reported[264].  Hyperactivity of the HPAA can be 
assessed by measuring CRH, ACTH or cortisol levels and by use of the 
dexamethasone suppression test (DST) or DST/CRH test.  The least invasive 
method of measuring HPAA overactivity relies on salivary cortisol levels.  
Measuring the morning rise cortisol level is a useful and reliable tool for assessing 
HPAA activity[265]. 
8.1.3 Inflammation and depression 
 
Evidence of the effects of cytokines on mood has been found through three types 
of studies: cytokine therapy studies, differences in levels of inflammation in 
depressed and non-depressed individuals, and neurobiological in vivo and in vitro 
studies investigating potential mechanisms by which cytokines may induce a 
change in mood. 
 
IL6, interleukin-2 (IL2) and interferon-alpha (IFNα) (no studies report findings from 
IFNγ) have been shown to induce low mood and sickness behaviour in patients 
and monkeys undergoing cytokine therapy[91, 92, 266, 267].  Also, one study showed 
that small increases in inflammatory mediators caused by an injection of the 
Salmonella typhi vaccine correlated with a decrease in mood, even though no 
febrile symptoms were reported[268].  However, Pasquini et al.[269] found differences 
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in symptoms between those who had cytokine induced depression and MDD 
unrelated to cytokine elevation.  They found that feelings of failure, guilt, 
dissatisfaction and self-dislike were all higher in MDD patients compared to those 
with IFNα induced low mood.  The mood altering effects of inflammation are 
especially relevant in studies involving cancer patients, due to the cancer related 
increase in levels of inflammation. 
 
Studies comparing actively depressed patients and controls have found increased 
levels of cytokines and CRP in patients with a DD[85, 252, 270-273].  Two recent meta-
analyses have reported significantly higher levels of IL6 in depressed patients[87, 90].  
One meta-analysis found CRP and IL6 to be significantly positively associated with 
depression, with respect to those with a DD and when assessed by self report 
measures.  This meta-analysis also found significantly increased levels of IL1 in 
depression, but only when adjusting for BMI and not differentiating between IL1ß 
and IL1α[87].  A more recent and comprehensive set of meta-analyses[90] only 
included studies which used DSM criteria and assessed TNFα, interleukins 1ß, 2, 
4, 6, 8 and 10 and IFNγ.  The conclusion was that only TNFα and IL6 were 
significantly higher in depressed patients.  Only one out of four studies found IFNγ 
to be significantly higher in those with MDD compared to controls[271].  Although 
some large studies (over 200 participants) still report no differences (e.g. Steptoe 
et al., 2003[274]) this may be due to choice of questionnaires, covariates or non 
specific timing of blood sampling, which is crucial given the circadian rhythm of 
cytokine production.  However, the same group also reported CRP and IL6 to be 
inversely associated with positive affect in women (only) in a much larger sample 
of almost 3000 participants[252]. 
 
Many studies have also reported decreases in IL-6 or TNFα levels following anti-
depressant treatment[258, 275-278] further supporting the correlation data and 
suggesting a state, rather than trait, relationship between depression and 
inflammation.  This is supported by another study showing that IL6 was not related 
to trait levels of depressive symptoms but was related to state depressive 
Chapter 8: Physiological factors 
178 
symptoms, over a 20 week study period[279].  Moreover, they found that changes in 
trait scores had an even greater association with IL6.  However, one longitudinal 
study found that high levels of inflammation (IL6 and CRP) were associated with 
increased cognitive symptoms of depression 12 years after the sampling date[280].  
These findings, together with the cytokine induction studies, suggest that cytokines 
may have a role in the development of depression. 
 
Of particular relevance to this study is that, as stated above and in chapter 1, 
inflammation is also increased in cancer patients and IL6 has been shown to 
increase in response to both physical and psychological stress[94, 95].  Notably, 
levels of inflammation increase after surgery[281].  That, and the findings that 
cytokines have induced low mood, suggest that inflammation may be a useful 
marker for risk for depression in cancer patients.  Three out of four studies found 
increased levels of IL6 in cancer patients with a current DE compared to cancer 
patients without a DD[138-140].  One study found lower post surgery increases in IL6 
in those with a current DE at the time of surgery compared to those without[137].  
However, the same study found increased levels of IL6 in those with high 
depressive symptoms.  Two of the studies that found an association between 
increased IL6 and a comorbid DE were carried out on cancer patients either 
planned for or undergoing chemotherapy[138, 140] and the other study does not 
report the cancer status[139].  Thus, it is possible that those with a DD have a 
decreased inflammatory response to surgery, though other studies have shown an 
increased inflammatory response in those with vulnerable depression (through PH 
or CT) to either physical or social stress[117, 282].  Also, this study reports 
contradictory findings of a positive association between depressive symptoms and 
IL6 suggesting that the results may be unreliable.  There have also been reports of 
an association between increased inflammation and poorer QoL in CR cancer 
patients[98].  Overall, the literature suggests that higher levels of inflammation would 
be expected to increase the risk of a DE6 in CR and HN cancer patients. 
 
Chapter 8: Physiological factors 
179 
Levels of inflammation in cancer patients can be measured by many methods; 
peripheral levels, stimulated monocyte production, tumour expression or cellular 
genetic transcripts.  To make matters more complicated, peripheral levels do not 
always correlate with that of the normal tissue or tumour expression of markers[234].  
Miki and colleagues[234] (2004) found increased circulatory CRP to be associated 
with increased tumour IL6 expression, but not IL6 expression in healthy mucosa 
and there was no association between CRP and TNFα.  The easiest and therefore 
most clinically useful method of assessing cytokines is to measure peripheral 
levels in blood.  Cytokine levels are expected to increase after surgery and then 
return to baseline[197].  Past studies suggest many cytokines may be potentially 
useful as risk markers but that IL6, TNFα, IL1ß and IFNγ and CRP are the most 
promising.  Therefore, in this study it was expected that IL6, TNFα, IL1ß, CRP and 
possibly IFNγ would be associated with increased risk of a DE6 in cancer patients.  
Higher levels of inflammation were also expected to be associated with increased 
depressive symptoms and poorer QoL. 
8.1.4 Conclusions 
 
In summary, both dysregulated stress hormone levels and higher levels of 
inflammation have been found to be associated with depression.  Cancer patients 
with depression are also reported to have increased levels of IL6.  Raised 
inflammation is of particular importance in cancer patients because tumours 
express cytokines leading to increased peripheral inflammation, therefore those at 
risk of depression may be more susceptible to an episode after a cancer diagnosis.  
Also cytokines are proposed as mediators of tumour progression and markers of 
poor prognosis.  Both dysregulated cortisol and increased inflammation are 
potential risk markers for development of a DE soon after a cancer diagnosis. 
8.2 Results 
 
The results are presented following a similar structure to the previous results 
chapter on psychological variables except that inflammation was measured at 
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multiple time points.  The results are shown first for cortisol and then for each of 
the cytokines, structured by time and diagnosis, starting with CR patients at 
baseline.  Two regression techniques are used in the analyses (using robust and 
bootstrap standard errors respectively) to increase the validity of the findings, as 
detailed in section 5.4.  The results of the regressions with robust standard errors 
are reported in the prose, but only the bootstrapped parameters are presented.  
The confidence interval parameters when using robust standard errors are 
reported in appendices, as referenced below. 
8.2.1 Cortisol 
8.2.1.1 Descriptives 
 
As can be seen in figure 8.1 the cortisol levels conform to the expected pattern of 
high waking levels, followed by a further sharp increase and then decreasing to 
relatively low levels by the evening.  There were no significant differences between 
CR and HN patients.  Full descriptives of the cortisol levels are provided in 
appendix 8. 1. 
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Figure 8.1: Mean cortisol levels by diagnosis. 
 
8.2.1.2 Depression findings 
 
There were no significant associations between cortisol and depressive symptoms 
at T1, T3 or T4, in either patient group.  There was a negative association between 
depressive symptoms at T5 and cortisol morning rise in CR patients [N=19, ß(CI)=-
0.83 (-1.49 to -0.16) p=0.018].  However, this association was not significant when 
using bootstrapped standard errors [ß(CI)=-0.83 (-1.76 to 0.10) p=0.082].  There 
were no significant findings in the HN group. 
 
There were no significant findings between cortisol and depressive symptoms 
overall, or over time, using longitudinal analyses.  Similarly there were no 
significant associations between cortisol levels and risk of a DE. 
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8.2.1.3 Quality of life findings 
 
There was no interpretable overall pattern of associations between cortisol and 
QoL.  All of the parameters for the cortisol regressions using robust standard errors 
are provided in appendix 8. 2.  However, there were some isolated findings, which 
are reported below. 
 
There was a significant association between an increased morning rise in cortisol 
levels and T1 QoL in CR patients which was still significant when using 
bootstrapping [ß(CI)=5.80 (0.17 to 11.43) p=0.043].  There were no significant 
findings in the HN group. 
 
At T3 there were no significant findings in the CR group.  However, in HN patients, 
there was a significant negative association between higher evening cortisol and 
reduced QoL, which remained significant when using bootstrapping techniques 
[ß(CI)=-16.65 (-31.23 to -2.06) p=0.025]. 
 
At T4 there was a significant positive association between Qol and cortisol levels at 
waking+30 and increased morning rise cortisol in CR patients.  After bootstrapping, 
the association between 30 minute waking cortisol and increased QoL remained 
[ß(CI)=5.01 (0.40 to 9.62) p=0.033] but the association between morning rise cortisol 
and QoL was reduced to a trend [ß(CI)=5.16 (-0.48 to 10.79) p=0.073].  There were 
no significant findings in the HN group. 
 
At T5 there was a significant positive association between morning rise cortisol and 
global QoL in CR patients, which was still significant when using bootstrapping 
[ß(CI)=6.64 (0.68 to 12.59) p=0.029].  There was also a significant negative 
association between evening cortisol and QoL in HN patients.  As with the CR 
finding this was still significant when using bootstrapping [ß(CI)=-15.83 (-29.48 to -
2.17) p=0.023]. 
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Overall, there was a significant association between increased cortisol morning rise 
and increased QoL in CR patients, but this finding was reduced to a trend after 
calculating bootstrapped standard errors [ß(CI)=4.93 (-0.34 to 10.20) p=0.067].  
There were no significant findings using longitudinal analyses in the HN group. 
8.2.1.4 Summary 
 
The findings did not support the hypothesis that increased cortisol levels and 
increased cortisol morning rise are associated with increased depressive 
symptoms and therefore decreased QoL.  On the contrary, there is some evidence 
that an increased cortisol morning rise was associated with increased QoL in CR 
patients. 
8.2.2 Inflammation 
8.2.2.1 Descriptives 
 
Figure 8.2 to figure 8.5, summarise the descriptives for all the inflammatory 
markers used in the study.  Levels of T2 IL6, T1 and T2 TNFα and T2 CRP were all 
significantly higher in the CR cancer patients, compared to the HN patients.  
However, T3 IFNγ was significantly higher in the HN cancer patients.  Full details 
are provided in appendix 8. 3.  As can be seen by the graphs, IL6 and CRP follow 
the anticipated pattern of an increase after treatment followed by a decline to near 
baseline levels at one month (see section 8.1.3).  However, whilst TNFα follows the 
same expected pattern in CR groups, it gradually increases in the HN group.  
Similarly, IFNγ levels show no significant change in CR patients but continue to 
increase in HN patients.  More details are provided in appendix 8. 4. 
Chapter 8: Physiological factors 
184 
0
1
0
2
0
3
0
4
0
5
0
IL
6
 (
p
g
/m
l)
CR HN
T1 T2 T3
 
Figure 8.2: IL6 levels at each time point by diagnosis. +significantly higher than 
baseline levels p<0.05.  Two CR patients levels were not included in this graph; their 
levels were 124.61 and 123.96. 
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Figure 8.3: TNFα levels at each time point by diagnosis. +significantly higher than 
baseline levels p<0.05. 
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Figure 8.4: IFNγ levels at each time point by diagnosis. + significantly higher than baseline levels 
p<0.05.  Levels from two CR patients were excluded from this graph (135.80, 54.85) and one HN 
patient (30.26). 
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Figure 8.5: CRP levels at each time point by diagnosis. + significantly higher than baseline levels 
p<0.05.  Levels from four CR patients were excluded from this graph (319.45, 213.8, 224.4, and 
205.17) and one HN patient (243.42). 
8.2.2.2 Depression findings 
 
Consistent with the cortisol results, only the regression parameters for the 
bootstrapped standard errors are reported here; the parameters for the regressions 
using robust standard errors are all reported in appendix 8. 5  to appendix 8. 16. 
 
Depressive symptoms at T1: 
There was no evidence to suggest an association between increased inflammation 
at T1 and depressive symptoms at T1 in either cancer group. 
 
Depressive symptoms at T3: 
At T3 there was a positive association between T1 IL6, TNFα, IFNγ and CRP and 
HADS-D in CR patients, but only the TNFα association remained significant after 
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bootstrapping [N=20, p=0.190;N=21, ß(CI)=0.95 (0.25 to 1.66) p=0.008; N=21, 
p=0.570; N=21, p=0.280]. 
 
At T3 there was also a positive association between T2 and T3 IFNγ and HADS-D 
in CR patients, but neither of these were significant after using bootstrapped 
standard errors [N=23, p=0.523; N=21,p=0.550 respectively].  Similarly, evidence 
was found in support of an association between increased perioperative IFNγ and 
increased HADS-D.  Again, this was no longer significant when using bootstrapped 
standard errors [N=21, p=0.419]. 
 
There were no significant associations between T1 or T2 inflammation and T3 
HADS-D in CR patients, but there was a significant association between T3 IL6, 
TNFα and CRP and HADS-D at T3 in HN patients.  Only the TNFα finding 
remained significant after bootstrapping [N=33, p=0.177;N=33, ß(CI)=0.78 (0.07 to 
1.48) p=0.030; N=33, p=0.634, respectively]. 
 
Depressive symptoms at T4: 
At T4 there was a positive association between T1 IL6, TNFα, IFNγ and CRP and 
HADS-D in CR patients.  As with depressive symptoms at T3, only the association 
between T1 TNFα and HADS-D remained when using bootstrapping [N=20, 
p=0.124; N=21, ß(CI)=1.04 (0.09 to 2.01) p=0.033; N=21, p=0.342; N=21, p=0.236, 
respectively]. 
 
In CR patients there was a positive association between T2 IFNγ and HADS-D at 
T4.  There was also a significant association between T2 TNFα and HADS-D.  
Again, only the TNFα finding remained significant when using bootstrapping [N=23, 
p=0.617; ß(CI)=1.02 (0.15 to 1.90) p=0.022 for IFNγ and TNFα respectively].  There 
were no significant associations between T3 inflammation and HADS-D at T4 in 
CR patients, but there was a trend towards an association between T3 TNFα and 
HADS-D.  This trend was slightly reduced when using bootstrapped standard 
errors [N=22, ß(CI)=1.09 (-0.14 to 2.32), p=0.082].  Finally, as with T3, evidence was 
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found in support of an association between greater post operative rise in IFNγ 
levels and increased HADS-D scores, but this did not remain significant in the 
bootstrapped model [p=0.478]. 
 
There were no associations between inflammation and T4 depressive symptoms in 
the HN group. 
 
Depressive symptoms at T5: 
There were few significant associations between inflammation and depressive 
symptoms at T5.  In CR patients there was a significant negative association 
between T2 IFNγ and HADS-D at T5.  This was no longer significant after 
bootstrapping [p=0.203].  There was also evidence towards a positive association 
between increased perioperative CRP and HADS-D and an association between 
decreased perioperative IFNγ and HADS-D.  After bootstrapping, the CRP finding 
was still significant [N=18, ß(CI)=0.03 (0.00 to 0.05) p=0.042] whereas the IFNγ 
finding was not [p=0.198].There were no significant findings in the HN group. 
 
There were many associations between T1 inflammation and mood overall when 
using longitudinal analyses, but very few of these associations were still significant 
when using bootstrapped standard errors.  When using robust standard errors 
there was evidence towards the following in CR patients: 
1. A positive relationship between TNFα at T1 and HADS-D overall, which 
remained after adjusting for time, but no interaction. 
2. A positive association between IFNγ at T1 and HADS-D overall.  This 
disappeared when including the interaction term meaning the association 
was only significant at T3 [p<0.0005], T4 [p=0.004] and T5 [p=0.025].  
The association at T5 was a negative association. 
3. No main effect of IL6 T1 or time, but a positive interaction between IL6 T1 
and HADS-D levels at T3 [p=0.035] and trend T4 [p=0.079]. 
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4. No main effect of CRP, but a significant positive interaction at T3 
[p=0.004], yet non significant at T4 [p=0.145] and negative at T5 
[p=0.044].  
 
There were no significant results in the HN group. 
 
As with the findings using linear regression, only the TNFα finding in CR patients 
remained significant when using bootstrapped standard errors [N=28, β(CI)=0.80 
(0.30 to 1.31) p=0.002] and no findings in the HN group were significant. 
 
There were no significant associations between increased inflammation at any time 
point and increased risk of a DE6, except an association between T3 IFNγ and 
reduced risk of a DE6 in HN patients, which was no longer significant when using 
bootstrapped standard errors [N=34,p=0.340]. 
8.2.2.3 Quality of life findings 
 
QoL at T1: 
At baseline, poorer QoL was associated with increased levels of TNFα and a trend 
towards increased CRP in CR patients.  Both the associations between TNFα and 
CRP and poorer QoL remained significant after bootstrap analyses [ß(CI)=-5.66 (-
11.20 to -0.12) p=0.045; ß(CI)=-0.29 (-0.88 to 0.30) p=0.025 respectively].  There were 
no significant findings in HN patients. 
 
QoL at T3: 
There were no significant associations in CR patients between inflammation at T1 
or T2 and poorer QoL at T3, but there was evidence towards increased T3 IL6, 
TNFα and IFNγ and poorer QoL at T3 in CR patients. 
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The only association that remained significant when using bootstrap analyses was 
with TNFα and QoL [N=20, p=0.086; N=21, ß(CI)=-9.10 (-17.47 to -0.72), p=0.033; 
N=21, p=0.534 for IL6, TNFα and IFNγ respectively]. 
 
There was a significant association between T2 IL6 and CRP and poorer QoL at 
T3 in HN patients.  Both of these findings remained significant when using 
bootstrapped standard errors [ß(CI)=-1.47 (-2.80 to -0.14) p=0.030; ß(CI)=-0.19 (-0.35 
to -0.02) p=0.025 for IL6 and CRP respectively]. 
 
There was also a significant association between increased T3 IL6, TNFα and CRP 
and poorer QoL at T3 in HN patients.  However, the only association that remained 
significant in the bootstrap analyses was between TNFα and QoL [N=33, p=0.068; 
N=33, ß(CI)=-5.37 (-9.97 to -0.76) p=0.022; N=33, p=0.162, for IL6, TNFα and CRP 
respectively]. 
 
Higher perioperative IL6 and CRP increase was associated with poorer QoL at T3 
in HN patients.  These results remained significant using bootstrap standard errors 
[ß(CI)=-1.72 (-3.24 to -0.19) p=0.028; ß(CI)=-0.22 (-0.41 to -0.03) p=0.026 for IL6 and 
CRP respectively]. 
 
QoL at T4: 
At T4, there was a significant association between T2 IFNγ and poorer QoL in CR 
patients, but this was no longer significant when using bootstrapping 
[N=23,p=0.821].  There was also an association between higher perioperative IFNγ 
and poorer QoL at T4 in CR.  Again, this was no longer significant when using 
bootstrapping [N=21,p=0.581].  There were no significant associations in HN 
patients.  
 
QoL at T5: 
There were no significant associations between inflammation at T1 or T2 and 
poorer QoL at T5 in CR patients.  There was weak evidence towards an 
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association between increased IFNγ at T3 and poorer QoL in CR patients.  
However, this association was no longer significant after bootstrapping [N=19, 
p=0.632].  There were no perioperative associations. 
 
In HN patients there was a significant association between T1 IFNγ and poorer 
QoL at T5 in HN patients.  There was also a trend towards an association between 
increased T1 IL6 and reduced QoL in HN patients.  The association between IFNγ 
and poorer QoL was also significant when using bootstrapping, but the association 
between IL6 and QoL was not [N=36, ß(CI)=-4.04 (-7.71 to -0.37) p=0.031; N=36, 
p=0.228 for IFNγ and IL6 respectively].  There was also a significant association 
between increased IL6 at T2 and poorer QoL at T5 in HN patients, which remained 
significant after bootstrapping [ß(CI)=-1.21 (-2.29 to -0.12) p=0.030].  Finally, there 
was a significant association between increased IL6 at T3 and reduced QoL at T5 
in HN patients, which was still significant when using bootstrapped standard errors 
[N=32, ß(CI)=-3.73 (-7.06 to -0.41) p=0.028].  As with the CR patients there were no 
perioperative associations.  
 
QoL overall: 
There was a significant association between T1 IFNγ and CRP and reduced QoL 
overall in CR patients in longitudinal analyses.  These associations were no longer 
significant when using bootstrapped standard errors [N=28,p=0.385; N=28,p=0.134 
for IFNγ and CRP respectively].  There were no significant associations in HN 
patients and no time interactions in either patient group. 
8.2.2.4 Summary 
 
There were no consistent findings that could be considered reliable between 
cortisol and either depressive symptoms, QoL or risk of a DE. 
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There were consistent associations between increased TNFα and increased 
depressive symptoms and poorer QoL.  These findings were much more robust in 
the CR group:  
 
 TNFα at baseline was associated with increased poorer QoL at baseline and 
depressive symptoms at one and three months post surgery. 
 TNFα at one week post surgery was associated with increased depressive 
symptoms at three months. 
 TNFα at one month post surgery was associated with increased depressive 
symptoms at one month. 
 There was a trend towards an association between TNFα at three months and 
poorer QoL at three months – which was also found in the HN group. 
 
The most consistent finding for the HN group was an association between 
increased perioperative IL6 and CRP and poorer QoL at one month post surgery.  
Also, increased baseline IFNγ and IL6 at one week post surgery were both 
associated with poorer QoL at six months. 
8.3 Discussion 
8.3.1 Cortisol 
 
Counter to the hypothesis, there were no consistent findings that could be 
considered reliable between cortisol and either depressive symptoms, QoL or risk 
of a DE. 
 
Overall, cortisol levels followed the expected pattern of higher morning levels, 
including a 30 minute post waking peak, followed by an evening nadir.  However, 
there were very few significant findings relating cortisol and depressive symptoms, 
risk of a DE6 or poorer QoL.  Although there were some significant associations in 
the cortisol analyses, there was no discernable pattern, suggesting that the results 
may not be reliable and would require replication.  This may be due to low power 
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as previous prospective designs all had larger sample sizes[252, 262, 283].  Cortisol 
levels can be affected by numerous other variables such as smoking, age, LE, time 
of waking, but this study did not have the power to adjust for all the measured 
factors without risking over adjustment.  Also, although patients reported the time 
of the first sample, which was not associated with cortisol levels (data not shown) 
patients did not report the time of waking, thus unreliable reporting and/or varied 
waking time may have made an impact on the results.  Investigations into 
participant compliance with the sampling procedure found that even though most 
participants reported full compliance 26% took samples outside of the sampling 
window[284].  A further study by the same group found that the non compliant 
samples resulted in flatter slopes[285].  In a recent meta-analysis[260] of over 21 
studies, there was a positive association between increased morning rise and life 
stress, but no association between depression and morning rise.  Also, studies 
investigating morning rise over three days tended to show increased levels, 
whereas studies using data from two or less sampling days tended to find an 
inverse association, thus issues of non-compliance may have further confounded 
the results.  One past study[283] found mean urinary cortisol significantly predicted 
high depressive symptoms after knee replacement surgery, implying that there is a 
relationship.  But a larger sample, and perhaps a more robust protocol, is required 
to detect a significant effect.  It is also possible that inclusion of the DST/CRH test 
may give more robust findings as it is reported to be more sensitive and 80% of 
patients test positive[61], but this is much more invasive and demanding of patients. 
8.3.2 Inflammation 
 
Increased inflammation was not associated with an increased risk of a DE6, but 
there were some positive associations between inflammation and depressive 
symptoms.   
 
Almost all of the levels of inflammatory markers were within detection range, with 
the exception of IL1ß, which was excluded from further analyses.  However, there 
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was substantial variation between individuals and over time.  Most levels increased 
soon after surgery and then fell back to near baseline by one month after surgery, 
except TNFα and IFNγ levels which continued to rise in HN patients.  Stratifying by 
radiotherapy indicated that the continued rise was only apparent in radiotherapy 
patients, which is consistent with previous research[286].  IL6 and CRP also 
increased at one month post operation in radiotherapy patients, but unlike TNFα 
and IFNγ, IL6 and CRP were also increased at baseline in those patients that 
received radiotherapy. 
 
The lack of an association between increased inflammation and increased risk of a 
DE6 in either patient group could be because of low power.  There were many 
significant findings between inflammation and increased depressive symptoms or 
poorer QoL in both cancer patients when using standard regression techniques.  
However, whilst most of these were in the hypothesised direction, some of the 
relationships were very strong but in the opposite direction.  Further investigations 
revealed that these results were over influenced by outliers.  A more conservative 
approach was used to verify the significant results, which allowed for non 
parametric distributions and weakened the role of outliers.  After using this 
technique fewer associations were significant, but all were in the hypothesised 
direction and the findings appeared more reliable.  The relationship between 
inflammation and depressive symptoms and QoL differed between the two cancer 
groups.  There appeared to be a strong relationship between TNFα and increased 
depressive symptoms in the CR patients, whereas in HN patients the main findings 
were between IL6 and QoL. 
 
In CR patients, increased TNFα levels were a significant risk factor for increased 
depressive symptoms for one and three months post surgery.  Pre treatment TNFα 
levels were associated with increased depressive symptoms at one and three 
months post surgery.  Increased TNFα one week after surgery was also associated 
with increased depressive symptoms three months post operation.  Increased 
TNFα levels at one month post operation were associated with concurrent low 
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mood and poorer QoL.  There was also a trend towards an association between 
increased TNFα levels at one month post surgery and increased depressive 
symptoms at three and six months after surgery.  Finally, a high perioperative 
increase in CRP levels was associated with increased depressive symptoms at T5 
in CR patients.  Interestingly, baseline TNFα and CRP were both associated with 
poorer baseline QoL in CR patients.  As a result, all of the findings were rechecked 
after adjusting for baseline QoL.  It was found that baseline QoL mediated the 
association between TNFα and later depressive symptoms, but was not as 
predictive of increased depressive symptoms as TNFα.  It is surprising that there 
were no findings relating to IL6 in this study as IL6 is often reported to be 
associated with increased depressive symptoms, but the meta-analyses[90] showed 
a greater effect size for TNFα than IL6, so it is possible that the sample size was 
only large enough to detect an effect of TNFα, but not IL6. 
 
In HN patients, the only association between inflammation and depressive 
symptoms was a cross sectional association at one month post surgery between 
TNFα and increased depressive symptoms.  TNFα was also associated with 
poorer QoL at this time point.  There were, however, some prospective findings 
relating to increased IL6 and poorer QoL.  Higher perioperative IL6 and CRP and 
one week post operative IL6 and CRP levels were associated with poorer QoL at 
T3.  Higher baseline IFNγ, increased IL6 levels at one week post surgery and at 
one month post surgery were all associated with poorer QoL at six months post 
surgery.  These findings were mediated by the surgical rating score, but were still 
the strongest predictor of poor QoL at T3 or T5.  This relationship is probably due 
to levels of sickness behaviour, some aspects of which are explored in the next 
chapter.  However, there is not even a trend towards an association between IL6 or 
CRP and poorer QoL at T4, which is hard to explain given the findings at T3 and 
T5.   There is also less of a relationship between depressive symptoms and QoL at 
this time point.  The reasons for this are not clear, but it may indicate that T4 is a 
bad time for sampling.  
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The findings of an association between inflammation and increased depressive 
symptoms in CR patients do follow a similar pattern to that of the psychological 
variables, indicated by an increased association at T4 which is much weaker at T5.  
In HN patients, however, the findings relating to QoL follow the opposite pattern, 
where no association is apparent at T4, but there are associations at T3 and T5.  
These findings further confound the strong effects of psychological factors at T4, 
especially with regard to that of CT, which is associated with depressive symptoms 
at T4 in CR patients, but not HN patients.  This is unlikely given the larger HN 
sample size.  However, they also show that physiological factors can be used as 
markers for high levels of depressive symptoms or poorer QoL at later time points 
after surgery.  The clinical value of these measures is discussed in chapter 12. 
 
The results suggest that TNFα may be a risk factor for increased depressive 
symptoms in CR patients, but only within a tight time window.  Although there was 
a trend towards an association between T3 TNFα and later depressive symptoms, 
these associations were not significant, suggesting that either the increased time 
difference between the two measures weakened the effect, or possibly that the 
association between TNFα and depressive symptoms was only apparent soon 
after surgery and could be a reflection of sickness behaviour[287].  It is interesting 
that the relationship between inflammation and mood was much less apparent in 
the HN patients, despite a larger sample.  This is most likely due to a combination 
of two reasons: 1) the CR group is much more homogenous (in terms of cancer 
site, symptoms, impact of treatment and life style), so any effect within the HN 
group may have been obscured by covariates such as smoking, cancer site and 
histology, and treatments 2) inflammation has been proposed as an aetiological 
factor in CR cancer[229] which may have augmented any inflammatory effects, (e.g. 
increased inflammation over a longer period, both pre and post operatively).  It is 
also possible that the relationship between inflammation and mood in the HN 
patients was not as apparent due to lower cytokine levels overall in the HN group, 
therefore less sensitivity.  Most studies that found differences in cytokine levels in 
Chapter 8: Physiological factors 
197 
cancer patients with depression, compared to those without, used heterogeneous 
groups, usually mainly breast or CR cancer patients[137-140]. 
8.3.3 Limitations and conclusions 
 
This study was limited by low power, especially given the number of variables that 
may affect the results.  The CR and HN patients were analysed separately as 
previous analyses suggested that they are very different, and accordingly the 
results differ greatly between the two diagnoses.  As is expected in small samples, 
the analyses were initially greatly skewed by patients with extreme cytokine levels, 
so two different methods were used and the results were only accepted if both 
analyses indicated a significant effect.  This helped to enhance the reliability of the 
findings, but did not help prevent a type II error.  The original findings are reported 
because it is noteworthy that the majority of the outliers generated findings in the 
hypothesised direction, suggesting that an increase in patient numbers and 
therefore greater data spread is likely to yield more positive results.  Even so, 
some significant effects were found, further indicating that this research area would 
benefit from using larger more homogenous samples.  It was surprising to see no 
effect from IL6, but such a robust effect between TNFα and depressive symptoms 
in CR patients, suggesting that it is worth investigating other cytokines.  A review of 
potential biological markers for depression proposed IL10 as one of the most 
promising cytokines for use as a marker (although no cytokine has a high enough 
predictive value to be considered for use as yet)[89] so future studies could consider 
using interleukin-10 (IL10).  IL10 has also been found to be a stronger indicator of 
cancer prognosis in colon cancer patients, over that of IL6[288].  If IL10 levels did 
not drop after treatment it was indicative of a future recurrence[288].  As IL10 is an 
anti-inflammatory cytokine the ratio between pro-inflammatory cytokines and IL10 
may also be of interest.  One study found that the ratio of IL6 to IL10 was 
significantly higher in depressed patients[289].  Given the low detection level of IL1ß 
it is probably worth testing IL10 instead of IL1ß. 
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8.3.4 Summary 
 
In summary, this chapter reported on the value of physiological markers as 
predictors of depression or poorer QoL in CR and HN cancer patients after 
surgery.  This study found no evidence to support the hypothesis that increased 
salivary cortisol levels would be associated with increased depressive symptoms; 
there were no reliable findings between cortisol and later depression or poorer 
QoL.  There was some evidence to support the hypothesis that increased 
inflammation would be associated with increased depressive symptoms: high 
levels of TNFα increased the risk of high depressive symptoms in CR patients.  
Inflammation was only useful as a marker of later depressive symptoms in CR 
patients.  However, IL6 and CRP were a marker of poorer QoL in post surgery HN 
patients.  Due to low power and some unexpected findings it is hard to make firm 
conclusions, but these results suggest that inflammation shows promise as a 
marker for post surgical mood and QoL in the two cancer groups and is therefore 
worthy of more investigation.  Inflammation may also be related to many other 
aetiological aspects of depression and cancer symptoms; the next chapter further 
investigates the inter-relationships between the psychological and physiological 
markers included in this study, which have been investigated in this and the 
previous chapter. 
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9 Covariates 
 
The last two chapters have focused on the relationships between psychological 
and physiological factors and depression and QoL.  However, as reported in the 
literature review and the hypotheses diagram (see page 58) it is likely that many of 
the investigated psychological and physiological variables are inter-related. 
Therefore, this chapter addresses part of the third aim of the thesis: to explore 
associations between other possible explanatory factors on inflammation and 
cortisol.  It will also test the fifth hypothesis: that patients with increased HPAA 
activity will show increased inflammation.  This chapter demonstrates the inter-
relation between the investigated variables, by reporting associations between: 
1. Psychosocial variables involved in the aetiology of DDs (CT, NE, LE). 
2. Physiological variables (cortisol and inflammatory markers). 
3. Physiological variables and psychosocial variables. 
4. Psychosocial variables and symptoms of fatigue and pain. 
 
This will introduce the rationale behind the choices of covariates in the final 
adjusted models presented in Chapter 10. 
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9.1 Background 
9.1.1  Psychological variables 
 
Many of the variables under investigation are likely to be related.  Past studies 
have demonstrated relationships between many of the investigated factors, and 
many of the aetiological factors that occur earlier in life are expected to be 
associated with a PH depression; depression is a recurrent disorder with an 
average age of onset of 25 years[199] whereas CR or HN cancers are more likely to 
occur in patients over the age of 50.  Therefore, most cancer patients with a 
vulnerability to a DD, such as high levels of NE, are likely to have already 
experienced a DE. 
9.1.1.1 Childhood trauma 
 
There is evidence that CT is related to NE, LE and PH depression.  Kendler‟s 
model[62] of risk for development of a DE (introduced in sections 1.2.2 and 7.1), 
reported an association between disturbed family environment and childhood 
sexual abuse and NE.  Similarly a more recent replication of Kendler‟s model by 
Sjöholm‟s group[200] found disturbed family environment increased the risk of NE, 
but found no association between parental loss and NE. This suggests that the 
relationship between CT and NE may be dependent on the form of CT 
experienced.  Another retrospective study found a relationship between three or 
more childhood stressful events (ranging from family discord to traumatising 
accidents) and NE in over 700 participants all free from mental illness[290].  Finally, 
one study using the CTQ found an association between emotional abuse and NE 
in those with a DD[291], but no significant association with any other scale and they 
did not report the CTQ total score. Thus an association between CT and NE would 
be expected. 
 
Kendler‟s group[62] also found sexual abuse to be associated with increased 
difficulties and independent stressful LE in the past year.  They found an 
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association between disturbed family environment and lifetime trauma, difficulties 
and marital problems in the last year.  Similar results were obtained by Sjöholm‟s 
group[200].  As stated in the section 1.3.3 and 7.2.1 CT is also associated with a 
DD, so those patients with high levels of CT are also more likely to have a PH 
depression, though interestingly neither Kendler[62] or Sjöholm[200] report a direct 
association between CT and PH depression, perhaps due to adjustments for 
confounding factors.  Based on these findings CT is hypothesised to be associated 
with NE, LE and PH depression. 
9.1.1.2 Neuroticism, life events and PH depression 
 
In addition both Kendler‟s[62] and Sjöholm‟s[200] models found that NE was 
associated with marital problems but not life difficulties, such as daily hassles, LE 
or PH depression.  The lack of association between NE and LE or PH depression 
is likely to be due to confounding factors, as previous reports have shown a strong 
relationship between NE and LE and past mental health[228].  Investigators have 
also reported that the risk of a DE after a stressful LE is amplified in those with 
higher levels of NE[228].  Kendler‟s group[292] replicated these findings with a larger 
sample of 7,500 (compared to 160).  Based on these findings NE is hypothesised 
to be associated with LE and PH depression. 
 
Finally, both Kendler‟s[62] and Sjöholm‟s group[200] found that PH depression was 
associated with dependent stressful LE (where the person‟s behaviour may have 
contributed to the event as rated by an independent informant).  It is a well 
documented finding that individuals with a current DE or in remission from a DE 
are more likely to generate stressors, particularly those involving interpersonal 
conflicts[293, 294].  Based on these findings PH depression is expected to be 
associated with more LE. 
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9.1.2  Physiological variables 
 
There is now a substantial amount of evidence to suggest a bidirectional link 
between cortisol and inflammation[295].  Inflammation has been reported to increase 
HPAA activity[296] and equally, glucocorticoids have been found to potentiate and 
suppress immune activity[297].  Evidence for this association has been found 
through correlations in animal and human samples and challenge studies. 
 
Challenge studies have shown a suppressive effect of cortisol on inflammation.   
High cortisol levels have been associated with lower IL6 responses after a stressor 
in 199 middle aged participants, suggesting a suppressive effect of glucocorticoids.  
Cortisol responders also expressed more subjective stress during the tasks[298].  
Similarly, pulsatile infusion of cortisol increased cortisol levels and significantly 
decreased levels of IL6 and TNFα in a small sample of 14 depressed patients[299].  
However, the relationship between cortisol and inflammatory activity appears to be 
dependent on timing; glucocorticoids can potentiate immune activity in response to 
immune challenge, demonstrated by increased IL1, (but not IL6) but only if the 
glucocorticoid is administered before the immune challenge.  Glucocorticoids were 
found to have a suppressive effect on cytokines if administered from five minutes 
after the immune challenge[297]. 
 
Challenge studies have also demonstrated that inflammation activates HPAA 
activity; IL1 administration increased an immobilisation stress associated ACTH 
rise, as well as dopamine and serotonin levels[300].  All of these effects could be 
prevented by using an IL1 receptor antagonist, providing the antagonist was 
administered before immobilisation stress started.  Pro-inflammatory cytokines are 
thought to activate the HPAA by increasing glucocorticoid resistance[80] and thus 
increasing CRH production.  Cytokines also stimulate vasopressin which stimulates 
ACTH production[296].  Correlation studies[85] have shown a time lagged correlation 
between IL6 and later cortisol secretion (of about 6 to 7 hours)[85].  Similarly, 
evening cortisol levels were found to correlate with immune stimulated 
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mononuclear cell TNFα levels, but not IL6 levels[250].  However, this relationship 
may be dysregulated in those with depression as those with MD did not show the 
time lagged association between IL6 and cortisol that was present in healthy 
controls[85].  Similarly, further work has reported that IFNα induced depressive 
symptoms are related to cytokine levels, but not to HPAA dysregulation[301].  
Interestingly, one study also found that monocytes incubated with dexamethasone 
(a glucocorticoid receptor agonist) from patients with a DD produced more TNFα 
compared to those of healthy controls[302], but only in monocytes from those 
individuals who responded to treatment (with amitriptyline).  This suggests that 
there is a complex relationship between cytokines and the HPAA, which may be 
dysregulated in some patients with a DD. 
 
Taking all of the studies into account, there clearly appears to be a relationship 
between inflammation and cortisol, though some of the results are a little 
conflicting.  Differences in these results are likely due to the instability of cytokines, 
the reliability of testing protocols.  It is also possible that there is a dysregulation in 
the relationship between patients with depression, which may depend on the 
aetiology or subtype of depression[269, 301, 303, 304].  However, most studies show a 
correlation between inflammation and cortisol. Therefore it was hypothesised that 
there would be a positive correlation between cortisol and inflammatory markers. 
9.1.3 Childhood trauma, neuroticism, life events, past history of depression 
and cortisol 
 
For the first nine months of life the HPAA has an irregular secretory pattern, which 
starts to show a regular rhythm from 12 months[259].  Numerous animal and human 
studies have shown a relationship between increased CT and increased HPAA 
activity.  Although the picture is complex[255], those with CT appear to show higher 
cortisol levels then those without.  Individuals with ELS also appear to be more 
responsive to social stress tests[305], although most of these findings use plasma 
ACTH and not cortisol measures.  Increased plasma cortisol response after a 
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social stressor has been reported in those with depression and high levels of ELS, 
although there was no difference in those with CT or MDD only and controls[106].  A 
recent prospective study also found higher salivary cortisol and plasma ACTH in 
men and women that had been separated from both parents (but not from their 
fathers only) during early childhood because of world war two.  They also found a 
greater effect if separated from their parents earlier[306].  On the other hand, they 
only found a difference in stress reactivity in the male sample, where those who 
were separated from both parents showed greater cortisol increases in response to 
a social stress test.  These findings were based on a sample of 282 older subjects 
and the associations were only reported after adjusting for current depressive 
symptoms.  Nevertheless, contradictory findings of decreased salivary cortisol 
awakening in undergraduate students who had experienced early life loss have 
also been reported[307].  Of note, many studies report HPAA hypoactivity in those 
suffering from chronic stress, post traumatic stress disorder and chronic fatigue.  
Hypoactivity of the HPAA is characterised by flattened cortisol awakening response 
and lower levels of cortisol overall.  Childhood trauma also increases the risk of 
post traumatic stress disorder[308] and chronic fatigue[255] it is possible that the 
spread of HPAA abnormalities obscures any relationships due to the inclusion of 
subgroups with diametrically opposed HPAA dysregulation.  Thus cortisol levels 
would be expected to be higher in those who reported higher levels of CT. 
 
A number of studies have also found a relationship between current stress and 
salivary cortisol levels. Increased cortisol awakening response has been reported 
in those experiencing chronic stress[253], but the authors did not investigate the 
prevalence of mental illness within their sample.  Of relevance to this study, a 
greater cortisol response to awakening has also been associated with number of 
severe LE in the previous month, though less severe LE had no association[263].  
However, the authors found lowered morning salivary cortisol in the same sample 
in those with a current DD, suggesting the sample may not have been 
representative.  Despite a long pathway from psychological stress to increased 
salivary cortisol levels, the evidence suggests increased levels of salivary cortisol 
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in those under chronic stress and who have experienced recent severe LE.  Thus, 
cortisol levels would be expected to be higher in those reporting more LE. 
 
Similarly there is evidence to suggest an association between NE and increased 
HPAA activity.  Healthy individuals free from any psychiatric disorder but with high 
levels of NE have been reported to have significantly higher cortisol levels at 30, 45 
and 60 minutes after waking compared to those with low NE scores[115].  Although 
they did not adjust for current depressive symptoms which appeared to be higher 
in the highly neurotic group.  Increased morning rise has also been shown to be 
associated with NE in breast cancer patients, but no association was found 
between NE and cortisol in the control group in that study[309].  However, despite 
these positive findings a recent meta-analysis reported no association between 
cortisol awakening response and NE[260]. 
 
Two studies have shown a positive association between a PH of depression and 
increased morning rise[251, 310].  One of those studies included 579 remitted MDD 
patients with 701 current MDD patients and 308 controls and found higher morning 
rise cortisol levels in the remitted and current MDD patients compared to controls. 
 
Past research suggests that patients with CT, recent severe LE, a PH of 
depression or high levels of NE have dysregulated HPAA which would probably 
result in an increased cortisol awakening response. 
9.1.4 Childhood trauma, neuroticism, life events, past history of depression 
and inflammation 
 
As stated previously, psychological and physical stress increase cytokine levels[94, 
95, 116, 300].  There is also a lot of evidence to suggest a relationship between 
increased inflammation and CT and ongoing stress.  Past studies have reported an 
association between CT and increased inflammation in adulthood.  A prospective 
study involving over 800 participants reported a dose response relationship 
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between no abuse, probable abuse and definite abuse and CRP levels[311], leading 
the authors to estimate that ELS could account for 10% of low grade inflammation 
in adults.  These findings are supported by studies showing increased inflammation 
in animals after ELS (reviewed by Jessop 2009[312]).  Also, perhaps of particular 
relevance to this study, a previous investigation found that social isolation stress 
increased colonic TNFα levels in rats that were exposed to psychological stress or 
no stress, but not when rats were subjected to experimentally induced colitis[313].  
However, one study reported increased inflammation in response to a stressor in 
those with MDD, but it did not find a relationship between CT and increased 
inflammation or increase in inflammation following a social stress test in a sample 
of 27 volunteers[116].  Indicating that perhaps present depression and current stress 
have a greater association with inflammatory reactivity then earlier life stressors.  
Studies have also reported higher increases in levels of IL6 in women with a PH 
depression soon after childbirth[282].  These studies imply that those at risk of a DD 
show increased inflammatory responses to stress, suggesting that cancer patients 
who experienced CT have a PH depression or experience other stressors at the 
time of diagnosis may show increased inflammation compared to those without 
these risk factors.   
 
There are fewer reliable studies investigating relationship between NE and 
inflammation.  One study found no relationship between NE and IL6 in a group of 
103 participants over 40 years of age.  However, two thirds of their samples were 
taken in the afternoon and the lack of consistency in the sampling time would have 
affected the results[314].  A smaller study of 44 patients found a positive association 
between NE and IL6 levels in older adults, based on stimulated monocyte IL6 
production from a morning blood sample[118]. 
 
Additionally, there is evidence towards an association between depression and 
prospective increases in inflammatory markers[315].  Hamer and colleagues[315] 
(2009) found an association between chronically high levels of depressive 
symptoms and increased CRP levels two years later based on a sample of over 
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3500 older adults.  It is possible that the link between inflammation and depression 
is bidirectional, thus the relationship between baseline depressive symptoms and 
later inflammation was investigated.  However, the relatively small effect may be 
confounded by the presence of current psychological and physiological stress 
experienced by newly diagnosed cancer patients.  Studies in physically healthy 
subjects report a greater increase in IL6 in response to psychological stress in 
those with a DD compared to those without depression[116].  Whereas, studies in 
CR cancer patients have reported a decreased IL6 response to surgical cancer 
treatment in those with a DD[137].  Nonetheless, baseline depressive symptoms 
were expected to be associated with increased inflammation post treatment. 
9.1.5 Psychological and physiological markers of fatigue and pain 
 
Past studies have suggested that pre diagnostic factors have an effect on somatic 
symptoms.  For instance, cancer patients‟ reports of somatic symptoms on the 
EORTC-QLQ were reported to be primarily affected by negative affect, or their 
emotional function score, more so than their overall health status as determined by 
a physician based on their physical function[148].  Similarly, NE has been associated 
with not only poorer QoL in HN patients, but also with greater fatigue, pain, 
dyspnoea, insomnia, diarrhoea and financial difficulties[212].  Negative affect has 
also been reported to be associated with more pain[316].  Childhood trauma has 
also been associated with increased physical symptom complaints in primary care 
patients in a retrospective study[317].  In line with these findings, higher IL6 scores 
have not only been associated with clinician rated function, but also increased 
nausea and fatigue[142], which is perhaps not surprising given the well founded 
relationship between raised inflammation and sickness behaviour, of which pain 
sensitivity and fatigue are two of the most prominent features[287]. 
 
Testing for relationships between all of the proposed risk factors and somatic 
symptoms would not be practical and could result in many chance findings due to 
multiple testing.  However, the relationship of the risk factors under study to 
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somatic symptoms is important to help interpret the fully adjusted models which are 
presented in the next chapter, and also to demonstrate the complexity of 
relationships between psychological and physiological markers and QoL.  Based 
on the above reports, the relationships between the markers under study and 
fatigue and pain scores were investigated.  Both psychological factors and 
increased inflammation were expected to increase fatigue and pain reporting. 
9.1.6 Conclusions 
 
The investigated psychological and physiological markers are likely to be related to 
each other.  There is strong evidence for an association between increased CT 
and current stress and increased inflammation, and probably increased HPAA 
activity.  There is also strong evidence towards an association between HPAA 
activity and inflammation.  Finally, there is also evidence to suggest a relationship 
between all of the risk factors for depression and increased symptom perception.  
This chapter reports the results for the most salient of these relationships, thereby 
incorporating the previous two results chapters and introducing the rationale for the 
final adjusted models presented in chapter 10. 
9.2 Results 
 
The results are presented following a similar structure to the literature review.  The 
results are shown first for inter-relationships between psychological variables, then 
the relationship between cortisol and inflammation, structured by time and 
diagnosis, starting with CR patients at baseline.  This is followed by a section 
investigating the relationship between psychological variables and levels of cortisol 
and inflammation, finally, finishing with the relationship between all of the variables 
and symptoms of fatigue and pain.  Consistent with chapter 8 on physiological 
factors, two regression techniques are used in the physiological analyses (using 
robust and bootstrap standard errors respectively) to increase the validity of the 
findings, as detailed in section 5.4.  The results of the regressions with robust 
standard errors are reported in the prose, but only the bootstrapped parameters 
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are presented.  The confidence interval parameters when using robust standard 
errors are reported in appendix 9. 1 to appendix 9. 3. 
9.2.1 Psychological variables 
9.2.1.1 Childhood trauma and neuroticism 
 
There was little evidence towards an association between CT and NE in CR 
patients [N=19, p=0.222].  There was weak evidence towards an association in HN 
cancer patients between CT and NE [N=34, ß(CI)=0.07 (-0.01 to 0.14) p=0.068].  
Both sets of data were following a similar trend and when the two were combined 
there was a significant positive association between total CTQ score and EPQ-N 
[N=53, ß(CI)=0.08 (0.01 to 0.14), p=0.021] indicating a weak but significant effect 
(see figure 9.1). 
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Figure 9.1: Association between CT and NE. 
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9.2.1.2 Childhood trauma, neuroticism and past history of depression 
 
There was no evidence towards a relationship between CT and PH depression. 
 
As expected high NE was associated with a PH of depression [N=62, OR(CI)=1.29 
(1.10-1.51) p=0.002]. 
9.2.1.3 Childhood trauma, neuroticism, PH depression and life events 
 
Childhood trauma, NE and PH depression were all associated with increased LE 
reporting.  There was a weak trend towards an association between CT and LE in 
CR patients [p=0.168] and a significant association in HN patients, so the results 
were combined and gave an overall significant effect [N=52, ß(CI)=0.03 (0.01 to 
0.05) p=0.005].  There was a weak trend towards an association between NE and 
LE in CR patients [p=0.180] and a stronger trend in HN patients [p=0.061] so the 
groups were combined and there was a significant effect overall [N=61, ß(CI)=0.10 
(0.02 to 0.18) p=0.016] indicating a weak positive association between NE and LE.  
Those with a PH depression also reported more LE [N=69, ß(CI)=1.93(0.85 to 3.01) 
p=0.001]. 
9.2.2 Physiological variables 
9.2.2.1 Cortisol and inflammation 
 
Significant findings were as follows: 
 
In CR patients there was a trend towards increased IL6 at T1 in patients with 
increased 30 minute morning and evening cortisol levels as well as overall mean 
cortisol.  There was also an association between increased evening levels of 
cortisol and increased IFNγ.  In HN patients increased morning cortisol (both 
waking and 30 minute levels) and overall mean cortisol were associated with 
decreased levels of IFNγ. 
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The models were then rerun using bootstrapped standard errors and only the 
association between overall mean cortisol level and IL6 in CR patients remained 
significant, and weak evidence of a negative association between IFNγ and waking 
cortisol in HN patients.  However many of the results still showed a trend (see table 
9.1). 
 
Group N Cytokine  Cortisol measure Coefficients (CI) P value 
CR 24 IL6 T1 Waking +30 mins 0.62 (-0.19 to 1.43) 0.133 
25 IL6 T1 PM 2.31 (-0.17 to 4.79) 0.068 
25 IL6 T1 Overall mean 0.96 (0.06 to 1.87) 0.038 
26 IFNγ T1 PM 0.73 (-0.89 to 2.35) 0.378 
HN 26 IFNγ T1 Waking -0.33 (-0.66 to 0.00) 0.049 
26 IFNγ T1 Waking +30 mins -0.18 (-0.31 to 0.02) 0.080 
27 IFNγ T1 Overall mean -0.30 (-0.61 to 0.01) 0.057 
Table 9.1: Relationship between cortisol and inflammation using bootstrapped standard errors. 
9.2.2.2 Cortisol and psychosocial variables 
 
There was no evidence towards an association between CT and increased cortisol 
levels. 
 
Contrary to expectations the only associations were an inverse correlation between 
NE and the cortisol morning rise in CR patients.  This remained significant after 
bootstrapping [N=19, ß(CI)=-0.11 (-0.19 to -0.03) p=0.008].  As this was a singular 
and counter hypothesis finding it was not investigated further, as noted by the point 
on multiple testing in section 5.4.3. 
 
No association between number of LE at T3 and baseline cortisol levels were 
found. 
 
There was no significant association between PH depression and cortisol levels. 
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9.2.2.3 Inflammation and psychosocial variables 
 
The only marker of inflammation at T1 that was associated with CT was CRP in CR 
patients, which was still significant after bootstrapping [N=18, ß(CI)=2.25 (0.14 to 
4.36) p=0.036, adjusted R
2
=0.42].  There was also a significant positive association 
between CT levels and increased TNFα levels at T2 in CR patients, which was still 
significant using bootstrapping [N=18, ß(CI)=0.19 (0.03 to 0.33) p=0.007].  There was 
also a trend towards an association between T1 TNFα and T1 IL6 and CT in CR 
patients [p=0.165, p=0.263 respectively].  There was no evidence towards a 
relationship between CT and increased inflammation in HN patients at T1 or T2 
and there were no associations between CT and inflammation at T3 in either 
patient group. 
 
There was no association between NE and inflammation in either patient group. 
 
There was a significant negative correlation between LE at T3 and IL6 and TNFα at 
T1 in CR patients.  These results were not significant when using bootstrapping 
[p=0.142, p=0.072 respectively]. 
 
PH depression was associated with a decrease in IFNγ at T3 in all patients which 
remained significant after bootstrapping [N=55, ß(CI)= -1.95 (-3.45 to -0.46) 
p=0.011]. 
 
There were no significant associations between baseline depressive symptoms 
and increased postoperative inflammation or perioperative rise. 
9.2.2.4 Psychosocial variables, inflammation and current symptoms 
 
Whilst developing the adjusted models it became apparent that many of the 
relationships between the variables under investigation and depressive symptoms 
and QoL were mediated by some symptoms, particularly fatigue and pain.  This 
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section reports the results for associations between the main risk factors used in 
this study and fatigue and pain partly to confirm the confounding effect and also in 
order to demonstrate potential mechanisms behind any previous findings. 
 
Psychosocial: 
 
There was a trend towards an association between CT and T1 fatigue in CR 
patients and a significant association in HN cancer patients.  When the two groups 
were combined there was a significant association between CT and T1 fatigue.  
There was also a significant association between CT and fatigue at T3 in both 
cancer groups.  The only other significant association was between CT and pain at 
T3 in HN cancer patients (see table 9.2). 
 
Group Variable N ß(CI) P value 
CR Fatigue T1 18 1.65 (-0.46 to 3.76) 0.117 
 Fatigue T3 20 2.02 (0.75 to 3.30) 0.004 
HN Fatigue T1 31 0.56 (0.22 to 0.90) 0.002 
 Fatigue T3 31 0.34 (0.01 to 0.68) 0.044 
 Pain T3 31 0.52 (0.09 to 0.94) 0.019 
All Fatigue T1 49 0.50 (0.10 to 0.89) 0.015 
Table 9.2: coefficients and p values for associations between CT and fatigue and pain. 
 
In longitudinal analyses in CR cancer patients there was a significant association 
between CT and fatigue [N=75(20) 1.54 (0.45 to 2.63), p=0.006], but there was no 
association between CT and pain [p=0.426].  There was a significant association 
between CT and pain and fatigue in HN patients [N=129(34), ß(CI)=0.49(0.13 to 
0.85) p=0.008; N=129(34) ß(CI)=0.30(0.00 to 0.60) p=0.050 respectively]. 
 
Neuroticism was associated with fatigue at baseline in HN patients and then in 
both patient groups after treatment.  Similarly NE was associated with increased 
pain at T3 in CR cancer patients and T4 in HN cancer patients and if combined, 
there was a significant association between NE and pain at both T3 and T4 (see 
table 9.3). 
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In longitudinal analyses there was no association between NE and pain in CR 
patients [p=0.362], but there was an association between NE and fatigue.  In HN 
patients there was an association between NE and pain and fatigue (see table 9.3). 
 
 Variable N Coeff (CI) P value 
CR Fatigue T3 21 3.47 (1.66 to 5.27) 0.001 
 Fatigue T4 21 3.05 (0.61 to 5.50) 0.017 
 Fatigue T5 18 2.69 (0.96 to 4.42) 0.005 
 Fatigue overall 
 
80 (22) 2.13 (0.12 to 4.15) 0.038 
 Pain T3 21 2.98 (0.29 to 5.66) 0.032 
HN Fatigue T1 37 1.82 (0.73 to 2.91) 0.002 
 Fatigue T3 38 1.40 (0.04 to 2.77) 0.044 
 Fatigue T4 41 2.78 (0.82 to 3.84) <0.0005 
 Fatigue T5 39 1.38 (0.11 to 3.29) 0.037 
 Fatigue overall 
 
155 (41) 1.87 (0.94 to 2.80) <0.0005 
 Pain T4 41 1.53 (0.00 to 3.06) 0.049 
 Pain overall 155 (41) 1.38(0.10 to 2.67 0.035 
All Pain T3 59 1.87 (0.41 to 3.33) 0.013 
Pain T4 62 1.68 (0.30 to 3.07) 0.018 
Table 9.3: Coefficients and p values for associations between NE and fatigue and pain. 
 
PH depression was associated with increased fatigue at all time points and 
increased pain at T3 and T4 in all patients and there was a significant association 
between PH depression and pain and fatigue in longitudinal analyses (see table 
9.4). 
 
Life events were associated with increased fatigue in CR cancer patients at T4 and 
T5 and in HN patients at all time points.  Life events were also associated with 
increased pain at baseline in HN patients, at T3 in all patients and T4 and T5 in CR 
patients only.  There was also a longitudinal relationship between LE and pain in 
both cancer groups and a trend towards fatigue in the CR group and a significant 
association in the HN group (see table 9.5). 
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Variable N Coeff (CI) P value 
Fatigue T1 70 21.76 (5.84 to 37.68) 0.008 
Fatigue T3 67 25.95 (11.26 to 40.63) 0.001 
Fatigue T4 63 26.95 (11.11 to 42.79) 0.001 
Fatigue T5 60 22.01 (1.11 to 42.91) 0.039 
Fatigue overall 
 
260 (76) 25.67 (12.67 to 38.36) <0.0005 
Pain T3 67 33.36 (10.03 to 56.69) 0.006 
Pain T4 63 31.17 (13.12 to 49.22) 0.001 
Pain T5 60 32.53 (5.11 to 59.95) 0.021 
Pain overall 260 (76) 32.27 (13.68 to 50.85) 0.001 
Table 9.4: Coefficients and p values for associations between PH depression and fatigue and pain. 
 
 Variable N Coeff (CI) P value 
CR Fatigue T4 24 5.37 (0.08 to 10.66) 0.047 
 Fatigue T5 22 5.18 (1.68 to 8.68) 0.006 
 Fatigue overall 
 
96 (27) 3.93(-0.24 to 8.10 0.065 
 Pain T3 25 5.76 (-0.18 to 11.70) 0.057 
 Pain T4 24 8.95 (2.67 to 15.22) 0.007 
 Pain T5 22 6.44 (0.46 to 12.42) 0.036 
 Pain overall 96 (27) 4.88(1.46 to 8.30) 0.055 
HN Fatigue T1 41 9.13 (4.41 to 13.85) <0.0005 
Fatigue T3 44 8.22 (4.45 to 12.00) <0.0005 
Fatigue T4 39 4.76 (-0.06 to 9.57) 0.053 
Fatigue T5 38 6.38 (2.08 to 10.69) 0.005 
 Fatigue overall 
 
162 (45) 7.85(4.24 to 11.46) <0.0005 
 Pain T1 41 7.95 (2.37 to 13.53) 0.006 
 Pain T3 44 8.96 (3.33 to 14.59) 0.003 
 Pain overall 162 (45) 7.27(2.82 to 11.72) 0.001 
All Pain T3 69 7.43 (3.43 to 11.43) <0.0005 
Table 9.5: Coefficients and p values for associations between LE and fatigue and pain. 
 
Physiological: 
 
Although the previous analyses have all been stratified by cancer group, the 
analyses with inflammatory markers was exploratory, and the aim was to look for 
patterns, in order to help interpret the adjusted models which are presented in 
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chapter 11.  As the relationships between inflammation and symptom reporting 
may be underpowered in this section, where there were trends towards an 
association in both groups, the groups were combined. 
 
Initial analyses using robust standard errors suggested that there were significant 
associations between T1 IFNγ, CRP and T1 fatigue in CR patients.  There was 
also significant association between IL6 and fatigue at T1 when both groups were 
combined, but no associations between inflammation and pain. 
 
T1 IFNγ and CRP were also positively associated with fatigue at T3 in CR patients, 
and there were negative associations between IL6, TNFα and IFNγ and pain at T4.  
Whereas, in HN patients the only associations were between T1 IFNγ and IL6 and 
pain at T5. 
 
T2 TNFα was associated with pain at T5 in CR patients only, whereas T2 CRP was 
associated with pain at T3 and T5 in HN patients.  However, there were trends 
towards an association between T2 IL6 and T2 CRP and fatigue at T3, T4 and T5 
in both groups of patients, to maximise power the groups were combined.  There 
was a significant association between T2 IL6 and CRP and fatigue when both 
groups were combined at T3, T4 and T5.  TNFα at T2 was also associated with 
increased fatigue at T5 in CR patients and when both groups were combined.  
Finally IL6 was positively associated with increased pain at T3 in HN cancer 
patients and when both groups were combined. 
 
After bootstrapping, the significant findings relating to fatigue were: 
 IL6 at baseline was associated with increased fatigue at baseline and at 
T3 in both patient groups. 
 There was also an association between TNFα at T2 and fatigue at T3 and 
a significant cross sectional association between TNFα and fatigue at T3. 
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 The most pronounced finding was that IL6 and CRP at T2 were 
associated with increased fatigue after treatment (T3, T4 and T5) when 
both patient groups were combined (see table 9.6). 
Marker DV N Coeff (CI) P value 
IL6 T1 Fatigue T1 70 2.31 (0.15 to 4.47) 0.036 
IL6 T1 Fatigue T3 59 1.97 (-0.03 to 3.98) 0.054 
IL6 T2 Fatigue T3 59 1.25 (0.01 to 2.49) 0.048 
IL6 T2 Fatigue T4 57 1.55 (0.54 to 2.56) 0.003 
IL6 T2 Fatigue T5 53 1.18 (0.26 to 2.10) 0.012 
TNFα T2 Fatigue T3 60 3.96 (0.25 to 7.68) 0.036 
TNFα T3 Fatigue T3 54 5.33 (1.05 to 9.62) 0.015 
CRP T2 Fatigue T3 60 0.19 (0.05 to 0.32) 0.007 
CRP T2 Fatigue T4 58 0.18 (0.05 to 0.31) 0.005 
CRP T2 Fatigue T5 54 0.17 (0.04 to 0.30) 0.009 
Table 9.6: Coefficients and p values for associations between fatigue and inflammation using 
bootstrapped standard errors. 
 
The significant associations between pain and inflammation using bootstrapped 
standard errors were: 
 A significant association between increased IL6 at T2 and greater pain at T3 
and at T5 in both patient groups.   
 The association between IL6 at T2 and pain at T5 showed a trend in the CR 
group, was significant in the HN group and when both groups were combined. 
 CRP at T2 was associated with pain at T5 to the same degree as the IL6 
findings. 
 There was also a significant association between TNFα at T2 and pain at T5 
in CR patients and CRP at T2 and pain at T3 in HN patients (see table 9.7). 
 
Group Marker DV N Coeff (CI) P value 
CR TNFα T2 Pain T5 20 6.66 (1.28 to 12.04) 0.015 
HN CRP T2 Pain T3 37 0.22 (0.03 to 0.41) 0.026 
All CRP T2 Pain T5 54 0.26 (0.11 to 0.41) 0.001 
All IL6 T2 Pain T3 59 1.23 (0.05 to 2.41) 0.041 
All  IL6 T2 Pain T5 53 1.31 (0.06 to 2.57) 0.041 
Table 9.7: Coefficients and p values for associations between pain and inflammation using 
bootstrapped standard errors. 
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9.3 Discussion 
9.3.1 Psychological variables 
 
Childhood trauma was only weakly associated with NE and was not associated 
with PH depression.  The non significance of these findings is most likely due to 
low power as many studies have reported a robust relationship between CT, NE 
and MDD, but most of these have used much larger samples[62, 74, 200, 318].  As 
expected, NE was associated with a PH of depression and CT, NE and PH 
depression were all associated with LE.  As the BLEQ does not give enough 
information to assess whether the LE may be partly caused by the individual it is 
not possible to tell whether this relationship is predominantly effected by dependent 
LE as suggested by the literature[62, 200, 294]. 
9.3.2 Physiological variables 
 
There were relatively few significant findings between inflammation and cortisol 
levels.  The only significant association was between increased baseline IL6 levels 
and increased daytime cortisol mean in CR patients, which is consistent with past 
correlational findings[85] (reported in section 9.1.2).  However, this was not 
significant in the HN group, despite similar sample sizes.  This may be due to the 
greater spread of IL6 levels in CR patients compared to HN patients (CR IL6 levels 
range from 0.25 - 14.87 pg/ml, HN IL6 levels range from 0.32-7.92 pg/ml in those 
that also completed the salivary aspects of the study).  The lack of effect is likely to 
be due to low power and increased noise from the large number of covariates (as 
demonstrated by this chapter).  For instance, presence of a DD or possibly even 
the presence of a tumour may impair the anti-inflammatory properties of 
glucocorticoids[295]. 
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9.3.3 Psychological and physiological variables 
 
There were no significant associations between psychosocial variables and cortisol 
levels.  There was no association between NE and cortisol consistent with the 
results from the meta-analysis based on data from 22 studies[260].  There was also 
no association between CT and cortisol levels.  This is probably due to low power, 
especially given the mixed findings in previous studies[106, 255].  Unfortunately, the 
current sample was not large enough to investigate sub groups or adjust for all of 
the possible covariates.  Similarly, there was no significant association between LE 
and cortisol.  Some larger studies also reported null effects[261, 262].  These null 
effects are perhaps not surprising given the sample size and large number of 
variables that also affect cortisol levels, such as genetic factors, type, timing and 
duration of stress, and gender[110]. 
 
There were some significant associations between psychological factors and 
inflammation.  Childhood trauma was associated with increased CRP at baseline 
and increased TNFα at T2, again only in CR patients.  There was also a trend 
towards an association between baseline TNFα and CT in CR patients.  
Interestingly, there was no association between inflammation and CT in HN 
patients, or between IL6 and CT in either cancer group.  There was a weak trend, 
though, towards an association between IL6 and CT in CR patients suggesting that 
the association between IL6 and CT is weaker and therefore non significant due to 
low power.  Interestingly, the findings of an association between CT and 
inflammation were non significant in the HN patients, which as previously stated 
probably reflects the heterogeneity of the HN patients compared to the CR 
patients, thus obscuring any relationships. 
 
In accordance with the cortisol findings there was no association between NE and 
increased inflammation. In a population study of over 6000 participants reported 
only a small association between NE and IL6[319], thus identification of any such 
association would be unlikely in this much smaller sample .  Equally, there was no 
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association between LE and inflammation, probably due to the imprecision of the 
stress measure and low power.  Finally, there was a negative association between 
PH depression and IFNγ three months after surgery in all patients.  Although this 
may be a chance finding given the low numbers with a PH depression, it is worthy 
of further investigation given previous reports of a trend towards higher IFNγ levels 
and increased survival[237] in CR patients.  The meta-analysis investigating the 
relationship between inflammation and DD found no association between IFNγ and 
MDD, but only four studies were included in the analyses, one of which found a 
negative association.  No studies have looked at the surgical response of IFNγ in 
those with a current or past DE.  Most studies report an increase in inflammation 
after surgery, which normally returns to baseline within a month[197].  Kudoh and 
colleagues[137] (2001) reported an inhibited post surgical rise of IL6 and IL8 in 
depressed patients, but levels of inflammation were monitored only up to three 
days post surgery: further supporting the need for more research in this area. 
 
There were no associations between increased baseline depressive symptoms and 
later inflammation.  This could be due to low power, especially as the reported 
cross sectional associations between depressive symptoms and inflammation are 
less robust then those between DD and inflammation[87].  The findings are also 
confounded by the mix of psychological and physiological stressors at the time of 
completing the HADS and blood sampling. 
9.3.4 Psychological and physiological variables and symptoms 
 
Many of the investigated variables were associated with increased pain or fatigue 
in both the CR and HN cancer patients.  CT was associated with increased fatigue 
at T1 and T3 and increased pain at T3.  Childhood trauma is an established risk 
factor for chronic fatigue in otherwise healthy individuals[320], though these findings 
were based predominantly on investigations using retrospective measures.  
Childhood trauma has also been associated with increased chronic wide spread 
pain reporting in a prospective study[321].  Though, intriguingly, those with CT have 
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also been shown to have decreased experimental pain perception[322].  Also one 
prospective study did not find an association using a case control follow up of 
abuse cases that were serious enough to lead to a court hearing[323].  Although, 
there was an association between retrospective measures of abuse and neglect 
and pain reporting in the same sample. 
 
Neuroticism was also associated with increased perioperative fatigue (at baseline 
and one month post surgery) and post treatment pain (at one and three months 
post surgery) in both patient samples, supporting previous research in HN 
patients[212, 227] and extending the findings to CR patients.  Past history of 
depression was associated with increased reporting of fatigue and pain throughout, 
demonstrating a robust effect of increased symptom reporting in those with a past 
psychiatric history.  Number of LE was also associated with increased fatigue at all 
time points and increased perioperative pain in HN patients (one and three 
months), and post operative pain in CR patients (at one, three and six months), 
again demonstrating a close link between psychological stress and symptom 
perception in cancer patients. 
 
Consistent with past studies increased inflammation was associated with increased 
post operative fatigue in both patient groups.  The most sustained relationship was 
between IL6 and CRP levels one week post operation and increased fatigue from 
one month onwards in both cancer patient groups.  There was also a relationship 
between post operative TNFα levels (at one and three months) and fatigue at three 
months post surgery.  The relationship between inflammation and pain reporting 
was less pronounced, but there remained a relationship between TNFα, IL6 and 
CRP levels one week post surgery and pain, but only at one and six months.  The 
association between TNFα and pain was only apparent in CR patients at six 
months, likewise CRP was only associated with increased pain perception at three 
months in HN patients, but was significantly associated with pain at T5 in both 
cancer groups.  This supports past studies investigating sickness behaviour and 
inflammation in cancer patients[31].  As with the findings from the previous chapter 
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relating to HN cancer and QoL (section 8.2.2.3), it should be noted that there was 
no relationship between inflammation and pain at three months post treatment, 
despite a relationship at one and six months.  Equally, the associations between 
psychological factors and symptom perception appear most robust at one and six 
and less so at three months, perhaps suggestive of a more complicated 
relationship between psychological and physiological factors at three months post 
operation. 
9.3.5 Limitations and Conclusions 
 
The analyses were limited by low power.  The findings are based on analyses from 
a small sample and thus the significant findings require replication and some of the 
non-significant findings, for which there was a well founded hypothesis, may be 
significant or more consistent in a larger sample.  As a result of low numbers, in 
some cases the cancer groups were combined, but this also increases the number 
of factors that may confound the results and obscure any effects.  Some of the 
results may also be chance findings due to the large number of tests that were 
carried out.  This notwithstanding, some strong inter-relationships between 
psychological and physiological factors were demonstrated emphasizing the 
importance using multivariate analyses. 
 
This chapter demonstrates that psychological and physiological factors that are 
associated with increased depressive symptoms, poorer QoL and risk of a DE are 
also associated with increased symptom perception.  The association between 
psychological factors and pain and fatigue may be partially related to increased 
vulnerability to sickness behaviour because the psychological factors may 
potentiate the inflammatory response to cancer and treatment.  Although only CT 
and CRP were significant in this study, it is feasible that the psychological factors 
increase symptoms and therefore increase the risk of a DE6 through higher cancer 
symptom burden although it is more likely that there are multiple pathways 
involved.  Also, it should be noted that these findings are based on symptom self-
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report measures; therefore it is not possible to say whether the relationship is due 
to heightened symptom perception or weakened tolerance.  As fatigue and pain 
are closely related to depression, it would also be interesting to test the 
relationships between the potential markers and more objectively somatic 
complaints. 
 
In summary, this chapter addressed the fifth hypothesis and the third aim of the 
thesis: to explore associations between the possible explanatory variables.  Thus, 
this chapter investigated the inter-relationships between psychological and 
physiological risk markers for depression as well as their relation to self reported 
symptoms.  The results showed that, counter to the hypothesis, there were very 
few associations between inflammation and cortisol in this sample.  The 
exploratory analyses showed that there were significant inter-relationships between 
many of the psychological risk factors, as was hypothesised in the literature review.  
The findings also suggest relationships between many of the psychological 
variables and some associations between CT and inflammation.  Both 
psychological and physiological variables were associated with increased self 
reported symptoms in both CR and HN patients.  This shows that there is a degree 
of overlap between the risk factors investigated in the previous chapters with 
regard to their association with depression and poorer QoL.  The next chapter 
investigates this overlap using multivariate models in order to elucidate the most 
predictive of the psychological or physiological markers. 
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10 Adjusted models 
 
Chapters 7 and 8 reported the relationships between the main variables of interest 
(CT, NE, PH depression, LE, cortisol and inflammation) and depression and QoL.  
The previous chapter laid out how many of these variables were related to each 
other and also introduced the relationship between these variables and other 
symptoms. 
 
So far, many of the investigated variables were related to depressive symptoms 
and QoL: this chapter consolidates these results to provide final models that 
address which of the investigated variables are most informative when trying to 
predict which patients would be at highest risk of increased depressive symptoms, 
a DE6 or poorer QoL soon after cancer treatment.  This chapter also presents 
adjustments for demographic and cancer related factors, including many of the 
symptoms in the EORTC-QLQ that were associated with increased depressive 
symptoms or poorer QoL.  This addresses the final aim of the study: to explore the 
mediating effects of perceived physical symptoms on depressive symptomatology 
and poorer QoL. 
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As with the previous chapters, this will comprise a brief literature review followed 
by the methods section (as the methods in this chapter are unique to this results 
section) and the results and discussion. 
10.1 Background 
The rationale for the predictive value of the investigated risk factors and their 
interrelations was presented in the previous chapters.  However, many 
demographic and cancer related factors are also associated with increased risk of 
depression and should be taken into account.  This review briefly covers what 
factors are being adjusted for and gives evidence for their association with 
depression.  Although in terms of adjustment, just knowing that a demographic or 
cancer related variable is associated with the outcome is sufficient justification to 
include the variable in the model, it may be more relevant to focus on certain 
variables given the relationship between demographic and lifestyle factors and the 
chosen psychological and physiological factors under investigation. 
 
Comorbid disability was included as a possible covariate.  The demographic and 
lifestyle factors that were included as possible covariates in the final models were: 
Age 
Sex 
Ethnicity 
Marital status 
Alcohol consumption 
Smoking 
BMI 
The following cancer related factors were also considered: 
TNM staging 
Treatment 
 
The measures used are reported in the methods section 6.2.1. 
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10.1.1  Risk for depression and poorer quality of life 
 
Age was included as a covariate because it is reported to be positively associated 
with increased depressive symptoms and risk of a DE in the general population[183, 
324].  However, a comprehensive review reported the prevalence of MD to be lower 
than that of younger individuals[325] and the higher levels of depressive symptoms 
are almost entirely explained by greater prevalence of physical illness and 
disability[326].  This perhaps explains why increasing age is also associated with 
increased variability in the levels of depressive symptoms[324].  However, despite 
this, Schroeff and colleagues[327] (2007) reported that age was not associated with 
poorer QoL or emotional functioning in a sample of 266 HN cancer patients from 
diagnosis and up to six years follow up.  Sex is included because women are 
known to be at higher risk of developing mood disorders[59].  Studies investigating 
gender differences in the prevalence of depression in cancer patients have found 
mixed results.  A review by DeFlorio and Massie[328] (1995) reported that 23 out of 
25 studies found no difference between women and men with regard to rates of 
depression, except in sub types of depression.  Ethnicity is also known to influence 
risk of a DD, where whites, (compared to Hispanics and non-Hispanic Black) are 
considered to be at greater risk of a mood disorder in an American population[59].  
However, Indian and Pakistani individuals have been shown to have higher levels 
of disorder compared to Whites and Bangladeshis in a British population, and no 
difference was found between Black Caribbean and White samples[329].  Marriage 
has also been found to be protective as married individuals show lower levels of 
depressive symptoms[330].  Similarly, living alone was associated with increased 
depressive symptoms in a small sample of 107 HN cancer patients[131]. 
 
Depression is also associated with several unhealthy lifestyle factors including 
smoking and alcohol consumption.  Alcohol consumption appears to have a J 
shaped relationship as moderate drinking is associated with lower depressive 
symptoms than rarely or never drinking[315].  Whereas relatively high alcohol 
consumption (three or more drinks per day) is also a risk factor for depressed 
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mood[49] when compared to abstinence.  Furthermore there is high comorbidity 
between alcohol and mood disorders; someone dependent on alcohol is at 3.7x the 
odds of having a mood disorder compared to someone without alcohol 
dependence[331].  Smoking is reported to have a bidirectional association with 
depression; daily smoking increases the risk of a DE at follow up one to five years 
later, but a baseline DD also increases the odds of starting to smoke by three times 
that of someone without a DD.  Finally, being unhealthily overweight or suffering 
from a physical disability are also associated with increased depressive symptoms 
or risk of a DE[49, 69, 332]. 
 
As well as the demographic and lifestyle choices associated with depression, the 
level of depressive symptoms and QoL in cancer patients is also affected by a 
number of cancer variables.  Cancer site has a major influence of QoL and 
depressive symptoms[186].  Also, patients with more advanced disease are reported 
to have increased depressive symptoms and poorer QoL[333].  As reviewed in 
chapter 3, cancer specific problems that interfere with social function as well as 
and symptoms common to both depression and cancer are likely to have a 
detrimental effect on QoL and be associated with increased depressive symptoms.  
Also, as reviewed in chapter 1, multimodal treatment including chemotherapy and 
radiotherapy are associated with increased symptom burden.  Radiotherapy has 
also been associated with poorer QoL during and after treatment in HN patients, 
though interestingly it was not associated with lower mood[180], thus HN patients 
who are treated with adjuvant radiotherapy may have lower QoL at one and three 
months after surgery compared to those without adjuvant treatment.  Radiotherapy 
is strongly associated with increased fatigue[334], which is reported to cause 
patients high levels of distress[335]. 
10.1.2  Relation to investigated variables 
 
Whilst an association with depression or QoL is enough to justify inclusion in a 
multivariate model, many demographic and cancer related factors are also related 
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to the variables under investigation in this study, therefore they would be expected 
to affect the results.  This is especially the case when the CR and HN cancer 
groups are combined and variables that differ between the two groups should be 
included to check for confounding. 
 
Some psychological risk factors are associated with demographic and lifestyle 
choices, for example, CT is associated with higher levels of smoking, alcohol 
consumption and lower physical activity[311, 336] and women tend to show higher 
levels of NE[337].  Also, as reported in chapter 7, smoking and alcohol consumption 
are more common in HN patients compared to CR patients due to their 
involvement in the aetiology of HN cancers.  Most intriguingly, many of the 
demographic and cancer related variables that are associated with increased 
depressive symptoms and poorer QoL are also associated with increased 
inflammation.  Increasing age has been shown to increase levels of TNFα[338].  
Women are reported to have higher levels of IL6, which cannot be accounted for 
by higher disease burden[314].  Smoking, alcohol consumption and lower physical 
activity levels are also associated with increased inflammation[315, 339].  
Interestingly, as with the association between alcohol consumption and depressive 
symptoms, the association between alcohol and inflammation also follows a J 
shaped curve; both high levels of alcohol consumption and never or rarely 
consuming alcohol are associated with increased CRP when compared to CRP 
levels in those that drink four or more alcoholic beverages in a week[315, 339].  
Increased BMI and comorbid disease are also associated with increased 
inflammation[91, 338, 340]. 
 
The previous chapter demonstrated how the psychological variables and 
inflammation are related to symptom perception.  The majority of studies 
investigating inflammation in CR and HN cancer patients have also found an 
association between IL6 and cancer stage[230].  Comorbid disease and stage are 
also associated with higher levels of IL6 in HN patients[242].  Finally, inflammation 
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increases in response to surgery[281] and radiotherapy has also been reported to 
increase inflammation[341]. 
10.1.3  Conclusions 
 
There is evidence that increasing age, female gender, white ethnicity, being 
unmarried, greater BMI, TNM staging, alcohol consumption, more comorbid 
disability, smoking, extensive surgery and adjuvant chemotherapy or radiotherapy 
would all be expected to be associated with increased depressive symptoms.  
These factors may moderate or confound the relationship between many of the 
psychological and physiological markers and are included in this study. 
 
In this study, the paucity of findings relating to cortisol and the questionable 
reliability of the few significant findings precluded the inclusion of cortisol measures 
from the multivariate analyses. 
 
Due to the small sample size, not every variable could be included in the model, as 
this would lead to overfitting and meaningless results.  The process of developing 
each multivariate model is explained in the methods below.  Although there is a 
robust association between demographic and cancer related factors, a study of 
breast cancer that used multivariate analyses to investigate which variables had 
the highest association with increased depressive symptoms found that none of the 
cancer related variables were associated with risk of a DE.  The main risk factors 
were younger age, past psychological treatment and high number of stressful LE 
other than the cancer diagnosis[214].  Thus, PH depression and LE would be 
expected to be highly associated with depressive symptoms, poorer QoL and 
increased risk of a DE6, more so than any of the cancer related variables.  
However, it was not clear how the relationships between all of the variables and 
depressive symptoms and QoL would change over the course of the study, as it is 
possible that symptoms may have more impact soon after diagnosis due to 
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unfamiliarity with the symptoms and heightened symptomatic burden, or they may 
have a greater impact later on due to the chronicity of the symptom. 
 
In summary, the previous chapters have focused on key psychological and 
physiological risk factors that are implicated in the aetiology of depression.  This 
chapter aims to bring those aspects together and investigate which of them is most 
relevant to the QoL of cancer patients.  The rationale for choosing these key 
psychological and physiological risk factors is described in the respective chapters, 
this literature review focuses on the multitude of demographic and cancer related 
variables that are also related to depression and poorer QoL, and are thus also 
important considerations.  Despite the importance of the cancer related variables, 
those variables that are known to be risk factors for depression in the general 
population are hypothesised to have the greatest association with depressive 
symptoms and QoL following a cancer diagnosis. 
10.2 Methods 
 
Univariate regression analyses were run between each symptom and demographic 
or cancer related variable and depressive symptoms or QoL as the dependent 
variable at each time point for each cancer diagnosis.  Only significant variables 
are reported in the results. 
 
Multivariate models were created using two methods: 
 
The first method started with the significantly associated identified variables 
reported in the previous chapters.  Each model started with the earliest 
chronologically occurring (significant) risk factor, after which the next chronological 
risk factor was added (in the order CT, NE, LE, inflammation).  In order to meet the 
assumptions of independence and to maximise power and avoid over adjustment, 
(especially as the main factors are all interrelated[342]) in instances where the 
added variable confounded the other variables so that they became non-
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significant, the variable with the least explanatory power in the model was dropped.  
The mediations are reported in the results section.  This is especially important in 
this data set because of the relatively low sample sizes and including too many 
variables in a regression model (with respect to the number of participants) can 
lead to instability and inconsistent findings. 
 
Current symptoms (i.e. cross sectional associations) and demographic variables 
that were found to be significant in the univariate analyses were added to the 
model in the order of greatest explanatory power, providing they met the inclusion 
criteria (see note on exclusions in prospective methods section in section 5.5.1).  
Past history of depression was not included in the final multivariate analyses due to 
the low frequency of cases.  However, where PH depression was significant in 
univariate analyses it is still included in the description of the development of the 
model.  The list of symptom variables was run through once and any independently 
significant variables were kept in the model.  The list of investigated variables and 
the symptom list were then run through one more time to check that no dropped 
items could contribute to the model as well as to check the stability of the model.  
HADS-A was not included in the model with HADS-D as a dependent variable 
because depression is usually accompanied by high anxiety and the aim of the 
multivariate model was to look at prognostic factors and then adjust for cancer 
related symptoms.  Although symptoms such as fatigue may also be due to 
depression, the HADS-D has no questions relating to fatigue and fatigue could also 
be a consequence of the cancer or cancer treatment. 
 
Finally, the model was checked for explanatory effects of a core group of variables: 
T stage 
N stage 
Age 
Comorbid disability 
Sex 
For T3 and onwards: 
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Chemotherapy 
Radiotherapy (in HN patients only) 
Surgical rating 
Baseline HADS-D 
Baseline global QoL 
For DE6: 
Diagnosis 
 
These items were only kept in the model if they were significant in univariate 
analyses in order to prevent over adjusting, but all confounding effects are 
reported. 
 
The second method used a stepwise approach as used in the prevalence study 
(see chapter 3).  This was used in order to prevent a bias towards the hypotheses 
(i.e. that HADS-D explains most of the variance in global QoL scores). 
 
The final models were checked using bootstrapped standard errors and the 
hypothesised model was compared with the stepwise model.  As noted in the main 
methods section, the number of patients in each model varies due to missing data.  
The number of patients in the univariate analyses and the final model is reported in 
each case.  If the numbers differed by more than 10 patients, then univariate 
analyses for each of the variables in the model were run.  Univariate analyses were 
rerun on each variable using only the complete case data (from patients whose 
data were included in the final model) to check that the relationship was similar to 
that of the entire sample.  If the relationship differed (so that it was non-significant) 
the results were compared to random samples of the same size. 
 
Again, the models were stratified, except for the model for a DE6, where due to low 
power the samples had to be combined. 
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Only T1 inflammation is used in the longitudinal analyses due to model constraints; 
if the inflammatory variables were entered as longitudinal data then only those time 
points where both data (inflammatory and questionnaire measures) were available 
were tested (i.e. at T1 and T3 only). No analyses were conducted using T2 and T3 
inflammation because that would have resulted in simultaneous retrospective and 
prospective analyses. 
 
It is acknowledged that many tests are being conducted on a small sample.  These 
tests were necessary to decipher which variables had the strongest association 
with depressive symptoms and QoL and therefore which could be most clinically 
useful.  These tests were carried out at each time point to investigate whether the 
relative associations between symptoms and psychological or physiological factors 
varied over time, as this was also an important clinical question. 
10.3 Results 
 
The results are reported for depressive symptoms, DE6 and QoL in turn: always 
reporting the findings for CR patients first, followed by HN patients.  This chapter 
also includes schematic models summarising the findings at each time point. 
10.3.1 Descriptives for EORTC-QLQ symptoms 
 
Table 10.1 shows the sample size, mean, standard deviation and medians of all of 
the core EORTC-QLQ scales that were used in the analyses.  The level of 
symptoms is similar in each patient set apart from lower levels of dyspnoea and 
diarrhoea in the HN patients compared to the CR patients [N=278(90), ß(CI)=-16.64 
(-29.39 to -3.90) p=0.010; N=279(90), ß(CI)=-14.13 (-22.52 to -5.74) p=0.001, 
respectively].  There is also a non significant trend towards increased appetite loss 
in the HN patients compared to the CR patients.  Fatigue increases before falling 
back to near baseline levels in both patients.  Levels of insomnia appear to 
increase in HN patients but decrease in CR patients over time. 
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Table 10.2 shows the N, mean, standard deviation and median of all the CR29 
items used in the study and table 10.3 shows the N, mean, standard deviation and 
median of all the H&N35 items used in the study.
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Mean 
(sd) 
 
CR HN 
T1 T3 T4 T5 T1 T3 T4 T5 
N  N  N  N  N  N  N  N  
Fatigue 32 36.98 
(30.64) 
 
25 41.33 
(31.35) 
 
24 43.06 
(29.55) 
 
22 31.82 
(22.82) 
 
52 26.92  
(26.53) 
 
45 35.56 
(23.16) 
 
41 33.33 
(23.83) 
 
40 30.18 
(24.13) 
 
Nausea and 
vomiting 
32 6.77 
(16.85) 
 
25 14.67 
(22.73) 
 
24 9.72 
(16.24) 
 
22 3.79 
(7.15) 
 
52 5.13 
(12.14) 
 
45 13.33 
(24.52) 
 
41 9.35 
(15.39) 
 
40 5.83 
(10.37) 
 
Pain 32 25.00 
(31.68) 
 
25 28.67 
(29.08) 
 
24 25.69 
(31.84) 
 
22 28.79 
(33.01) 
 
52 26.92 
(31.34) 
 
45 27.04 
(29.79) 
 
41 26.42 
(25.27) 
 
40 20.42 
(27.34) 
 
Dyspnoea 32 36.46 
(37.25) 
 
24 22.22 
(27.22) 
 
23 34.78 
(36.90) 
 
22 33.33 
(39.84) 
 
52 15.28 
(25.96) 
 
44 12.88 
(20.61) 
 
41 14.63 
(22.42) 
 
40 10.83 
(19.07) 
 
Insomnia 31 39.78 
(37.93) 
 
25 38.67 
(36.87) 
 
24 38.89 
(34.98) 
 
22 42.42 
(38.74) 
 
52 37.18 
(34.08) 
 
45 32.59 
(31.37) 
 
41 28.46 
(33.80) 
 
40 26.67 
(29.43) 
 
Appetite loss 32 18.75 
(29.26) 
 
25 22.67 
(30.00) 
 
24 13.89 
(23.91) 
 
22 6.06 
(13.16) 
 
52 22.44 
(27.79) 
 
45 22.96 
(27.36) 
 
41 31.71 
(33.29) 
 
40 27.50 
(35.32) 
 
Constipation 32 20.83 
(35.67) 
 
25 21.33 
(38.35) 
 
24 18.06 
(31.05) 
 
22 12.12 
(26.32) 
 
52 19.87 
(28.97) 
 
45 22.86 
(29.15) 
 
41 24.39 
(28.89) 
 
40 18.33 
(31.98) 
 
Diarrhoea 32 25.00 
(34.91) 
 
25 13.33 
(21.52) 
 
24 15.28 
(31.05) 
 
21 9.52 
(18.69) 
 
52 2.56 
(8.97) 
 
44 12.12 
(25.00) 
 
41 6.50 
(15.31) 
 
40 2.50 
(8.89) 
 
Financial 
difficulties 
32 10.42 
(23.09) 
 
25 16.00 
(34.85) 
 
24 12.50 
(23.70) 
 
20 6.67 
(17.44) 
 
52 18.59 
(34.56) 
 
44 25.76 
(35.85) 
 
41 21.95 
(34.65) 
 
37 16.22 
(31.05) 
 
Table 10.1: Descriptives for Core EORTC-QLQ scales used in the analyses.
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Mean 
(sd) 
T1 T3 T4 T5 
N  N  N  N  
Health anxiety* 17 54.90 
(31.60) 
 
15 56.67 
(32.00) 
 
17 59.80 
(30.39) 
 
20 73.33 
(11.45) 
 
Body image* 
Function 
6 94.44 
(9.30) 
 
9 79.01 
(21.83) 
 
12 79.93 
(28.75) 
 
14 79.37 
(29.83) 
 
Sexual function* 
(♂) 
3 55.56 
(19.26) 
 
5 66.67 
(40.82) 
 
7 61.90 
(48.80) 
 
7 61.90 
(44.84) 
 
Sexual function* 
(♀) 
3 66.67 
(57.74) 
 
3 44.44 
(50.92) 
 
4 75.00 
(50.00) 
 
5 86.67 
(18.26) 
 
Micturition 
problems 
6 33.33 
(26.29) 
 
9 27.16 
(18.52) 
 
12 21.30 
(18.02) 
 
14 19.05 
(14.73) 
 
Abdominal/pelvic 
pain 
6 16.67 
(20.79) 
 
9 13.58 
(18.24) 
 
12 7.40 
(10.94) 
 
14 3.97 
(8.28) 
 
Defaecation 
problems 
6 30.56 
(35.22) 
 
9 6.48 
(10.85) 
 
11 9.09 
(11.46) 
 
13 9.62 
(12.19) 
 
Faecal 
incontinence 
4 33.33 
(27.22) 
 
6 22.22 
(17.21) 
 
10 18.33 
(14.59) 
 
11 15.15 
(13.85) 
 
Bloating 16 10.42 
(15.96) 
 
15 20.00 
(30.34) 
 
17 11.76 
(20.21) 
 
20 10.00 
(15.67) 
 
Dry mouth 17 27.45 
(33.82) 
 
15 22.22 
(24.12) 
 
17 15.69 
(29.15) 
 
20 18.33 
(31.48) 
 
Hair loss 17 1.96 
(8.08) 
 
15 6.67 
(25.82) 
 
17 7.84 
(14.57) 
 
20 8.33 
(18.34) 
 
Taste problems 17 7.84 
(18.74) 
 
15 20.00 
(32.85) 
 
17 15.69 
(29.15) 
 
20 10.00 
(30.78) 
 
Sore skin 4 25.00 
(50.00) 
 
6 11.11 
(17.21) 
 
10 10.00 
(16.10) 
 
11 15.15 
(22.92) 
 
Embarrassment 4 33.33 
(47.14) 
 
6 27.78 
(28.97) 
 
9 25.93 
(32.39) 
 
11 21.21 
(34.23) 
 
Stoma problems 0 - 3 11.11 
(19.25) 
 
4 16.67 
(33.33) 
 
4 8.33 
(16.67) 
 
Impotence 3 33.33 
(33.33) 
 
4 41.67 
(41.94) 
 
5 40.00 
(43.46) 
 
5 40.00 
(43.46) 
 
Dyspareunia 2 0 2 0 4 0 4 0 
Table 10.2: Descriptives for CR29 module of EORTC-QLQ. 
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Mean 
(sd) 
T1 T3 T4 T5 
N  N  N  N  
HN pain 35 25.95 
(19.88) 
 
31 26.34 
(18.52) 
 
32 31.25 
(26.61) 
 
39 16.88 
(14.87) 
 
Swallowing 
difficulties 
35 14.05 
(22.03) 
 
31 25.81 
(23.12) 
 
32 26.82 
(29.08) 
 
39 16.31 
(21.28) 
 
Problems with 
taste and smell 
35 14.29 
(26.86) 
 
31 20.43 
(26.07) 
 
32 28.65 
(30.60) 
 
39 28.63 
(32.21) 
 
Speech 
problems 
35 17.46 
(23.38) 
 
30 28.33 
(28.60) 
 
29 32.95 
(27.29) 
 
38 22.51 
(24.16) 
 
Problems with 
social eating 
35 18.33 
(25.71) 
 
30 38.70 
(32.16) 
 
29 37.36 
(37.90) 
 
38 27.41 
(30.93) 
 
Problems with 
social contact 
35 10.52 
(21.60) 
 
30 20.37 
(24.80) 
 
29 18.39 
(24.79) 
 
38 14.21 
(22.74) 
 
Less sexuality 31 29.03 
(37.75) 
 
24 32.64 
(37.90) 
 
27 40.12 
(40.89) 
 
35 34.29 
(40.61) 
 
Problems with 
teeth 
34 26.47 
(29.34) 
 
31 35.48 
(38.43) 
 
32 30.21 
(37.25) 
 
36 32.41 
(36.94) 
 
Restricted mouth 
opening 
35 17.14 
(28.44) 
 
31 38.71 
(41.36) 
 
32 31.25 
(37.80) 
 
39 27.35 
(34.09) 
 
Dry mouth 34 22.55 
(26.87) 
 
31 39.78 
(35.92) 
 
32 39.58 
(34.33) 
 
39 42.74 
(39.70) 
 
Sticky saliva 35 19.05 
(24.64) 
 
31 40.86 
(37.23) 
 
32 47.92 
(33.80) 
 
38 35.09 
(39.47) 
 
Coughing 35 22.86 
(31.07) 
 
31 27.96 
(28.67) 
 
32 41.67 
(36.91) 
 
39 26.50 
(31.70) 
 
Taking pain 
killers 
35 62.86 
(49.02) 
 
30 60.00 
(49.83) 
 
29 41.38 
(50.12) 
 
38 39.47 
(49.84) 
 
On nutritional 
supplements 
35 34.29 
(48.16) 
 
30 53.33 
(50.74) 
 
29 51.72 
(50.85) 
 
38 50.00 
(50.67) 
 
Presence of 
feeding tube 
35 5.71 
(23.55) 
 
30 23.33 
(43.02) 
 
29 24.14 
(43.55) 
 
38 10.53 
(31.10) 
 
Weight loss 35 42.86 
(50.21) 
 
29 48.28 
(50.85) 
 
27 22.22 
(42.37) 
 
38 21.05 
(41.32) 
 
Weight gain 35 5.71 
(23.55) 
 
29 17.24 
(38.44) 
 
27 37.04 
(49.21) 
 
37 27.03 
(45.02) 
 
Table 10.3: Descriptives for H&N35 EORTC-QLQ module. 
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10.3.2 T1: Depressive symptoms at baseline 
10.3.2.1  CR model (T1 HADS-D) 
 
Only fatigue and sex were independently associated with HADS-D at T1 in CR 
patients (see figure 10.1 and table 10.5). 
 
 
Table 10.4: Univariate associations between 
variables and T1 HADS-D.  Symptoms are in 
order of R
2
 value. 
Past history 
of 
depression
⁭ inflammation
High depressive symptoms
Childhood trauma
Neuroticism
= multivariate association = univariate association
CR cancer
Cancer related 
symptoms
Life events
= univariate association=univariate trend
=univariate association with fatigue, pain (respectively)
Sex (female)
 
Figure 10.1: Variables associated with HADS-
D at baseline in CR cancer patients. 
 
Variable N ß (CI) P value Adjusted R2 
Fatigue 32 0.07 (0.02 to 0.12) 0.009 0.40 
Sex 2.52 (0.33 to 4.71) 0.025 
Table 10.5: Coefficients and p values for all variables associated with baseline HADS-D in CR 
patients. 
Univariate associations (N) 
PH depression 
Trend towards NE (21) 
T1 EORTC-QLQ symptoms: 
Sore skin (4) 
Embarrassment (4) 
Defaecation problems (6) 
Abdominal or pelvic pain (6) 
Problems with taste and 
smell (17) 
Fatigue (32) 
Nausea and vomiting (32) 
Hair loss (17) 
Sex (being female) (33) 
HADS-A (33) 
Chapter 10: Adjusted models 
239 
10.3.2.2 CR model workings (T1 HADS-D)  
 
 Table 10.4 shows the variables univariately associated with HADS-D at T1. 
 Starting with NE and PH, entering sex into the model reduced the relationships 
between NE and PH and depressive symptoms so that they became non-
significant and sex was the only hypothesised variable entered into the symptom 
adjusted model.  Fatigue was the only additional variable that was independently 
significantly associated with HADS-D. 
 Adding T stage, N stage, age, comorbid disability or chemotherapy did not 
change the model.  The model did not change when using bootstrapping and 
using a stepwise approach generated the same results. 
 Univariate post hoc analyses indicated no biases in the complete case sample. 
10.3.2.3 HN model workings (T1 HADS-D) 
 
 Table 10.6 shows univariate associations with T1 HADS-D in HN cancer 
patients  
 PH depression and LE were no longer significant when adjusted for CT and NE, 
and CT was no longer significant after adjusting for fatigue. 
 None of the other symptoms were significant. 
 None of the demographic or cancer related variables changed the model.  Sex 
was significantly related to HADS-D in the model, showing males were at 
increased risk of higher depressive symptoms, but sex wasn‟t significant in 
univariate analyses and the relationship is in the opposite direction to previous 
findings, thus it is not included in the final model. 
 The model was still significant when using bootstrapped standard errors and the 
same model was reached when using a stepwise approach. 
 Univariate post-hoc analyses indicated no biases in the complete case sample. 
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10.3.2.4 HN model (T1 HADS-D) 
 
Only fatigue and NE were significantly independently associated with HADS-D at 
baseline in HN patients (see table 10.7 and figure 10.2) 
 
Table 10.6: Univariate associations between 
variables and T1 HADS-D in HN patients.  
EORTC-QLQ variables are in order of R
2
. 
Past history 
of 
depression
⁭ inflammation
High depressive symptoms
Childhood trauma
Neuroticism
HN cancer
Cancer related 
Symptoms
Life events
= multivariate association = univariate association
= univariate association=univariate trend
=univariate association with fatigue, pain (respectively)
 
Figure 10.2: Variables associated with HADS-
D at baseline in HN cancer patients. 
 
Variable N ß (CI) P value Adjusted R2 
Fatigue 37 0.08 (0.03 to 0.12) 0.001 0.47 
NE 0.20 (0.05 to 0.36) 0.012 
Table 10.7: Coefficients and p values for variables associated with baseline HADS-D in 
HN patients. 
Univariate associations (N) 
CT (32) 
NE (38) 
LE (42) 
PH depression 
T1 EORTC-QLQ symptoms: 
Fatigue (52) 
Insomnia (52) 
Pain (52) 
Weight loss (35) 
Dyspnoea (52) 
Nausea and vomiting (52) 
Teeth problems (34) 
Appetite loss (52) 
Constipation (52) 
Financial difficulties (52) 
HADS-A (53) 
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10.3.3 T3: Depressive symptoms at one month post treatment 
10.3.3.1 CR model (T3 HADS-D) 
 
Only NE and T1 TNFα were independently significantly associated with HADS-D at 
T3 (see table 10.9 and figure 10.3).
 
Table 10.8: Univariate associations between 
variables and T3 HADS-D in CR patients.  
EORTC-QLQ variables are in order of R
2
. 
Past history 
of 
depression
⁭ inflammation
High depressive symptoms
Childhood trauma
Neuroticism
= multivariate association = univariate association
CR cancer
Life events
= univariate association=univariate trend
=univariate association with fatigue, pain (respectively)
Cancer related 
symptoms
Increasing 
age
 
Figure 10.3: Variables associated with HADS-
D at T3 in CR patients. 
 
 
Variable N ß (CI) P value AdjustedR2 
NE 18 0.52 (0.32 to 0.72) <0.0005 0.76 
T1 TNFα 1.11 (0.71 to 1.50) <0.0005 
Table 10.9: Variables associated with HADS-D at T3 in CR patients 
Univariate associations (N) 
CT (20) 
NE (21) 
T1 TNFα (21) 
PH depression 
T3 EORTC-QLQ symptoms: 
Fatigue (25) 
Constipation (25) 
Problems with micturition (9) 
Appetite loss (25) 
Bloating (15) 
Pain (25) 
Health anxiety (15) 
Increasing age 
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10.3.3.2 CR model working (T3 HADS-D) 
 
 Table 10.8 shows the variable univariately associated with T3 HADS-D in CR 
patients. 
 PH depression was no longer significant when controlling for NE and CT. 
 TNFα at T2 and CT were no longer significant when controlling for TNFα at T1, 
thus the only hypothesised variables to be independently associated with HADS-
D at T3 were NE and T1 TNFα. 
 None of the symptom variables were still significant when controlling for NE and 
T1 TNFα. 
 None of the main covariates affected the model.  The model was still significant 
when using bootstrapped standard errors and adjusting for baseline HADS-D or 
global QoL did not change the model.  This model is the same as the stepwise 
derived model. 
 Univariate post hoc analyses indicated no biases in the complete case sample. 
10.3.3.3 HN model workings (T3 HADS-D) 
 
 Table 10.10 shows the variables univariately associated with HADS-D at T3 in 
HN cancer patients. 
 Increased number of LE was the only investigated variable independently 
associated with HADS-D at T3. 
 Pain and constipation were the only symptoms positively associated with HADS-
D and weight gain was also significantly negatively associated.  Diarrhoea was 
excluded because only three patients scored greater than zero on the scale. 
 None of the demographic or cancer related variables affected the model. 
 Adding baseline HADS-D to the model reduced the association between weight 
gain and depressive symptoms. 
 All the variables were still significant when using bootstrapped standard errors, 
but using a stepwise approach resulted in a slightly different model.  However, 
that model was confounded by many other variables, suggesting that it was 
under powered. 
 Univariate post hoc analyses indicated no biases in the complete case sample. 
Chapter 10: Adjusted models 
243 
10.3.3.4 HN model (T3 HADS-D) 
 
The final model included LE, pain, constipation and weight gain (see table 10.11 
and figure 10.4).
 
 
Univariate associations (N) 
CT (31) 
PH depression 
LE (44) 
T3 EORTC-QLQ symptoms: 
Fatigue (45)  
Pain (45) 
speech problems (30) 
difficulty with social contact (30) 
difficulty with social eating (30) 
constipation (45) 
dry mouth (31) 
less sexuality (24) 
insomnia (45) 
nutritional supplements (30) 
senses problems (31) 
dyspnoea (44) 
sticky saliva (31) 
weight loss (29 
diarrhoea (44) 
presence of feeding tube (30) 
nausea and vomiting (45) 
swallowing difficulties (31) 
weight gain (protective) (29) 
Alcohol abuse (42) 
 
Table 10.10: Univariate associations between 
variables and T3 HADS-D in HN patients.  
EORTC-QLQ variables are in order of R
2
. 
 
Past history 
of 
depression
⁭ inflammation
High depressive symptoms
Childhood trauma
Neuroticism
HN cancer
Cancer related 
Symptoms
Life events
= multivariate association = univariate association
= univariate association=univariate trend
=univariate association with fatigue, pain (respectively)
 
 
Figure 10.4: Variables associated with HADS-
D at T3 in HN patients. 
 
 
 
 
 
Variable N ß (CI) P value Adjusted R2 
LE 28 1.08 (0.62 to 1.54) <0.0005 0.77 
Pain 0.04 (0.01 to 0.06) 0.004 
Constipation 0.05 (0.03 to 0.07) <0.0005 
Weight gain -0.03 (-0.04 to -0.01) 0.002 
Table 10.11: Coefficients and p values for variables significantly and independently 
associated with HADS-D at T3. 
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10.3.4 T4: Depressive symptoms at three months post treatment 
10.3.4.1 CR model (T4 HADS-D) 
 
CT, NE, financial difficulties and fatigue were the only variables significantly 
independently associated with HADS-D at T4 in CR patients (see table 10.13 and 
figure 10.5).
 
Table 10.12: Univariate associations between 
variables and T4 HADS-D in CR patients.  
EORTC-QLQ variables are in order of R
2
. 
m=male. 
 
Past history 
of 
depression
⁭ inflammation
High depressive symptoms
Childhood trauma
Neuroticism
= multivariate association = univariate association
CR cancer
Life events
= univariate association=univariate trend
=univariate association with fatigue, pain (respectively)
Cancer related 
symptoms
 
Figure 10.5: Variables associated with HADS-
D at T4 in CR cancer patients. 
 
 
 
Variable N ß (CI) P value Adjusted R2 
CT 19 0.31 (0.13 to 0.48) 0.002 0.71 
NE 0.25 (0.02 to 0.48) 0.037 
Financial difficulties 0.05 (0.00 to 0.09) 0.038 
Fatigue 0.03 (0.01 to 0.06) 0.009 
Table 10.13: Variables associated with HADS-D at T4 in CR patients. 
Univariate associations (N) 
CT (20) 
PH depression 
NE (21) 
T1 TNFα (21) 
T2 TNFα (23) 
T4 EORTC-QLQ symptoms: 
Impotence (5) 
Health anxiety (17), 
Loss of libido (m, 7) 
Body image (12), 
Financial difficulties (24) 
Constipation (24) 
Insomnia (24), 
Problems with taste and smell (17) 
Fatigue (24) 
Current alcohol consumption (19) 
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10.3.4.2 CR model workings (T4 HADS-D) 
 Table 10.12 shows the variables univariately associated with HADS-D at T4. 
 Impotence, health anxiety, body image and problems with taste and smell were 
excluded due to low numbers. 
 PH depression has a greater association than NE, but was excluded from the 
multivariate model due to the low numbers. 
 TNFα at T1 or T2 were no longer significantly associated with depressive 
symptoms when controlling for CT, NE, or alcohol consumption, thus only CT 
and NE were used in the fully adjusted model. 
 Financial difficulties and fatigue were the only other variables independently 
associated with HADS-D at T4. 
 T stage confounded the relationship between financial difficulties and depressive 
symptoms, but this is likely to be due to suppression as T stage was inversely 
associated with depressive symptoms.  Chemotherapy, comorbid disability and 
age all reduced the association between fatigue and HADS-D, but were not 
significant factors in the model.  Similarly sex confounded NE, and surgical 
rating confounded financial difficulties, but neither was significant. 
 Adjusting for baseline depressive symptoms did not change the model.  
Childhood trauma was not significant when bootstrapped, this may be due to the 
very low numbers. 
 The final model is the same as when using a stepwise approach. 
 Univariate post hoc analyses indicated no biases in the complete case sample. 
10.3.4.3 HN model working (T4 HADS-D) 
 Table 10.14 shows the variables univariately associated with HADS-D at T4 
 PH depression and LE were no longer significant when adjusting for NE 
 The only significant symptom variable was problems with social contact 
(although less sexuality also fitted in the model in place of social contact). 
 None of the demographic or cancer related variables changed the model, except 
from comorbid disability which confounded social contact and baseline HADS-D 
which confounded NE. 
 All of the variables were still significant when using bootstrapped standard errors 
and the same model was reached when using a stepwise approach. 
 Univariate post hoc analyses indicated no biases in the complete case sample. 
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10.3.4.4 HN model (T4 HADS-D) 
 
Only NE and problems with social contact were significantly associated with 
increased depressive symptoms at T4 in HN patients (see table 10.15 and figure 
10.6).
 
Table 10.14: Univariate associations between 
variables and T4 HADS-D in CR patients.  
EORTC-QLQ variables are in order of R
2
. 
 
Past history 
of 
depression
⁭ inflammation
High depressive symptoms
Childhood trauma
Neuroticism
HN cancer
Cancer related 
symptoms
Life events
= multivariate association = univariate association
= univariate association=univariate trend
=univariate association with fatigue, pain (respectively)
 
Figure 10.6: Variables associated with HADS-D 
at T4 in HN cancer patients. 
 
Variable N ß (CI) P value Adjusted R2 
Problems with social contact 29 0.09 (0.04 to 0.14) 0.001 0.52 
NE 0.22 (0.03 to 0.41) 0.027 
Table 10.15: Variables associated with HADS-D at T4 in HN patients. 
Univariate associations (N) 
NE (41) 
LE (40) 
PH depression 
T4 EORTC-QLQ symptoms: 
Social contact (29) 
Less sexuality (27) 
Fatigue (41) 
Appetite loss (41) 
Speech problems (29) 
Problems with senses (32) 
Problems with social eating (29) 
Insomnia (41) 
Constipation (41) 
T stage (41) 
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10.3.5  T5: Depressive symptoms at six months post treatment 
10.3.5.1 CR model (T5 HADS-D) 
Only CT and diarrhoea were independently associated with T5 HADS-D in CR 
patients (see table 10.17 and figure 10.7). 
 
 
Table 10.16: Univariate associations between 
variables and T5 HADS-D in CR patients.  
EORTC-QLQ variables are in order of R
2
. 
Past history 
of 
depression
⁭ inflammation
High depressive symptoms
Childhood trauma
Neuroticism
= multivariate association = univariate association
CR cancer
Life events
= univariate association=univariate trend
Alcohol
=univariate association with fatigue, pain (respectively)
Cancer related 
symptoms
 
Figure 10.7: Variables associated with HADS-
D at T5 in CR patients. 
 
Variable N ß (CI) P value Adjusted R2 
Diarrhoea 17 0.09 (0.03 to 0.15) 0.006 0.56 
CT 0.32 (0.04 to 0.61) 0.030 
Table 10.17: Variables associated with HADS-D at T5 in CR patients. 
Univariate associations (N) 
CT (18) 
NE (18) 
Perioperative CRP (18) 
PH depression 
T5 EORTC-QLQ symptoms: 
Impotence (5) 
Fatigue (22) 
Dry mouth (20) 
Diarrhoea (21) 
Problems with taste (20) 
Health anxiety (20) 
Hair loss (20) 
Alcohol consumption (18) 
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10.3.5.2 CR model working (T5 HADS-D) 
 
 Table 10.16 shows the variables univariately associated with HADS-D at T5 in 
CR cancer patients. 
 Neuroticism, PH depression, CRP and alcohol consumption were no longer 
significant after controlling for CT. 
 When adjusting for symptoms CT and fatigue were equally associated with 
HADS-D but collinear. 
 Only diarrhoea was independently associated with HADS-D at T5.  Thus the 
final model included either CT and diarrhoea or fatigue and diarrhoea.  CT was 
chosen as a baseline variable is more clinically useful.  However, only five pts 
scored greater than zero on the diarrhoea scale. 
 Neither adjusting for the core covariates nor using bootstrapping affected the 
model.  Inserting T1 HADS-D into the model mediated the association between 
fatigue and T5 HADS-D, but not CT.  Using a stepwise approach derived the 
same model. 
 Univariate post hoc analyses indicated no biases in the complete case sample. 
10.3.5.3 HN model working (T5 HADS-D) 
 Table 10.18 shows the variables univariately associated with HADS-D at T5 in 
HN cancer patients. 
 Childhood trauma, PH depression and LE were non-significant when adjusting 
for NE. 
 Neuroticism was no longer significant after adjusting for fatigue. 
  Childhood trauma was still significant even when adjusting for fatigue. 
 The only other symptom was lower sexuality. 
 Childhood trauma was confounded by comorbid disability and baseline HADS-D, 
but no other demographic or cancer related variables affected the model. 
 All variables were still significant when using bootstrapped standard errors and 
the same model was come to when using a stepwise approach. 
 Univariate post hoc analyses indicated no biases in the complete case sample. 
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10.3.5.4 HN model (T5 HADS-D) 
 
Thus only CT, fatigue and less sexuality were significantly independently 
associated with HADS-D at T5 in HN patients (see table 10.19 and figure 10.8).
 
 
Table 10.18: Univariate associations between 
variables and T5 HADS-D in HN patients.  
EORTC-QLQ variables are in order of R
2
. 
Past history 
of 
depression
⁭ inflammation
High depressive symptoms
Childhood trauma
Neuroticism
HN cancer
Cancer related 
symptoms
Life events
= multivariate association = univariate association
= univariate association=univariate trend
=univariate association with fatigue, pain (respectively)
T 
stage
 
 
Figure 10.8: Variables associated with HADS-
D at T5 in HN patients.
 
 
Variable N ß (CI) P value Adjusted R2 
Less sexuality 29 0.03 (0.01 to 0.05) 0.014 0.60 
Fatigue 0.06 (0.04 to 0.09) <0.0005 
CT 0.07 (0.01 to 0.13) 0.052 
Table 10.19: Variables associated with HADS-D at T5 in HN patients. 
 
Univariate associations (N) 
CT (33) 
NE (39) 
PH depression 
LE (39) 
T5 EORTC-QLQ symptoms: 
Less sexuality (35) 
Fatigue (40) 
Speech problems (38) 
Problems with social contact (38) 
Pain (40) 
Insomnia (40) 
Problems with senses (39) 
Coughing (39) 
Constipation (40) 
Problems with social eating (38) 
T stage (40) 
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10.3.6 Longitudinal analysis: depressive symptoms at all time points 
10.3.6.1 CR model (overall HADS-D) 
Neuroticism, LE, fatigue and constipation were the only variables significantly 
independently associated with HADS-D in CR patients (see table 10.21 and figure 
10.9).
 
 
Table 10.20: Univariate associations between 
baseline variables and overall HADS-D  in CR 
patients.  EORTC-QLQ variables are in order of 
R
2
. 
Past history 
of 
depression
⁭ inflammation
High depressive symptoms
Childhood trauma
Neuroticism
= multivariate association = univariate association
CR cancer
Life events
= univariate association=univariate trend
=univariate association with fatigue, pain (respectively)
Cancer related 
symptoms
 
Figure 10.9: Variables associated with HADS-
D overall in CR patients. 
 
 
Variable N ß (CI) P value Between R2 
Fatigue 22 0.03 (0.00 to 0.07) 0.038 0.79 
Constipation 0.03 (0.01 to 0.06) 0.003 
LE 0.52 (0.24 to 0.79) <0.0005 
NE 0.18 (0.07 to 0.28) 0.001 
Table 10.21: Variables associated with HADS-D in CR patients. 
 
Univariate associations (N) 
CT (20) 
NE (22) 
PH depression 
LE (27) 
Overall EORTC-QLQ symptoms: 
Fatigue (34) 
Impotence (7) 
Stoma problems (5), 
Loss of libido (m, 8) 
Nausea and vomiting (34) 
Micturition (16) 
Body image (16) 
Constipation (34) 
Problems with taste (26) 
Financial difficulties (34) 
T stage (34) 
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10.3.6.2 CR model working (overall HADS-D) 
 Table 10.25 shows the baseline variables associated with overall HADS-D. 
 Micturition problems and body image were both significant in the multivariate 
model, but were excluded due to low numbers, along with impotence, stoma 
problems, problems with sexual function, and taste problems. 
 Childhood trauma was no longer significant when adjusting for LE and PH 
depression was no longer significant after adjusting for NE, thus only NE and LE 
were entered into the final model. 
  After adding the remaining symptoms only fatigue and constipation were 
significantly independently associated with increased HADS-D. 
 Chemotherapy, T stage and N stage were all associated with decreased 
depressive symptoms when added to the model, despite no univariate 
association. 
 As there results were counter to any univariate findings and did not change the 
rest of the model the findings they were probably due to over fitting. 
 Comorbid disability, surgical rating and age confounded the relationship 
between fatigue and HADS-D, but were not significant in the model. 
 All the variables in the model were also significant when bootstrapped and the 
model was the same as the stepwise generated model. 
 Univariate post hoc analyses indicated no biases in the complete case sample. 
10.3.6.3 HN model working (overall HADS-D) 
 
 Table 10.22 shows the variables univariately associated with overall HADS-D. 
 PH depression was no longer significant after adjusting for NE and CT was no 
longer significant after adjusting for LE and LE was no longer significant after 
adjusting for fatigue. 
 The only other symptoms independently associated with HADS-D were less 
sexuality and diarrhoea.  
 None of the core set of covariates affected the model and all the variables 
included were still significant when using bootstrapped standard errors and the 
same set was derived when using a stepwise approach. 
 Univariate post hoc analyses indicated no biases in the complete case sample. 
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10.3.6.4 HN model (overall HADS-D) 
 
The only variables significantly and independently associated with increased 
depressive symptoms in HN patients were fatigue, NE, less sexuality and 
diarrhoea (see table 10.23 and figure 10.10).
Table 10.22: Univariate associations between 
variables and overall HADS-D  in HN cancer 
patients. EORTC-QLQ variables are in order 
of R
2
. 
Past history 
of 
depression
⁭ inflammation
High depressive symptoms
Childhood trauma
Neuroticism
HN cancer
Cancer related 
symptoms
Life events
= multivariate association = univariate association
= univariate association=univariate trend
=univariate association with fatigue, pain (respectively)
 
 
Figure 10.10: Variables associated with 
HADS-D overall in HN patients. 
 
 
 
 
 
 
 
 
Variable N ß (CI) P value Between R2 
Fatigue 38 0.06 (0.03 to 0.09) <0.0005 0.56 
NE 0.15 (0.02 to 0.29) 0.025 
Less sexuality 0.02 (0.01 to 0.04) 0.006 
Diarrhoea 0.04 (0.01 to 0.06) 0.015 
Table 10.23: Variables associated with HADS-D in HN patients. 
Univariate associations (N) 
CT (34) 
NE (41) 
PH depression 
LE (45) 
Overall EORTC-QLQ symptoms: 
Fatigue (56) 
Pain (56) 
Insomnia (56) 
Problems with social contact (51) 
Constipation (56) 
Dyspnoea (56) 
Less sexuality (49) 
Speech problems (51) 
Problems with social eating (51) 
Nausea and vomiting (56) 
Problems with senses (51) 
Nutritional supplements (51) 
Appetite loss (56) 
Financial difficulties (56) 
Dry mouth (50) 
Weight loss (51) 
Difficulty swallowing (51) 
Sticky saliva (51) 
Restricted mouth opening (51) 
Use of feeding tube (51) 
Diarrhoea (56) 
HADS-A (56) 
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10.3.7 Depressive episode 
10.3.7.1 Using baseline data 
PH depression, NE and LE were the only factors independently associated with 
increased risk of a DE6 in HN or CR cancer patients (see table 10.25 and figure 
10.11).
 
Table 10.24: Univariate associations between 
baseline variables and DE6. EORTC-QLQ 
variables are in order of R
2
. 
 
Past history 
of 
depression
⁭ inflammation
Episode of depression
Childhood trauma
Neuroticism
= multivariate association = univariate association
HN or CR 
cancer
HADS-D
Life events
= univariate association=univariate trend
=univariate association with fatigue, pain (respectively)
Cancer related 
symptoms
 
Figure 10.11: Baseline variables associated 
with a DE6.
 
 
 
Variable N OR (CI) P value Between R2 
PH depression 58 23.41 (2.88 to 190.20) 0.003 0.59 
NE 1.48 (1.07 to 2.06) 0.019 
LE 1.76 (1.06 to 2.91) 0.028 
Table 10.25: Baseline variables associated with increased risk of a DE6. 
Univariate associations (N) 
PH depression (65) 
NE (60) 
LE (63) 
T1 HADS-D (66) 
T1 EORTC-QLQ symptoms: 
Fatigue (60) 
Insomnia (59) 
Global QoL (60) 
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10.3.7.2 Baseline model workings 
 
 Table 10.24 shows the baseline variables associated with increased odds of a 
DE6. 
 Past history of depression, NE and LE were all independently associated with a 
DE whereas none of the baseline symptoms or alcohol abuse were. 
 Increasing age (N=66) was also a significant risk factor when added to the 
model (but not univariately associated) but did not change the strength of the 
other associations.   
 Diagnosis, sex and comorbid disability all confounded LE but were not 
significant. 
 As with the depression findings in the previous chapter, using bootstrapped 
standard errors reduced all findings to non significant effects.  Using a stepwise 
approach derived the same model. 
 Univariate post-hoc analyses indicated no biases in the complete case sample. 
10.3.7.3 Longitudinal analyses workings 
 
The analyses were rerun using longitudinal analyses as the longitudinal analyses 
allow inclusion of the repeated symptom measures which may give a better 
representation of the symptoms than using only baseline scores. 
 
 Table 10.26 shows the variables univariately associated with a DE6. 
 Alcohol abuse was excluded as no CR patients had a PH of alcohol abuse. 
 In this model HADS-D was no longer significant after adjusting for PH 
depression and T stage and age were no longer significant after adjusting for 
surgical rating. 
 No other variables in the core set of covariates confounded the relationships, 
including diagnosis 
 As before, nothing was significant when using bootstrapped standard errors, but 
the same model was derived when using a stepwise approach. 
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10.3.7.4 Longitudinal analyses 
Only PH depression, NE, LE and surgical rating were independently significantly 
associated with DE6 when using longitudinal analyses (see table 10.27 and figure 
10.12).
 
 
Table 10.26: Univariate associations between 
baseline variables and DE6. EORTC-QLQ 
variables are in order of R
2
. 
 
 
Past history 
of 
depression
⁭ inflammation
Episode of depression
Childhood trauma
Neuroticism
= multivariate association = univariate association
HN or CR 
cancer
HADS-D
Life events
= univariate association=univariate trend
T stage Age
=univariate association with fatigue, pain (respectively)
Cancer related 
symptoms
SR
 
 
Figure 10.12: Variables associated with a 
DE6. SR=surgical rating.
 
 
Variable N ß (CI) P value 
PH depression 260 (52) 17.55 (11.56 to 23.54) <0.0005 
NE 2.15 (1.38 to 2.92) <0.0005 
LE 5.55 (2.99 to 8.10) <0.0005 
Surgical rating 1.91 (0.13 to 3.68) 0.035 
Table 10.27: Coefficients and P values for variables associated with DE within 6 months using 
longitudinal modelling. 
 
Univariate associations (N) 
PH depression (65) 
NE (60) 
LE (63) 
T1 HADS-D (66) 
T stage (65) 
N stage (62) 
Increasing age (protective) (66) 
Surgical rating (60) 
Alcohol abuse (65) 
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10.3.8 T1: QoL at baseline 
The same set of analyses as used previously with depressive symptoms and DE6 
were also carried out using global QoL as an outcome.  It was of interest to find out 
which variables were most strongly associated with poorer QoL at each time point, 
as this may differ from depressive symptoms. 
10.3.8.1 CR model (T1 QoL) 
HADS-D, T stage and fatigue were the only variables associated with poorer QoL 
at baseline in CR cancer patients.  Please see univariate associations in table 
10.28, unadjusted model in table 10.29 and adjusted model in table 10.30. 
Table 10.28: Univariate associations 
between baseline variables and T1 QoL. 
EORTC-QLQ variables are in order of R
2
. 
 Faecal incontinence, abdominal/pelvic 
pain, hair loss and defaecation 
problems were not included in the final 
model due to low numbers. 
 Fatigue was not significant after 
adjusting for TNFα.   
 Adjusting for N stage, age, comorbid 
conditions and sex did not change the 
model. 
 TNFα was no longer significant after 
adjusting for T stage. 
 All models were the same when 
bootstrapped and fit with the stepwise 
generated model. 
Variable N ß (CI) P value Adjusted R2 
HADS-D 27 -5.00 (-6.23 to -3.76) <0.0005 0.71 
T1 TNFα -2.87 (-5.01 to -0.73) 0.011 
Table 10.29: Unadjusted coefficients and p values for variables independently 
associated with QoL at baseline. 
 
Variable N ß (CI) P value Adjusted R2 
HADS-D 32 -4.23 (-5.68 to -2.78) <0.0005 0.70 
T stage -0.19 (-0.36 to -0.02) 0.031 
Fatigue -8.62 (-14.07 to -3.17) 0.003 
Table 10.30: Adjusted coefficients and p values for variables independently 
associated with QoL at baseline. 
Univariate associations (N) 
HADS-D (32) 
T1 TNFα (27) 
T1 EORTC-QLQ symptoms: 
Faecal incontinence (4) 
Abdominal/pelvic pain (6) 
Health anxiety (17) 
Pain (32) 
Dry mouth (17) 
Taste problems (17) 
Appetite loss (32) 
Nausea and vomiting (32) 
Constipation (32) 
Dyspnoea (32) 
Insomnia (31) 
Hair loss (17) 
HADS-A (32) 
Trend T stage (32) 
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10.3.8.2 HN model (T1 QoL) 
 
The only variables independently associated with baseline global QoL were 
fatigue, nausea and vomiting, T stage and problems with social eating (see table 
10.32).
 
Table 10.31: Variables univariately 
associated with poorer QoL at baseline in HN 
cancer patients. EORTC-QLQ symptoms are 
presented in order of R
2
. 
 
 
 
 Use of feeding tube was not 
included in the multivariate model 
because only two patients were 
using a feeding tube.  
 Neuroticism, LE, HADS-A and PH 
depression were no longer 
significant after adjusting for 
HADS-D. 
 HADS-D was no longer significant 
after adjusting for fatigue. 
 N stage confounded social eating.  
Comorbid disability confounded T 
stage and social eating. 
 All of the variables were still 
significant when using 
bootstrapped standard errors and 
the model was similar to the model 
derived using stepwise methods. 
 
 
Variable N ß (CI) P value Adjusted R2 
Fatigue 35 -0.46 (-0.65 to -0.28) <0.0005 0.75 
Nausea/Vomiting -0.71 (-1.10 to -0.32) 0.001 
T stage -4.09 (-7.07 to -1.11) 0.009 
Problems with 
social eating 
-0.20 (-0.40 to 0.00) 0.050 
Table 10.32: Coefficients and P values for variables independently associated with 
baseline global QoL in HN patients. 
Univariate associations (N) 
Neuroticism (37) 
LE (41) 
PH depression 
HADS-D (52) 
T1 EORTC-QLQ symptoms: 
Social contact (35) 
Fatigue (52) 
Pain (52) 
Dyspnoea (52) 
Nausea and vomiting (52) 
Constipation (52) 
Feeding tube (35) 
Weight loss (35) 
Nutritional supplements (35) 
Social eating problems (35) 
Less sexuality (31) 
Financial difficulties (52) 
Speech problems (35) 
Appetite loss (52) 
Insomnia (52) 
Teeth problems (34) 
HADS-A (52) 
T stage (52) 
Current alcohol consumption (41) 
Lack of partner (50) 
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10.3.9 T3: QoL at one month post treatment 
10.3.9.1 CR model (T3 QoL) 
HADS-D was the only variable independently associated with poorer global QoL at 
T3 in CR patients 
Univariate associations (N) 
CT (20) 
NE (21) 
HADS-D (25) 
T3 EORTC-QLQ symptoms: 
Body image (9) 
Fatigue (25) 
Micturition problems (9) 
Appetite loss (25) 
Health anxiety (15) 
Dyspnoea (24) 
Constipation (25) 
HADS-A (52) 
Increasing age (25) 
Table 10.33: Univariate associations between variables 
and global QoL at T3 in CR cancer patients. EORTC-
QLQ symptoms are given in order of R
2
. 
 
 Table 10.33 shows the variables that are univariately associated with poorer 
QoL at T3 in CR cancer patients. 
 Too few people completed the body image, micturition problems and health 
anxiety scales for these items to be used in the multivariate models. 
 After entering HADS-D into the model, HADS-D was found to be the only 
significant independent variable associated with poorer QoL at T3.  
 Including T stage, N stage, age comorbid disabilities, sex, chemotherapy, 
baseline QoL, HADS-D or using bootstrapped standard errors all made no 
difference to the model and the same model was derived when using a stepwise 
approach. 
 
Variable N ß (CI) P value Adjusted R2 
HADS-D 25 -4.25 (-6.58 to -1.92) 0.001 0.75 
Table 10.34: Coefficients and P values for variables independently associated with T3 
global QoL in CR patients. 
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10.3.9.2 HN model (T3 QoL) 
HADS-D, smoking and dry mouth were the only significant independently 
associated variables (see table 10.36).  Univariate associations are presented in 
table 10.35.
 
Univariate associations (N) 
PH depression  
LE (44) 
HADS-D (45) 
T2 IL6 and CRP (37,37) 
Perioperative IL6 and CRP (36, 35) 
T3 TNFα 
T3 EORTC-QLQ symptoms: 
Fatigue (45), 
Dry mouth (31) 
Pain (45) 
Speech problems (30) 
Insomnia (45) 
Financial difficulties (44) 
Senses problems (31) 
Constipation (45) 
Problems with social eating (30) 
Sticky saliva (31) 
Problems with social contact (30) 
Nausea and vomiting (45) 
On feeding tube (30) 
Diarrhoea (44) 
Less sexuality (24) 
Dyspnoea (44) 
Nutritional supplements (30) 
Pain killers (30) 
Swallowing (31) 
Coughing (31) 
HADS-A (45) 
Alcohol abuse (42) 
Table 10.35: Univariate associations between 
variables and global QoL at T3 in HN cancer 
patients. EORTC-QLQ symptoms are given in 
order of R
2
. 
 
 
 PH depression, LE, and alcohol 
abuse were no longer significant after 
adjusting for HADS-D. 
 None of the inflammatory factors 
were significant after adjusting for T2 
IL6, but this was no longer significant 
after adjusting for smoking. 
 Comorbid disability confounded 
HADS-D and chemotherapy 
confounded dry mouth and smoking.   
 Dry mouth was also confounded by 
surgical rating, T1 HADS-D and 
global QoL, but no other variables 
affected the model. 
 All the variables in the model were 
still significant when using 
bootstrapped errors.  The model is 
the same as the one obtained when 
using a stepwise approach. 
 Univariate analyses showed no 
biases in the complete case sample, 
except some indication of a reduced 
relationship between dyspnoea and 
QoL in the analysed sample. 
 
 
Variable N ß (CI) P value Adjusted R2 
Fatigue 27 -0.37 (-0.57 to -0.17) 0.001 0.77 
HADS-D -2.02 (-3.59 to -0.45) 0.014 
Dry mouth -0.16 (-0.30 to -0.02) 0.025 
Current smoker -10.49 (-19.53 to -1.46) 0.025 
Table 10.36: coefficients and p values for variables associated with global QoL at T3 in HN patients. 
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10.3.10 T4: QoL at three months post treatment 
10.3.10.1 CR model (T4 QoL) 
Only comorbid disability and LE were significantly independently associated with 
poorer QoL in CR patients (see table 10.38). 
 
Univariate associations (N) 
CT (19) 
NE(21) 
LE (21) 
HADS-D (24) 
T4 EORTC-QLQ symptoms: 
Loss of libido (m 7, f 4), 
Impotence (5), 
Health anxiety (17), 
Dyspnoea (23), 
Abdominal/pelvic pain (12) 
Current smoking (19) 
Comorbid disability (24) 
Table 10.37: Univariate associations between variables and 
global QoL at T4 in CR cancer patients. EORTC-QLQ 
symptoms are given in order of R
2
. m=male, f=female. 
 
 Table 10.37 shows the variables univariately associated with global QoL at T4. 
 Loss of libido, impotence, health anxiety and abdominal/pelvic pain were not 
included in multivariate analyses due to low numbers. 
 LE, NE and CT were no longer significant after adjusting for HADS-D. 
 Comorbid disability explained more of the variance than HADS-D in which case 
LE could be re-entered into the model.  No other symptoms were significant. 
 T stage and age confounded LE, but no other variables from the core set 
affected the model. 
 All of the variables were still significant when using bootstrapped standard errors 
and using a stepwise approach reached the same model. 
 Post hoc univariate analyses showed no biases in the complete case sample. 
 
Variable N ß (CI) P value Adjusted R2 
Comorbid disability 24 -17.26 (-26.82 to -7.69) 0.001 0.45 
LE -4.65 (-8.82 to -0.48) 0.030 
Table 10.38: Variables associated with T4 global QoL in CR patients. 
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10.3.10.2 HN model (T4 QoL) 
 
The final model included fatigue, current alcohol consumption and LE (see table 
10.40). 
Univariate associations (N) 
NE(41) 
PH depression 
LE (39) 
HADS-D (41 
Trend CT (34)) 
T4 EORTC-QLQ symptoms: 
Fatigue (41) 
Pain (41) 
Problems with senses (32) 
Problems with speech (29) 
Problems with social contact (29) 
Dyspnoea (41) 
Less sexuality (27) 
Appetite loss (41) 
Financial difficulties (41) 
Insomnia (41) 
HADS-A (41), 
T stage (40) 
Current alcohol consumption (37). 
Table 10.39: Univariate associations between variables and 
global QoL at T4 in HN cancer patients. EORTC-QLQ 
symptoms are given in order of R
2
. 
 Table 10.39 shows the variables univariately associated with poorer QoL at T4. 
 Neuroticism, PH depression and HADS-A were no longer significant after 
adjusting for HADS-D. 
 HADS-D was no longer significant after adjusting for fatigue. 
 None of the core set of variables were significant or confounded the results, nor 
did baseline HADS-D or global QoL. 
 All of the results were still significant when using bootstrapped standard errors 
and using a stepwise approach came to the same conclusion. 
 Post hoc univariate analyses showed no biases in the complete case sample. 
Variable N ß (CI) P value AdjustedR2 
Fatigue 35 -0.41 (-0.54 to -0.27) <0.0005 0.57 
Current alcohol use* -15.00 (-23.77 to -6.44) 0.001 
LE -4.86 (-7.65 to -2.06) 0.001 
Table 10.40: Variables associated with poorer global QoL at T4 in HN patients. * N=30 vs 7. 
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10.3.11 T5: QoL at six months post treatment 
10.3.11.1 CR model (T5 QoL) 
 
Only HADS-D and comorbid disability were significantly independently associated 
with poorer QoL at T5 (see table 10.42). 
 
 
Univariate associations (N) 
CT (17) 
HADS-D (24) 
T5 EORTC-QLQ symptoms: 
Dry mouth (19) 
Fatigue (21) 
Body image (14) 
Hair loss (19) 
Comorbid disability (21) 
Table 10.41: Univariate associations between variables and 
global QoL at T5 in CR cancer patients. EORTC-QLQ 
symptoms are given in order of R
2
. 
 
 Table 10.41 shows the variables univariately associated with poorer global QoL 
at T5 
 Dry mouth, body image and hair loss were not included in the multivariate 
analyses because very few patients completed the body image scale and less 
than 2 patients reported any symptoms for the other excluded scales. 
 Childhood trauma and fatigue were no longer significant after adjusting for 
HADS-D. 
 Baseline global QoL and age, both confounded the effect of comorbid disability. 
 Using bootstrapped standard errors did not affect the model and the same 
model was derived when using a stepwise approach. 
 Post hoc univariate analyses showed no biases in the complete case sample. 
 
Variable N ß (CI) P value Adjusted R2 
HADS-D 21 -4.82 (-6.76 to -2.89) <0.0005 0.61 
Comorbs -13.85 (-23.39 to -4.30) 0.007 
Table 10.42: Variables associated with poorer global QoL at T5 in CR patients. 
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10.3.11.2 HN model (T5 QoL) 
Fatigue and dyspnoea were the only variables significantly independently 
associated with poorer QoL at T5 in HN patients (see table 10.44).
 
 
Univariate associations (N) 
HADS-D (40) 
T1 IFNγ (36) 
T2 IL6 (40) 
T5 EORTC-QLQ symptoms: 
Fatigue (40), 
Dyspnoea (40), 
Constipation (40), 
Less sexuality (35), 
Speech problems (38), 
Problems with social contact (38), 
Pain (40), 
Problems with teeth (36), 
Problems with social eating (38), 
Coughing (39) 
Restricted mouth opening (39) 
Table 10.43: Univariate associations between 
variables and global QoL at T5 in HN cancer 
patients. EORTC-QLQ symptoms are given in 
order of R
2
. 
 
 
 
 Table 10.50 shows variables 
univariately associated with QoL at 
T5. 
 IFNγ was no longer significant after 
adjusting for IL6. 
 HADS-D and IL6 were both 
independently associated with 
poorer QoL when adjusting for 
each other, but neither was 
significant after adjusting for 
fatigue and dyspnoea. 
 
 
 
 
 Dyspnoea was confounded by surgical rating, otherwise none of the core set of 
variables affected the model or were significant. 
 Baseline HADS-D was not significant and did not affect the model.  Baseline 
global QoL did not confound or mediate the other variables, but was significantly 
associated with QoL at T5. 
 Using a stepwise approach generated the same model and using bootstrapping 
methods did not change the model. 
 Post hoc univariate analyses showed no biases in the complete case sample. 
 
Variable N ß (CI) P value Adjusted R2 
Fatigue 40 -0.35 (-0.55 to -0.40) 0.001 0.44 
Dyspnoea -0.33 (-0.58 to -0.07) 0.013 
Table 10.44: Variables associated with poorer global QoL at T5 in HN patients. 
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10.3.12 Longitudinal analyses: QoL at all time points 
10.3.12.1 CR model (overall QoL) 
The final model included HADS-D, fatigue and past smoking as the only variables 
significantly associated with poorer QoL (see table 10.46).
 
Univariate associations (N) 
CT (20) 
NE (22) 
PH depression 
HADS-D (34) 
Overall EORTC-QLQ symptoms: 
Fatigue (34) 
Dry mouth (26) 
Loss of libido (m 8) 
Impotence (7) 
Nausea and vomiting (34) 
Appetite loss (34) 
Constipation (34) 
Insomnia (34) 
Dyspnoea (34) 
Problems with taste (26) 
Age (34) 
Comorbid disability (33) 
HADS-A (34) 
Past smoking (25) 
Table 10.45: Univariate associations between 
variables and overall global QoL in CR cancer 
patients. EORTC-QLQ symptoms are given in 
order of R
2
. m=male. 
 
 Table 10.45 shows the variables 
univariately associated with overall 
QoL. 
 
 Life events were no longer 
significant after adjusting for CT. 
 
 Neuroticism was no longer 
significant after adjusting for CT. 
 
 Fatigue confounded CT. 
 
 Smoking was partially mediated by 
comorbidity and surgical rating, but 
none of the other demographic or 
cancer related variables affected 
the model. 
 
 
 All of the variables in the model were still significant after bootstrapping and was 
the same as the stepwise derived model  
 
 Univariate post-hoc analyses indicated no biases in the complete case sample. 
 
Variable N ß (CI) P value Between R2 
HADS-D 25 -3.01 (-4.33 to -1.76) <0.0005 0.76 
Fatigue -0.43 (-0.65 to -0.22) <0.0005 
Past smoking -9.21 (-18.34 to -0.08) 0.048 
Table 10.46: Variables associated with poorer QoL in CR patients. 
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10.3.12.2 HN model (overall QoL) 
HADS-D, fatigue, financial difficulties, current alcohol consumption and nausea and 
vomiting were the only variables significantly independently associated with poorer 
QoL at T5 in HN patients (see table 10.48).
 
Univariate associations (N) 
PH depression  
LE (45)  
HADS-D (56) 
Overall EORTC-QLQ symptoms: 
Fatigue (56) 
Dyspnoea (56) 
Nausea and vomiting (56) 
Constipation (56) 
Problems with social contact (51) 
Insomnia (56) 
Financial difficulties (56) 
Problems with social eating (51) 
Speech problems (51) 
Less sexuality (49) 
Nutritional supplements (51) 
Use of feeding tube (51) 
Weight loss (51) 
Appetite loss (56) 
Diarrhoea (56) 
Problems with senses (51) 
Sticky saliva (51) 
Coughing (51) 
Dry mouth (50) 
Pain killers (51) 
T stage (55), 
HADS-A (56) 
Current alcohol consumption (45) 
Table 10.47: Univariate associations between 
variables and overall global QoL in HN cancer 
patients. EORTC-QLQ symptoms are given in 
order of R
2
. m=male. 
 
 Table 10.47 shows the variables 
univariately associated with overall 
QoL in HN cancer patients. 
 Neuroticism and PH of depression 
were no longer significant after 
adjusting for HADS-D. 
 Life events were no longer 
significant after adjusting for 
fatigue. 
 Nausea and vomiting was slightly 
confounded by surgical rating, but 
adjusting for any other variables in 
the core set did not affect the 
model. 
 The same model was derived 
when using a stepwise approach 
and using bootstrapped standard 
errors did not affect the model. 
 Univariate post-hoc analyses 
indicated no biases in the complete 
case sample.
 
 
Variable N ß (CI) P value Between R2 
Fatigue 45 -0.30 (-0.42 to -0.18) <0.0005 0.53 
HADS-D  -1.56 (-2.71 to -0.41) 0.008 
Financial difficulties -0.08 (-0.15 to -0.02) 0.014 
Alcohol consumption -8.64 (-15.30 to -1.98) 0.011 
Nausea/vomiting -0.16 (-0.30 to -0.02) 0.026 
Table 10.48: Variables associated with poorer QoL in HN patients. 
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10.4 Summary  
Time HADS-D QoL 
T1 Fatigue 
Sex 
HADS-D 
Fatigue 
T stage 
 
T3 Neuroticism 
Baseline TNFα 
 
HADS-D 
T4 Childhood trauma 
Fatigue 
Neuroticism 
Financial difficulties 
 
Comorbid disability 
Life events 
T5 Diarrhoea 
Childhood trauma 
HADS-D 
Comorbid disability 
 
Longitudinal Life events 
Neuroticism 
Constipation 
Fatigue 
HADS-D 
Fatigue 
Past smoking 
Table 10.49: Variables associated with increased HADS-D and poorer QoL in CR cancer patients 
 
Time HADS-D QoL 
T1 Fatigue 
Neuroticism 
Fatigue 
Nausea and vomiting 
T stage 
Problems with social eating 
 
T3 Life events 
Constipation 
Pain 
Lack of weight gain 
Fatigue 
HADS-D 
Dry mouth 
Current smoking 
 
T4 Problems with social contact 
Neuroticism 
Fatigue 
Current alcohol use 
Life events 
 
T5 Fatigue 
Less sexuality 
Childhood trauma 
 
Fatigue 
Dyspnoea 
Longitudinal Fatigue 
Less sexuality 
Diarrhoea 
Neuroticism 
Fatigue 
HADS_D 
Alcohol consumption 
Financial difficulties 
Nausea and vomiting 
Table 10.50: Variables associated with increased HADS-D and poorer QoL in HN cancer patients 
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10.5 Discussion 
 
Table 10.49 and table 10.50 show the variables associated with increased 
depressive symptoms and poorer QoL at each time point and overall in CR cancer 
patients and HN cancer patients respectively. 
 
This discussion addresses each time point in turn, followed by a comparison of 
time points.  The variables associated with depressive symptoms are compared to 
those associated with a DE6.  Each section first summarises findings for HADS-D 
for CR and HN cancer patients, interpreting the findings and comparing the results 
of the two cancer groups.  This is followed by a similar structure for the QoL 
findings.  Finally, the HADS-D and QoL findings are interpreted together.  The 
discussion concludes with a summary of the main theme of the results referring to 
the hypotheses and a review of the overall strengths and weaknesses. 
10.5.1 Baseline findings 
 
Fatigue and sex (female) were the only variables independently associated with 
increased depressive symptoms at baseline in CR cancer patients.  These 
variables explained 40% of the variance in depressive symptoms.  Similarly, only 
fatigue and NE were independently associated with increased depressive 
symptoms in HN cancer patients, explaining 47% of the variance in HN patients‟ 
baseline HADS-D scores.  The results were not explained by any other 
demographic or cancer related factor.  Fatigue is highly associated with depression 
and is one of the symptoms of a DD[343], thus levels of fatigue are likely to be 
associated with depressive symptoms.  Neuroticism and sex are also likely to be 
associated with increased depressive symptoms: past studies have reported strong 
associations between NE and depression (see McWilliams, 2003[344]) and women 
in the general population have been found to report higher depressive 
symptoms[345].  Women are also at 1.5x greater odds of developing a DD[59].  
Women are also more likely to show high levels of NE compared to men[337], 
suggesting some similarity between the CR and HN model.  Thus, the variables 
associated with depressive symptoms at baseline in both CR and HN cancer 
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patients are factors related to depression and similar to what would be expected in 
the general population. 
 
Baseline TNFα levels were associated with poorer baseline QoL in CR patients.  
However, this relationship was no longer significant after adjusting for T stage. 
After including extent of tumour (T stage) in the model, only T stage, depressive 
symptoms and fatigue were independently associated with poorer QoL, explaining 
70% of the variance of QoL scores.  Whereas in HN patients, T stage, fatigue, 
nausea and vomiting and problems with social eating were all associated with 
poorer QoL at baseline, explaining 75% of the variance of HN patient QoL scores.  
Interestingly, as reported in chapter 9, TNFα was also highly related to fatigue.  
This suggests that T stage is associated with higher TNFα levels, thus increased T 
stage may be associated with poorer QoL partially due to increased TNFα 
production and fatigue.  However T stage is probably also related to other aspects 
of function, thus has a greater association with poorer QoL, compared to TNFα 
levels alone.  Self-reported somatic symptoms in HN cancer patients appear to 
have a large impact on their global QoL at baseline, more so than depressive 
symptoms.  Whereas depressive symptoms were strongly related to QoL in CR 
cancer patients, even in the multivariate analysis.  This may be because HN 
patients have a higher cancer related symptom burden than CR cancer patients 
before treatment.  However, it is important to note that fewer CR cancer patients 
completed the cancer specific aspects of the QoL questionnaire, therefore, due to 
low numbers, cancer specific symptoms are less likely to be included in the CR 
cancer models. 
 
No cancer related factors were associated with depressive symptoms at baseline 
in CR or HN cancer patients.  On the other hand, T stage was associated with 
poorer QoL in both groups of cancer patients.  Also, whilst the factors associated 
with depressive symptoms were similar in CR and HN cancer patients, the 
variables associated with poorer QoL appeared to be more symptom related in the 
HN group than in the CR group. 
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10.5.2 T3: One month post treatment 
 
Increased baseline TNFα levels and NE were the only variables associated with 
increased depressive symptoms at T3 in CR cancer patients, explaining 76% of the 
variance in HADS-D scores.  Life events, pain and constipation were the only 
variables associated with increased depressive symptoms at T3 in HN cancer 
patients, and weight gain was associated with decreased depressive symptoms.  In 
total LE, pain, constipation and weight gain explained 77% of the variance in 
HADS-D scores for HN cancer patients.  This shows that the association between 
baseline TNFα and increased depressive symptoms at one month post surgery in 
CR cancer patients is a robust finding as it has a higher impact than any other 
cancer related of psychological factor.  Also, the association between TNFα levels 
and depressive symptoms remains after adjustment for baseline global QoL.  No 
association between inflammation and HADS-D was found in univariate analyses 
as reported in chapter 8 on the role of physiological factors.  However, a similar 
amount of variance of depressive symptoms in HN cancer patients, compared to 
the amount explained in CR patients, has been explained through somatic 
symptoms and stressful LE.  Thus, inflammation is an important risk factor for 
increased depressive symptoms one month after surgery in CR cancer patients, 
but LE and current symptoms are more important factors in HN cancer patients. 
 
Depressive symptoms was the only variable independently associated with poorer 
QoL one month post treatment in CR cancer patients, which explained 36% of the 
variance in QoL scores alone.  Whereas, HADS-D, fatigue, dry mouth and current 
smoking were the only variables independently associated with poorer QoL in HN 
cancer patients, collectively explaining 77% of the variance.  The CR cancer 
finding demonstrates the strength of the relationship between HADS-D and global 
QoL in CR cancer patients.  However, once again, somatic symptoms appear to 
play a more important role in HN cancer patients.  It is interesting that current 
smoking is related to poorer QoL at this time point in HN cancer patients.  This may 
be because the smokers are struggling to break their addiction.  Also, a recent 
study found an association between current smoking and increased pain in HN 
patients before treatment[346].  Dry mouth may be a particular problem in HN cancer 
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patients that have started chemoradiation treatment.  Part of the association 
between dry mouth and QoL was related to chemotherapy, as indicated by the 
mediating effect of chemotherapy.  Symptoms of dry mouth in HN cancer patients 
have been shown to start within two months after primary treatment in samples 
where a large proportion of patients were undergoing radiotherapy treatment[146, 
347].  Moreover, these symptoms endured over the next year, with only a slight 
reduction by five years post treatment[146, 347, 348].  Nevertheless whilst the 
symptoms of dry mouth persisted, patients‟ global QoL improved[124, 347], 
suggesting that the association between dry mouth and poorer global QoL 
decreases over time.  This is supported by the finding that dry mouth is associated 
with poorer global QoL in HN cancer patients at T3, but not at any later time points.  
Thus, depressive symptoms are the only factor associated with poorer QoL in CR 
cancer patients.  Depressive symptoms are strongly associated with poorer QoL in 
HN cancer patients, but fatigue, dry mouth and smoking are also independently 
related to poorer QoL. 
 
It is noteworthy that increased inflammation was a risk factor for increased 
depressive symptoms one month after surgery in CR cancer patients and this 
relationship was not affected by any cancer related variables.  Inflammation was 
not associated with increased depressive symptoms in HN patients.  As stated in 
chapter 9, this could be due to the greater heterogeneity of the HN cancer group.  
In both the HN and CR cancer patients the models explained a lot of the variance 
in HADS-D scores.  Depressive symptoms were independently related to poorer 
QoL in both cancer groups, indicating the importance of depressive symptoms in 
cancer patient treatment outcome at one month after surgery. 
10.5.3 T4: Three months post treatment 
 
Childhood trauma, fatigue, NE and financial difficulties were the only variables 
independently associated with depressive symptoms in CR cancer patients, 
explaining 71% of the variance.  Neuroticism and problems with social contact 
were the only variables associated with increased depressive symptoms in HN 
cancer patients, explaining 52% of the variance.  Similarly, T3 somatic symptoms 
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appear to be more important factors in HN cancer patients than CR cancer 
patients.  The results for this time point for the HN cancer patients are similar to the 
findings from the cross sectional study reported in chapter 4.  The cross sectional 
analyses found fatigue and problems with social contact were associated with 
increased depressive symptoms in HN cancer patients.  As reported in chapter 9, 
NE was also associated with increased fatigue post treatment, thus the two 
variables are strongly related and NE may have been an important factor in the 
cross sectional analyses had the information been available.  The variables 
associated with HADS-D in CR patients were markedly different to those in the 
cross sectional study, which were fatigue, body image and defaecation problems.  
However, this could be due to the low completion rates for cancer specific 
symptoms in the CR group. 
 
Life events and comorbid disability were the only variables that were associated 
with poorer QoL in CR cancer patients at three months post treatment, explaining 
45% of the variance.  Fatigue, alcohol consumption and LE were the only variables 
associated with poorer QoL in CR cancer patients, explaining 57% of the variance.  
It is intriguing that despite the high level of variance explained by HADS-D at one 
month post treatment, at this time point HADS-D was not independently associated 
with QoL in either cancer group.  However, LE as reported in chapter 7, were 
strongly associated with increased depressive symptoms.  Also, as reported in 
chapter 9, LE were strongly related to increased fatigue and increased pain at this 
time point in CR patients.  This suggests that LE may be an important factor 
influencing both increased depressive symptoms and poorer QoL in post operative 
ambulatory cancer patients. 
 
The adjusted models for T4 explain less of the variance of depressive symptoms 
and QoL than those of T3, but still explain at least 40% of the variance.  Similar to 
the findings at T3, somatic symptoms are related to increased depressive 
symptoms in HN cancer patients, but not CR cancer patients.  This may be due to 
the low completion rates in the CR cancer sample.  Notably, depressive symptoms 
were not independently associated with poorer QoL in either cancer group, 
whereas LE appeared to be more influential factors.  Previous studies have also 
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found that LE are strongly related to depressive symptoms: LE, NE and ethnicity 
accounted for 53% of the variance in depressive symptoms in breast cancer 
patients three months post surgical treatment[210].  In addition, 88% of the variance 
in depressive symptoms in a sample of breast cancer patients three months past 
treatment was explained by number of stressful LE and PH of depression[349].  This 
study shows that the number of stressful LE a patient experiences around the time 
of the cancer diagnosis is also an important risk factor for poorer QoL three months 
post treatment. 
10.5.4 T5: Six months post treatment 
 
Only CT and diarrhoea were independently associated with increased depressive 
symptoms at T5 in CR cancer patients, explaining 56% of the variance in HADS-D 
scores.  Furthermore, only CT, fatigue and less sexuality were associated with 
increased depressive symptoms in HN cancer patients, explaining 60% of the 
variance in HADS-D scores.  The CR findings for this time point indicate some 
association between cancer specific symptoms and increased depressive 
symptoms.  This is especially true when compared to the findings from the cross 
sectional study showing defaecation problems to be one of the variables with the 
strongest association with depressive symptoms.  Similarly, less sexuality (less 
desire and enjoyment) was significantly associated with increased depressive 
symptoms in HN cancer patients, which has been reported as an important factor 
in HN cancer patients post treatment[350].  It is interesting that CT was a significant 
factor in both cancer groups, and it remains an important risk factor for high 
depressive symptoms in cancer patients, even when adjusting for symptoms. 
 
Only HADS-D and comorbid disability were independently associated with poorer 
QoL in CR cancer patients, explaining 61% of the variance.  Whereas only fatigue 
and dyspnoea were associated with poorer QoL in HN cancer patients, explaining 
just 44% of the variance.  The factors most associated with poorer QoL in the cross 
sectional study were HADS-D, taste problems, dry mouth and sore skin.  Given the 
low completion rate of the symptom aspects of the CR specific questionnaire in the 
prospective study, these results may be comparable.  Similarly, the variables most 
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associated with poorer QoL in HN cancer patients in the cross sectional study were 
fatigue, problems with social contact, age and pain: indicating that fatigue is an 
important issue in HN cancer patients, whereas depressive symptoms are an 
important factor in CR cancer patients. 
10.5.5 Overall 
 
In the longitudinal analyses only fatigue, NE, LE and constipation were associated 
with HADS-D in CR cancer patients, explaining 79% of the variance.  Fatigue, NE, 
less sexuality and diarrhoea were the only variables significantly associated with 
depressive symptoms in HN cancer patients, explaining 56% of the variance.  This 
shows that fatigue is consistently associated with depressive symptoms over time 
in both cancer groups, which would be expected given the close association 
between fatigue and depression.  Similarly, NE is strongly associated with 
depressive symptoms in both patient groups, again this would be expected given 
the close relationship between NE and depressive symptomatology (see 
McWilliams, 2003[344]). 
 
Only HADS-D, fatigue and past smoking were independently associated with 
poorer QoL overall in CR cancer patients, explaining 76% of the variance.  
Interestingly fatigue, HADS-D, alcohol consumption, financial difficulties and 
nausea and vomiting were the only variables independently associated with poorer 
QoL in HN cancer patients, explaining 53% of the variance.  This is interesting 
because only depressive symptoms were related to poorer QoL at T3 in the 
previous analyses.  This, perhaps, indicates that HADS-D is consistently 
associated with poorer QoL, but there is only a small effect.  A similar effect could 
explain the finding of financial difficulties and nausea and vomiting.  Furthermore, 
the association between past smoking and poorer QoL in CR cancer patients may 
be due to a similar effect and is perhaps related to comorbid disability; smoking is a 
risk factor for many chronic diseases, such as stroke, heart attack or emphysema.  
Current smoking was unlikely to be significant as only three people in the CR group 
smoked at the time of the study.  Despite past studies suggesting an important role 
for body image in CR cancer patients[57, 174], body image was not significant in any 
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of the multivariate models.  However, it was often associated with depressive 
symptoms in CR cancer patients, but not included in the final models due to low 
numbers. 
 
Overall, there does not appear to be a clearly discernable pattern between the 
investigated psychological and physiological variables, EORTC-QLQ symptoms 
and depressive symptoms in either the CR or HN cancer group.  This is probably 
partly explained by the close inter-relationships between the investigated variables 
and symptom reporting.  Also, large fluctuations in patient well-being, in terms of 
their level of symptoms and mood, could occur soon after treatment, which would 
also be affected by their cancer type and treatment regime.  These issues could 
obscure any patterns, which is possible given the low power. 
 
One notable pattern is that the hypothesised psychological and physiological 
variables appear to be more relevant to depressive symptoms than to global QoL.  
However, depressive symptoms are often related to QoL, suggesting that 
depressive symptoms may be on a pathway from predisposition to depression to 
poorer QoL post treatment.  This could only be investigated using structural 
equation modelling which would require much larger samples.  Also, it is interesting 
that variables that were not significant when analysed at each time point were 
significant in the longitudinal analyses.  This indicates that they may have a small 
but consistent effect.  Given the fluctuations in these associations over this period 
of time, longitudinal analyses may not be the most appropriate form of analysis, but 
they can indicate which are the most robust aetiological factors overall. 
 
When combined with the cross sectional results, depressive symptoms appear to 
be strongly related to poorer QoL in CR cancer patients, but less so in HN cancer 
patients.  Although past studies have found associations between increased 
depressive symptoms and poorer QoL in HN cancer patients[56], these results had 
not been adjusted for other factors.  Depressive symptoms are associated with 
poorer QoL in HN cancer patients in both the cross sectional and prospective 
studies, but after adjustment fatigue appears to have a stronger association with 
poorer QoL.  Also, some factors, such as dry mouth in HN cancer patients are 
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related to poorer QoL at one month post operation, but then not from then on.  
Although the symptoms of dry mouth persist for over a year, overall QoL is 
reported to return to near baseline levels by 12 months[56].  This could be because 
patients adjust to the symptoms. 
10.5.6 Depressive disorder compared to depressive symptoms 
 
Past history of depression, NE and LE were associated with increased likelihood of 
a DE6, explaining 59% of the variance.  As no symptoms were associated with 
increased risk of depression, a longitudinal analysis was carried out in order to give 
fair representation of the symptoms.  However, even in these analyses only PH 
depression, NE, LE and surgeons‟ rating of extent of surgery and complications 
were related to an increased risk of a DE6.  Notably, whilst somatic and cancer 
related symptoms were associated with increased depressive symptoms, they 
were not associated with increased risk of a DE6.  This could be because 
depressive symptoms are a common response to cancer diagnosis and treatment, 
but only those individuals who have an underlying vulnerability to stressors are at 
increased risk of a DE.  However, whilst depressive symptoms were associated 
with poorer QoL a DE was not.  This could be an effect of the study design 
because DE6 was only coded as „present‟ or „absent‟ whereas symptoms and QoL 
varied at each time point.  When compared to the cross sectional results for CR 
patients, although HADS-D and PH depression were the most significant factors 
associated with a DE, body image was also significantly associated with increased 
risk of a DE.  In agreement with past studies, the symptoms that impact on function 
were strongly associated with increased depressive symptoms[123, 177].  No other 
studies have investigated baseline psychological factors compared to symptoms 
with respect to risk of a DE in either CR or HN cancer patients, therefore it is worth 
investigating the relationship of psychological variables further. 
10.5.7 Limitations and conclusions 
 
The study is limited by low power, which may have led to some inconsistent 
findings.  Also, the relatively small numbers mean that although the models have 
high explanatory power in these samples, the models are unlikely to fit so well in 
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other samples.  As reported in section 6.2, there is also a bias towards healthier 
individuals taking part in the study, which may have affected the results.  Due to 
the low numbers of patients that experienced a DE6, it was not possible to code 
DE according to time, which may have obscured any associations with symptoms 
or global QoL. 
 
It is acknowledged that in order to reach the final models many tests were carried 
out.  This was necessary to determine which factors are most strongly associated 
with increased depressive symptoms and poorer QoL at each time point. However, 
this was carried out in an exploratory manner thus the results are reported in such 
a way as to identify trends to inform future studies.  Also, very little research had 
previously compared the comparative associations between psychological and 
cancer related risk factors for depression in curative cancer patients. 
 
Whilst it is important to gain insight into how perceived symptoms are associated 
with poorer QoL, it would be really interesting to investigate how the investigated 
factors relate to cancer related symptoms, depressive symptoms and poorer QoL.  
This could only be investigated using much larger samples and structural equation 
modelling, which could show the direct and indirect pathways to poorer QoL.  
Furthermore, some variables that could be considerable covariates are not 
included in this study.  For instance, it is beyond the scope of this thesis to include 
analyses and adjustments for the many well founded genetic influences on 
inflammation, depression and QoL.  Future studies with larger samples should also 
consider measuring social economic status, which has been found to be 
associated with increased depressive symptoms[66], though the analyses were not 
adjusted for relevant social variables such as smoking.  Nonetheless, social 
economic status has also been inversely associated with increased IL6 and CRP 
levels.  Although the association between greater social economic status and 
decreased CRP levels was no longer significant after adjustment for lifestyle 
factors, the association between IL6 and community social economic status 
remained even after adjusting for lifestyle factors, personal income and 
education[351].  Medication is also likely to affect inflammatory levels, but due to the 
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small number of participants and large number of medications it is impractical to 
adjust for each medication. 
 
Based on past studies it was expected that cancer related variables would have 
limited effect[214].  The results from this study show that the clinical measures of 
cancer, such as extent of tumour and treatment mode, have relatively little impact 
on depressive symptoms or QoL.  They also show that symptoms associated with 
cancer are related to depressive symptoms and QoL, but not a DE6.  The results 
indicate that depressive symptoms and global QoL in cancer patients soon after 
treatment are related to both established vulnerability factors common to 
individuals in the general population and to current symptoms due to the cancer.  
However, as reported in chapter 9, patients‟ perceived symptoms were also 
affected by factors considered to increase the risk of a DE.  Using both vulnerability 
and symptom measures resulted in models which explained a high proportion of 
the variance in depressive symptoms and QoL scores in CR and HN cancer 
patients. 
 
This study also found an association between TNFα and prospective depressive 
symptoms in CR cancer patients.  Previous studies have found cross sectional 
associations between increased inflammation in cancer patients with a DD 
compared to cancer patients without a DD[138-140].  Inflammation has been shown to 
be positively associated with depressive symptoms in cancer patients[141].  This is 
the first study to look at a prospective association and to use multivariate measures 
to adjust for other factors that may confound the relationship between inflammation 
and depression.  This indicates the importance of psychological and physiological 
risk factors for depression in cancer patients alongside cancer related issues in 
respect to cancer patients self rated QoL. 
 
This chapter further tested the study hypotheses (section 2.7.1) by exploring how 
cancer related factors mediate the relationship between the investigated variables 
and depressive symptoms and QoL in cancer patients.  Patients with a PH 
depression were at increased risk of a DE6 and this relationship remained even 
after adjusting for cancer related factors.  The association between increased 
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cytokine levels and increased depressive symptoms in CR cancer patients was 
stronger then that of any other cancer related variables.  Finally, depressive 
symptoms have a stronger association with QoL in CR cancer patients than any 
other variable, but this is not true for HN cancer patients. 
 
In summary, this chapter combined the results from the previous three chapters on 
psychological and physiological risk factors for depression in cancer patients 
addressing the third aim of the study: to explore associations between other 
possible explanatory factors and depressive symptoms and poorer QoL in cancer 
patients.  As there was a lot of covariance between many of the investigated 
variables, using multivariate analyses helped to identify which variables would be 
most predictive of later depressive symptoms and QoL, and therefore which would 
be most clinically useful.  Whilst some of the results may appear quite random, 
some patterns did emerge:  
1. There was a close relationship between inflammation and mood in CR 
cancer patients though this was not as apparent in the HN cancer group. 
2. Cancer related symptoms had a stronger association with depressive 
symptoms and poorer QoL in HN cancer patients compared to CR cancer 
patients. 
3. HADS-D was strongly related to QoL in both patient groups, but more so in 
the CR cancer group.  Whereas fatigue appeared to be a more important 
factor with respect to HN cancer patients‟ self rated global QoL. 
This chapter addressed the third exploratory aim of the thesis and has reported the 
relative importance of CT, NE, LE, PH of depression and increased inflammation 
as markers of increased depressive symptoms, poorer QoL and increased risk of a 
DE in patients soon after a diagnosis of cancer. 
A summary and discussion of the clinical implications of the data from this chapter 
and the previous sections are presented in the next and final chapter.  
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11 General discussion 
 
This section discusses the overall conclusions that can be drawn from the results 
of this study.  Firstly, a summary of the data from each section and how these 
relate to the original aims of the thesis are presented.  This is followed by a 
discussion of the clinical significance of these findings, with reference to cancer 
patient treatment, as well as the research implications of the study.  The methods 
of the prospective study are critically discussed with suggestions for possible 
improvements.  Finally, the practical applications and recommendations are 
reported. 
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11.1 Aims and findings 
 
The main aims of this study were to: 
3. Measure the prevalence of depressive disorders in two different 
cancer clinic populations (at Barts and The London). 
4. Test the hypotheses that: 
(i) Patients with a PH of depression are more likely to 
experience a DE following a cancer diagnosis. 
(ii) Depressive symptoms have a significant negative effect 
on QoL. 
(iii) Patients with higher cytokine levels show more 
depressive symptoms. 
(iv) Patients with increased HPAA activity (increased salivary 
cortisol levels) will show increased depressive symptoms. 
(v) Patients with increased HPAA activity will show increased 
inflammation (increased cytokine and CRP levels). 
5. Explore associations between other possible explanatory factors on 
depressive symptomatology, inflammation and cortisol dysregulation, 
such as associations between coping styles, personality and patient 
rated cancer related symptoms and depressive symptoms. 
 
The cross sectional study (chapter 4) addressed Aim 1 and showed an estimated 
point prevalence of a DD of 14% in CR cancer patients and 5% in HN cancer 
patients.  The study also tested the first two hypotheses and found that patients 
with a PH depression were more likely to experience a DE following a cancer 
diagnosis and depressive symptoms were associated with poorer QoL.  These 
findings were further supported by work from the prospective study, which found a 
six month prevalence of DD of 12% in CR cancer patients and 21% in HN cancer 
patients (chapter 6).  Again, there was a significant negative association between 
depressive symptoms and poorer QoL. 
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Chapter 7, on the role of psychological factors, supported the findings from the 
cross sectional study, showing that patients with a PH depression are at increased 
risk of a DE6 and have higher levels of depressive symptoms.  Chapter 7 also 
explored the effect of mediating factors on depressive symptomatology and QoL.  
The results showed that LE and NE significantly increased the probability of a DE6.  
Childhood Trauma, PH depression, LE and NE were each associated with 
increased depressive symptoms and poorer QoL.  However, there was little 
consistent effect of coping style.  Chapter 8 investigated the role of physiological 
factors in depressive symptoms and QoL, addressing hypotheses iii and iv.  Very 
few reliable associations between cortisol and depression or QoL measures were 
found, but there was evidence of a prospective association between increased 
inflammation and later increased depressive symptoms in CR cancer patients: 
increased levels of the pro-inflammatory cytokine TNFα were associated with 
increased depressive symptoms at later time points. 
 
Chapters 9 and 10 addressed hypothesis v and aim 3.  Chapter 9 reported on the 
inter-relations of the investigated variables and the association between the 
investigated variables and some of the self report symptoms on the EORTC-QLQ 
(fatigue and pain) providing evidence of an association between CT and increased 
inflammation.  Besides CT, there were no associations between inflammation and 
any other psychological variables, or between cortisol and any psychological 
variables.  There were also no associations between cortisol levels and increased 
inflammation, counter to the hypothesis.  However, many of the psychological and 
inflammatory measures were associated with increased fatigue and pain. 
 
Finally, chapter 10 reported on the factors most strongly associated with increased 
depressive symptomatology and poorer QoL, addressing the third aim of the 
thesis.  Psychological factors such as NE, LE and CT were important risk markers 
for increased depressive symptoms and poorer QoL in both CR and HN cancer 
patients.  Inflammation was also associated with increased depressive symptoms 
post surgery in CR cancer patients.  Current patient-reported symptoms were also 
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important factors in predicting later depressive symptoms and poorer QoL, but 
objective cancer related factors were less likely to be significant in the multivariate 
models. 
11.2 Clinical significance 
11.2.1 Treatment outcome 
 
The reported results and previous discussions focus on statistical significance, but 
statistically significant associations and differences do not necessarily translate to 
clinically significant relationships.  Large samples can result in statistically 
significant findings from a relatively small change in QoL scores that would not 
make much difference clinically.  One of the advantages of examining a small 
sample is that the lower power requires a bigger change for statistical significance, 
thus more likely to have clinical significance.  However, this is with the proviso that 
the sample is representative and can be generalised to patient populations.  In 
terms of the clinical significance of the EORTC-QLQ, some researchers suggest a 
change greater than the standard error mean of the results indicates a significant 
change as it indicates a change greater than that due to chance[352, 353].  In this 
sample, that would mean that a change of more than three points on the global 
QoL scale would be clinically significant, whereas, others have suggested that a 10 
point change on the EORTC-QLQ indicates clinical significance.  This is especially 
important given the scoring translation procedure of the EORTC-QLQ, which 
scales every score from 0-100.  Therefore, with respect to the global QoL measure, 
the minimal change is seven points (based on the transformation of two seven item 
scales).  This implies that a patient increasing or decreasing their response on the 
Likert scale by just one point is clinically significant. 
 
To give an example: for every one point on the HADS, a patients‟ QoL decreases 
by between three and four points, which may indeed indicate a significant change – 
depending on which definition of clinical significance is chosen.  Additionally, for 
every one pg/ml increase in baseline TNFα, a patient‟s HADS-D score at one 
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month post operation increases by one (the HADS-D range is 0-21).  Given the 
range of baseline TNFα levels in CR patients, from one to 10 pg/ml, this could have 
significant clinical implications.  A small increase in baseline TNFα levels could 
easily increase the probability of case level depressive symptoms after surgery.  
Eight is suggested as the threshold indicative of possible or probable depression 
on the HADS-D[58].  Following these guidelines, an increase of one pg/ml in TNFα 
levels increases the odds of case level depressive symptoms by two (confidence 
interval 1.16 to 3.46).  However, this is not as clinically significant as a PH of 
depression, which is associated with an increase of five points on the HADS-D and 
a decrease of 14 on the global QoL scale: both of which would be interpreted as 
clinically significant. 
 
The evidence towards the association between PH depression, LE, CT, NE and 
increased inflammation is of relevance to patient treatment outcome.  Previous 
papers[146, 181] and the findings from this thesis have shown a high correlation 
between depressive symptoms and poorer QoL.  This study also found a direct 
association between the investigated factors and poorer QoL.  The fact that these 
factors were rarely associated with poorer QoL in the adjusted models in chapter 
10 suggests that the association between the investigated markers and QoL is 
mediated by depressive symptoms. 
 
The association between increased inflammation and depressive symptoms is of 
special interest given the association between inflammation and cancer survival.  
However, it is already well documented that individuals suffering from a DD are at 
increased risk of all cause mortality[72].  Moreover, one study that found a 
relationship between increased mortality in cancer patients with a DD, reported that 
the increased mortality was comparable to that of patients with a DD but no 
cancer[354].  Similarly, increased inflammation has been associated with increased 
all cause mortality (even after excluding cardiovascular deaths) in general 
population samples[355], and this increased risk is not significantly greater in cancer 
patients[144].  This suggests that any reported associations between depression, 
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inflammation and decreased cancer survival may not be related to the effect of 
inflammation on tumour progression.  Although, a primary care intervention aimed 
at improving treatment of depression in older general practice patients resulted in 
decreased mortality that was mainly attributable to a decrease in cancer deaths in 
the intervention arm[356].  Nevertheless, there are many possible reasons why 
comorbid depression may increase cancer mortality: patients with comorbid MD 
and cancer are known to be less compliant with treatment; in the case of HN 
cancer, patients show less adherence to smoking cessation programmes[149, 150] 
and there is some evidence of an association between depression and later 
presentation of cancer, therefore greater disease[357].  Thus, if the association 
between depression and inflammation is related to increased mortality, it is almost 
surprising that there is not more robust evidence of increased mortality in cancer 
patients with a DD.  However, at present the association is still very much under 
debate (see Coyne et al. (2007)[358], comment by Spiegel and Kraemer[359] and 
author reply[360]). 
11.2.2 Future treatment of cancer patients 
 
Despite the increased risk of a DE and the fact that mental health specialists 
continue to raise awareness of this risk, depression remains under diagnosed and 
under treated[6, 7, 347].  In one interesting study, patients were asked what they 
would most like the surgeon to attend to on a clinic visit and also asked the 
surgeons to rate what they think is important to the patients from a list of possible 
answers[361].  They found that whilst 26% of cancer patients wanted surgeons to 
attend to their emotional state, none of the surgeons thought that this was 
important to the patients.  This shows just how important it is to continue alerting 
clinicians to the psychological impact of cancer.  Given the time constraints in most 
clinics, easy screening techniques may be of interest to surgeons. 
 
This study found the prevalence of depression to be slightly higher than that of the 
general population.  This is most likely because those that are at risk for 
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depression (e.g. have a PH of depression) often experience a recurrent episode 
soon after their cancer diagnosis.  Higher rates of DE have been found in breast 
cancer patients around the time of diagnosis[362].  However, if patients with a 
recurrent DD were excluded, there was no evidence of a higher prevalence of new 
DEs when compared to an age matched control sample[362].  Therefore, PH 
depression is a simple and useful way of identifying patients at high risk of a DE 
soon after a cancer diagnosis. 
 
The findings that baseline information such as PH depression, other LE, NE and 
CT are associated with increased depressive symptomatology are also clinically 
useful.  That PH depression is so highly associated with increased risk of a DD is 
especially relevant as it would only involve one extra screening question at the first 
presentation to a cancer clinic.  Although the predictive value of PH depression is 
greatest when using a PH depression as rated by a diagnostic interview, the 
findings from the cross sectional study suggest that asking whether the patient has 
received past treatment for depression is also an effective way of assessing 
whether a patient is at increased risk of a DE.  This question could be incorporated 
into a medical history questionnaire which is often used in cancer clinics at the first 
patient visit.  This could prove very useful, especially given the reported 
reservations of screening efficacy[125].  Even so, depressive symptoms at baseline 
have been found to be important in prediction of later QoL[363]. 
 
The robust finding of an association between LE and increased depressive 
symptoms, DE6 and poorer QoL also suggests that it is important to consider the 
social situation of cancer patients.  Training oncology staff in psychiatric 
interviewing has been shown to help staff identify those with a DD in the training 
setting[364].  However, they did not report whether this training resulted in a higher 
proportion of patients with depression being identified.  Nevertheless, a number of 
interventions may help identify those at increased risk of a DE soon after their 
cancer diagnosis: 1) clinicians showing increased awareness of patients‟ emotional 
state, 2) brief training regimes for the nursing staff; but mostly 3) increased 
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awareness of psychological markers for depression in cancer patients, especially 
the use of a past mental health screening question. 
 
Increased identification is particularly important because depression in cancer 
patients is readily treatable.  Although the type of treatment is dependent on clinic 
resources, pharmacological and psychosocial interventions have all been shown to 
be useful[365].  Pharmacological treatment has been shown to be effective in 
treating depression even in terminally ill cancer patients[365, 366].  Psychological 
therapies, such as supportive group therapy[367] and mindfulness[368] have also 
proved to be effective in increasing QoL[369].  Moreover, psychological interventions 
not only reduced depressive symptoms, but also pain, fatigue and inflammation in 
breast cancer patients[370].  Alternative medicine interventions have also been 
used; Qigong has been shown to improve QoL and reduce fatigue and CRP levels 
in cancer patients[371].  Similarly, yoga has been shown to reduce anxiety and 
depression and cortisol levels in cancer patients[372].  In addition, treatment with 
anti-depressants has been shown to reduce depressive symptoms in cancer 
patients and increase compliance to chemotherapy or hormone treatment in breast 
cancer patients[373].  Prophylactic treatment with anti-depressants has also been 
shown to decrease the risk of developing depression in HN cancer patients with 
greater than stage II tumours[374].  However, given the side effects to anti-
depressants, this may be considered unethical.  Whilst the information is useful 
when considered in context with the other findings, the prophylactic treatment of all 
patients is not recommended. 
 
Reduction of depressive symptoms and inflammation is especially appealing as 
reducing inflammatory markers is likely to lead to lower levels of sickness 
behaviour, such as increased pain and fatigue that is reported in this study.  Very 
little work has been done on anti-inflammatory treatments in cancer patients, but 
early stage clinical trials have shown some promising results with respect to 
reducing inflammation and cancer related symptoms[375].  It is also worth 
considering treatment regimes, for instance using local anaesthetic as well as 
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general anaesthetic for operating on CR cancer patients resulted in a suppressed 
post operative cytokine surge[376].  Patients who received local anaesthetic during 
their operation were also quicker to start eating post surgery and required less post 
operative pain relief. 
 
Whilst this section has focused on possible improvements to cancer care, it is 
important to note that the level of cancer care in the two clinics was consistently 
very good.  For instance, the HN cancer multi-disciplinary team always considered 
the patients‟ social situations and the cancer nurse specialists were very aware of 
the emotional implications of a cancer diagnosis.  However, both clinics were 
limited by resources, so anything that would help identify at risk patients would 
help, as would knowledge about possible treatments.  Previous work in other 
clinics found 26% of female cancer patients and 11% of male cancer patients 
would have liked a social support intervention[377].  These results were not 
mediated by depressive symptoms.  However, whilst the data from this study 
showed some robust and consistent findings, as a result of the close interaction 
with individual patients, it was also apparent that each patient was very different.  
Even if each difference could be measured, it would be unfeasible to consider 
every aspect of each patient.  This suggests that holistic and patient oriented 
approaches, where the patient has more control over their own care, would be the 
most beneficial.  Very broad approaches, which include lectures, nutritional 
information, exercise classes, support sessions have proven to be very popular[378]. 
11.3 Scientific implications 
 
This thesis has demonstrated how factors unrelated to the cancer diagnosis 
influence cancer patients‟ treatment outcome with respect to their QoL.  Childhood 
trauma, NE, LE and PH depression were all associated with increased depressive 
symptoms and poorer QoL.  In many cases, this risk appeared to be even higher 
between one and three months post operatively.  Also, all but CT were associated 
with an increased risk of a DE6.  These psychological markers were associated 
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with increased self rated symptoms of pain and fatigue.  Notably, this thesis also 
found a relationship between inflammation and later depressive symptoms in CR 
cancer patients.  This is important as it shows a potential physiological mechanism 
to psychological symptoms and adds to the current understanding of mind and 
body interactions.  Even so, patients‟ QoL and depressive symptoms returned to 
near baseline by six months irrespective of the factors unrelated to their cancer 
diagnosis.  This study showed that there are important interrelations between 
vulnerability to a DD, inflammation, depressive symptoms and poorer QoL, and 
these relationships are especially important soon after a cancer diagnosis.  Further 
work on the relationship between inflammation and mood in cancer patients at later 
stages of the illness is recommended. 
 
This study also found substantially more significant results in the CR cancer patient 
group compared to the HN cancer patient group.  As the CR group was 
considerably smaller than the HN group, this is most likely due to greater 
homogeneity in the CR group.  This supports the need for homogenous samples in 
cancer research – especially when investigating inflammatory markers, given the 
number of factors that affect cytokine levels. 
11.4 Methodological evaluation 
11.4.1 Measures 
 
The CTQ, EPQ and LE may all have been affected by recall bias which was 
discussed in chapter 7 on the role of psychological factors. 
11.4.1.1 Childhood trauma 
 
Using the total score of the CTQ resulted in greater sensitivity to CT, but less 
specificity.   This is useful in a pilot study (such as this) as it gives more power, 
especially since the measures of abuse and neglect are often associated with each 
other.  However, some of the findings relating to CT were inconsistent, suggesting 
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that either the relationship varies according to the type of trauma or the results are 
unreliable.  Further studies with larger samples could help clarify this.  Also, the 
CTQ only measures some forms of chronic ELS, not other forms, such as parental 
illness and no acute trauma (e.g. parental loss, accident, early illness).  However, a 
study that included parental loss, physical illness and economic adversity found 
they were not associated with development of a mood disorder after adjusting for 
family conflict (such as parental mental illness and abuse or neglect)[379].  In 
contrast, the different types of abuse and neglect were all associated with 
increased risk of a mood disorder even after adjusting for all the other types[379].  
This suggests that the CTQ may have covered most of the possible risk factors.  
Thus, where a prospective measure is not available, the CTQ is a quick and 
comprehensive validated tool to assess for the importance of ELS. 
11.4.1.2 Neuroticism 
 
Whilst the EPQ is considered a reliable measure of NE, the use of NE for 
prediction of psychopathology has been heavily criticised[228].  There is little doubt 
that NE scores correlate highly with depressive symptoms[228, 380].  Neuroticism also 
mediates much of the genetic risk of a DD[62] and is associated with increased risk 
of numerous psychopathologies and psychosomatic disorders (see Ormel et al, 
2004[228]).  Neuroticism also correlates with PH of mental illness and family history 
of mental illness[380].  However, previous studies have also shown that levels of NE 
decrease after recovery from a DE (see McWilliams, 2003[344]).  Thus it has been 
proposed as merely a “pseudo” depression measure, simply measuring the 
average level of distress over a period of time[228].  Neuroticism would therefore 
often be reported as related to risk of DE and personal and family history of mood 
disorders, but more closely relate to current depressive symptoms.  However, other 
studies have shown that there appear to be trait and state like properties to the 
personality measure[344]; suggesting that the trait level could confer a useful 
indication of risk.  Nevertheless, questionnaires assessing NE are much longer 
than the average depressive symptom questionnaire and, given the high 
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correlation, it may well be simpler to rely on level of depressive symptoms – 
depending on the degree of variation in the NE scores. 
11.4.1.3 Life events 
 
Although the BLEQ may be influenced by current mood, the number of LE around 
the time of diagnosis was a useful marker of psychological distress and poorer 
QoL.  Using the rating of the LE did not add to the explanatory power of the BLEQ, 
so future work may consider omitting the extra questions. 
11.4.1.4 Coping 
 
There was limited consistency in the coping results.  The relationship between 
coping strategies, depressive symptoms and poorer QoL varied a lot over time and 
between patient samples, which may be because of the fluctuations in mood over 
time and the differences in the patient samples.  However, the questionnaire was 
very long and gave insufficient significant results to be considered in future 
research, although the humour question is probably worth keeping.  On the other 
hand, there is much more evidence of an association between increased social 
support and greater QoL[55, 214, 381].  In addition, social attachment and seeking 
instrumental support have both been linked to lower levels of IL6 in cancer 
patients[119, 120].  Thus a measure of social support may be more informative. 
11.4.1.5 Schedules for Clinical Assessment in Neuropsychiatry and 
Hospital Anxiety and Depression Scale 
 
The SCAN gave diagnoses according to both ICD-10 and DSM-IV criteria, which 
was useful in determining borderline patients.  This is especially useful given the 
difficulty in assessing depression in cancer patients.  As discussed in chapter 1, 
using different diagnostic criteria leads to a lot of variation in the prevalence of 
DD[382].  Also, this study included any diagnosis of depression, but in future work, 
separation of any cases that appear to be secondary to pain, given the high 
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association between pain and depression, may be useful.  Due to a high 
correlation between pain and depression in many studies and longer pain duration 
being associated with increased risk of a DE, some postulate that pain and 
depression are interrelated[383].  As a result, depression relating to cancer pain may 
be aetiologically distinct from depression in cancer patients with less pain. 
 
Secondly, the SCAN rarely gave a PH or current diagnosis of anxiety and it would 
be worth comparing the anxiety ratings in the SCAN to that of other clinical 
interviews. 
 
The HADS was well tolerated by patients and showed good reliability.  In some 
respects, it would be more useful to have used the HADS as a categorical 
measure, choosing a threshold of eight or eleven as case level depression[58].  
However, using the HADS categorically is dependent on trusting the reliability of 
the decreed threshold.  Whilst the authors of the HADS suggest a threshold of 
eight (which is often used)[58], studies in HN cancer patients have found a threshold 
of five is the optimal threshold for detection of a possible DE[130].  Moreover, 
relatively few patients scored above the threshold of eight for case level depression 
or anxiety, which would have resulted in reduced power.  Finally, the use of the 
threshold is normally to indicate a DD, which was already assessed here, so using 
the HADS as a scale gave greater sensitivity. 
11.4.1.6 European Organisation for Research and Treatment of Cancer – 
Quality of Life Questionnaire 
 
Despite some studies showing that QoL measures compare equally to other 
medical measures in terms of the degree of measurement error[384], there are still a 
number of limitations to the self report method. 
 
With regard to the self reported symptom items, previous studies have shown that 
cancer patients with depression report higher levels of symptoms[385].  Also, levels 
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of NE correlate with greater symptom reporting, but not to objective measures of 
symptoms[228].  This evidence suggests that those with a DD are more likely to 
report symptoms, but may not show increased symptom levels when assessed 
with more objective measures.  However, self ratings of swallowing function have 
been shown to correlate with objective measures (such as Barium swallow test) in 
HN cancer patients[177].  There is a large overlap between fatigue and pain and 
some other cancer related symptoms (e.g. loss of appetite)[343, 383] and depression, 
therefore it is tricky to interpret the findings when fatigue is included in the model.  
Thus, the self rated nature of the questionnaires means it is harder to tell what 
aspects are influenced by mood and what are more objective impairments.  It 
would be interesting to test for more objective measures of symptoms, but if the 
rating scale offers a measure of symptom perception this should also be 
considered a useful measure. 
 
The study is limited by the use of the global QoL scale for a dependent variable.  
The scale only consists of two seven item measures where a single point change 
could be interpreted as resulting in a clinically significant change (see section 
11.2).  Also, patients with depression, both in the general population and in cancer 
samples, have been shown to report lower QoL, but show equivocal QoL when 
assessed by more objective measures[148, 386].  Self rated QoL is important, as the 
subjective nature of the report is valuable.  However, the two item scale of the 
EORTC-QLQ does not provide much sensitivity, so future work may benefit from a 
more detailed generic QoL measure with a total score, which would give a broader 
view of patients‟ QoL and result in a more sensitive measure.  This could also be 
combined with more objective functional assessments. 
11.4.1.7 Physiological assessments 
 
The cortisol results suggest that cortisol measures would be of little clinical value.  
This is especially true given that patients tended to be more concerned about the 
Chapter 11: General discussion 
294 
saliva samples compared to providing blood samples, probably due to the extra 
cognitive demand and responsibility required for the saliva samples. 
 
The findings on inflammation were interesting and suggest that the relationship 
between TNFα and depressive symptoms is worthy of further investigation.  As 
discussed in chapter 8, other cytokines, such as IL-10, may also be worth including 
in further analyses. 
11.4.2  Protocol 
11.4.2.1 Timing of questionnaires 
 
The timing of questionnaires at three months post surgery (T4) may have 
confounded the results.  Some of the psychological variables are associated with a 
further increase in depressive symptoms at this time point (see chapter 7).  
However, there were actually fewer associations between inflammation and pain at 
this point despite associations at one and six month post surgery (see chapter 9).  
This may be because T4 is associated with increased vulnerability to depression 
compared to other time points; past research suggests that depressive symptoms 
are at their highest at two to three months after diagnosis[124].  Thus, it is hard to 
say whether the increased association between the psychological variables and 
depressive symptoms at T4 is due to the timing of the questionnaires, or because 
those that are vulnerable to low mood are especially susceptible to lowered mood 
at three months.  Also, for some patients, they may have just finished a course of 
adjuvant therapy which could have an emotional impact.  It was decided to assess 
the psychological variables at this time point as it was thought unethical to burden 
the patients around the time of their diagnosis and treatment, but leaving them until 
the end of the study would risk lower completion rates due to sample attrition.  
However, given these results, future studies could consider moving this 
assessment to another time point. 
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11.4.2.2 Analysis 
 
Due to the small sample size and multiple testing there is a risk of both type I and 
type II errors.  Also, complete case analysis may have led to biases because the 
patients that remained in the study were healthier than those who did not.  Also, 
the chosen analysis may be considered over complicated given the sample size.  
However, these analyses were chosen in order to cope with the smaller sample 
size, for instance two analysis methods had to be significant in order to interpret a 
finding as significant in the cytokine analyses.  Colinearity between many of the 
variables also resulted in a much more complicated multivariate analysis, as 
including many of these measures would lead to over fitting a model.  Whilst the 
more complicated analyses were considered necessary in order to ensure reliable 
results, more complicated analyses can make results harder to interpret.  Future 
work with larger samples is less likely to require multiple testing methods and could 
use imputation to reduce the biases from missing data. 
11.4.2.3 Methodology 
 
The findings of the study are limited as they are only applicable to curative CR and 
HN cancer patients who undergo surgical treatment.  The study appears to be 
further limited by the heterogeneity of the HN cancer patients; previous studies 
have found large differences in QoL and symptoms by type of HN cancer[146].  This 
highlights the need for more homogenous groups in research. 
 
Also, due to the smaller sample, some aspects of QoL could not be fully 
investigated in the adjusted models, despite initial findings of a strong correlation 
between some symptoms and poorer global QoL.  For example, very few patients 
had stomas, but stoma problems were very often associated with poorer QoL (see 
chapter 4 and chapter 10).  Although as reported in chapter 1, a meta-analysis 
found no difference in QoL between patients with and without a colostomy bag, 
studies continue to report significantly poorer QoL in patients with a stoma[173, 387].  
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In addition, studies have reported high levels of stoma problems in those with 
stomas[388], with up to 80% of patients still struggling with some aspects of stoma 
function up to two years post treatment.  However, it would be very hard to 
represent properly this confounding factor in a study investigating inflammation and 
QoL in cancer patients due to the large numbers it would require. 
11.5 Practical applications and recommendations 
11.5.1 Research 
 
Further work on this data set could include more investigations into the correlation 
of depressive symptoms and QoL.  Despite the longitudinal nature of the study, 
none of the results indicate causality with respect to the relationship between 
increased depressive symptoms and poorer QoL.  Whilst the relationship is most 
likely to be bidirectional, a time lagged analysis of the data may indicate whether 
the depressive symptoms are a stronger predictor of poorer QoL than vice versa.  
Further work on this data set could include investigating the impact of extraversion 
on depressive symptoms and QoL.  
 
Further research projects should involve larger, more homogeneous samples.  
These studies would take longer to carry out, but would result in more reliable data.  
Also, the studies would benefit from following patients for a full year from 
diagnosis, as past research has shown that it takes up to a year for QoL to return 
to baseline levels[146, 172].  Beyond one year of follow up is less likely to be 
beneficial, as studies have reported few differences in QoL between one and three 
years post diagnosis[177].  These projects may benefit from using a different QoL 
measure either instead of or as well as the EORTC-QLQ.  Also, the questionnaires 
on personality and CT should be issued at a later time point.  Moreover, social 
support measures may prove a more informative marker of depression than the 
current coping assessment.  It would also be worth considering assessing IL10 
levels instead of IL1ß levels, given the low levels of IL1ß that were found in this 
sample.  Finally, larger samples would allow for multiple imputation which would be 
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a more reliable way to deal with missing data than complete case analysis.  Really 
large samples would also allow for structural equation modeling, which could help 
identify exactly how vulnerability to DD, self reported symptoms and depressive 
symptoms relate to QoL. 
11.5.2 Clinical 
 
The study suggests that asking patients about PH of depression at their first visit to 
the clinic may help clinicians identify patients at increased risk of a DD.  The study 
also shows how important non cancer related issues are to risk of a DE6 and 
cancer patients‟ QoL.  This indicates that any moves towards more holistic and 
patient centered health care would benefit patients. 
11.6 Summary 
 
This thesis sought to identify psychological and physiological markers for 
depression in colorectal and head and neck cancer patients.  Depression has been 
shown to be under diagnosed and under treated in cancer clinics, despite being 
associated with poorer treatment outcome in terms of poorer quality of life and 
some evidence of increased mortality.  Two studies were conducted on colorectal 
cancer patients attending the colorectal clinic at The Royal London Hospital and in 
head and neck cancer patients attending the head and neck clinic at St 
Bartholomew‟s Hospital.  One study was cross sectional and the other was 
prospective in design.  The results show the prevalence of a depressive episode 
was higher than that of the general population in the head and neck clinic, but 
comparable to the prevalence in the general population in the colorectal clinic.  
Both studies found a strong association between increased depressive symptoms 
and poorer quality of life in both groups of cancer patients. 
 
Results from the prospective study found that past history of depression, 
neuroticism and number of stressful life events were all important factors in 
predicting high depressive symptoms and risk of a depressive episode within six 
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months after diagnosis.  These factors were more closely related to risk of a 
depressive episode than any cancer related symptom.  Childhood trauma was also 
related to increased depressive symptoms and poorer quality of life.  Importantly, 
increased inflammation before treatment in colorectal cancer patients was 
associated with increased depressive symptoms at one and three months post 
surgery.  This not only adds to the literature on a link between physical and mental 
illness, but may also offer a rationale for the development of anti-inflammatory 
therapeutic agents.  Also, the results suggest that inflammation and psychological 
risk markers for depression are very closely related to mood and self rated 
symptoms of fatigue and pain and it would be hard to separate the relationship 
between each of the factors. 
 
The results show that it is necessary to consider all the psychological and 
physiological aspects of cancer patients during their cancer treatment.  Cancer 
clinicians and other researchers would benefit from increased awareness of the 
close relationship between physiological and psychological aspects of cancer.  
Further research on inflammation and depression could increase the 
understanding of the relationship between physiology and mood, although, as this 
study demonstrates, it is hard to separate the two.  Along with parallel research 
into the links between the mind and the body, such research should contribute to a 
more holistic health care approach and help reduce the divide between mental and 
physical health. 
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Appendices 
 
Appendix 1. 1: Prevalence of depression in colorectal cancer patients 
 
Study N Patients  Method Time of 
assessment 
% 
MDD 
Pugliese 
et al. 
9
8 
Italian advanced 
chemo patients, with 
liver metastases 
Semi structured 
interview to DSM-IIIR 
(unclear which 
interview) 
Before treatment 
and at 18 weeks 
0 
 
Fujita et 
al. 
3
6 
Japanese 
gastrectomy 
abdominal patients 
HADS, plus 
psychiatric exam on 
those >7 
Before treatment 
and one year 
post operation 
6 
Prevalence of MDD in CR cancer patients. 
 
Study N Patients Method Criteria Time of 
assessment 
„Case 
level‟ 
depressive 
symptoms 
Richardson 
et al. 
47 American rectal 
patients with 
colostomy 
BDI >13 1-3 months 
post 
treatment 
6 
Alacacioglu 
et al. 
110 Turkish colorectal 
undergoing 
chemotherapy 
BDI >16 During 
treatment 
24 
Kurtz et al.  154 Mid western 
American 
colorectal 
CES-D >15 Diagnosis 18.2 
Ramsey et 
al. 
227 American most 
stage II colon 
CES-D >15 Over 5 years 
post 
diagnosis 
14 
Simon et 
al. 
128 Colorectal 
including palliative 
CES-D >12 Average 257 
days post 
diagnosis 
14 
Part one of prevalence of case level depressive symptoms in CR cancer patients. BDI= Beck 
Depression Inventory; CES-D=Centre for Epidemiologic Studies Depression Scale 
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Appendix 2. 1: Hospital Anxiety and Depression Scale 
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Appendix 2. 2 : European Organisation for Research and Treatment of 
Cancer, Quality of Life Questionnaire 
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Appendix 2. 3: Colorectal CR29 QLQ module 
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Appendix 2. 4: Head and neck 35 QLQ module 
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Appendix 3. 1: Past mental health screening questionnaire – colorectal 
patients 
 
 
Appendices 
334 
 
Appendices 
335 
Appendix 3. 2: Past mental health screening questionnaire – head and neck 
patients 
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Appendix 5. 1: Patient information sheet 
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Appendix 5. 2: Childhood Trauma Questionnaire 
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Appendix 5. 3: Eysenck Personality Questionnaire 
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Appendix 5. 4: Brief Life Events Questionnaire 
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Appendix 5. 5: Brief COPE 
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Appendix 5. 6: Salivette Instructions 
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Appendix 5. 7: Cortisol protocol 
 
Salivary cortisol radioimmunoassay protocol 
 
DAY 1 
 
 Label LP3 tubes: 
o 4 x Non-Specific Binding (NSB) 
o 4 x Total 
o 1 - 10 in triplicate for calibration curve 
 Add 100ul buffer to NSB and tubes 2 - 10 of the calibration curve. 
 Add 200ul buffer to NSB tubes. 
 Add 200ul of cortisol standard (20ul stock in 10ml buffer, top tube 5ng/ml) and 
serially dilute. 
o Samples: 0.2ml saliva + 0.2ml buffer; 0.1ml/tube in duplicate. 
 Add 100ul tracer (stock + Buffer to give c5000 cpm) to all tubes and vortex. 
 Add 100ul of antibody (rabbit polyclonal, final titre 1:132 000) to all tubes except 
NSB and tracer.  
 Vortex, cover in cling film and leave in cold room until next day. 
 
DAY 2 
 
 Make up dextran-coated charcoal solution and add 0.5ml to each tube except 
tracer and vortex. 
 Spin for 15 minutes at 4ºC speed 4 (except tracer). 
 Aspirate and count using crystal gamma counter. 
 
Analytes: 
 
Tracer: cortisol-3CMO-[125-I]histamine, Institute of Isotopes, Budapest, Hungary 
 
Buffer: sodium citrate/sodium dehydrate orthophosphate dehydrate with 0.1% 
bovine serum albumin, pH3 
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Appendix 5. 8: Cytokine protocol 
 
Blood collection protocol 
 
 Take 5mls of blood with 150μl monoparin and keep on crushed ice. 
 
 Centrifuged at 1500 rpm or 3000 rcf for 10 minutes at 4°C.   
 
 Aliquot plasma into 5 x 200 µl aliquots.  The remaining plasma should be 
aliquoted in 1ml volumes into appropriately labelled vials. Dispose of blood pellet. 
 
 Snap freeze plasma placing the tubes into liquid nitrogen.  
 
 Store samples at -80 until analysed. 
 
Assay protocol: 
 
1. Defrost samples and aliquot into eppendorfs.  Spin for 3 minutes at 
2.5rpm and keep on ice until required for assay. 
 
2. Addition of human serum cytokine assay diluent: Dispense 25μL of 
human serum cytokine assay diluent into each well. Pipette to the bottom of 
the plate so as to allow the fluid to cover the entire bottom of the well. A 
slight tap may be necessary to allow the fluid to settle to the bottom. Seal 
the plate with an adhesive plate seal and incubate for 30 minutes with 
vigorous shaking (300-1000 rpm) at room temperature. 
 
3. Addition of sample or calibrator: Dispense 25 μL of each calibrator or 
sample solution into a separate well of the MSD plate. Seal the plate with an 
adhesive plate seal and incubate for 2 hours with vigorous shaking (300-
1000 rpm) at room temperature. 
 
4. Wash and addition of detection antibody solution: Wash the plate 3X 
with PBS + 0.05% Tween-20. Dispense 25μL of the 1X detection antibody 
solution into each well of the MSD plate. Seal the plate and incubate for 2 
hours with vigorous shaking (300-1000 rpm) at room temperature. 
 
5. Wash and Read: Wash the plate 3X with PBS + 0.05% Tween-20. Add 150 
μL of 2X read buffer T to each well of the MSD plate. Analyze the plate on 
the MSD SECTOR® Imager. Plates may be read immediately after addition 
of Read Buffer. Note: Bubbles in the fluid will interfere with reliable reading 
of the MULTI-SPOT plate. Use reverse pipetting techniques to insure 
bubbles are not created when dispensing the read buffer. 
 
Data analysis 
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Assay results were saved into excel files.  In total 9 plates were carried out.  Plates 
1-4 were carried out over two years and kit analytes were from different batches.  
Plates 5-9 were carried out in quick succession and were all from the same batch.  
Due to the different batch analytes the inter assay CV for plates 1-4 reached 
>100% with an average of 56%.  This was deemed too high to give meaningful 
results in a clinical population.   
 
Samples with an intra assay coefficient of variation (CV) from plates 1-4 were 
repeated in later plates as were a random selection of 3 samples from each plate 
with CV‟s of less than 10%.  The repeated samples with CV‟s of less than 10% in 
plates 1-4 and 5-9 were used to calculate the ratio between the results from the 
first plates and plate 5 (assay result from plate 1-4 divided by assay result from 
plate 5) which was used to assign a fiddle factor for each cytokine from each plate 
(one for IL6, IL1ß, TNFα and IFNγ for each plate).  The fiddle factors for plate 5 
were comparable to the fiddle factors for plates 6-9 and the ratios were comparable 
across different samples, indicating that the results from assays 1-4 are consistent, 
thus it would be appropriate to use a fiddle factor.  Therefore the following fiddle 
factors were applied to plates 1-4: 
 
Assay number IL6 IL1ß IFNγ TNFα 
1 1.07 3.27 3.89 1.42 
2 1.60 3.06 4.04 1.57 
3 0.32 0.76 0.34 0.47 
4 4.67 4.39 10.97 5.66 
Fiddle factors for each cytokine 
 
For the majority of samples (151) results from assays 5-9 could be used (where the 
inter assay CV was <11%).  Fifty-eight samples (38%) were from assays 1-4 using 
the fiddle factor. 
 
In the case of IL1ß many samples were below the lower limit of detection, in which 
case the level of the lowest limit of detection was entered.  This was also the case 
in a few results for IFNγ where the same rule was applied. 
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Appendix 6. 1: Representativeness of recruited sample 
 
 Not recruited, N(%) Recruited, N(%) OR (95% CI) 
Diagnosis 
HN 
CR 
 
45 (73.77) 
16 (26.23) 
 
62 (60.78) 
40 (39.22) 
 
 
0.55 (0.27-1.11) 
Sex 
M 
F 
 
36 (59.02) 
25 (40.98) 
 
56 (54.90) 
46 (45.10) 
 
 
1.18 (0.62-2.25) 
Age                         N 
Mean (sd) 
61 
68.50 (11.75) 
102 
64.94 (13.74) 
 
0.98 (0.95-1.00) 
Marital status 
Married (reference) 
Cohabiting 
Widowed 
Divorced 
Single 
Missing 
 
27 (64.29) 
0 
2 (4.76) 
4 (9.52) 
9 (21.43) 
19 
 
56 (58.33) 
9 (9.38) 
10 (10.42) 
120 (10.42) 
11 (11.46) 
6 
 
 
 
 
 
 
χ2(4)=7.21, p=0.13Ŧ 
Married 
Yes 
No 
 
27 (64.29) 
15 (35.71) 
 
65 (67.71) 
31 (32.29) 
 
 
0.86 (0.40 to 1.85) 
Ethnicity 
White (reference) 
Other 
Missing 
 
45 (77.59) 
13 (22.41) 
3 
 
87 (85.29) 
15 (14.71) 
0 
 
 
 
0.60 (0.26-1.37) 
Not recruited includes patients who were uncontactable before their treatment and patients who 
declined participation. N=number; OR=Odds Ratio, CI= confidence interval.  Ŧ Chi
2
 reported due to 
empty cells. 
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Appendix 6. 2: Alphas for all questionnaires in prospective study 
 
 
Scale Alpha Scale Alpha 
CTQ – EA 0.79 CTQ – EN 0.86 
CTQ – PA 0.86 CTQ – PN 0.57 
CTQ – SA 0.92 CTQ-L 0.76 
CTQ total 0.90   
 
EPQ – N 0.86 EPQ-Ex 0.87 
EPQ-P 0.51 EPQ-L 0.82 
 
Cope – self 
destruction 
0.67 Venting 0.63 
Active 0.87 Positive 
reframing 
0.77 
Denial 0.76 Planning 0.96 
Substance use 0.79 Humour 0.91 
Emotional 
support 
0.87 Acceptance 0.59 
Instrumental 
support 
0.83 Religion 0.85 
Behavioural 
disengagement 
0.62 Self-blame 0.45 
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Scale Alpha 
T1 T3 T4 T5 
HADS-A 0.84 0.88 0.89 0.85 
HADS-D 0.82 0.81 0.87 0.87 
HADS-T 0.87 0.90 0.91 0.87 
  
Global QoL 0.89 0.88 0.90 0.91 
Physical 0.86 0.83 0.83 0.85 
Role 0.91 0.87 0.94 0.85 
Emotional 0.80 0.89 0.92 0.81 
Cognitive 0.72 0.63 0.56 0.51 
Social 0.90 0.84 0.84 0.82 
Fatigue 0.87 0.81 0.86 0.77 
Nausea/vomiting 0.57 0.61 0.34 0.22 
Pain 0.85 0.85 0.84 0.84 
HN pain 0.70 0.68 0.84 0.66 
HN swallowing 0.82 0.73 0.88 0.78 
HN senses 
problems 
0.76 0.72 0.55 0.72 
HN speech 
problems 
0.74 0.75 0.57 0.65 
HN social eating 0.81 0.89 0.94 0.91 
HN social 
contact 
0.86 0.83 0.88 0.85 
HN less 
sexuality 
0.93 0.91 0.98 0.98 
CR anxiety 0.75 0.64 0.61 0.11 
CR body image 0.37  0.73 0.89 0.86 
CR micturition 
problems 
0.88 0.75 0.64 0.14 
CR 
abdominal/pelvic 
pain 
0.54 0.36 Too little 
variation for 
one answer 
0.87 
CR defaecation 
problems 
1.00 0.37 0.64 0.37 
CR faecal 
incontinence 
0.74 Too few 
completions 
0.12 0.47 
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Appendix 6. 3: Representativeness of T2 sample 
 
 
Baseline 
characteristic 
 
T2 data 
N (%) 
No T2 data 
N (%) 
 
OR (95% CI) 
Age                    N 
Mean (sd) 
20 
70.86 (12.47) 
70 
63.96 (12.15) 
 
0.95 (0.90-1.00) 
IL6 T1                 N              
Mean (sd) 
Median 
67 
3.45 (3.86) 
2.11 
8 
1.59 (0.62) 
1.59 
 
 
1.45 (1.10-1.90) 
OR=Odds ratio.  CI= confidence interval 
 
Appendix 6. 4: Representativeness of T3 sample 
 
 
Baseline 
characteristic 
 
T3 data 
N (%) 
No T3 data 
N (%) 
 
OR (95% CI) 
Age                    N 
Mean (sd) 
16 
72.38 (8.59) 
74 
64.01 (12.74) 
 
0.94 (0.90-0.98) 
Comorbidity rating 
0 
1 
2 
Missing 
 
2 (14.29) 
7 (50.00) 
5 (35.71) 
2 
 
39 (56.52) 
15 (21.74) 
15 (21.74) 
5 
 
 
 
 
0.44 (0.24-0.82) 
IL6 T2                N 
Mean (sd) 
Median 
7 
46.28 (55.66) 
11.35 
63 
8.68 (7.70) 
6.80 
 
 
0.94 (0.90-0.99) 
TNFα T2             N 
Mean (sd) 
Median 
64 
4.22 (2.17) 
3.79 
7 
8.33 (3.85) 
6.08 
 
 
0.63 (0.51-0.79) 
IFNγ T2              N 
Mean (sd) 
Median 
64 
2.94 (7.04) 
1.26 
7 
21.06 (50.61) 
1.89 
 
 
0.97 (0.95-0.99) 
CRP T2              N 
Mean (sd) 
Median 
64 
54.73 (56.60) 
36.39 
7 
132.86 (110.59) 
97.95 
 
 
0.99 (0.98-1.00) 
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Appendix 6. 5: Representativeness of T4 sample 
 
Baseline 
characteristic 
 
T4 data 
N (%) 
No T4 data 
N (%) 
 
OR (95% CI) 
Comorbidity rating 
0 
1 
2 
Missing 
 
 
5 (26.32) 
7 (36.84) 
7 (36.84) 
4 
 
36 (56.25) 
15 (23.44) 
13 (20.31) 
3 
 
 
 
(As trend) 
0.51 (0.28-0.93) 
IL6 T2                 N              
Mean (sd) 
Median 
 
12 
34.64 (44.38) 
11.15 
58 
7.85 (6.45) 
5.93 
 
 
0.72 (0.87-0.97) 
TNFα T2             N 
Mean (sd) 
Median 
 
59 
4.10 (2.01) 
3.78 
12 
7.22 (3.83) 
5.93 
 
 
0.67 (0.54-0.83) 
IFNγ T2              N 
Mean (sd) 
Median 
 
59 
3.08 (7.31) 
1.28 
12 
12.84 (38.74) 
1.40 
 
 
0.98 (0.96-1.00) 
CRP T2              N 
Mean (sd) 
Median 
 
59 
47.78 (46.31) 
31.76 
12 
134.43 (100.40) 
106.83 
 
 
0.98 (0.97-0.99) 
IL6 T3                 N 
Mean (sd) 
Median 
 
54 
2.17 (1.64) 
1.67 
3 
10.11 (12.42) 
3.43 
 
 
0.73 (0.64-0.83) 
IFNγ T3              N 
Mean (sd) 
Median 
 
55 
2.88 (4.60) 
1.26 
3 
1.40 (0.16) 
1.40 
 
 
1.32 (1.11-1.58) 
CRP T3              N 
Mean (sd) 
Median 
54 
8.05 (16.88) 
3.39 
4 
61.09 (115.50) 
4.2 
 
 
0.98 (0.97-0.99) 
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Appendix 6. 6: Representativeness of T5 sample 
 
Baseline 
characteristic 
No T5 data 
N (%) 
T5 data 
N (%) 
 
OR (95% CI) 
Comorbidity rating 
0 
1 
2 
Missing 
 
 
6 (26.09) 
8 (24.78) 
9 (39.13) 
4 
 
35 (58.33) 
14 (23.33) 
11 (18.33) 
3 
 
 
 
 
0.46 (0.25-0.82) 
TNFα T1             N 
Mean (sd) 
Median 
 
55 
3.65 (1.57) 
3.26 
21 
4.41(1.98) 
3.87 
 
 
0.78 (0.61-1.00) 
IL6 T2                 N 
Mean (sd) 
Median 
 
16 
28.68 (39.56) 
11.27 
54 
7.62 (6.48) 
5.56 
 
 
0.92 (0.87-0.92) 
TNFα T2             N 
Mean (sd) 
Median 
 
55 
3.98 (1.85) 
3.78 
16 
6.85 (3.70) 
5.54 
 
 
0.66 (0.54-0.82) 
IFNγ T2              N 
Mean (sd) 
Median 
 
55 
2.17 (2.63) 
1.19 
16 
13.50 (35.21) 
1.66 
 
 
0.94 (0.90-0.99) 
CRP T2              N 
Mean (sd) 
Median 
 
55 
47.47 (47.40) 
31.61 
16 
133.87 (94.58) 
88.66 
 
 
0.99 (0.98-0.99) 
IL6 T3                 N 
Mean (sd) 
Median 
 
52 
2.21 (1.67) 
1.72 
5 
6.54 (10.04) 
1.98 
 
 
0.73 (0.64-0.83) 
IFNγ T3              N 
Mean (sd) 
Median 
 
53 
2.96 (4.67) 
1.31 
5 
1.19 (0.35) 
1.24 
 
 
1.65 (1.06-2.58) 
CRP T3              N 
Mean (sd) 
Median 
52 
8.20 (17.18) 
3.39 
6 
42.14 (94.18) 
3.50 
 
 
0.98 (0.97-1.00) 
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Appendix 6. 7: All variables tested – results for T5 only 
 
 
Baseline 
characteristic 
 
OR (95% CI) 
Gender 2.06 (0.81-5.29) 
Diagnosis 0.67 (0.27-1.68) 
Age                     0.98 (0.94-1.02) 
BMI                     0.92 (0.79-1.06) 
Ethnicity 0.55 (0.16-1.92) 
Marital status χ2(4)=8.06, p=0.09 
T stage 0.73 (0.78-1.11) 
N stage 0.78 (0.45-1.36) 
Presence of 
metastases 
 
0.54 (0.11-2.61) 
Surgery 1.17 (0.10-13.51) 
Chemotherapy 1.1 (0.36-3.34) 
Radiotherapy 1.24 (0.39-3.95) 
Comorbidity 
rating 
 
0.46 (0.25-0.83)* 
Smoking χ2(4)=0.92, p=0.92 
Alcohol χ2(4)=1.16, p=0.56 
Alcohol abuse χ2(4)=0.21, p=0.64 
HADS-D baselineŦ 0.96 (0.85-1.08) 
HADS-A baselineŦ 0.99 (0.89-1.11) 
Global Qol 
baseline   
1.01 (1.00-1.04) 
HADS-D T3Ŧ 0.90 (0.77-1.06) 
HADS-A T3Ŧ 0.91 (0.80-1.05) 
Global Qol T3 1.02 (0.99-1.05) 
HADS-D T4Ŧ 0.91 (0.75-1.10) 
HADS-A T4Ŧ 0.93 (0.76-1.14) 
Global Qol T4     1.03 (0.99-1.08) 
Life events T3    0.96 (0.66-1.40) 
IL6 T1                  0.90 (0.77-1.02) 
IL6 T2                  0.92 (0.86-0.99)* 
IL6 T3                  0.82 (0.64-1.04) 
Neuroticism         1.05 (0.89-1.25) 
Emotional abuse 1.17 (0.75-1.82) 
Physical abuse 1.52 (0.52-4.46) 
Sexual abuse 1.20 (0.92-2.34) 
Physical neglect 1.00 (0.72-1.42) 
Emotional neglect 0.89 (0.86-1.05) 
* P<0.05 Ŧ Test for trend – no significant effect when treated as categorical variable. 
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Appendix 6. 8: Cases for possible and probable depression as indicated by 
HADS-D thresholds 
 
 Score CR 
N (%) 
HN 
N (%) 
Significance 
HADS-D T1 0-7 29 (87.88) 46 (86.79)  
 
χ2(2)=0.77, p=0.52 
8-10 2 (6.06) 5 (9.43) 
≥ 11 2 (6.06) 2 (3.77) 
 
HADS-D T3 0-7 19 (76.00) 34 (73.91)  
 
χ2(2)=1.79, p=0.41 
8-10 4 (16.00) 4 (8.70) 
≥ 11 2 (8.00) 8 (17.39) 
 
HADS-D T4 0-7 16 (66.67) 31 (73.81)  
 
χ2(2)=1.46, p=0.48 
8-10 4 (16.67) 3 (7.14) 
≥ 11 4 (16.67) 8 (19.05) 
 
HADS-D T5 0-7 18 (81.82) 33 (80.49)  
 
χ2(2)=0.69, p=0.71 
8-10 3 (13.64) 4 (9.76) 
≥ 11 1 (4.55) 4 (9.76) 
 
HADS-A T1 0-7 20 (58.82) 31 (58.49)  
 
χ2(2)=0.10, p=0.95 
8-10 9 (26.47) 13 (24.53) 
≥ 11 5 (14.71) 9 (16.98) 
 
HADS-A T3 0-7 17 (68.00) 31 (67.39)  
 
χ2(2)=0.18, p=0.91 
8-10 5 (20.00) 8 (17.39) 
≥ 11 3 (12.00) 7 (15.22) 
 
HADS-A T4 0-7 15 (62.50) 28 (66.67)  
 
χ2(2)=0.75, p=0.69 
8-10 3 (12.50) 7 (16.67) 
≥ 11 6 (25.00) 7 (16.67) 
 
HADS-A T5 0-7 14 (63.64) 32 (78.05)  
 
χ2(2)=1.66, p=0.44 
8-10 6 (27.27) 6 (14.63) 
≥ 11 2 (9.09) 3 (7.32) 
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Appendix 6. 9: Differences in HADS-D scores compared to baseline after 
adjusting for global QoL 
 
Cancer group 
N* 
 ß(CI) P value 
CR 
102 (34) 
(ref) T1   
T3 1.20 (-0.15 to 2.54) 0.081 
T4 1.23 (-0.57 to 3.02) 0.181 
T5 0.60 (-0.65 to 1.86) 0.347 
Global QoL -0.09 (-0.12 to -0.05) <0.0005 
HN (ref) T1   
178 (56) T3 1.25 (0.18 to 2.32) 0.022 
 T4 1.09 (0.04 to 2.13) 0.041 
 T5 0.45 (-0.51 to 1.42) 0.357 
Global QoL -0.09 (-0.11 to -0.07) <0.0005 
All (ref) T1   
280 (90) T3 1.24 (0.433 to 2.06) 0.003 
 T4 1.14 (0.23 to 2.06) 0.014 
 T5 0.51 (-0.24 to 1.26) 0.183 
Global QoL -0.09 (-0.011 to -0.07) <0.0005 
*N=total data, number in parentheses is number of patients. 
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Appendix 6. 10: HADS-D scores at each data wave 
 
 
 CR HN Significance 
N Mean (sd) 
Median 
N Mean (sd) 
Median 
HADS-D T1 34 
 
3.32 (4.03) 
1.5 
 
53 
 
3.49 (3.45) 
3 
 
z=0.31, p=0.76 
HADS-D T3 25 
 
4.89 (3.72) 
5 
 
45 
 
5.24 (4.19) 
4 
 
z=0.25, p=0.81 
HADS-D T4 25 
 
5.17 (4.61) 
3 
 
42 
 
4.83 (4.19) 
3 
 
z=-0.12, p=0.90 
HADS-D T5 22 4.14 (3.81) 
2 
 
41 
 
3.95 (3.98) 
3 
 
z=-0.07, p=0.95 
HADS-A T1 34 
 
6.00 (4.19) 
6 
 
53 
 
6.52 (4.01) 
6 
 
z=0.50, p=0.62 
HADS-A T3 25 
 
5.98 (4.51) 
6 
 
45 
 
6.09 (4.48) 
5 
 
z=0.02, p=0.99 
HADS-A T4 25 
 
6.61 (5.26) 
6 
 
42 
 
6.05 (3.93) 
6 
 
z=-0.17, p=0.87 
HADS-A T5 22 
 
5.55 (4.23) 
5 
41 
 
5.17 (3.15) 
4 
 
z=-0.25, p=0.81 
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Appendix 6. 11: Global QoL scores at each data wave 
 
 
 CR HN Significance 
N Mean (sd) 
Median 
N Mean (sd) 
Median 
Global QoL 
T1 
32 63.54 (25.82) 
66.67 
 
52 68.11 (23.67) 
75 
 
z=0.97, p=0.33 
Global QoL 
T3 
25 62.67 (25.47) 
66.67 
 
45 60.74 (22.86) 
66.67 
 
z=-0.45, p=0.66 
Global QoL 
T4 
24 60.76 (24.63) 
58.33 
 
41 65.85 (20.31) 
66.67 
 
z=0.87, p=0.39 
Global QoL 
T5 
21 65.87 (27.63) 
58.33 
 
40 68.75 (19.41) 
75.00 
 
z=0.39, p=0.70 
 
Appendix 6. 12: Differences in HADS-D scores compared to baseline 
 
Cancer group 
N* 
Standardised ß (CI) P value 
CR  
 105 (34)                 
(ref) T1 
T3 
T4 
T5 
 
1.44 (-0.06 to 2.95) 
1.46 (-0.32 to 3.24) 
0.46 (-1.20 to 2.12) 
 
0.060 
0.107 
0.587 
HN                    
181 (56)  
(ref) T1 
T3 
T4 
T5 
 
1.97 (0.84 to 3.09) 
1.75 (0.73 to 2.77) 
0.97 (-0.05 to 1.98) 
 
0.001 
0.001 
0.061 
Total 
286 (90)             
(ref) T1 
T3 
T4 
T5 
 
1.78 (0.88 to 2.67) 
1.64 (0.73 to 2.55) 
0.78 (-0.09 to 1.66) 
 
<0.0005 
<0.0005 
0.080 
*N=total data, number in parentheses is number of patients. 
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Appendix 6. 13: Differences in global QoL scores compared to baseline 
 
Cancer group 
N* 
ß (CI) P value 
CR 
102 (34)                  
(ref) T1 
T3 
T4 
T5 
 
-2.96 (-13.99 to 8.07) 
-4.45 (-15.37 to 6.48) 
0.52 (-10.88 to 11.93) 
 
0.599 
0.425 
0.928 
HN 
178 (56)            
(ref) T1 
T3 
T4 
T5 
 
-7.35 (-12.96 to -1.73) 
-5.48 (-11.67 to 0.71) 
-2.82 (-8.49 to 2.85) 
 
0.010 
0.083 
0.330 
Total 
280 (90)             
(ref) T1 
T3 
T4 
T5 
 
-5.84 (-11.16 to -0.53) 
-5.05 (-10.62 to 0.52) 
-1.56 (-6.96 to 3.84) 
 
0.031 
0.076 
0.571 
*N=total data, number in parentheses is number of patients.  
 
Appendix 6. 14: Differences in global QoL scores compared to baseline after 
adjusting for HADS-D 
 
Cancer group 
N* 
 ß(CI) P value 
CR 
 
(ref) T1   
T3 3.52 (-5.61 to 12.65) 0.450 
T4 2.50 (-9.03 to 14.02) 0.671 
T5 3.90 (-4.56 to 12.37) 0.366 
HADS-D -3.82 (-5.04 to -2.61) <0.0005 
HN (ref) T1   
 T3 -1.37 (-6.68 to 3.94) 0.613 
 T4 0.10 (-6.15 to 6.35) 0.976 
 T5 0.06 (-5.67 to 5.79) 0.984 
HADS-D -3.13 (-3.87 to -2.39) <0.0005 
All (ref) T1   
 T3 0.41 (-4.31 to 5.13) 0.864 
 T4 1.05 (-4.69 to 6.78) 0.721 
 T5 1.38 (-3.40 to 6.15) 0.572 
HADS-D -3.46 (-4.09 to -2.82) <0.0005 
*N=total data, number in parentheses is number of patients. 
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Appendix 8. 1: Cortisol descriptives 
 
Cortisol variable CR HN Mann Whitney 
sign test 
significance 
N Mean (sd) 
MedianŦ 
N Mean (sd) 
MedianŦ 
Morning cortisol 28 2.10 (1.45) 
1.70 
 
30 2.04 (1.17) 
1.96 
 
z=0.34, p=0.74 
Morning cortisol 
+30mins 
28 2.63 (1.02) 
1.92 
 
31 2.82 (1.79) 
2.30 
 
z=0.62, p=0.53 
Morning rise 28 0.53 (1.33) 
0.36 
 
30 0.80 (1.25) 
0.65 
 
z=0.69, p=0.49 
Evening cortisol 29 0.71 (0.73) 
0.52 
 
30 0.74 (0.64) 
0.57 
 
z=0.55, p=0.59 
Overall cortisol level 29 2.01 (1.22) 
1.68 
31 2.13 (1.19) 
2.04 
 
z=0.64, p=0.52 
Ŧ All values given in ng/ml. 
 
Appendix 8. 2: Robust standard error parameters for cortisol and QoL 
regressions 
 
 
Patient 
group 
Cortisol measure Time N ß(CI) P value 
CR Morning rise cortisol T1 QoL 27 5.80 (0.69 to 10.92) 0.028 
CR 30 minute waking T4 QoL 21 5.01 (0.49 to 9.53) 0.032 
CR Morning rise cortisol T4 QoL 21 5.16 (0.28 to 10.03) 0.039 
CR Morning rise cortisol T5 QoL 18 6.64 (1.49 to 11.78) 0.015 
CR Overall cortisol QoL 87 (28) 4.93 (0.67 to 9.19) 0.023 
HN Evening cortisol T3 QoL 23 -16.65 (-25.26 to -8.04) 0.0001 
HN Evening cortisol T5 QoL 23 -15.83 (-21.41 to -10.24) <0.0005 
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Appendix 8. 3: Inflammatory descriptives 
 
Inflammatory 
marker 
CR HN Mann Whitney sign test 
significance N Mean (sd) 
MedianŦ 
N Mean (sd) 
MedianŦ 
IL-6 T1 27 4.08 (4.22) 
2.45 
 
48 2.78 (3.32) 
1.71 
 
z=-1.48, p=0.14 
IL-6 T2 30 19.78 (31.06) 
10.84 
 
41 7.25 (6.11) 
5.33 
 
z=-2.03, p=0.04 
IL-6 T3 21 2.16 (1.85) 
1.55 
 
36 2.84 (3.99) 
1.87 
 
z=0.83, p=0.41 
TNF-α T1 28 4.73 (1.98) 
4.64 
 
48 3.35 (1.31) 
3.00 
 
z=-3.49, p<0.001 
TNF-α T2 30 6.12 (3.04) 
5.40 
 
41 3.53 (1.66) 
3.22 
 
z=-4.06, p<0.0005 
TNF-α T3 22 4.23 (1.49) 
4.11 
 
36 4.34 (2.20) 
3.68 
 
z=-0.39, p=0.70 
IFN-γ T1 28 1.35 (1.11) 
0.93 
 
48 1.35 (1.11) 
0.93 
 
z=-1.22, p=0.22 
IFN-γ T2 30 8.11 (26.06) 
1.32 
 
41 2.25 (2.62) 
1.30 
 
z=-0.36, p=0.77 
IFN-γ T3 22 1.56 (2.12) 
1.02 
 
36 3.57 (5.34) 
1.58 
 
z=2.77, p=0.01 
CRP T1 28 16.25 (26.74) 
4.02 
 
47 9.60 (17.99) 
2.50 
 
z=-1.91, p=0.06 
CRP T2 30 86.28 (80.10) 
66.18 
 
41 44.97 (48.61) 
31.61 
 
z=-2.28, p=0.02 
CRP T3 22 9.54 (24.29) 
2.03 
 
36 13.04 (38.93) 
3.85 
 
z=1.83, p=0.07 
Ŧ All values are in pg/ml 
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Appendix 8. 4: Significant changes in levels of inflammation over time 
 
 
 CR HN 
N ß (CI) N ß (CI) 
IL6 T1 27  48  
T2 29 16.00 (5.27 to 26.73)* 41 4.35 (2.63 to 6.08)* 
T3 21 1.03 (-1.32 to 3.39) 
 
36 -0.08 (-1.49 to 1.34) 
TNFα T1 28  48  
T2 30 1.43 (0.46 to 2.40)* 41 0.24 (-0.17 to 0.64) 
T3 22 0.10 (-0.48 to 0.69) 
 
36 0.96 (0.40 to 1.51)* 
IFNγ T1 28  48  
T2 30 5.13 (-3.75 to 14.01) 41 0.90 (0.17 to 1.62)* 
T3 22 0.66 (-1.94 to 3.26) 
 
36 2.21 (0.48 to 3.95)* 
CRP T1 28  47  
T2 30 71.00 (44.96 to 97.04)* 41 35.08 (21.89 to 48.26)* 
T3 22 1.13 (-11.69 to 13.95) 36 3.21 (-8.12 to 14.54) 
*indicates significantly different (p<0.05) compared to T1 
 
Appendix 8. 5: Robust standard error parameters for inflammatory markers 
and HADS-D at T3 in CR cancer patients 
 
 
N Marker ß (CI) P value 
20 T1 IL6 0.50 (0.21 to 0.80) 0.004 
21 T1 TNFα 0.95 (0.40 to 1.50) 0.002 
21 T1 IFNγ 0.28 (0.19 to 0.38) <0.0005 
21 T1 CRP 0.12 (0.05 to 0.18) 0.002 
23 T2 IFNγ 0.16 (0.11 to 0.21) <0.0005 
21 T3 IFNγ 0.50 (0.22 to 0.77)  0.001 
21 Peri* IFNγ 0.34 (0.23 to 0.44) P<0.0005 
*Peri=perioperative rise (T2 – T1) 
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Appendix 8. 6: Robust standard error parameters for inflammatory markers 
and HADS-D at T3 in HN cancer patients 
 
N Marker ß (CI) P value 
33 T3 IL6 0.38 (0.27 to 0.48) <0.0005 
33 T3 TNFα 0.78 (0.06 to 1.49) 0.034 
33 T3 CRP 0.04 (0.03 to 0.05) <0.0005 
 
Appendix 8. 7: Robust standard error parameters for inflammatory markers 
and HADS-D at T4 in CR cancer patients 
 
N Marker ß (CI) P value 
20 T1 IL6 0.63 (0.23 to 1.02) 0.004 
21 T1 TNFα 1.04 (0.20 to 1.89) 0.018 
21 T1 IFNγ 0.35 (0.24 to 0.45) <0.0005 
21 T1 CRP 0.12 (0.05 to 0.18) 0.002 
23 T2 IFNγ 0.18 (0.12 to 0.24) p<0.0005 
23 T2 TNFα 1.02 (0.16 to 1.89) 0.022 
22 T3 TNFα 1.09 (-0.08 to 2.26) 0.066 
21 Peri* IFNγ 0.34 (0.05 to 0.66 0.025 
*Peri=perioperative rise (T2 – T1) 
 
Appendix 8. 8: Robust standard error parameters for inflammatory markers 
and HADS-D at T5 in CR cancer patients 
 
N Marker ß (CI) P value 
20 T2 IFNγ -0.52 (-1.04 to 0.00) 0.048 
18 Peri* CRP 0.03 (0.00 to 0.05) 0.039 
18 Peri* IFNγ 0.52 (-0.87 to -0.18) 0.006 
*Peri=perioperative rise (T2 – T1) 
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Appendix 8. 9: Robust standard error parameters for inflammatory markers 
and HADS-D overall in CR cancer patients 
 
N Marker ß(CI) P value 
88 (28) T1 TNFα 0.80 (0.43 to 1.18) <0.0005 
88(28) T1 IFNγ 0.19 (0.11 to 0.27) <0.0005 
 
Appendix 8. 10: Robust standard error parameters for inflammatory markers 
risk of DE6 in HN cancer patients 
 
N Marker OR(CI) P value 
34 T3 IFNγ 0.61 (0.38-0.98) 0.040 
 
Appendix 8. 11: Robust standard error parameters for inflammatory markers 
and T1 QoL in CR cancer patients 
 
N Marker ß(CI) P value 
27 T1 TNFα -5.66 (-10.62 to -0.70) 0.027 
27 T1 CRP -0.29 (-0.59 to 0.01) 0.057 
 
Appendix 8. 12: Robust standard error parameters for inflammatory markers 
and T3 QoL in CR cancer patients 
 
N Marker ß (CI) P value 
20 T3 IL6 -9.07 (-17.78 to -0.36) 0.042 
21 T3 TNFα -9.10 (-17.14 to -1.06) 0.029 
21 T3 IFNγ -4.13 (-5.92 to -2.33) <0.0005 
 
Appendices 
376 
Appendix 8. 13: Robust standard error parameters for inflammatory markers 
and T3 QoL in HN cancer patients 
 
N Marker ß (CI) P value 
37 T2 IL6 -1.47 (-2.68 to -0.27) 0.018 
37 T2 CRP -0.19 (-0.33 to -0.05) 0.009 
33 T3 IL6 -2.78 (-3.34 to -2.23) <0.0005 
33 T3 TNFα -5.37 (-9.95 to -0.78) 0.023 
33 T3 CRP -0.29 (-0.33 to -0.24) <0.0005 
36 Peri IL6 -1.72 (-2.98 to -0.45) 0.0009 
35 Peri CRP -0.22 (-0.35 to -0.08) 0.002 
 
Appendix 8. 14: Robust standard error parameters for inflammatory markers 
and T4 QoL in CR cancer patients 
 
 
N Marker ß (CI) P value 
23 T2 IFNγ -0.50 (-0.79 to -0.22)  0.002 
21 Peri* IFNγ -1.44 (-2.33 to -0.54) 0.003 
*Peri=perioperative rise (T2 – T1) 
 
Appendix 8. 15: Robust standard error parameters for inflammatory markers 
and T5 QoL in CR and HN cancer patients 
 
Cancer 
group 
N Marker ß (CI) P value 
CR 19 T3 IFNγ -3.41 (-6.92 to 0.11)  0.057 
HN 36 T1 IFNγ -4.04 (-7.03 to -1.04) 0.010 
HN 36 T1 IL6 -1.13 (-2.40 to 0.13 0.077 
HN 34 T2 IL6 -1.21 (-2.35 to -0.06) 0.040 
HN 32 T3 IL6 -3.73 (-6.91 to -0.56) 0.023 
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Appendix 8. 16: Robust standard error parameters for inflammatory markers 
and overall QoL in CR cancer patients 
 
N Marker ß (CI) P value 
86 (28) T1 IFNγ -0.78 (-1.33 to -0.23) 0.005 
86 (28) T1 CRP -0.22 (-0.41 to -0.03) 0.027 
 
Appendix 9. 1: Robust standard error parameters for associations between 
cortisol and inflammation 
 
Group N Cytokine  Cortisol measure ß (CI) P value 
CR 24 IL6 Waking +30 mins 0.62 (-0.04 to 1.29) 0.065 
25 IL6 PM 2.31 (0.40 to 4.22) 0.020 
25 IL6 Overall mean 0.96 (0.12 to 1.81) 0.027 
26 IFNγ PM 0.73 (0.24 to 1.22) 0.005 
HN 26 IFNγ Waking -0.33 (-0.65 to -0.02) 0.040 
26 IFNγ Waking +30 mins -0.18 (-0.37 to -0.01) 0.056 
27 IFNγ Overall mean -0.30 (-0.58 to -0.03) 0.032 
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Appendix 9. 2: Robust standard error parameters for associations between 
psychological and physiological markers in CR cancer patients 
 
Psychological Physiological N ß(CI) P value 
NE Cortisol morning rise 19 -0.11 (-0.18 to -0.04) 0.005 
CT CRP T1 16 2.25 (0.17 to 4.33) 0.036 
CT TNFα T2 18 0.19 (0.08 to 0.30) 0.002 
LE TNFα T1 23 -0.28 (-0.53 tp -0.02) 0.003 
LE IL6 T1 22 -0.36 (-0.72 to 0.00) 0.052 
 
Appendix 9. 3: Robust standard error parameters for associations between 
inflammation and fatigue and pain 
 
Group Marker Symptom N ß (CI) P value 
CR IFNγ T1 Fatigue T1 27 2.36 (1.65 to 3.08) <0.0005 
 CRP T1 Fatigue T1 27 0.57 (1.00 to 0.94) 0.004 
 IFNγ T1 Fatigue T3 21 1.33 (0.74 to 2.58) 0.001 
 CRP T1 Fatigue T3 21 0.66 (0.28 to 1.04 0.002 
 IL6 T1  Pain T4 20 -2.27 (-3.96 to -0.57) 0.012 
 TNFα T1 Pain T4 21 -4.67 (-8.21 to -1.13) 0.012 
 IFNγ Pain T4 21 -0.93 (-1.65 to -0.21) 0.014 
 TNFα T2 Pain T5 20 6.66 (1.53 to 11.79) 0.014 
HN IFNγ T1 Pain T5 36 6.30 (0.13 to 12.46) 0.046 
 IL6 T1 Pain T5 36 1.89 (0.00 to 3.79) 0.050 
 CRP T2 Pain T3 37 0.22 (0.04 to 0.40) 0.017 
 CRP T2 Pain T5 34 0.42 (0.15 to 0.68) 0.003 
 IL6 T3 Pain T3 33 2.99 (1.98 to 4.00) <0.0005 
All IL6 T2 Fatigue T3 59 1.25 (-0.03 to 2.54) 0.056 
 IL6 T2 Fatigue T4 57 1.55 (0.53 to 2.57) 0.003 
 IL6 T2 Fatigue T5 53 1.18 (0.23 to 2.13) 0.016 
 CRP T2 Fatigue T3 60 0.19 (0.04 to 0.33) 0.011 
 CRP T2 Fatigue T4 58 0.18 (0.05 to 0.31) 0.006 
 CRP T2 Fatigue T5 54 0.17 (0.04 to 0.31) 0.014 
 
 
